methamphetamine profile

Methamphetamine: A central nervous system stimulant and sympathomimetic with actions and uses similar to DEXTROAMPHETAMINE. The smokable form is a drug of abuse and is referred to as crank, crystal, crystal meth, ice, and speed. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

methamphetamine : A member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

methamphetamine is involved in 1 pathway(s), involving a total of 0 unique proteins and 8 unique compounds

ID Source	ID
PubMed CID	10836
CHEMBL ID	1201201
CHEBI ID	6809
SCHEMBL ID	42615
MeSH ID	M0013551

Synonym
44ral3456c ,
crank
meth (street name)
crystal meth
speed [street name]
methamphetaminum
crystal meth [street name]
ice [street name]
unii-44ral3456c
crank [street name]
(s)-phenylmethylaminopropane
j6.362b ,
CHEMBL1201201
benzeneethanamine, n,.alpha.-dimethyl-, (s)-
phenethylamine, n,.alpha.-dimethyl-, (s)-(+)-
d-methamphetamine
d-(s)-methamphetamine
1-phenyl-2-methylaminopropane
nsc25115
(+)-(s)-deoxyephedrine
wln: 1my1&1r -d
(+)-n-methylamphetamine
d-1-phenyl-2-methylaminopropane
metamphetamine
d-deoxyephedrine
nsc-25115
methyl-.beta.-phenylisopropylamine
benzeneethanamine,.alpha.-dimethyl-, (s)-
d-1-phenyl-2-methylaminopropan
d-desoxyephedrine
phenethylamine,.alpha.-dimethyl-, (s)-(+)-
(+)-methamphetamine
d-n,.alpha.-dimethylphenethylamine
d-phenylisopropylmethylamine
norodin
n-methylamphetamine
d-n-methylamphetamine
(+)-methylamphetamine
phenethylamine,.alpha.-dimethyl-, (+)-
benzeneethanamine,.alpha.-dimethyl-, (+)-
methylamphetamine
d-methylamphetamine
desoxyephedrine hydrochloride
dea no. 1105
phenethylamine, n,alpha-dimethyl-, (s)-(+)-
metamfetamine [inn]
metanfetamina [spanish]
n-methyl-beta-phenylisopropylamine
methamphetaminum [inn-latin]
metamfetaminum [inn-latin]
stimulex
methamphetaminum [jp]
metamfetamina [inn-spanish]
metamfetaminum [latin]
nsc 25115
metanfetamina [inn-spanish]
(+)-n,alpha-dimethylphenethylamine
phenethylamine, n,alpha-dimethyl-, (+)-
n-methyl-beta-phenylisopropylamin [german]
einecs 208-668-7
speed
benzeneethanamine, n,alpha-dimethyl-, (+)-
s-(+)-methamphetamine
hsdb 3359
(alphas)-n,alpha-dimethylbenzeneethanamine
(+)-(s)-n-alpha-dimethylphenethylamine
metanfetamina
(2s)-n-methyl-1-phenylpropan-2-amine
(s)-n,alpha-dimethylbenzeneethanamine
metamfetaminum
dextromethamphetamine
CHEBI:6809 ,
PDSP2_001388
PDSP2_001389
PDSP1_001404
(s)-methamphetamine
(s)-(+)-deoxyephedrine
(s)-methylamphetamine
benzeneethanamine, n,alpha-dimethyl-, (s)-
(s)-(+)-methamphetamine
metamfetamine
desyphed
d-1-phenyl-2-methylaminopropan [german]
phenethylamine, n,alpha-dimethyl-, (s)-(+)- (8ci)
benzeneethanamine, n,alpha-dimethyl-, (alphas)- (9ci)
(s)-n,alpha-dimethylbenzeneethanoamine
1-phenyl-2-methylamino-propan [german]
d-n,alpha-dimethylphenethylamine
methyl-beta-phenylisopropylamine
(+)-n,alpha-dimethyl-beta-phenylethylamine
benzeneethanamine, n,alpha-dimethyl-, (alphas)-
metamfetamina
(+)-2-(n-methylamino)-1-phenylpropane
2s-(+)-methamphetamine
(s)-(+)-n,alpha,dimethylphenethylamine
meth
methamphetamine
C07164
537-46-2
DB01577
PDSP1_001405
n methylamphetamine
B40 ,
D08187
metamfetamine (inn)
n-methyl-beta-phenylisopropylamin
1-phenyl-2-methylamino-propan
(+ )-methylamphetamine
n-methyl-1-phenyl-2-propanamine
bdbm50359499
EPITOPE ID:178090
methamphetamine [vandf]
methamphetamine [mi]
methamphetamine [hsdb]
metamfetamine [who-dd]
d-n,a-dimethylphenethylamine
SCHEMBL42615
desyphed hydrochloride (salt/mix)
(+)-n,.alpha.-dimethyl-.beta.-phenylethylamine
benzeneethanamine, n,.alpha.-dimethyl-, (+)-
phenethylamine, n,.alpha.-dimethyl-, (+)-
(+)-n,.alpha.-dimethylphenethylamine hydrochloride (salt/mix)
(+)-n,.alpha.-dimethylphenethylamine
(+)-(s)-n-.alpha.-dimethylphenethylamine
desoxyephedrine hydrochloride (salt/mix)
n-methyl-1-phenyl-2-propanamine #
DTXSID8037128 ,
methyl[(2s)-1-phenylpropan-2-yl]amine
intra-venous methamphetamine
(s)-n-methyl-1-phenylpropan-2-amine
methamphetamine (ma)
Q191924
n,i+/--dimethyl-phenethyl amine
dtxcid6017128
metamfetaminum (latin)
n06ba03
crystal meth (street name)
metamfetaminum (inn-latin)
ice (street name)
crank (street name)
metamfetamina (inn-spanish)
methamphetaminum (inn-latin)
speed (street name)
metamfetamine racemate
metanfetamina (inn-spanish)

Role	Description
neurotoxin	A poison that interferes with the functions of the nervous system.
psychotropic drug	A loosely defined grouping of drugs that have effects on psychological function.
central nervous system stimulant	Any drug that enhances the activity of the central nervous system.
xenobiotic	A xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.
environmental contaminant	Any minor or unwanted substance introduced into the environment that can have undesired effects.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
amphetamines	Amines that constitute a class of central nervous system stimulants based on the structure of the parent amphetamine 1-phenylpropan-2-amine.
secondary amine	A compound formally derived from ammonia by replacing two hydrogen atoms by hydrocarbyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
4p16.3 copy number variation	0	8

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Solute carrier family 22 member 3	Rattus norvegicus (Norway rat)	IC50 (µMol)	248.0000	4.9000	6.6500	8.4000	AID682029
Amine oxidase [flavin-containing] B	Rattus norvegicus (Norway rat)	Ki	270.0000	0.0008	1.0927	6.0000	AID125210
Amine oxidase [flavin-containing] B	Bos taurus (cattle)	Ki	550.0000	0.0540	1.8390	6.0000	AID125205
Synaptic vesicular amine transporter	Rattus norvegicus (Norway rat)	Ki	41.2800	0.0010	1.3009	6.2600	AID1233246; AID778856
Sigma non-opioid intracellular receptor 1	Homo sapiens (human)	Ki	8.3200	0.0000	0.4901	10.0000	AID203990
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Sodium-dependent noradrenaline transporter	Homo sapiens (human)	EC50 (µMol)	0.9200	0.0820	31.0243	168.9080	AID635292
Sodium-dependent serotonin transporter	Homo sapiens (human)	EC50 (µMol)	1.3000	0.0011	2.3883	8.7000	AID635296
Trace amine-associated receptor 1	Macaca mulatta (Rhesus monkey)	EC50 (µMol)	5.3000	1.0100	2.5775	5.3000	AID635287
Trace amine-associated receptor 1	Mus musculus (house mouse)	EC50 (µMol)	0.6217	0.0020	0.6970	5.4000	AID1066366; AID1066368; AID1066370; AID635292; AID635293
Trace amine-associated receptor 1	Rattus norvegicus (Norway rat)	EC50 (µMol)	0.8173	0.0139	0.4263	2.0440	AID1066367; AID1066369; AID1066371; AID635289
Trace amine-associated receptor 1	Homo sapiens (human)	EC50 (µMol)	1.4000	0.0150	1.4143	7.1900	AID635286; AID635296
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
monoamine transport	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neurotransmitter transport	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
chemical synaptic transmission	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
response to xenobiotic stimulus	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
response to pain	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
norepinephrine uptake	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neuron cellular homeostasis	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
amino acid transport	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
norepinephrine transport	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
dopamine uptake involved in synaptic transmission	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
sodium ion transmembrane transport	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
monoamine transport	Sodium-dependent serotonin transporter	Homo sapiens (human)
response to hypoxia	Sodium-dependent serotonin transporter	Homo sapiens (human)
neurotransmitter transport	Sodium-dependent serotonin transporter	Homo sapiens (human)
response to nutrient	Sodium-dependent serotonin transporter	Homo sapiens (human)
memory	Sodium-dependent serotonin transporter	Homo sapiens (human)
circadian rhythm	Sodium-dependent serotonin transporter	Homo sapiens (human)
response to xenobiotic stimulus	Sodium-dependent serotonin transporter	Homo sapiens (human)
response to toxic substance	Sodium-dependent serotonin transporter	Homo sapiens (human)
positive regulation of gene expression	Sodium-dependent serotonin transporter	Homo sapiens (human)
positive regulation of serotonin secretion	Sodium-dependent serotonin transporter	Homo sapiens (human)
negative regulation of cerebellar granule cell precursor proliferation	Sodium-dependent serotonin transporter	Homo sapiens (human)
negative regulation of synaptic transmission, dopaminergic	Sodium-dependent serotonin transporter	Homo sapiens (human)
response to estradiol	Sodium-dependent serotonin transporter	Homo sapiens (human)
social behavior	Sodium-dependent serotonin transporter	Homo sapiens (human)
vasoconstriction	Sodium-dependent serotonin transporter	Homo sapiens (human)
sperm ejaculation	Sodium-dependent serotonin transporter	Homo sapiens (human)
negative regulation of neuron differentiation	Sodium-dependent serotonin transporter	Homo sapiens (human)
positive regulation of cell cycle	Sodium-dependent serotonin transporter	Homo sapiens (human)
negative regulation of organ growth	Sodium-dependent serotonin transporter	Homo sapiens (human)
behavioral response to cocaine	Sodium-dependent serotonin transporter	Homo sapiens (human)
enteric nervous system development	Sodium-dependent serotonin transporter	Homo sapiens (human)
brain morphogenesis	Sodium-dependent serotonin transporter	Homo sapiens (human)
serotonin uptake	Sodium-dependent serotonin transporter	Homo sapiens (human)
membrane depolarization	Sodium-dependent serotonin transporter	Homo sapiens (human)
platelet aggregation	Sodium-dependent serotonin transporter	Homo sapiens (human)
cellular response to retinoic acid	Sodium-dependent serotonin transporter	Homo sapiens (human)
cellular response to cGMP	Sodium-dependent serotonin transporter	Homo sapiens (human)
regulation of thalamus size	Sodium-dependent serotonin transporter	Homo sapiens (human)
conditioned place preference	Sodium-dependent serotonin transporter	Homo sapiens (human)
sodium ion transmembrane transport	Sodium-dependent serotonin transporter	Homo sapiens (human)
amino acid transport	Sodium-dependent serotonin transporter	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Trace amine-associated receptor 1	Homo sapiens (human)
lipid transport	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
nervous system development	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
G protein-coupled opioid receptor signaling pathway	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
regulation of neuron apoptotic process	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
protein homotrimerization	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
actin binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neurotransmitter:sodium symporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
dopamine:sodium symporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
norepinephrine:sodium symporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
protein binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
monoamine transmembrane transporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
alpha-tubulin binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
metal ion binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
beta-tubulin binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
integrin binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
monoatomic cation channel activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
serotonin:sodium:chloride symporter activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
protein binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
monoamine transmembrane transporter activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
antiporter activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
syntaxin-1 binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
cocaine binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
sodium ion binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
identical protein binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
nitric-oxide synthase binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
actin filament binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
serotonin binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
primary amine oxidase activity	Amine oxidase [flavin-containing] B	Bos taurus (cattle)
aliphatic amine oxidase activity	Amine oxidase [flavin-containing] B	Bos taurus (cattle)
monoamine oxidase activity	Amine oxidase [flavin-containing] B	Bos taurus (cattle)
G protein-coupled receptor activity	Trace amine-associated receptor 1	Homo sapiens (human)
trace-amine receptor activity	Trace amine-associated receptor 1	Homo sapiens (human)
G protein-coupled opioid receptor activity	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
protein binding	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
cell surface	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neuronal cell body membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
presynaptic membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
plasma membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
axon	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
plasma membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
focal adhesion	Sodium-dependent serotonin transporter	Homo sapiens (human)
endosome membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
endomembrane system	Sodium-dependent serotonin transporter	Homo sapiens (human)
presynaptic membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
membrane raft	Sodium-dependent serotonin transporter	Homo sapiens (human)
synapse	Sodium-dependent serotonin transporter	Homo sapiens (human)
postsynaptic membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
serotonergic synapse	Sodium-dependent serotonin transporter	Homo sapiens (human)
synapse	Sodium-dependent serotonin transporter	Homo sapiens (human)
plasma membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
neuron projection	Sodium-dependent serotonin transporter	Homo sapiens (human)
mitochondrion	Amine oxidase [flavin-containing] B	Bos taurus (cattle)
mitochondrial outer membrane	Amine oxidase [flavin-containing] B	Bos taurus (cattle)
plasma membrane	Trace amine-associated receptor 1	Homo sapiens (human)
nuclear envelope	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
nuclear inner membrane	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
nuclear outer membrane	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
endoplasmic reticulum	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
endoplasmic reticulum membrane	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
lipid droplet	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
cytosol	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
postsynaptic density	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
membrane	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
growth cone	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
cytoplasmic vesicle	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
anchoring junction	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
postsynaptic density membrane	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
endoplasmic reticulum	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID1066366	Activation of mouse TAAR1 transmembrane domain 7 Tyr287(7.39)Asn mutant expressed in HEK293 cells assessed as stimulation of cAMP production after 1 hr by chemiluminescent assay	2014	Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2	Exploring the determinants of trace amine-associated receptor 1's functional selectivity for the stereoisomers of amphetamine and methamphetamine.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID678722	Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588212	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1066364	Activation of mouse wild type TAAR1 expressed in HEK293 cells assessed as stimulation of cAMP production at at 0.0001 to 100 uM after 1 hr by chemiluminescent assay relative to beta-phenylethylamine	2014	Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2	Exploring the determinants of trace amine-associated receptor 1's functional selectivity for the stereoisomers of amphetamine and methamphetamine.
AID1066368	Activation of mouse TAAR1 transmembrane domain 6 Thr268(6.55)Met mutant expressed in HEK293 cells assessed as stimulation of cAMP production after 1 hr by chemiluminescent assay	2014	Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2	Exploring the determinants of trace amine-associated receptor 1's functional selectivity for the stereoisomers of amphetamine and methamphetamine.
AID1066372	Activation of mouse TAAR1 Asp102(3.32)Ala mutant expressed in HEK293 cells assessed as stimulation of cAMP production at 0.0001 to 100 uM after 1 hr by chemiluminescent assay	2014	Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2	Exploring the determinants of trace amine-associated receptor 1's functional selectivity for the stereoisomers of amphetamine and methamphetamine.
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID203990	Binding affinity towards sigma opioid receptor in guinea pig cerebral homogenate using [3H]DTG as radioligand	1991	Journal of medicinal chemistry, Mar, Volume: 34, Issue:3	Identification and exploitation of the sigma-opiate pharmacophore.
AID635292	Activation of mouse TAAR1 expressed in human HEK293 cells assessed as accumulation of [3H]cAMP after 1 hr by liquid scintillation counting	2011	Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23	Trace amine-associated receptor 1 is a stereoselective binding site for compounds in the amphetamine class.
AID781325	pKa (acid-base dissociation constant) as determined by Liao ref: J Chem Info Model 2009	2014	Pharmaceutical research, Apr, Volume: 31, Issue:4	Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID635294	Activation of chimeric rat-human expressed in human HEK293 cells assessed as accumulation of [3H]cAMP after 1 hr by liquid scintillation counting	2011	Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23	Trace amine-associated receptor 1 is a stereoselective binding site for compounds in the amphetamine class.
AID1066359	Selectivity ratio of EC50 for mouse wild type TAAR1 to EC50 for mouse TAAR1 transmembrane domain 6 Thr268(6.55)Met mutant	2014	Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2	Exploring the determinants of trace amine-associated receptor 1's functional selectivity for the stereoisomers of amphetamine and methamphetamine.
AID678714	Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1066361	Activation of rat TAAR1 transmembrane domain 7 Asn287(7.39)Tyr mutant expressed in HEK293 cells assessed as stimulation of cAMP production at at 0.0001 to 100 uM after 1 hr by chemiluminescent assay relative to beta-phenylethylamine	2014	Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2	Exploring the determinants of trace amine-associated receptor 1's functional selectivity for the stereoisomers of amphetamine and methamphetamine.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID682266	TP_TRANSPORTER: inhibition of TEA uptake (TEA: 20 uM, Methamphetamine: 5000 uM) in OCTN2-expressing HeLa cells	1998	Biochemical and biophysical research communications, May-29, Volume: 246, Issue:3	cDNA sequence, transport function, and genomic organization of human OCTN2, a new member of the organic cation transporter family.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1442374	Induction of stimulus generalization in rat trained to discriminate S(+)methamphetamine assessed as appropriate responding level to training drug by two lever method	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	The 2014 Philip S. Portoghese Medicinal Chemistry Lectureship: The "Phenylalkylaminome" with a Focus on Selected Drugs of Abuse.
AID1066374	Selectivity ratio of EC50 for rat TAAR1 transmembrane domain 6 Met268(6.55)Thr mutant to EC50 for rat wild type TAAR1	2014	Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2	Exploring the determinants of trace amine-associated receptor 1's functional selectivity for the stereoisomers of amphetamine and methamphetamine.
AID1233247	Inhibition of VMAT2-mediated [3H]DA uptake in rat brain synaptic vesicles by liquid scintillation spectrometry	2015	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 25, Issue:13	Quinolyl analogues of norlobelane: novel potent inhibitors of [(3)H]dihydrotetrabenazine binding and [(3)H]dopamine uptake at the vesicular monoamine transporter-2.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID678721	Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1066363	Activation of rat TAAR1 transmembrane domain 6 Met268(6.55)Thr mutant expressed in HEK293 cells assessed as stimulation of cAMP production at at 0.0001 to 100 uM after 1 hr by chemiluminescent assay relative to beta-phenylethylamine	2014	Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2	Exploring the determinants of trace amine-associated receptor 1's functional selectivity for the stereoisomers of amphetamine and methamphetamine.
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1066370	Activation of mouse wild type TAAR1 expressed in HEK293 cells assessed as stimulation of cAMP production after 1 hr by chemiluminescent assay	2014	Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2	Exploring the determinants of trace amine-associated receptor 1's functional selectivity for the stereoisomers of amphetamine and methamphetamine.
AID1066371	Activation of rat wild type TAAR1 expressed in HEK293 cells assessed as stimulation of cAMP production after 1 hr by chemiluminescent assay	2014	Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2	Exploring the determinants of trace amine-associated receptor 1's functional selectivity for the stereoisomers of amphetamine and methamphetamine.
AID635293	Activation of mouse TAAR1 expressed in human HEK293 cells assessed as accumulation of cAMP after 15 mins	2011	Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23	Trace amine-associated receptor 1 is a stereoselective binding site for compounds in the amphetamine class.
AID1066367	Activation of rat TAAR1 transmembrane domain 7 Asn287(7.39)Tyr mutant expressed in HEK293 cells assessed as stimulation of cAMP production after 1 hr by chemiluminescent assay	2014	Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2	Exploring the determinants of trace amine-associated receptor 1's functional selectivity for the stereoisomers of amphetamine and methamphetamine.
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID681698	TP_TRANSPORTER: inhibition of TEA uptake (TEA: 20 uM, Methanphetamine: 2500 uM) in OCTN2-expressing HRPE cells	1999	The Journal of pharmacology and experimental therapeutics, Sep, Volume: 290, Issue:3	Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter.
AID237685	Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system	2005	Journal of medicinal chemistry, May-05, Volume: 48, Issue:9	Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
AID635287	Activation of rhesus monkey TAAR1 expressed in RD-HGA16 cells co-expressing Gq protein assessed as cAMP accumulation by fluorescence plate reader	2011	Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23	Trace amine-associated receptor 1 is a stereoselective binding site for compounds in the amphetamine class.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1323834	Displacement of [3H]rosiglitazone from recombinant human C-terminal His-tagged MitoNEET cytosolic domain (32 to 108 residues) expressed in Escherichia coli BL21 by scintillation proximity assay	2016	Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21	Identification of small molecules that bind to the mitochondrial protein mitoNEET.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID635289	Activation of rat TAAR1 expressed in HEK293 cells assessed as accumulation of [3H]cAMP after 1 hr by liquid scintillation counting	2011	Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23	Trace amine-associated receptor 1 is a stereoselective binding site for compounds in the amphetamine class.
AID635286	Activation of C-terminal HA epitope tagged human TAAR1 expressed in RD-HGA16 cells co-expressing Gq protein, Galpha16 by cAMP accumulation assay	2011	Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23	Trace amine-associated receptor 1 is a stereoselective binding site for compounds in the amphetamine class.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID125205	Inhibitory activity against Monoamine Oxidase B of Bovine liver in competitive inhibition assay at 25 degree C (pH=7.4)	1988	Journal of medicinal chemistry, Aug, Volume: 31, Issue:8	Stereoisomers of allenic amines as inactivators of monoamine oxidase type B. Stereochemical probes of the active site.
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID678717	Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID678716	Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID125210	Competitive inhibition of Rat liver Monoamine Oxidase B at 37 degree C (pH= 7.4)	1988	Journal of medicinal chemistry, Aug, Volume: 31, Issue:8	Stereoisomers of allenic amines as inactivators of monoamine oxidase type B. Stereochemical probes of the active site.
AID1066365	Activation of rat wild type TAAR1 expressed in HEK293 cells assessed as stimulation of cAMP production at at 0.0001 to 100 uM after 1 hr by chemiluminescent assay relative to beta-phenylethylamine	2014	Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2	Exploring the determinants of trace amine-associated receptor 1's functional selectivity for the stereoisomers of amphetamine and methamphetamine.
AID1066360	Activation of mouse TAAR1 transmembrane domain 7 Tyr287(7.39)Asn mutant expressed in HEK293 cells assessed as stimulation of cAMP production at at 0.0001 to 100 uM after 1 hr by chemiluminescent assay relative to beta-phenylethylamine	2014	Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2	Exploring the determinants of trace amine-associated receptor 1's functional selectivity for the stereoisomers of amphetamine and methamphetamine.
AID678712	Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1233246	Displacement of [3H]DTBZ from VMAT2 in rat whole brain by liquid scintillation spectrometry	2015	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 25, Issue:13	Quinolyl analogues of norlobelane: novel potent inhibitors of [(3)H]dihydrotetrabenazine binding and [(3)H]dopamine uptake at the vesicular monoamine transporter-2.
AID186425	Effect on the spontaneous locomotor activity of rats at 0-60 min upon ip administration of the compounds at a dose of 100 mg/kg.	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Synthesis, antibacterial activities, and pharmacological properties of enantiomers of temafloxacin hydrochloride.
AID678713	Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1233249	Ratio of Ki for displacement of [3H]DTBZ from VMAT2 in rat whole brain to Ki for inhibition of VMAT2-mediated [3H]DA uptake in rat brain synaptic vesicles	2015	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 25, Issue:13	Quinolyl analogues of norlobelane: novel potent inhibitors of [(3)H]dihydrotetrabenazine binding and [(3)H]dopamine uptake at the vesicular monoamine transporter-2.
AID682029	TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 1 uM) in OCT3-expressing HRPE cells	1998	The Journal of biological chemistry, Dec-04, Volume: 273, Issue:49	Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain.
AID1066369	Activation of rat TAAR1 transmembrane domain 6 Met268(6.55)Thr mutant expressed in HEK293 cells assessed as stimulation of cAMP production after 1 hr by chemiluminescent assay	2014	Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2	Exploring the determinants of trace amine-associated receptor 1's functional selectivity for the stereoisomers of amphetamine and methamphetamine.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1323835	Displacement of [3H]rosiglitazone from recombinant human C-terminal His-tagged MitoNEET cytosolic domain (32 to 108 residues) expressed in Escherichia coli BL21 by Cheng-Prusoff analysis	2016	Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21	Identification of small molecules that bind to the mitochondrial protein mitoNEET.
AID1066362	Activation of mouse TAAR1 transmembrane domain 6 Thr268(6.55)Met mutant expressed in HEK293 cells assessed as stimulation of cAMP production at at 0.0001 to 100 uM after 1 hr by chemiluminescent assay relative to beta-phenylethylamine	2014	Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2	Exploring the determinants of trace amine-associated receptor 1's functional selectivity for the stereoisomers of amphetamine and methamphetamine.
AID186415	Effect on the spontaneous locomotor activity of rats at 0-15 min upon ip administration of the compounds at a dose of 1 mg/kg	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Synthesis, antibacterial activities, and pharmacological properties of enantiomers of temafloxacin hydrochloride.
AID1442398	Induction of stimulus generalization in Sprague-Dawley rat trained to discriminate S(+)AMPH assessed as appropriate responding level to training drug by two lever method	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	The 2014 Philip S. Portoghese Medicinal Chemistry Lectureship: The "Phenylalkylaminome" with a Focus on Selected Drugs of Abuse.
AID1442399	Induction of stimulus generalization in Sprague-Dawley rat trained to discriminate S(-)MCAT assessed as appropriate responding level to training drug by two lever method	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	The 2014 Philip S. Portoghese Medicinal Chemistry Lectureship: The "Phenylalkylaminome" with a Focus on Selected Drugs of Abuse.
AID635296	Activation of human TAAR1 expressed in human HEK293T cells assessed as cAMP accumulation after 10 mins by BRET assay	2011	Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23	Trace amine-associated receptor 1 is a stereoselective binding site for compounds in the amphetamine class.
AID678715	Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID778856	Inhibition of VMAT2-mediated [3H]-dopamine uptake in rat striata isolated synaptic vesicles by liquid scintillation spectroscopy	2013	Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21	Synthesis and evaluation of novel azetidine analogs as potent inhibitors of vesicular [3H]dopamine uptake.
AID1066373	Activation of rat TAAR1 Asp102(3.32)Ala mutant expressed in HEK293 cells assessed as stimulation of cAMP production at 0.0001 to 100 uM after 1 hr by chemiluminescent assay relative to control	2014	Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2	Exploring the determinants of trace amine-associated receptor 1's functional selectivity for the stereoisomers of amphetamine and methamphetamine.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1569 (15.19)	18.7374
1990's	1102 (10.67)	18.2507
2000's	2456 (23.78)	29.6817
2010's	3661 (35.45)	24.3611
2020's	1538 (14.89)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	409 (3.75%)	5.53%
Reviews	765 (7.01%)	6.00%
Case Studies	461 (4.22%)	4.05%
Observational	35 (0.32%)	0.25%
Other	9,244 (84.70%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (134)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
The Early Glasses Study: Can Early Glasses Prevent the Development of Amblyopia in Children With High Refractive Errors at Age One[NCT04740593]		4,000 participants (Anticipated)	Interventional	2021-05-10	Active, not recruiting
Promoting Cognitive Resilience and Reducing Frailty in Older Veterans With Bright Light Therapy[NCT05631236]		35 participants (Anticipated)	Interventional	2024-01-01	Not yet recruiting
The Effect of High-speed Power Training on Muscle Performance, Function and Pain in Older Adults With Knee OA[NCT01328340]		48 participants (Actual)	Interventional	2005-06-30	Completed
WEAR (Wearability and Evaluation of Adjustable Refraction) III: A Randomized Non-inferiority Trial of Children's Wear of Adjustable Glasses[NCT02529540]		324 participants (Actual)	Interventional	2015-09-01	Completed
High Velocity Resistance Training in Older Men and Women[NCT01211496]		52 participants (Actual)	Interventional	2004-06-30	Completed
Randomized Controlled Multicenter Clinical Trial of Multi-Periscopic Prism Glasses for Homonymous Hemianopia[NCT04827147]		65 participants (Anticipated)	Interventional	2022-10-03	Recruiting
Glasses for Adolescent Delayed Sleep-Wake Phase Disorder (GLAD)[NCT04378933]		34 participants (Actual)	Interventional	2019-02-27	Completed
Effects of Audiovisual Distraction Versus Standard Sedation on Desaturation and Airway Intervention in OSA-patients Undergoing Total Knee Arthroplasty Under Neuraxial Anesthesia[NCT03020914]		19 participants (Actual)	Interventional	2017-01-31	Completed
Speed-dependent Treadmill Training is Effective to Improve Gait and Balance Performance in Patients With Sub-acute Stroke[NCT01328301]		30 participants (Actual)	Interventional	2008-12-31	Completed
Regenerative Potential of Advanced Platelet Rich Fibrin (A-PRF) and Bioactive Glass (Perioglas®) Bone Graft in the Treatment of Intrabony Defects; A Comparative Clinico Radiographic Study.[NCT04767243]	Phase 4	48 participants (Actual)	Interventional	2020-12-01	Completed
Acute Effects of Two Different Speed Endurance Protocols on Performance, Muscle Damage Markers and Neuromuscular Fatigue in Soccer Players[NCT03602248]		10 participants (Actual)	Interventional	2018-05-08	Completed
Systematic Light Exposure to Treat Cancer-Related Fatigue in Breast Cancer Patients[NCT03217201]		194 participants (Actual)	Interventional	2018-01-25	Completed
Muti-center Clinical Trial to Evaluate the Safety and Efficacy of Two Types of Circular Column Modulated Lenses for Delaying the Progression of Myopia[NCT05288335]		240 participants (Actual)	Interventional	2022-05-01	Active, not recruiting
Improving Functional Capacity in Heart Failure Patients Supported With Continuous-flow Left Ventricular Assist Devices. -Effects of Increased Pump Speed During Sustained Submaximal Exercise[NCT02335684]		31 participants (Anticipated)	Interventional	2013-11-30	Completed
Drug Effects on EEG[NCT05003076]	Early Phase 1	30 participants (Anticipated)	Interventional	2021-07-01	Recruiting
Identification of Optimum Spectacle Prescriptions for Patients With Down Syndrome[NCT03367793]		30 participants (Actual)	Interventional	2018-01-26	Completed
Blood Glucose Response After Oral Intake of Lactulose (Laevolac®) in Mildly Constipated Patients With Diabetes Mellitus Type 2[NCT03666546]	Phase 4	24 participants (Actual)	Interventional	2018-11-26	Completed
Clinical Performance of Bioactive Restorative Material Versus Glass Hybrid Restorative in Posterior Restorations of High Caries Risk Patients: Randomized Clinical Trial[NCT03608306]		50 participants (Anticipated)	Interventional	2018-10-31	Not yet recruiting
Mapping the Influence of Drugs of Abuse on Risk and Reward Circuits - MDMA[NCT04060108]		40 participants (Anticipated)	Observational	2021-11-02	Recruiting
Impact of Speed Of Rewarming After CaRdiac Arrest and ThErapeutic Hypothermia. A Randomized Controlled Pilot Study[NCT02555254]		50 participants (Actual)	Interventional	2016-02-12	Completed
Clinical Performance of Bioactive Bioceramic Glass Ionomer Restorations vs Conventional High Viscous Glass Ionomer Restorations in Geriatric Patients With Carious Cervical Lesions: A One Year Randomized Clinical Trial.[NCT05624008]		28 participants (Anticipated)	Interventional	2022-06-01	Recruiting
Effect of Stimulant Drugs on Social Perception[NCT03790618]	Phase 1	40 participants (Anticipated)	Interventional	2016-06-01	Recruiting
Influence of Luting Cement on the Clinical Outcomes of Zirconia Pediatric Crowns. A 3 Year Split-Mouth Randomized Controlled Trial[NCT03993431]		25 participants (Actual)	Interventional	2015-07-31	Completed
Assessing the Effects of a Commercial Lemonade Beverage and Potassium Citrate on Urinary Stone Risk Factors[NCT05389995]		10 participants (Anticipated)	Interventional	2022-08-01	Recruiting
Phase 1 Safety-interaction Study of Mirtazapine for the Treatment of Methamphetamine Use Disorder[NCT04614584]	Phase 1	24 participants (Anticipated)	Interventional	2021-07-12	Recruiting
A Randomized Clinical Trial for the Influence of Injection Rate of Intrathecal Mixture of Local Anesthesia on Hypotension in Cesarean Section[NCT03517683]		159 participants (Actual)	Interventional	2018-04-15	Completed
Survival of Abutment Teeth of Removable Partial Dentures Rehabilitated With Post-retained Restorations: Randomized Clinical Trial[NCT03466437]		105 participants (Anticipated)	Interventional	2018-02-28	Recruiting
Treating Cancer-Related Fatigue Through Systematic Light Exposure[NCT03119363]		194 participants (Actual)	Interventional	2015-09-01	Completed
Potentiating Rural Investment in Children's Eyecare (PRICE)[NCT02231606]		10,234 participants (Actual)	Interventional	2014-09-30	Completed
A Novel Drug Combination as a Pharmacotherapeutic for Methamphetamine-Use Disorder[NCT04178993]	Phase 1	8 participants (Actual)	Interventional	2019-09-01	Completed
Gait Speeds and Demands in Chronic Stroke Patients: A Multi-dimensional Investigation[NCT04436536]	Phase 1/Phase 2	60 participants (Anticipated)	Interventional	2020-02-26	Recruiting
Evaluation of Clinical Performance for Recently Introduced Non Coated Glass Ionomer in Occlusal Caries in Posterior Teeth Compared to Conventional Glass Ionomer With Coating: A Randomized Clinical Trial[NCT04463342]	Phase 1	20 participants (Actual)	Interventional	2019-09-03	Active, not recruiting
The Use of Repetitive Transmagnetic Stimulation to Target Craving in Methamphetamine Use Disorder[NCT03470480]		50 participants (Anticipated)	Interventional	2018-02-07	Recruiting
High-Speed Circuit Resistance Training vs. High-Speed Multidirectional Yoga on Changes in Cognition in Healthy Older Adults.[NCT05735353]		40 participants (Actual)	Interventional	2023-01-17	Completed
Minimally Invasive Restorations in Primary Molars Using Encapsulated ou Hand-mixed Glass Ionomer Cement: Clinical Trial With 24 Months of Follow-up[NCT02274142]		145 participants (Actual)	Interventional	2014-10-31	Completed
Mephedrone and Alcohol Interactions After Single-dose Administration in Humans[NCT02294266]	Phase 1	12 participants (Actual)	Interventional	2014-12-31	Completed
Nitrate Supplementation and Exercise Tolerance in Patients With Type 2 Diabetes[NCT02804932]		65 participants (Anticipated)	Interventional	2016-06-30	Recruiting
Objective Adherence With Optical Correction in Children With Bilateral and Unilateral Refractive Amblyopia[NCT03780205]		1 participants (Actual)	Observational	2019-03-20	Terminated(stopped due to Unable to recruit sufficient number of subjects)
Effect of Pulp Protection After Selective Carious Tissue Removal in Permanent Teeth, a Randomized Controlled Clinical Trial[NCT04250142]		142 participants (Actual)	Interventional	2019-03-13	Completed
Randomized Double-blind Study on the Effect of Orthoptic Rehabilitation in Pisa Syndrome Associated With Parkinson's Disease[NCT03737773]		40 participants (Actual)	Interventional	2016-07-31	Completed
Evaluating the Consequences of Mistimed Light-emitting Device Use on Cardiac Activity and Sleep Health[NCT05342662]		34 participants (Actual)	Interventional	2022-11-23	Completed
A Randomized Controlled Trial of Injection Technique for Infant Vaccination[NCT02504398]	Phase 3	120 participants (Anticipated)	Interventional	2015-07-31	Recruiting
Randomized Trial to Assess the Safety and Tolerability of a Novel Amino-acid Based Hydration Drink in Healthy Volunteers[NCT05592951]		40 participants (Actual)	Interventional	2022-09-30	Completed
Clinical Evaluation of Glass Ionomer With Glass Hybrid Technology Versus Conventional High Viscosity Glass Ionomer in Class I Cavities of High Caries Risk Patients: Randomized Controlled Trial[NCT02856932]		31 participants (Anticipated)	Interventional		Not yet recruiting
Drugs Brain and Behavior[NCT04642820]	Early Phase 1	160 participants (Anticipated)	Interventional	2020-11-01	Recruiting
Exercise Tolerance in Patients With Implanted Left Ventricular Assist Device[NCT05063006]		22 participants (Actual)	Interventional	2017-02-15	Completed
Assessment of the Accuracy of the Clinical Parameters and Radiographs in Determining the Topography of Implant Bony Lesions[NCT03698851]		24 participants (Anticipated)	Interventional	2018-03-02	Recruiting
The Effect of Negatively Fluid Balancing Speed for ICU Patients With Acute Respiratory Distress Syndrome[NCT03552601]		70 participants (Anticipated)	Interventional	2018-08-01	Recruiting
Clinical Evaluation of the Effect of Low Speed Drilling Versus Conventional Drilling Technique on Crestal Bone Level in Maxilla. A Randomized Controlled Clinical Trial[NCT03220815]		20 participants (Anticipated)	Interventional	2016-07-31	Active, not recruiting
A Randomized Trial Of The SYNC APP[NCT04827446]		139 participants (Actual)	Interventional	2021-07-15	Completed
Sleep in Psychiatric Care (SIP): A Transdiagnostic Group-based Sleep-school as Treatment for Comorbid Delayed Sleep-Wake Phase Disorder (DSWPD)[NCT05177055]		60 participants (Anticipated)	Interventional	2022-05-23	Recruiting
Sleep in Psychiatric Care: A Transdiagnostic Group-based Sleep-school as Treatment for Comorbid Insomnia[NCT04463498]		60 participants (Anticipated)	Interventional	2021-12-17	Recruiting
Multi-speed Ergonomic Wheelchair[NCT05776030]		30 participants (Anticipated)	Interventional	2024-07-08	Not yet recruiting
Performance of Glass-ionomer Cements in the Pit and Fissure Sealing and Atraumatic Restorative Treatment: a Randomized 2-year Clinical Trial[NCT02659917]	Phase 1	147 participants (Actual)	Interventional	2008-08-31	Completed
Implementation of a Stroke Protocol for Emergency Evaluation and Disposition[NCT06094478]		900 participants (Anticipated)	Interventional	2024-08-02	Not yet recruiting
Development of a Family-Based Treatment for Adolescent Methamphetamine Use[NCT00680511]	Phase 1	60 participants (Actual)	Interventional	2007-09-30	Completed
Acute and Residual Effects of Beer VS. Caffeinated Beer On Simulated Driving[NCT00515294]	Phase 1/Phase 2	154 participants (Actual)	Interventional	2006-10-31	Completed
Community-based Multi-center Randomized Control Trial of Peripheral Prism Glasses for Hemianopia[NCT00494676]		73 participants (Actual)	Interventional	2007-09-30	Completed
Effects of Stimulants on Behavioral and Neural Markers of Social Motivation, Ability, and Neural Markers of Social Function[NCT05379959]	Early Phase 1	36 participants (Anticipated)	Interventional	2022-05-11	Recruiting
Neurobiological Effects of Light on MDD[NCT02940769]		7 participants (Actual)	Interventional	2014-09-04	Terminated(stopped due to Funding no longer available)
Differences in Energy Expenditure of Two Commonly Used Yoga Protocols[NCT02818881]		22 participants (Actual)	Interventional	2015-08-31	Completed
Drug Refractory Partial Epilepsy, A Therapeutic Trial With Transcranial Magnetic Stimulation[NCT00001666]		32 participants	Observational	1997-03-31	Completed
Effect of Rose-colored Glass on Mood: A Randomized Clinical Trial[NCT03992586]		38 participants (Actual)	Interventional	2018-08-30	Completed
Comparison of Robot-assisted Gait Training According to Gait Speed in Participants With Stroke[NCT03991364]		20 participants (Anticipated)	Interventional	2019-07-01	Not yet recruiting
The Effect Of Watchıng Vıdeo Wıth Vırtual Realıty Glasses On Paın, Anxıety And Satısfactıon Durıng Epızıotomy Repaır[NCT05641467]		82 participants (Actual)	Interventional	2022-06-06	Completed
Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse[NCT01967381]	Early Phase 1	24 participants (Actual)	Interventional	2013-10-31	Completed
Effect of Virtual Reality (VR) Therapy on Patients Undergoing Hand Surgery Under Ultrasound-guided Regional Anesthesia: A Randomized Controlled Superiority Trial.[NCT05183412]		120 participants (Actual)	Interventional	2022-01-26	Completed
Balanced Solution Versus Saline in Intensive Care Study[NCT02875873]	Phase 3	11,075 participants (Actual)	Interventional	2017-05-27	Completed
[NCT00829634]		12 participants (Actual)	Interventional	2008-10-31	Completed
Clinical Performance of a Newly Developed Glass Ionomer Restorative Material for Posterior Restorations in an Adolescent Population[NCT02705729]		60 participants (Actual)	Interventional	2016-08-03	Completed
Feasibility and Safety Properties of Metabolic Flow Anesthesia Driven by Automated Gas Control in Pediatric Patients[NCT05644340]		130 participants (Actual)	Interventional	2022-12-16	Completed
Effects of Slow-speed Traditional Resistance Training, High-speed Resistance Training and Multicomponent Training With Variable Resistances on Molecular, Body Composition, Neuromuscular, Physical Function and Quality of Life Variables in Older Adults.[NCT03455179]		192 participants (Actual)	Interventional	2018-03-05	Completed
Randomised Controlled Clinical Trial to Compare Restorative Materials in the Treatment of Root Caries in an Older Irish Population.[NCT01866059]		130 participants (Anticipated)	Interventional	2012-07-31	Active, not recruiting
Immunotherapy Combined With Yttrium-90 RadioEmbolization in the Treatment of Colorectal Cancer With Liver Metastases [iRE-C - Clinical Trial][NCT04108481]	Phase 1/Phase 2	18 participants (Anticipated)	Interventional	2020-10-05	Suspended(stopped due to Working on revisions)
Stroke Inpatient Rehabilitation Reinforcement of Walking Speed[NCT00428480]	Phase 1	216 participants (Actual)	Interventional	2007-05-31	Completed
Clinical Evaluation of Nano Hydroxyapatite Reinforced Glass Ionomer Versus Conventional Glass Ionomer in Treatment of Root Caries in Geriatric Patients: A Randomized Controlled Clinical Trial[NCT04701320]	Phase 1	20 participants (Actual)	Interventional	2019-07-07	Active, not recruiting
Antimicrobial Activity and Clinical Performance of Glass Ionomer Cement Modified With Chlorhexidine and Titanium Dioxide in Primary Molars: A Randomized Clinical Trial[NCT05645029]	Phase 2/Phase 3	39 participants (Anticipated)	Interventional	2022-09-01	Recruiting
Esthetic Patient Satisfaction and Peri-Implant Tissue Success of Crystal Ultra Hybrid Ceramic Compared to E-Max Superstructures in Esthetic Zone[NCT02941575]		22 participants (Anticipated)	Interventional	2016-12-31	Not yet recruiting
Effects of Preoperative Fluid Therapy on Microcirculatory Reactivity in Patients With MIDCAB After General Anesthesia[NCT04982016]		126 participants (Anticipated)	Interventional	2021-09-30	Not yet recruiting
Clinical Evaluation of the Effect of Low Speed Drilling Versus Conventional Drilling Technique on Crestal Bone Level in Maxilla. A Randomized Controlled Clinical Trial[NCT03212820]		20 participants (Anticipated)	Interventional	2016-07-31	Active, not recruiting
Randomized Controlled Clinical Trial of Low Dose Corticosteroids vs Anti TNF Treatment in Methotrexate Inadequate Responder Rheumatoid Arthritis Patient- a Pilot Study[NCT01724268]	Phase 3	80 participants (Anticipated)	Interventional	2012-05-31	Recruiting
Nightly Light Exposure in Pregnancy: Blue-blocking Glasses as an Intervention to Ease Sleep Disturbances and to Improve Mood[NCT03114072]		60 participants (Anticipated)	Interventional	2017-06-06	Active, not recruiting
A Randomized Clinical Trial of the Effectiveness of Base-in Prism Reading Glasses Vs. Placebo Reading Glasses for Symptomatic Convergence Insufficiency in Children[NCT00347581]	Phase 3	72 participants	Interventional	2003-05-31	Completed
Injection Speed of Spinal Anaesthesia for Asian Women Undergoing Lower Segmental Caesarean Section and the Incidence of Hypotension and/or Use of Vasopressors[NCT02275897]		77 participants (Actual)	Interventional	2013-03-31	Completed
the Antibacterial Effect of Different Glass Ionomer Restoration Containing Zinc ,Silver and Fluoride Ion:in Situ Study[NCT04329858]		50 participants (Anticipated)	Interventional	2021-07-15	Not yet recruiting
A Clinical Assessment of Class II Glass Carbomer Cement Restorations Compared to Resin Modified Glass Ionomer Cement and Composite Resin Restorations in Primary Molars.[NCT03030690]		50 participants (Actual)	Interventional	2016-11-30	Completed
Demonstration of a Digital Care Program for Methamphetamine Use Disorder[NCT05206175]		100 participants (Actual)	Interventional	2022-02-14	Completed
Addressing Intersectional Stigma Through Coping, Resistance, and Resilience to Improve Methamphetamine Use and Factors Influencing PrEP Uptake Among Latino MSM: a Step Towards Ending HIV by 2030[NCT05784467]		20 participants (Anticipated)	Interventional	2024-06-01	Not yet recruiting
[NCT01520766]	Phase 4	91 participants (Actual)	Interventional	2003-01-31	Completed
An Open-Label Study to Evaluate the Impact of Genetic Variation in CYP2D6 on the Pharmacokinetics and Pharmacodynamics of Methamphetamine in Healthy Adults[NCT01529892]	Phase 4	0 participants (Actual)	Interventional		Withdrawn
Evaluation of Virtual Reality Glasses Use During Inhaler Treatment in Children[NCT05839054]		135 participants (Actual)	Interventional	2022-11-10	Completed
Blood Glucose Response After Oral Intake of Lactulose in Healthy Volunteers[NCT02968498]		24 participants (Actual)	Interventional	2016-11-30	Completed
Behavioral Therapy Development for Methamphetamine Abuse[NCT00252434]	Phase 1	0 participants	Interventional	2004-08-31	Terminated(stopped due to Slow enrollment)
Effects of Genotype on Resting State Connectivity During Methamphetamine Administration[NCT03973489]	Phase 4	69 participants (Actual)	Interventional	2019-08-16	Completed
Evaluation of Silver Diamine Fluoride Application in Molar-Incisor Hypomineralisation-Affected Molars[NCT06165042]		120 participants (Anticipated)	Interventional	2023-12-31	Not yet recruiting
Esthetic Evaluation of Onlay Restorations Constructed From Two Types of Glass Ceramics:A Randomized Clinical Trial.[NCT05437432]		50 participants (Actual)	Interventional	2022-03-01	Active, not recruiting
Effect of Blue Light Filtration on Visual Performance[NCT01938989]		158 participants (Actual)	Interventional	2013-09-30	Completed
Comparative Evaluation of Cleaning Agents on Color and Roughness of Invisalign Clear Aligners: A Cross-Over Randomized Trial[NCT05213650]		20 participants (Actual)	Interventional	2021-10-18	Completed
Short-term Effects of Methamphetamine Exposure on Residual Viral Transcription During Treated HIV Disease[NCT03825536]	Phase 4	10 participants (Actual)	Interventional	2021-01-01	Completed
MDMA-Assisted Cognitive Behavioral Therapy (CBT) Compared With Methamphetamine-Assisted CBT in Obsessive-Compulsive Disorder (OCD): A Phase II Study[NCT05783817]	Phase 2	40 participants (Anticipated)	Interventional	2023-12-01	Not yet recruiting
Clinical Results of Chronic Cavitary Long-bone Osteomyelitis Treatment Using S53P4 Bioactive Glass; a Multi-center Study[NCT04945434]		78 participants (Actual)	Interventional	2011-09-01	Active, not recruiting
Light Therapy to Treat Cancer-related Fatigue, Sleep Problems, Depression and Cognitive Impairment Among Breast Cancer Patients.[NCT04418856]		240 participants (Anticipated)	Interventional	2020-06-08	Recruiting
To Understand the Effect of Speed Dependent Treadmill Training on Dual Task Performance in Patient With Parkinson's Disease.[NCT05903755]		22 participants (Anticipated)	Interventional	2023-01-02	Recruiting
Functional Benefit With ACRYSOF® Natural Chromophore[NCT02219997]		90 participants (Actual)	Interventional	2014-10-31	Completed
Effects of Parenteral Nutrition in Hematopoietic Stem Cell Transplantation: a Randomized Controlled Trial[NCT04425642]		120 participants (Actual)	Interventional	2020-02-01	Completed
Exploring Immunologic Effects of Oral Insulin in Relatives at Risk for Type 1[NCT02580877]	Phase 2	92 participants (Actual)	Interventional	2016-01-31	Completed
Error Based Learning for Restoring Gait Symmetry Post-Stroke[NCT01598675]		48 participants (Actual)	Interventional	2012-01-31	Completed
Field Study of a Digital Therapeutic Platform to Facilitate Treatment for Methamphetamine-Primary Stimulant Use Disorder[NCT05266716]		79 participants (Actual)	Interventional	2021-02-18	Completed
Acquisition of Responses to a Methamphetamine-associated Cue in Healthy Humans: Self-report, Behavioral, and Psychophysiological Measures.[NCT02323048]		90 participants (Actual)	Interventional	2014-07-31	Completed
Buspirone as a Candidate Medication for Methamphetamine Abuse[NCT01843205]	Phase 1	9 participants (Actual)	Interventional	2013-04-30	Completed
A Randomized Control Trial of the Effectiveness of Blue-blocking Glasses for Mania in Inpatients With Bipolar Disorder[NCT05206747]		51 participants (Anticipated)	Interventional	2022-09-07	Recruiting
Contingency Management for PrEP Adherence and/or Methamphetamine UseDisorder Among MSM and TW in Los Angeles: A Pilot Feasibility Study[NCT04563962]		20 participants (Actual)	Interventional	2021-03-15	Completed
Pilot Study of the Dose Response of Entacapone on Methamphetamine Induced Interest, Mood Elevation, and Reward[NCT02058966]	Early Phase 1	29 participants (Actual)	Interventional	2014-06-30	Completed
Comparison of AmblyzTM Glasses and Patching for Amblyopia[NCT01973348]		45 participants (Actual)	Interventional	2013-11-30	Terminated(stopped due to funding and personnel are lack.)
Assessment of Light Therapy in Insomnia Disorder[NCT05715411]		66 participants (Anticipated)	Interventional	2023-09-01	Not yet recruiting
The Effect of Virtual Reality on Preoperative Anxiety Before Abdominal Surgery[NCT05718661]		96 participants (Anticipated)	Interventional	2022-12-01	Active, not recruiting
Using Pharmacogenetics to Better Evaluate Naltrexone for Treating Stimulant Abuse[NCT03226223]	Phase 2	18 participants (Actual)	Interventional	2016-09-15	Completed
Clinical Evaluation of the Effect of Low Speed Drilling Versus Conventional Drilling Technique on Crestal Bone Level in Maxilla. A Randomized Controlled Clinical Trial[NCT03220789]		20 participants (Anticipated)	Interventional	2016-07-31	Active, not recruiting
A Randomised, Controlled Trial of MDMA-assisted Prolonged Exposure Therapy for Comorbid Alcohol Use Disorder and Post-traumatic Stress Disorder[NCT05709353]	Phase 2	120 participants (Anticipated)	Interventional	2023-09-19	Recruiting
Dietary Nitrate Supplementation and Physiological Function in Older Adults[NCT02593305]		23 participants (Actual)	Interventional	2015-10-31	Completed
Phase 1 Safety-interaction Study of Pomaglumetad Methionil for Methamphetamine Use Disorder[NCT03106571]	Phase 1	19 participants (Actual)	Interventional	2017-08-01	Terminated(stopped due to Deemed unable to enroll targeted participants in part due to COVID-19 shut downs)
Evaluation of the Effectiveness of Dentin Hypersensitivity Treatment Using Glass Ionomer Cements: A Randomized Clinical Trial[NCT02378129]	Phase 2/Phase 3	20 participants (Actual)	Interventional	2014-04-02	Completed
Cost-efficacy and Applicability of the Treatment of Moderate Caries Using Sealants as an Alternative to the Restorations on Occlusal Surfaces of Deciduous Teeth: a Randomized Controlled Trial[NCT03005405]		96 participants (Anticipated)	Interventional	2015-02-28	Active, not recruiting
The Effect of Bifocals in Children With Down Syndrome[NCT02241356]		120 participants (Actual)	Interventional	2014-03-31	Completed
Treating Cognitive Deficits in Traumatic Spinal Cord Injury (SCI): A Randomized Clinical Trial[NCT03985540]		104 participants (Anticipated)	Interventional	2016-11-16	Completed
The Effect of Robot-assisted Gait Training on Gait Ability in Children With Cerebral Palsy[NCT04909151]		39 participants (Anticipated)	Interventional	2021-06-18	Recruiting
Effect of Cervical Margin Relocation With Different Restorative Materials on Three-year Clinical Performance and In-Vitro Fracture Resistance of Indirect Hybrid Ceramic Onlay Restorations[NCT06155773]		64 participants (Actual)	Interventional	2021-08-24	Active, not recruiting
Evaluation of the Efficacy and Tolerance of Crystal Peel (a Salicylic Acid Based Peel) in the Treatment of Acne[NCT05821296]		33 participants (Actual)	Interventional	2023-01-23	Completed
The Effect of Exercise Conducted With Virtual Reality Glasses on Pain, Daily Life Activities and Quality of Life In Individuals With Lumbar Disc Herniation[NCT05463588]		68 participants (Actual)	Interventional	2021-08-20	Completed
Comparative Evaluation of Porous and Non Porous Variants of Bioactive Glass in the Treatment of Periodontal Intrabony Defects: A Cone Beam Computed Tomography Analysis[NCT02463006]	Phase 2/Phase 3	10 participants (Actual)	Interventional	2014-01-31	Completed
A Comparison of the Outcomes of Two Existing Routine Clinical Therapies for Dental Prophylaxis[NCT03471325]		89 participants (Actual)	Interventional	2016-12-08	Completed
A Clinical Evaluation of a Glass Ionomer Cement (GIC) Based Restorative System[NCT02479711]		35 participants (Actual)	Interventional	2014-01-31	Active, not recruiting
Single Center Study Evaluating the Possible Effect of Virtual Reality Spectacles on Pain Following Total Knee Replacement Surgery[NCT03311971]	Phase 4	50 participants (Anticipated)	Interventional	2017-11-30	Active, not recruiting
Intermittent Exotropia Study 6: A Pilot Randomized Clinical Trial of Base-in Prism Spectacles for Intermittent Exotropia[NCT03998670]		61 participants (Actual)	Interventional	2019-09-01	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Dim Light Melatonin Onset (DLMO) Phase Shift

The time in hours the circadian clock shifted the sleep onset time. Using a light lux meter, the lighting in the room will be limited to no more than 5 lux of light. Measured by self-reported logs and a wrist actigraphy that detects when subjects are active or sleeping. (NCT04378933)
Timeframe: baseline, week 2

Intervention	hours (Mean)
Amber Glasses and Fixed Wake	1.0
Clear Glasses and Free Wake	0.4

Change in Non-school Night Sleep Onset Time

The time in hours that sleep onset time shifted earlier during non-school nights. Measured by self-reporting logs and a wrist actigraphy that detects when subjects are active or sleeping. (NCT04378933)
Timeframe: baseline, week 3

Intervention	hours (Mean)
Amber Glasses and Fixed Wake	1.1
Clear Glasses and Free Wake	0.03

Change in School Night Sleep Onset Time

The time in hours that sleep onset time shifted earlier during school nights. Measured by self-reporting logs and a wrist actigraphy that detects when subjects are active or sleeping. (NCT04378933)
Timeframe: baseline, week 3

Intervention	hours (Mean)
Amber Glasses and Fixed Wake	0.4
Clear Glasses and Free Wake	0.6

Change in Dim Light Melatonin Onset (DLMO)

"The time of day the subject feels sleepy during the overnight lab stays. It is a marker of biological time. Data are provided in decimal and military time (e.g., 10:00 pm equals 22.00).~Using a light lux meter, the lighting in the room was limited to no more than 5 lux of light. Measured by self-reported logs and a wrist actigraphy that detects when subjects are active or sleeping." (NCT04378933)
Timeframe: baseline, week 3

Intervention	decimal military time (Mean)
	baseline	week 3
Amber Glasses and Fixed Wake	21.51	21.11
Clear Glasses and Free Wake	22.36	23.05

Additional Sedation

Patient request for additional sedation (NCT03020914)
Timeframe: intraoperative

Intervention	Participants (Count of Participants)
Audiovisual Distraction	2
Standard of Care Sedation	1

Airway Interventions

each airway intervention (defined as one of the following: jaw thrust, oropharyngeal airway, nasopharyngeal airway, mask ventilation, larynx mask or intubation) that is implemented during this time frame will be observed and documented by research staff, if it occurs. (NCT03020914)
Timeframe: start of anesthesia until 30 minutes after recovery room admission (ca. 3 hours)

Intervention	airway interventions (Number)
Audiovisual Distraction	2
Standard of Care Sedation	7

Alertness Levels

Alertness levels measured using the Modified Observer's Assessment of Alertness/Sedation Scale (MOAA/S), which rates alertness on a scale of 0-5, with higher ratings representing increased alertness (e.g. '5 - Responds readily to name spoken in normal tone'). Results reflect a median score of ratings collected at 4 time points. (NCT03020914)
Timeframe: 4 times: preoperative, intraoperative, at time of recovery room admission, 10 minutes before recovery room discharge

Intervention	score on a scale (Median)
Audiovisual Distraction	0
Standard of Care Sedation	0

Desaturations

number of desaturation events (SpO2< 90% for ≥ 10 sec) measured during this time frame (NCT03020914)
Timeframe: start of anesthesia until 30 minutes after recovery room admission (ca. 3 hours)

Intervention	number of desaturation events (Median)
Audiovisual Distraction	0
Standard of Care Sedation	1

Patient Satisfaction

Patient satisfaction at recovery room discharge as measured by the Heidelberg perianesthetic questionnaire, which assesses patients' peri-anaesthetic satisfaction on a four-point Likert scale ranging from 0 (unimportant to me) to 3 (very important to me). Scores for each question are summed for a final score, with higher total score signifying higher satisfaction and lower total score signifying lower satisfaction. The score scale has a minimum value of 0 and a maximum value of 114 (based off 3 as the highest response score for 38 individual questions). (NCT03020914)
Timeframe: 10 minutes before recovery room discharge

Intervention	score on a scale (Mean)
Audiovisual Distraction	55
Standard of Care Sedation	54

Adapted Visual Acuity

Aided LogMAR distance visual acuity obtained with either the British Standard Letters or HOTV - matching for subjects unable to name letters. (NCT03367793)
Timeframe: two months

,,,,,

Intervention	logMAR (Mean)
	Period 2 Treatment 1 Dispense to 2 Months Wear	Period 3 Treatment 2 Dispense to 2 Months Wear	Period 4 Treatment 3 Dispense to 2 Months Wear
Clinical, Then Metric #1, Then Metric #2	0.256	0.272	0.288
Clinical, Then Metric #2, Then Metric #1	0.440	0.412	0.424
Metric #1, Then Clinical, Then Metric #2	0.356	0.370	0.320
Metric #1, Then Metric #2, Then Clinical	0.300	0.256	0.216
Metric #2, Then Clinical, Then Metric #1	0.284	0.316	0.276
Metric #2, Then Metric #1, Then Clinical	0.364	0.316	0.372

Initial Visual Acuity

Aided LogMAR distance visual acuity obtained with either the British Standard Letters or HOTV - matching for subjects unable to name letters. (NCT03367793)
Timeframe: 1 day

,,,,,

Intervention	logMAR (Mean)
	Treatment 1 Initial Dispense	Treatment 2 Initial Dispense	Treatment 3 Initial Dispense
Clinical, Then Metric #1, Then Metric #2	0.28	0.25	0.31
Clinical, Then Metric #2, Then Metric #1	0.43	0.43	0.44
Metric #1, Then Clinical, Then Metric #2	0.34	0.36	0.40
Metric #1, Then Metric #2, Then Clinical	0.29	0.30	0.28
Metric #2, Then Clinical, Then Metric #1	0.28	0.30	0.32
Metric #2, Then Metric #1, Then Clinical	0.33	0.34	0.40

Spectacle Assessment Survey Question 1

Participants were asked to select a face from a survey with five expressions (large frown, small frown, neutral, small smile, large smile) depicting their response to the question 'Do you like wearing this pair of glasses?' Responses were coded 1 through 5 with 5 = large smile. (NCT03367793)
Timeframe: two months

,,,,,

Intervention	score on a scale (Median)
	Period 2 Treatment 1 Dispense to 2 Months Wear	Period 3 Treatment 2 Dispense to 2 Months Wear	Period 4 Treatment 3 Dispense to 2 Months Wear
Clinical, Then Metric #1, Then Metric #2	5	5	5
Clinical, Then Metric #2, Then Metric #1	5	5	5
Metric #1, Then Clinical, Then Metric #2	5	5	5
Metric #1, Then Metric #2, Then Clinical	5	5	5
Metric #2, Then Clinical, Then Metric #1	5	5	5
Metric #2, Then Metric #1, Then Clinical	5	4	4

Spectacle Assessment Survey Question 2

Participants were asked to select a face from a survey with five expressions (large frown, small frown, neutral, small smile, large smile) depicting their response to the question 'How well do you see with this pair of glasses when looking far away?' Responses were coded 1 through 5 with 5 = large smile. (NCT03367793)
Timeframe: two months

,,,,,

Intervention	score on a scale (Median)
	Period 2 Treatment 1 Dispense to 2 Months Wear	Period 3 Treatment 2 Dispense to 2 Months Wear	Period 4 Treatment 3 Dispense to 2 Months Wear
Clinical, Then Metric #1, Then Metric #2	5	5	5
Clinical, Then Metric #2, Then Metric #1	5	5	5
Metric #1, Then Clinical, Then Metric #2	5	4.5	5
Metric #1, Then Metric #2, Then Clinical	5	5	5
Metric #2, Then Clinical, Then Metric #1	5	5	5
Metric #2, Then Metric #1, Then Clinical	5	4	5

Spectacle Assessment Survey Question 3

Participants were asked to select a face from a survey with five expressions (large frown, small frown, neutral, small smile, large smile) depicting their response to the question 'How well do you see with this pair of glasses when looking up close?' Responses were coded 1 through 5 with 5 = large smile. (NCT03367793)
Timeframe: two months

,,,,,

Intervention	score on a scale (Median)
	Period 2 Treatment 1 Dispense to 2 Months Wear	Period 3 Treatment 2 Dispense to 2 Months Wear	Period 4 Treatment 3 Dispense to 2 Months Wear
Clinical, Then Metric #1, Then Metric #2	5	5	5
Clinical, Then Metric #2, Then Metric #1	5	5	5
Metric #1, Then Clinical, Then Metric #2	5	5	5
Metric #1, Then Metric #2, Then Clinical	5	5	5
Metric #2, Then Clinical, Then Metric #1	5	5	5
Metric #2, Then Metric #1, Then Clinical	5	5	5

Spectacle Wear Time

Total wear time of each pair of spectacles as measured objectively by a temperature sensor data logger mounted to the spectacle temple. (NCT03367793)
Timeframe: two months

,,,,,

Intervention	Hours (Mean)
	Period 2 Treatment 1 Dispense to 2 Months Wear	Period 3 Treatment 2 Dispense to 2 Months Wear	Period 4 Treatment 3 Dispense to 2 Months Wear
Clinical, Then Metric #1, Then Metric #2	11.93	9.50	11.61
Clinical, Then Metric #2, Then Metric #1	13.15	12.68	13.32
Metric #1, Then Clinical, Then Metric #2	10.48	12.31	11.95
Metric #1, Then Metric #2, Then Clinical	8.40	9.26	9.54
Metric #2, Then Clinical, Then Metric #1	9.81	9.67	9.47
Metric #2, Then Metric #1, Then Clinical	11.62	11.25	11.31

Attentional Bias

"Subjects will complete an attentional bias task. The number of inhibitory failures (i.e., commission errors) to no-go targets following methamphetamine-related stimuli will be used to evaluate attentional bias (range 0 - 1: greater values represent greater number of errors committed). Commission errors are when you response (i.e., press the corresponding key on a computer) when you were instructed not to respond." (NCT04178993)
Timeframe: 12 sessions over approximately 4.5 weeks

Intervention	Proportion of Responses (Mean)
	Methylphenidate (0mg)	Methylphenidate (20mg)	Methylphenidate (40mg)	Methylphenidate (60mg)
Active Comparator: Duloxetine (60 mg)	0.08	0.13	0.11	0.12
Placebo Comparator: Placebo	0.07	0.04	0.08	0.12

Delay Discounting for Methamphetamine

"Subjects will complete a delay discounting task in 4 sessions following 4 days of medication maintenance. Subjects are presented a series of hypothetical choices between a smaller amount of methamphetamine offered now or a larger amount of methamphetamine offered a later times in the future (e.g., 4 hours, a day, 3 weeks). The discounting rate, 'k', is calculated and log10-transformed. Greater values of log-transformed 'k' correspond with greater rates of discounting (i.e., preference for smaller reinforcer provided now rather than larger, delayed reinforcers [e.g., smaller amount of methamphetamine given now as opposed to a larger amount given later]). The units for discounting rates are theoretical and not linked to a physical dimension (e.g., number of button presses) and the range is theoretically not bound (i.e., negative infinity to positive infinity)." (NCT04178993)
Timeframe: 4 sessions over approximately 4.5 weeks

Intervention	log(k) (Mean)
	Methylphenidate (0mg)	Methylphenidate (20mg)	Methylphenidate (40mg)	Methylphenidate (60mg)
Active Comparator: Duloxetine (60 mg)	-1.31	-1.27	-1.15	-1.04
Placebo Comparator: Placebo	-1.40	-1.04	-1.45	-1.17

Delay Discounting for Money

"Subjects will complete a delay discounting task in 4 sessions following 4 days of medication maintenance. Subjects are presented a series of hypothetical choices between a smaller sum of money offered now or a larger sum of money offered a later times in the future (e.g., 4 hours, a day, 3 weeks). The discounting rate, 'k', is calculated and log10-transformed. Greater values of log-transformed 'k' correspond with greater rates of discounting (i.e., preference for smaller reinforcer provided now rather than larger, delayed reinforcers [e.g., smaller sum of money given now as opposed to a larger sum given later]). The units for discounting rates are theoretical and not linked to a physical dimension (e.g., number of button presses) and the range is theoretically not bound (i.e., negative infinity to positive infinity)." (NCT04178993)
Timeframe: 4 sessions over approximately 4.5 weeks

Intervention	log(k) (Mean)
	Methylphenidate (0mg)	Methylphenidate (20mg)	Methylphenidate (40mg)	Methylphenidate (60mg)
Active Comparator: Duloxetine (60 mg)	-1.29	-1.37	-1.15	-1.04
Placebo Comparator: Placebo	-1.40	-1.40	-1.45	-1.48

Diastolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (0 mg) Maintenance.

Diastolic blood pressure (millimeter of mercury) is recorded following administration of methamphetamine. Data are presented as mean peak effect. Peak effect means the highest rated value following administration of methamphetamine (0, 10, and 20 mg) (NCT04178993)
Timeframe: Daily over approximately 1 week of inpatient stay.

Intervention	Millimeter of Mercury (Mean)
	Methamphetamine (0 mg)	Methamphetamine (10 mg)	Methamphetamine (20 mg)
Active Comparator: Duloxetine	78.50	83.75	86.25
Placebo Comparator: Placebo	80.00	82.33	87.33

Diastolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (20 mg) Maintenance.

Intervention	Millimeter of Mercury (Mean)
	Methamphetamine (0 mg)	Methamphetamine (10 mg)	Methamphetamine (20 mg)
Active Comparator: Duloxetine	74.50	83.25	85.00
Placebo Comparator: Placebo	81.67	85.33	83.00

Diastolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (40 mg) Maintenance.

Intervention	Millimeter of Mercury (Mean)
	Methamphetamine (0 mg)	Methamphetamine (10 mg)	Methamphetamine (20 mg)
Active Comparator: Duloxetine	81.00	82.25	85.00
Placebo Comparator: Placebo	78.00	84.67	84.67

Diastolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (60 mg) Maintenance.

Intervention	Millimeter of Mercury (Mean)
	Methamphetamine (0 mg)	Methamphetamine (10 mg)	Methamphetamine (20 mg)
Active Comparator: Duloxetine	82.25	82.25	84.25
Placebo Comparator: Placebo	82.67	81.67	88.33

Heart Rate After Methamphetamine Administration Following Methylphenidate (0 mg) Maintenance.

Heart Rate (beats per minute) is recorded following administration of methamphetamine. Data are presented as mean peak effect. Peak effect means the highest rated value following administration of methamphetamine (0, 10, and 20 mg) (NCT04178993)
Timeframe: Daily over approximately 1 week of inpatient stay.

Intervention	Beats Per Minute (Mean)
	Methamphetamine (0 mg)	Methamphetamine (10 mg)	Methamphetamine (20 mg)
Active Comparator: Duloxetine	78.00	77.25	83.75
Placebo Comparator: Placebo	77.67	87.33	81.33

Heart Rate After Methamphetamine Administration Following Methylphenidate (20 mg) Maintenance.

Intervention	Beats Per Minute (Mean)
	Methamphetamine (0 mg)	Methamphetamine (10 mg)	Methamphetamine (20 mg)
Active Comparator: Duloxetine	76.00	78.50	89.50
Placebo Comparator: Placebo	83.67	84.33	85.67

Heart Rate After Methamphetamine Administration Following Methylphenidate (40 mg) Maintenance.

Intervention	Beats Per Minute (Mean)
	Methamphetamine (0 mg)	Methamphetamine (10 mg)	Methamphetamine (20 mg)
Active Comparator: Duloxetine	91.25	87.75	87.00
Placebo Comparator: Placebo	85.00	89.67	87.67

Heart Rate After Methamphetamine Administration Following Methylphenidate (60 mg) Maintenance.

Intervention	Beats Per Minute (Mean)
	Methamphetamine (0 mg)	Methamphetamine (10 mg)	Methamphetamine (20 mg)
Active Comparator: Duloxetine	88.00	87.50	88.00
Placebo Comparator: Placebo	87.33	83.67	99.67

Reinforcing Effects of Methamphetamine Following Methylphenidate (0 mg; Placebo) Maintenance.

"Number of methamphetamine doses earned by subjects on a progressive ratio schedule of reinforcement. Subjects sample a dose of methamphetamine (0, 10, or 20 mg) and then have ten opportunities (e.g., trials) to work for a 1/10th of the sampled dose via clicking on a computer mouse (i.e., 10 completed trials is the full sampled dose)." (NCT04178993)
Timeframe: Following at least 4 days of maintenance on placebo during inpatient admission, up to 1 week

Intervention	Trials Completed (Mean)
	Methamphetamine (0mg)	Methamphetamine (10mg)	Methamphetamine (20mg)
Active Comparator: Duloxetine (60 mg)	0	7.25	9.75
Placebo Comparator: Placebo	0	3.33	10

Reinforcing Effects of Methamphetamine Following Methylphenidate (20 mg) Maintenance.

"Number of methamphetamine doses earned by subjects on a progressive ratio schedule of reinforcement. Subjects sample a dose of methamphetamine (0, 10, or 20 mg) and then have the ten opportunities (e.g., trials) to work for a 1/10th of the sampled dose via clicking on a computer mouse (i.e., 10 completed trials is the full sampled dose)." (NCT04178993)
Timeframe: Following at least 4 days of maintenance on drug during inpatient admission, up to 1 week

Intervention	Trials Completed (Mean)
	Methamphetamine (0mg)	Methamphetamine (10mg)	Methamphetamine (20mg)
Active Comparator: Duloxetine (60 mg)	2.50	7.00	9.75
Placebo Comparator: Placebo	0	6.67	8.00

Reinforcing Effects of Methamphetamine Following Methylphenidate (40 mg) Maintenance.

Intervention	Trials Completed (Mean)
	Methamphetamine (0mg)	Methamphetamine (10mg)	Methamphetamine (20mg)
Active Comparator: Duloxetine	0	5.00	10
Placebo Comparator: Placebo	1.67	10	10

Reinforcing Effects of Methamphetamine Following Methylphenidate (60 mg) Maintenance.

Intervention	Trials Completed (Mean)
	Methamphetamine (0mg)	Methamphetamine (10mg)	Methamphetamine (20mg)
Active Comparator: Duloxetine (60 mg)	0	7.50	9.75
Placebo Comparator: Placebo	2.33	3.33	10

Snaith-Hamilton-Pleasure Scale to Measure Anhedonia (Inability to Experience Pleasure)

A 14-item Snaith-Hamilton-Pleasure Scale covers four domains of pleasure response (interest/pastimes, social interaction, sensory experience and food/drink) with higher scores representing less anhedonia. Scores range from 0 to 56 units: lower scores representing greater anhedonia. (NCT04178993)
Timeframe: 4 times over approximately 4.5 weeks

Intervention	Units on a Scale (Mean)
	Methylphenidate (0 mg)	Methylphenidate (20 mg)	Methylphenidate (40 mg)	Methylphenidate (60 mg)
Active Comparator: Duloxetine (60 mg)	51.25	52.75	54.00	53.00
Placebo Comparator: Placebo	44.33	44.00	44.33	44.67

Subjective Effects of Methamphetamine (0 mg) Administration Following Methylphenidate (0 mg) Maintenance.

Subjective effects (i.e., mood) of methamphetamine are recorded following administration. Data are presented as mean peak effect. Peak effect means the highest rated value (0 - 100 mm) following administration of methamphetamine. (NCT04178993)
Timeframe: Daily over approximately 1 week of inpatient stay.

Intervention	Millimeters (Mean)
	Sluggish/Fatigued/Lazy	Restless	Nervous/Anxious	Nauseated/Queasy/Sick to Stomach	Talkative/Friendly	Irregular/Racing Heartbeat	Euphoric	Shaky/Jittery	Active/Alert/Energetic	Will Pay For	Will Take Again	Performance Improved	Performance Impaired	Stimulated	Like Drug	Rush	High	Good Effects	Bad Effects	Any Effect
Active Comparator: Duloxetine	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.50	0.25	1.50	0.00	0.00	2.25	0.00	0.25	0.00	0.25	0.00	1.25
Placebo Comparator: Placebo	1.33	1.00	1.00	1.00	1.00	1.33	0.67	1.33	1.33	1.33	1.67	1.33	1.00	1.00	1.00	1.00	0.67	1.33	1.00	1.00

Subjective Effects of Methamphetamine (0 mg) Administration Following Methylphenidate (20 mg) Maintenance.

Intervention	Millimeters (Mean)
	Sluggish/Fatigued/Lazy	Restless	Nervous/Anxious	Nauseated/Queasy/Sick to Stomach	Talkative/Friendly	Irregular/Racing Heartbeat	Euphoric	Shaky/Jittery	Active/Alert/Energetic	Will Pay For	Will Take Again	Performance Improved	Performance Impaired	Stimulated	Like Drug	Rush	High	Good Effects	Bad Effects	Any Effect
Active Comparator: Duloxetine	0.00	1.00	0.00	0.00	0.75	0.25	0.00	0.00	0.75	1.00	1.50	0.75	0.25	0.25	1.50	0.00	1.50	1.50	0.00	1.50
Placebo Comparator: Placebo	3.00	1.33	1.67	1.67	4.00	1.67	4.00	3.00	3.33	8.00	11.67	2.67	2.33	4.67	7.67	4.67	4.33	4.00	2.67	3.67

Subjective Effects of Methamphetamine (0 mg) Administration Following Methylphenidate (40 mg) Maintenance.

Intervention	Millimeters (Mean)
	Sluggish/Fatigued/Lazy	Restless	Nervous/Anxious	Nauseated/Queasy/Sick to Stomach	Talkative/Friendly	Irregular/Racing Heartbeat	Euphoric	Shaky/Jittery	Active/Alert/Energetic	Will Pay For	Will Take Again	Performance Improved	Performance Impaired	Stimulated	Like Drug	Rush	High	Good Effects	Bad Effects	Any Effect
Active Comparator: Duloxetine	0.00	0.50	0.00	0.00	0.50	0.00	0.00	0.00	0.50	0.75	1.00	0.00	0.00	0.50	1.25	0.00	1.25	1.25	0.00	4.25
Placebo Comparator: Placebo	0.00	0.00	0.00	0.00	8.00	0.67	7.00	0.67	10.33	17.33	23.00	6.67	7.67	17.33	16.33	8.00	10.67	8.33	6.33	7.00

Subjective Effects of Methamphetamine (0 mg) Administration Following Methylphenidate (60 mg) Maintenance.

Intervention	Millimeters (Mean)
	Sluggish/Fatigued/Lazy	Restless	Nervous/Anxious	Nauseated/Queasy/Sick to Stomach	Talkative/Friendly	Irregular/Racing Heartbeat	Euphoric	Shaky/Jittery	Active/Alert/Energetic	Will Pay For	Will Take Again	Performance Improved	Performance Impaired	Stimulated	Like Drug	Rush	High	Good Effects	Bad Effects	Any Effect
Active Comparator: Duloxetine	0.00	0.00	0.00	0.00	0.00	0.50	0.00	0.00	0.25	0.00	3.00	0.00	0.00	0.00	0.50	0.00	2.00	0.75	0.00	3.50
Placebo Comparator: Placebo	0.00	0.00	0.00	0.00	12.33	0.00	15.33	0.00	14.00	32.33	31.00	9.00	14.33	24.00	29.67	13.33	12.00	13.67	3.00	15.33

Subjective Effects of Methamphetamine (10 mg) Administration Following Methylphenidate (0 mg) Maintenance.

Intervention	Millimeters (Mean)
	Sluggish/Fatigued/Lazy	Restless	Nervous/Anxious	Nauseated/Queasy/Sick to Stomach	Talkative/Friendly	Irregular/Racing Heartbeat	Euphoric	Shaky/Jittery	Active/Alert/Energetic	Will Pay For	Will Take Again	Performance Improved	Performance Impaired	Stimulated	Like Drug	Rush	High	Good Effects	Bad Effects	Any Effect
Active Comparator: Duloxetine	0.00	1.00	0.00	0.00	12.50	2.25	18.25	0.00	25.50	22.25	23.50	11.50	0.00	14.25	15.00	8.25	12.00	13.75	0.00	16.00
Placebo Comparator: Placebo	22.33	1.00	0.67	3.00	4.33	0.33	15.67	1.00	15.33	23.00	46.33	7.00	11.33	21.33	33.67	10.67	9.33	12.67	2.67	12.67

Subjective Effects of Methamphetamine (10 mg) Administration Following Methylphenidate (20 mg) Maintenance.

Intervention	Millimeters (Mean)
	Sluggish/Fatigued/Lazy	Restless	Nervous/Anxious	Nauseated/Queasy/Sick to Stomach	Talkative/Friendly	Irregular/Racing Heartbeat	Euphoric	Shaky/Jittery	Active/Alert/Energetic	Will Pay For	Will Take Again	Performance Improved	Performance Impaired	Stimulated	Like Drug	Rush	High	Good Effects	Bad Effects	Any Effect
Active Comparator: Duloxetine	0.50	0.50	0.00	0.00	13.75	0.00	13.00	0.00	16.25	18.50	21.75	13.00	0.00	11.75	14.00	3.00	14.25	9.75	0.25	14.75
Placebo Comparator: Placebo	10.67	2.00	2.00	0.33	14.67	0.00	22.00	0.67	17.33	33.33	40.00	15.00	5.67	20.33	35.33	19.00	21.67	21.00	6.33	16.00

Subjective Effects of Methamphetamine (10 mg) Administration Following Methylphenidate (40 mg) Maintenance.

Intervention	Millimeters (Mean)
	Sluggish/Fatigued/Lazy	Restless	Nervous/Anxious	Nauseated/Queasy/Sick to Stomach	Talkative/Friendly	Irregular/Racing Heartbeat	Euphoric	Shaky/Jittery	Active/Alert/Energetic	Will Pay For	Will Take Again	Performance Improved	Performance Impaired	Stimulated	Like Drug	Rush	High	Good Effects	Bad Effects	Any Effect
Active Comparator: Duloxetine	5.50	1.00	0.00	0.25	13.75	1.25	9.75	0.00	20.25	17.00	17.25	11.25	2.25	9.50	15.00	4.50	10.25	9.25	2.50	11.50
Placebo Comparator: Placebo	8.67	5.33	3.00	2.00	18.67	2.00	30.00	6.33	22.33	33.00	39.33	20.00	6.00	31.33	33.67	30.00	30.33	31.33	3.67	30.33

Subjective Effects of Methamphetamine (10 mg) Administration Following Methylphenidate (60 mg) Maintenance.

Intervention	Millimeters (Mean)
	Sluggish/Fatigued/Lazy	Restless	Nervous/Anxious	Nauseated/Queasy/Sick to Stomach	Talkative/Friendly	Irregular/Racing Heartbeat	Euphoric	Shaky/Jittery	Active/Alert/Energetic	Will Pay For	Will Take Again	Performance Improved	Performance Impaired	Stimulated	Like Drug	Rush	High	Good Effects	Bad Effects	Any Effect
Active Comparator: Duloxetine	0.00	1.00	0.00	0.00	11.00	3.75	11.75	2.00	23.00	18.00	23.75	9.50	0.00	17.25	23.75	10.75	15.75	20.25	0.00	20.75
Placebo Comparator: Placebo	0.00	5.00	0.00	4.67	29.00	0.00	28.33	3.67	25.00	36.00	33.33	14.67	5.33	33.00	32.67	27.33	27.00	25.33	4.67	24.67

Subjective Effects of Methamphetamine (20 mg) Administration Following Methylphenidate (0 mg) Maintenance.

Intervention	Millimeters (Mean)
	Sluggish/Fatigued/Lazy	Restless	Nervous/Anxious	Nauseated/Queasy/Sick to Stomach	Talkative/Friendly	Irregular/Racing Heartbeat	Euphoric	Shaky/Jittery	Active/Alert/Energetic	Will Pay For	Will Take Again	Performance Improved	Performance Impaired	Stimulated	Like Drug	Rush	High	Good Effects	Bad Effects	Any Effect
Active Comparator: Duloxetine	0.00	0.50	0.00	0.00	13.75	4.25	16.00	0.00	27.99	20.50	25.25	12.00	0.25	23.50	26.25	16.00	20.50	23.00	0.25	24.50
Placebo Comparator: Placebo	10.33	0.67	0.67	0.33	20.00	1.00	21.67	0.67	35.67	36.67	50.00	26.33	32.67	38.33	37.67	31.33	36.67	30.33	23.67	38.33

Subjective Effects of Methamphetamine (20 mg) Administration Following Methylphenidate (20 mg) Maintenance.

Intervention	Millimeters (Mean)
	Sluggish/Fatigued/Lazy	Restless	Nervous/Anxious	Nauseated/Queasy/Sick to Stomach	Talkative/Friendly	Irregular/Racing Heartbeat	Euphoric	Shaky/Jittery	Active/Alert/Energetic	Will Pay For	Will Take Again	Performance Improved	Performance Impaired	Stimulated	Like Drug	Rush	High	Good Effects	Bad Effects	Any Effect
Active Comparator: Duloxetine	0.00	1.00	0.00	0.50	14.50	3.50	14.25	0.00	24.50	17.25	24.75	14.50	0.25	19.75	18.75	12.75	16.50	14.25	0.00	13.75
Placebo Comparator: Placebo	4.33	9.33	3.33	1.67	22.67	3.00	33.33	1.33	30.00	45.67	48.00	16.67	11.33	36.67	47.33	33.33	33.33	35.67	6.33	36.33

Subjective Effects of Methamphetamine (20 mg) Administration Following Methylphenidate (40 mg) Maintenance.

Intervention	Millimeters (Mean)
	Sluggish/Fatigued/Lazy	Restless	Nervous/Anxious	Nauseated/Queasy/Sick to Stomach	Talkative/Friendly	Irregular/Racing Heartbeat	Euphoric	Shaky/Jittery	Active/Alert/Energetic	Will Pay For	Will Take Again	Performance Improved	Performance Impaired	Stimulated	Like Drug	Rush	High	Good Effects	Bad Effects	Any Effect
Active Comparator: Duloxetine	0.00	1.25	0.00	0.00	15.50	0.75	14.75	1.25	24.75	21.25	23.75	15.00	0.00	23.25	24.75	6.75	20.50	22.75	0.00	19.50
Placebo Comparator: Placebo	1.33	0.33	0.00	0.00	25.33	2.33	33.00	7.00	28.00	38.00	41.67	12.33	5.33	31.67	34.33	29.00	28.00	35.00	12.00	33.67

Subjective Effects of Methamphetamine (20 mg) Administration Following Methylphenidate (60 mg) Maintenance.

Intervention	Millimeters (Mean)
	Sluggish/Fatigued/Lazy	Restless	Nervous/Anxious	Nauseated/Queasy/Sick to Stomach	Talkative/Friendly	Irregular/Racing Heartbeat	Euphoric	Shaky/Jittery	Active/Alert/Energetic	Will Pay For	Will Take Again	Performance Improved	Performance Impaired	Stimulated	Like Drug	Rush	High	Good Effects	Bad Effects	Any Effect
Active Comparator: Duloxetine	0.00	1.25	0.00	0.00	18.25	1.00	18.00	0.25	21.50	18.75	21.50	18.75	13.50	20.25	21.50	2.50	20.25	20.25	0.00	19.25
Placebo Comparator: Placebo	6.67	0.00	0.33	0.00	29.33	30.67	32.33	2.00	37.33	34.00	37.67	22.00	10.33	36.00	36.33	35.67	37.00	39.00	9.67	38.00

Systolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (0 mg) Maintenance.

Systolic blood pressure (millimeter of mercury) is recorded following administration of methamphetamine. Data are presented as mean peak effect. Peak effect means the highest rated value following administration of methamphetamine (0, 10, and 20 mg) (NCT04178993)
Timeframe: Daily over approximately 1 week of inpatient stay.

Intervention	Millimeter of Mercury (Mean)
	Methamphetamine (0 mg)	Methamphetamine (10 mg)	Methamphetamine (20 mg)
Active Comparator: Duloxetine	128.75	131.00	144.25
Placebo Comparator: Placebo	132.67	133.00	132.67

Systolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (20 mg) Maintenance.

Intervention	Millimeter of Mercury (Mean)
	Methamphetamine (0 mg)	Methamphetamine (10 mg)	Methamphetamine (20 mg)
Active Comparator: Duloxetine	124.25	128.00	132.75
Placebo Comparator: Placebo	129.67	131.67	130.33

Systolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (40 mg) Maintenance.

Intervention	Millimeter of Mercury (Mean)
	Methamphetamine (0 mg)	Methamphetamine (10 mg)	Methamphetamine (20 mg)
Active Comparator: Duloxetine	129.75	132.25	139.25
Placebo Comparator: Placebo	133.33	129.00	130.00

Systolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (60 mg) Maintenance.

Intervention	Millimeter of Mercury (Mean)
	Methamphetamine (0 mg)	Methamphetamine (10 mg)	Methamphetamine (20 mg)
Active Comparator: Duloxetine	127.00	129.75	135.25
Placebo Comparator: Placebo	139.00	138.67	139.67

Temperature After Methamphetamine Administration Following Methylphenidate (0 mg) Maintenance.

Oral temperature (degrees fahrenheit) is recorded following administration of methamphetamine. Data are presented as mean peak effect. Peak effect means the highest rated value following administration of methamphetamine (0, 10, and 20 mg) (NCT04178993)
Timeframe: Daily over approximately 1 week of inpatient stay.

Intervention	Degrees Fahrenheit (Mean)
	Methamphetamine (0 mg)	Methamphetamine (10 mg)	Methamphetamine (20 mg)
Active Comparator: Duloxetine	98.45	98.48	98.48
Placebo Comparator: Placebo	98.10	98.23	98.40

Temperature After Methamphetamine Administration Following Methylphenidate (20 mg) Maintenance.

Intervention	Degrees Fahrenheit (Mean)
	Methamphetamine (0 mg)	Methamphetamine (10 mg)	Methamphetamine (20 mg)
Active Comparator: Duloxetine	98.50	98.75	98.35
Placebo Comparator: Placebo	98.37	98.10	98.27

Temperature After Methamphetamine Administration Following Methylphenidate (40 mg) Maintenance.

Intervention	Degrees Fahrenheit (Mean)
	Methamphetamine (0 mg)	Methamphetamine (10 mg)	Methamphetamine (20 mg)
Active Comparator: Duloxetine	98.60	98.65	98.55
Placebo Comparator: Placebo	98.17	98.13	98.43

Temperature After Methamphetamine Administration Following Methylphenidate (60 mg) Maintenance.

Intervention	Degrees Fahrenheit (Mean)
	Methamphetamine (0 mg)	Methamphetamine (10 mg)	Methamphetamine (20 mg)
Active Comparator: Duloxetine	98.65	98.65	98.58
Placebo Comparator: Placebo	98.37	98.43	98.47

Lane Position Deviation

The reported lane position deviation indicates the position of the car relative to the center line in feet in the driver simulator. A deviation of 0 indicates no deviation from the center line (the car is positioned farthest from the road edge). Negative numbers indicate deviations to the right of the center line with the car positioned within the lane closer to the road edge. Positive numbers indicate deviations to the left of the center line with the car positioned in the lane of oncoming traffic closer to the road edge (NCT00515294)
Timeframe: 30 minutes post dosing

Intervention	feet (Mean)
1Caffeinated Alcoholic Beer	-1.25
2Non-Caffeinated Alcoholic Beer	-1.36
3Caffeinated Non-Alcoholic Beer	-1.22
4Non-Alcoholic, Non-Caffeinated Beer	-1.21

Psycho-motor Vigilance Test (PVT)

Participants completed 10 test trials to assess their psycho-motor response using a hand held box that randomly starts a scroll of numbers in milliseconds and as soon as it starts to scroll the participant needs to press a button to stop the scrolling. The mean and standard deviations for the 10 tests were calculated as a single outcome score for each study arm. Response times were measured in milliseconds. The lower the number of milliseconds the faster the response to the random stimuli. (NCT00515294)
Timeframe: 30 minutes post dosing

Intervention	milliseconds (Mean)
1Caffeinated Alcoholic Beer	278.7
2Non-Caffeinated Alcoholic Beer	293.3
3Caffeinated Non-Alcoholic Beer	233.1
4Non-Alcoholic, Non-Caffeinated Beer	241.8

"Overall Proportion Saying Yes to Real Prism Glasses"

"At the end of each crossover period, participants were asked a yes/no question: If the study were to end today, would you want to continue with these prism glasses (i.e. the prism glasses worn in that period)? The primary outcome was the overall difference, across the two periods of the crossover, between the proportion of participants saying yes to real prism glasses and the proportion saying yes to sham prism glasses." (NCT00494676)
Timeframe: Evaluated after 4 weeks of wearing each type of prism glasses

Intervention	participants (Number)
	Said yes to real prism glasses	Said yes to sham prism glasses
Entire Study Population	39	22

Mobility Change Score (All Participants Who Completed Crossover)

Perceived difficulties with mobility were quantified using a 5-point rating scale (no difficulty to extreme difficulty) for 7 situations (items) relevant to people with hemianopia, including at home, in stores, outdoors, in unfamiliar areas, in familiar areas, in crowded areas, and noticing objects off to the side when walking. The questionnaire was administered at baseline (without prisms) and after each period of the crossover. Interval scale measures of perceived difficulty with overall mobility for each participant were estimated using Rasch analysis of the responses to all seven items (Winsteps software, version 3.70.0.226). Rasch measures were expressed as logits (log odds ratios). Mobility change scores for real and sham prisms were defined as the difference in perceived difficulty relative to baseline (in logits). (NCT00494676)
Timeframe: Evaluated after 4 weeks of wearing each type of prism glasses

Intervention	logits (Mean)
	Mobility change score for real prisms	Mobility change score for sham prisms
Entire Study Population	1.9	1.3

Mobility Change Score (Only Participants Who Continued Prism Wear in the Long Term)

Intervention	logits (Mean)
	Mobility change score for real prisms	Mobility change score for sham prisms
Entire Study Population Who Continued	3.0	1.1

Mobility Change Score (Only Participants Who Discontinued Prism Wear in the Long Term)

Perceived difficulties with mobility were quantified using a 5-point rating scale (no difficulty to extreme difficulty) for 7 situations (items) relevant to people with hemianopia, including at home, in stores, outdoors, in unfamiliar areas, in familiar areas, in crowded areas, and noticing objects off to the side when walking. The questionnaire was administered at baseline (without prisms) and after each period of the crossover. Interval scale measures of perceived difficulty with overall mobility for each participant were estimated using Rasch analysis of the responses to all seven items (Winsteps software, version 3.70.0.226). Rasch measures were expressed as logits (log odds ratios). Mobility improvement scores for real and sham prisms were defined as the difference in perceived difficulty relative to baseline (in logits). (NCT00494676)
Timeframe: Evaluated after 4 weeks of wearing each type of prism glasses

Intervention	logits (Mean)
	Mobility change score for real prisms	Mobility change score for sham prisms
Entire Study Population Who Discontinued	1.1	1.6

Photostress Recovery Time

Photostress Recovery Time is the time necessary to recover function (e.g., contrast discrimination) following exposure to a bright glare source. The subject fixated on an image (black and white grating) and underwent photostress (glare) for 5 seconds. Only 1 eye (study eye) was assessed. (NCT01938989)
Timeframe: Day 1

Intervention	seconds (Mean)
Blue Light Filter	5.66
Clear	6.94

Change in Braking Reaction Time From No-glare to Glare (ACRYSOF® IQ IOL + Placebo Filter; Clear IOL + BLF)

Braking reaction time (time to brake, in seconds) was assessed using a driving simulator in no-glare and glare conditions. The subject was presented with a driving scenario during which an obstruction (car pulling over from either side of the road in a random fashion) was presented. Subjects braked in an attempt to avoid colliding with the obstruction, and the braking reaction time was recorded. The experiment was repeated with a glare source present. Both assessments (no-glare and glare) occurred on the same day. Change in braking reaction time was calculated as glare minus no-glare. (NCT02219997)
Timeframe: Visit 2, Up to Day 30

Intervention	seconds (Mean)
ACRYSOF IQ IOL + Placebo Filter	0.12
Clear IOL + BLF	0.16

Change in Braking Reaction Time From No-glare to Glare (Clear IOLs)

Intervention	seconds (Mean)
Placebo Filter	0.17
Blue Light Filter	0.16

Change in Braking Reaction Time From No-glare to Glare

Intervention	seconds (Mean)
AcrySof IQ IOL	0.07
Clear IOL	0.15

Change in GAD65 Autoantibody Titer (DK Units/mL)

Change in T-lymphocyte (GAD65) biomarker of beta cell specific immune response (NCT02580877)
Timeframe: 13 and 26 weeks after first dose versus baseline

Intervention	DK Units/mL (Mean)
	13 weeks	26 weeks
500 mg Oral Insulin Crystals Every Other Week	234	196
67.5 mg Oral Insulin Crystals Daily	247	193

Change in mIAA Autoantibody Titer From Baseline

Micro-islet autoantibodies (mIAA) autoantibody titers are a measure of of beta cell immune response (NCT02580877)
Timeframe: 13 and 26 weeks after first dose versus baseline

Intervention	DK Units/mL (Mean)
	13 weeks	26 weeks
500mg Oral Insulin Crystals Every Other Week	0.020	0.017
67.5 mg Oral Insulin Crystals Daily	0.021	0.020

"Subjective Effects as Assessed by Score on Feel Drug, Feel High, Like Drug, and Want More Subscales of the Drug Effects Questionnaire"

"The Drug Effects Questionnaire (DEQ) is a visual analog scale questionnaire that assesses the extent to which subjects experience four subjective states: Feel Drug, Feel High, Like Drug, and Want More. The Feel Drug, Feel High, Like Drug, and Want More subscales are reported. All subscales are scored on a visual analogue scale (scroll bar on computer screen) ranging from 0-100. 100 represents the highest score for that subjective state, and the higher the score, the worse the outcome." (NCT02323048)
Timeframe: End of study (time 0 and approximately 4 weeks later)

,,,,

Intervention	units on a scale (Mean)
	Feel Drug	Like Drug	Feel High	Want More
Paired no Reward (Methamphetamine Sessions)	41.22	60.55	38.88	61.55
Paired, High Reward (Methamphetamine Sessions)	50.39	68.85	42.04	65.11
Paired, Low Reward (Methamphetamine Sessions)	45.25	64.25	41.04	62.44
Unpaired, High Reward (Methamphetamine Sessions)	48.55	61.55	39.55	60.55
Unpaired, Low Reward (Methamphetamine Sessions)	42.22	60.2	38.0	59.5

"Peak Ratings of Active, Alert, Energetic on the Visual Analog Scale"

"Subjects rated their feelings of Active, Alert, Energetic on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each methamphetamine dose under both buspirone and placebo conditions." (NCT01843205)
Timeframe: Subjects completed this measure at 15 minute intervals for 2 hours after sampling each methamphetamine dose under both buspirone and placebo maintenance conditions.

Intervention	units on a scale (Mean)
	Placebo Methamphetamine	10 mg Methamphetamine	30 mg Methamphetamine
Buspirone	8.75	14.5	29.25
Placebo	2.13	19	35

"Peak Ratings of Any Effect on the Visual Analog Scale"

"Subjects rated their feelings of Any Effect on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each methamphetamine dose under both buspirone and placebo conditions." (NCT01843205)
Timeframe: Subjects completed this measure at 15 minute intervals for 2 hours after sampling each methamphetamine dose under both buspirone and placebo maintenance conditions.

Intervention	units on a scale (Mean)
	Placebo Methamphetamine	10 mg Methamphetamine	30 mg Methamphetamine
Buspirone	10	21.5	33
Placebo	0.75	25.75	34.38

"Peak Ratings of Bad Effects on the Visual Analog Scale"

"Subjects rated their feelings of Bad Effects on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each methamphetamine dose under both buspirone and placebo conditions." (NCT01843205)
Timeframe: Subjects completed this measure at 15 minute intervals for 2 hours after sampling each methamphetamine dose under both buspirone and placebo maintenance conditions.

Intervention	units on a scale (Mean)
	Placebo Methamphetamine	10 mg Methamphetamine	30 mg Methamphetamine
Buspirone	1.5	7.63	8.38
Placebo	0.13	7	3.13

"Peak Ratings of Euphoric on the Visual Analog Scale"

"Subjects rated their feelings of Euphoric on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each methamphetamine dose under both buspirone and placebo conditions." (NCT01843205)
Timeframe: Subjects completed this measure at 15 minute intervals for 2 hours after sampling each methamphetamine dose under both buspirone and placebo maintenance conditions.

Intervention	units on a scale (Mean)
	Placebo Methamphetamine	10 mg Methamphetamine	30 mg Methamphetamine
Buspirone	0	3.88	8.5
Placebo	0.63	4.88	7.63

"Peak Ratings of Good Effects on the Visual Analog Scale"

"Subjects rated their feelings of Good Effects on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each methamphetamine dose under both buspirone and placebo conditions." (NCT01843205)
Timeframe: Subjects completed this measure at 15 minute intervals for 2 hours after sampling each methamphetamine dose under both buspirone and placebo maintenance conditions.

Intervention	units on a scale (Mean)
	Placebo Methamphetamine	10 mg Methamphetamine	30 mg Methamphetamine
Buspirone	9.63	17.38	31.5
Placebo	0.88	21	30.63

"Peak Ratings of High on the Visual Analog Scale"

"Subjects rated their feelings of High on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each methamphetamine dose under both buspirone and placebo conditions." (NCT01843205)
Timeframe: Subjects completed this measure at 15 minute intervals for 2 hours after sampling each methamphetamine dose under both buspirone and placebo maintenance conditions.

Intervention	units on a scale (Mean)
	Placebo Methamphetamine	10 mg Methamphetamine	30 mg Methamphetamine
Buspirone	10.5	16.5	31
Placebo	0.63	22.13	28.63

"Peak Ratings of Irregular/Racing Heartbeat on the Visual Analog Scale"

"Subjects rated their feelings of Irregular/Racing Heartbeat on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each methamphetamine dose under both buspirone and placebo conditions." (NCT01843205)
Timeframe: Subjects completed this measure at 15 minute intervals for 2 hours after sampling each methamphetamine dose under both buspirone and placebo maintenance conditions.

Intervention	units on a scale (Mean)
	Placebo Methamphetamine	10 mg Methamphetamine	30 mg Methamphetamine
Buspirone	8.5	10.75	16.13
Placebo	0.75	10.63	14.38

"Peak Ratings of Like Drug on the Visual Analog Scale"

"Subjects rated their feelings of Like Drug on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each methamphetamine dose under both buspirone and placebo conditions." (NCT01843205)
Timeframe: Subjects completed this measure at 15 minute intervals for 2 hours after sampling each methamphetamine dose under both buspirone and placebo maintenance conditions.

Intervention	units on a scale (Mean)
	Placebo Methamphetamine	10 mg Methamphetamine	30 mg Methamphetamine
Buspirone	9.63	18.50	30.50
Placebo	0.63	22.63	32.75

"Peak Ratings of Nauseous on the Visual Analog Scale"

"Subjects rated their feelings of Nauseous on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each methamphetamine dose under both buspirone and placebo conditions." (NCT01843205)
Timeframe: Subjects completed this measure at 15 minute intervals for 2 hours after sampling each methamphetamine dose under both buspirone and placebo maintenance conditions.

Intervention	units on a scale (Mean)
	Placebo Methamphetamine	10 mg Methamphetamine	30 mg Methamphetamine
Buspirone	0	2.38	5
Placebo	0	6.38	3.50

"Peak Ratings of Nervous/Anxious on the Visual Analog Scale"

"Subjects rated their feelings of Nervous/Anxious on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each methamphetamine dose under both buspirone and placebo conditions." (NCT01843205)
Timeframe: Subjects completed this measure at 15 minute intervals for 2 hours after sampling each methamphetamine dose under both buspirone and placebo maintenance conditions.

Intervention	units on a scale (Mean)
	Placebo Methamphetamine	10 mg Methamphetamine	30 mg Methamphetamine
Buspirone	0	1	3.75
Placebo	0.88	2.38	4

"Peak Ratings of Performance Impaired on the Visual Analog Scale"

"Subjects rated their feelings of Performance Impaired on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each methamphetamine dose under both buspirone and placebo conditions." (NCT01843205)
Timeframe: Subjects completed this measure at 15 minute intervals for 2 hours after sampling each methamphetamine dose under both buspirone and placebo maintenance conditions.

Intervention	units on a scale (Mean)
	Placebo Methamphetamine	10 mg Methamphetamine	30 mg Methamphetamine
Buspirone	0	0	1.38
Placebo	0.25	2.13	0

"Peak Ratings of Performance Improved on the Visual Analog Scale"

"Subjects rated their feelings of Performance Improved on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each methamphetamine dose under both buspirone and placebo conditions." (NCT01843205)
Timeframe: Subjects completed this measure at 15 minute intervals for 2 hours after sampling each methamphetamine dose under both buspirone and placebo maintenance conditions.

Intervention	units on a scale (Mean)
	Placebo Methamphetamine	10 mg Methamphetamine	30 mg Methamphetamine
Buspirone	9.25	13.38	22.75
Placebo	0	15	19.13

"Peak Ratings of Restless on the Visual Analog Scale"

"Subjects rated their feelings of Restless on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each methamphetamine dose under both buspirone and placebo conditions." (NCT01843205)
Timeframe: Subjects completed this measure at 15 minute intervals for 2 hours after sampling each methamphetamine dose under both buspirone and placebo maintenance conditions.

Intervention	units on a scale (Mean)
	Placebo Methamphetamine	10 mg Methamphetamine	30 mg Methamphetamine
Buspirone	0	0.50	1.13
Placebo	5	3.13	0.25

"Peak Ratings of Rush on the Visual Analog Scale"

"Subjects rated their feelings of Rush on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each methamphetamine dose under both buspirone and placebo conditions." (NCT01843205)
Timeframe: Subjects completed this measure at 15 minute intervals for 2 hours after sampling each methamphetamine dose under both buspirone and placebo maintenance conditions.

Intervention	units on a scale (Mean)
	Placebo Methamphetamine	10 mg Methamphetamine	30 mg Methamphetamine
Buspirone	10.25	16.50	26.13
Placebo	0.13	21.63	21.75

"Peak Ratings of Shaky/Jittery on the Visual Analog Scale"

"Subjects rated their feelings of Shaky/Jittery on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each methamphetamine dose under both buspirone and placebo conditions." (NCT01843205)
Timeframe: Subjects completed this measure at 15 minute intervals for 2 hours after sampling each methamphetamine dose under both buspirone and placebo maintenance conditions.

Intervention	units on a scale (Mean)
	Placebo Methamphetamine	10 mg Methamphetamine	30 mg Methamphetamine
Buspirone	8.38	0.75	5.50
Placebo	0.13	1.88	2.88

"Peak Ratings of Sluggish/Fatigued/Lazy on the Visual Analog Scale"

"Subjects rated their feelings of Sluggish/Fatigued/Lazy on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each methamphetamine dose under both buspirone and placebo conditions." (NCT01843205)
Timeframe: Subjects completed this measure at 15 minute intervals for 2 hours after sampling each methamphetamine dose under both buspirone and placebo maintenance conditions.

Intervention	units on a scale (Mean)
	Placebo Methamphetamine	10 mg Methamphetamine	30 mg Methamphetamine
Buspirone	0	2.88	2.25
Placebo	1.5	1.88	3.13

"Peak Ratings of Stimulated on the Visual Analog Scale"

"Subjects rated their feelings of Stimulated on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each methamphetamine dose under both buspirone and placebo conditions." (NCT01843205)
Timeframe: Subjects completed this measure at 15 minute intervals for 2 hours after sampling each methamphetamine dose under both buspirone and placebo maintenance conditions.

Intervention	units on a scale (Mean)
	Placebo Methamphetamine	10 mg Methamphetamine	30 mg Methamphetamine
Buspirone	9.88	17.88	24.25
Placebo	1.25	21.88	21.50

"Peak Ratings of Talkative/Friendly on the Visual Analog Scale"

"Subjects rated their feelings of Talkative/Friendly on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each methamphetamine dose under both buspirone and placebo conditions." (NCT01843205)
Timeframe: Subjects completed this measure at 15 minute intervals for 2 hours after sampling each methamphetamine dose under both buspirone and placebo maintenance conditions.

Intervention	units on a scale (Mean)
	Placebo Methamphetamine	10 mg Methamphetamine	30 mg Methamphetamine
Buspirone	9.25	13.75	27.25
Placebo	0	18.50	26.00

"Peak Ratings of Willing to Pay For on the Visual Analog Scale"

"Subjects rated their feelings of Willing to Pay For on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each methamphetamine dose under both buspirone and placebo conditions." (NCT01843205)
Timeframe: Subjects completed this measure at 15 minute intervals for 2 hours after sampling each methamphetamine dose under both buspirone and placebo maintenance conditions.

Intervention	units on a scale (Mean)
	Placebo Methamphetamine	10 mg Methamphetamine	30 mg Methamphetamine
Buspirone	9.38	17.75	31.63
Placebo	1.63	19.88	34.00

"Peak Ratings of Willing to Take Again on the Visual Analog Scale"

"Subjects rated their feelings of Willing to Take Again on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each methamphetamine dose under both buspirone and placebo conditions." (NCT01843205)
Timeframe: Subjects completed this measure at 15 minute intervals for 2 hours after sampling each methamphetamine dose under both buspirone and placebo maintenance conditions.

Intervention	units on a scale (Mean)
	Placebo Methamphetamine	10 mg Methamphetamine	30 mg Methamphetamine
Buspirone	9.62	20.63	33.00
Placebo	1.25	22.00	35.00

Number of Methamphetamine Doses Self-Administered

The reinforcing effects of methamphetamine will be determined during placebo and buspirone treatment using a modified progressive ratio procedure in which subjects are offered the opportunity to earn previously sampled doses of methamphetamine. Each ratio completed on the task will earn 1/10th of the sampled dose. (NCT01843205)
Timeframe: One test per methamphetamine dose level per intervention for each participant over his/her approximate 25 day inpatient admission

Intervention	Number of Methamphetamine Doses (Mean)
	Placebo Methamphetamine	10 mg Methamphetamine	30 mg Methamphetamine
Buspirone	0	4	7.5
Placebo	1.25	6.13	7.88

Peak Diastolic Blood Pressure

Diastolic blood pressure was measured with an automated monitor. Higher values represent greater diastolic pressure. Peak scores were calculated from multiple assessments for each methamphetamine dose under both buspirone and placebo conditions. (NCT01843205)
Timeframe: Subjects completed this measure at 15 minute intervals for 2 hours after sampling each methamphetamine dose under both buspirone and placebo maintenance conditions.

Intervention	mm Hg (Mean)
	Placebo Methamphetamine	10 mg Methamphetamine	30 mg Methamphetamine
Buspirone	80.13	83.00	84.50
Placebo	77.50	80.75	83.80

Peak Heart Rate

Heart rate was measured with an automated monitor. Higher values represent greater heart rate. Peak scores were calculated from multiple assessments for each methamphetamine dose under both buspirone and placebo conditions. (NCT01843205)
Timeframe: Subjects completed this measure at 15 minute intervals for 2 hours after sampling each methamphetamine dose under both buspirone and placebo maintenance conditions.

Intervention	beats per minute (Mean)
	Placebo Methamphetamine	10 mg Methamphetamine	30 mg Methamphetamine
Buspirone	81.25	85.13	90.63
Placebo	82.75	86.13	85.38

Peak Score on Sedative Subscale of the Adjective Rating Scale

"Subjects completed 16 items that loaded into the Sedative Subscale of the Adjective Rating Scale. The items were rated 0-4 on a Likert-type scale and the sum for the 16 sedative items was summed to yield the Sedative Subscale score. The maximum score for this scale was 64, the minimum was 0. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each methamphetamine dose under both bupsirone and placebo conditions." (NCT01843205)
Timeframe: Subjects completed this measure at 15 minute intervals for 2 hours after sampling each methamphetamine dose under both buspirone and placebo maintenance conditions.

Intervention	units on a scale (Mean)
	Placebo Methamphetamine	10 mg Methamphetamine	30 mg Methamphetamine
Buspirone	2.75	3.75	3.25
Placebo	3.38	3.63	3

Peak Score on Stimulant Subscale of the Adjective Rating Scale

"Subjects completed 16 items that loaded into the Stimulant Subscale of the Adjective Rating Scale. The items were rated 0-4 on a Likert-type scale and the sum for the 16 stimulant items was summed to yield the Stimulant Subscale score. The maximum score for this scale was 64, the minimum was 0. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each methamphetamine dose under both bupsirone and placebo conditions." (NCT01843205)
Timeframe: Subjects completed this measure at 15 minute intervals for 2 hours after sampling each methamphetamine dose under both buspirone and placebo maintenance conditions.

Intervention	units on a scale (Mean)
	Placebo Methamphetamine	10 mg Methamphetamine	30 mg Methamphetamine
Buspirone	7.25	9.25	13
Placebo	5.63	9.88	11.38

Peak Systolic Blood Pressure

Systolic blood pressure was measured with an automated monitor. Higher values represent greater systolic pressure. Peak scores were calculated from multiple assessments for each methamphetamine dose under both buspirone and placebo conditions. (NCT01843205)
Timeframe: Subjects completed this measure at 15 minute intervals for 2 hours after sampling each methamphetamine dose under both buspirone and placebo maintenance conditions.

Intervention	mm Hg (Mean)
	Placebo Methamphetamine	10 mg Methamphetamine	30 mg Methamphetamine
Buspirone	125.00	131.63	137.13
Placebo	125.38	131.25	139.63

Peak Temperature

Oral temperature was measured with an automated monitor. Higher values represent greater temperature. Peak scores were calculated from multiple assessments for each methamphetamine dose under both buspirone and placebo conditions. (NCT01843205)
Timeframe: Subjects completed this measure at 15 minute intervals for 2 hours after sampling each methamphetamine dose under both buspirone and placebo maintenance conditions.

Intervention	degrees Fahrenheit (Mean)
	Placebo Methamphetamine	10 mg Methamphetamine	30 mg Methamphetamine
Buspirone	98.41	98.46	98.43
Placebo	98.48	98.44	98.33

Effect of Entacapone on Methamphetamine-induced Mood

Profile of Mood States is a 65 item questionnaire using a Likert rating scale to assess transient, distinct moods. The questionnaire contains 65 words/statements that describe feelings people have. The test requires you to indicate for each word or statement how you have been feeling in the past week including today. A Total Mood Disturbance score is calculated by adding scores for Tension, Depression, Anger, Fatigue and Confusion and then subtracting the Vigour score. The Total Mood Disturbance scale ranges from -32 to 200 with lower scores indicative of people with more stable mood profiles. (NCT02058966)
Timeframe: Measurements acquired before drug ingestion (baseline) then hourly for 4 hours. The peak interaction effect of entacapone and methamphetamine occurs 1 hour after ingestion, therefore the reported values are from this timepoint.

Intervention	units on a scale (Mean)
Baseline	12.500
Placebo Followed by Placebo	13.750
Placebo Followed by Methamphetamine	7.500
Entacapone Followed by Placebo	9.833
Entacapone Followed by Methamphetamine	8.750

Effect of Entacapone on Methamphetamine-induced Stimulation

"The Global Rating of Stimulation is a 1-item question I feel light-headed, restless, or speeded-up in which the participant is asked to circle one answer on a scale from 0-4, 0 is 'normal', 1 is 'slightly', 2 is 'moderately', 3 is 'very much', and 4 is 'extremely'. Whichever number they circled is their reported score. A higher score is indicative of a greater stimulating effect." (NCT02058966)
Timeframe: Measurements acquired before drug ingestion (baseline) then hourly for 4 hours. The peak interaction effect of entacapone and methamphetamine occurs 1 hour after ingestion, therefore the reported values are from this timepoint.

Intervention	units on a scale (Mean)
Baseline	0.1667
Placebo Followed by Placebo	0.1667
Placebo Followed by Methamphetamine	1.4167
Entacapone Followed by Placebo	0.4167
Entacapone Followed by Methamphetamine	1.3333

Cognitive Function

Two computer tests were administered to measure how each medication intervention effects cognitive functioning. The tests administered included the Rapid Visual Information Processing Task (RVIPT), a 6 minute test of sustained attention in which participants are requested to detect target sequences of digits and the Digit Symbol Substitution Task (DSST), a 2 minute test of psychomotor speed and sustained attention consisting of digit-symbol pairs followed by a list of digits where the subject identifies the symbol that corresponds to each digit as fast as possible. The number of correct responses within the allowed time is measured. Higher scores on both tasks indicate better performance. (NCT02058966)
Timeframe: Measurements acquired before drug ingestion (baseline) then hourly for 4 hours. The peak interaction effect of entacapone and methamphetamine occurs 1 hour after ingestion, therefore the reported values are from this timepoint.

,,,,

Intervention	number of correct answers (Mean)
	Rapid Visual Information Processing Task	Digital Symbol Substitution Task
Baseline	38.813	73.167
Entacapone Followed by Methamphetamine	40.083	72.750
Entacapone Followed by Placebo	42.583	72.750
Placebo Followed by Methamphetamine	41.333	71.167
Placebo Followed by Placebo	40.500	72.000

Effect of Entacapone on Subjective Effects of Methamphetamine

The subjective effects of the study drug were evaluated with the Addiction Research Center Inventory (ARCI-49), a 49 item questionnaire consisting of true/false items. True items receive a score of 1 if answer is 'True', false items receive a score of 1 if answer is 'False'. No points are given when answer is opposite to scoring direction. There are 5 subscales: Morphine Benzedrine group scale to measure euphoria (range: 0-16 with higher numbers indicating more euphoria), A Lysergic Acid Diethylamide group scale to estimate dysphoria and agitation (range: 0-14 with higher scores indicating more dysphoria), a Pentobarbital Chlorpromazine Alcohol group scale to measure sedation (range: 0-15 with higher scores indicating more sedation), and a Benzedrine group scale and an Amphetamine Scale to assess stimulant effects (range: 0-13 and 0-11, respectively, with higher scores indicating higher stimulant effects) . (NCT02058966)
Timeframe: Measurements acquired before drug ingestion (baseline) then hourly for 4 hours. The peak interaction effect of entacapone and methamphetamine occurs 1 hour after ingestion, therefore the reported values are from this timepoint.

,,,,

Intervention	units on a scale (Mean)
	Morphine Benzedrine	Lysergic Acid Diethylamide	Pentobarbital Chlorpromazine Alcohol	Benzedrine	Amphetamine
Baseline	1.9375	3.0625	4.8125	4.9583	2.0000
Entacapone Followed by Methamphetamine	6.9167	3.8333	2.0000	7.8333	5.5833
Entacapone Followed by Placebo	2.5833	3.25	4.0833	5.3333	2.5833
Placebo Followed by Methamphetamine	7.9167	4.75	1.5833	8.6667	5.9167
Placebo Followed by Placebo	1.8333	3.25	5.0000	5.1667	2.1667

Reverse Amblyopia

it is defined that the strong eye of the patient decreases two logMAR lines over 3 months. (NCT01973348)
Timeframe: 3 Months

Intervention	Participants (Count of Participants)
4-hour AmblyZ Glasses	0
2-hour Eye Patching	0
12-hour AmblyZ Glasses	0
6-hour Eye Patching	0

Significant Ocular Deviation Increase From the Baseline

The significant ocular deviation is defined as equal or over 10 degrees of deviation more than that of the baseline. (NCT01973348)
Timeframe: 3 Months

Intervention	Participants (Count of Participants)
4-hour AmblyZ Glasses	0
2-hour Eye Patching	0
12-hour AmblyZ Glasses	0
6-hour Eye Patching	0

Visual Acuity Change During 12 Weeks

Visual acuity change during 12 weeks: the difference of visual acuity at baseline and 12 weeks. (NCT01973348)
Timeframe: 12 weeks

Intervention	logMAR (Mean)
4-hour AmblyZ Glasses	.15
2-hour Eye Patching	.15

Methamphetamine Self-Administration

To assess the reinforcing effects of methamphetamine, participants complete a drug self-administration procedure. The outcome measure for this procedure is the number of operant responses (clicks on a mouse) participant are willing to make in order to receive drug (methamphetamine). (NCT03226223)
Timeframe: 1 day.

Intervention	Clicks on a computer mouse (Mean)
Naltrexone 0 mg	8890
Naltrexone 50 mg	7116

Positive Subjective Effects of Methamphetamine.

"Participant ratings of methamphetamine Liking, on a 100 mm visual analog scale. Participants are asked to indicate on a 100 mm line the extent to which they agree with the description of the drug provided. The 0 mm end of the line indicates Not at All, while the 100 mm indicates Extremely." (NCT03226223)
Timeframe: 1 day

Intervention	units on a scale (Mean)
Naltrexone 0 mg	53.6
Naltrexone 50 mg	57.2

Change in Carotid Chemosensitivity Following 4 Weeks of Dietary Nitrate Supplementation and Placebo in Older Adults

Carotid chemosensitivity examined by measuring hypoxia ventilatory responsiveness in older adults before and after 4 weeks of beet root juice supplementation and placebo. Chemoreflex sensitivity was quantified as the change in ventilation in relation to the change in pulse oxygen saturation. (NCT02593305)
Timeframe: Pre and post 4 weeks dietary nitrate supplementation and pre and post 4 weeks of placebo.

Intervention	L/min/%SpO2 (Mean)
Nitrate Pre	-0.13
Nitrate Post	-0.05
Placebo Pre	-0.10
Placebo Post	-0.11

Change in Systolic Blood Pressure During Metaboreflex Testing Following 4 Weeks of Dietary Nitrate Supplementation and Placebo in Older Adults.

Muscle metaboreflex examined by measuring systolic blood pressure responses to ischemic isometric muscle contraction in older adults before and after 4 weeks of beet root juice supplementation and placebo. (NCT02593305)
Timeframe: Pre and post 4 weeks dietary nitrate supplementation and pre and post 4 weeks of placebo.

Intervention	mmHg (Mean)
Nitrate Pre	19.2
Nitrate Post	13
Placebo Pre	16.1
Placebo Post	17

Exodeviation by PACT at Distance, Continuous

The measure of ocular alignment at distance by PACT will be summarized at 8 weeks for each treatment group. A higher deviation is worse. (NCT03998670)
Timeframe: 8 Weeks

Intervention	prism diopters (Mean)
Prism Group	30.6
Non-Prism Group	26.5

Exodeviation by PACT at Near, Continuous

The measure of ocular alignment at near by PACT will be summarized at 8 weeks for each treatment group. A higher deviation is worse. (NCT03998670)
Timeframe: 8 Weeks

Intervention	prism diopters (Mean)
Prism Group	28.7
Non-Prism Group	19.0

Exotropia Control Score at Distance and Near, % With No Spontaneous Tropia

"The proportion of participants with no spontaneous tropia at 8 weeks will be compared between treatment groups using a two-sided Barnard's test with alpha of 0.05, with calculation of a two-sided 95% confidence interval on the difference in proportions.~No spontaneous tropia at the 8-week primary outcome exam is defined as a score of ≤2 (0, 1, or 2) on all three assessments of control at distance and at near." (NCT03998670)
Timeframe: 8 Weeks

Intervention	percentage of participants (Number)
Prism Group	48
Non-Prism Group	51

Exotropia Control Score at Distance, % With Treatment Response

"The secondary analysis will calculate the percentage of participants with a treatment response, defined as ≥1 point improvement in control of their distance exodeviation (average of 3 measurements) between baseline and the 8-week outcome exam." (NCT03998670)
Timeframe: 8 weeks

Intervention	percentage of participants (Number)
Prism Group	32
Non-Prism Group	24

Exotropia Control Score at Distance, Continuous Change Between Baseline and 8 Weeks

Control of the exodeviation was measured at distance using the IXT Office Control Score, (Mohney, 2006) which ranges from 0 (phoria) to 5 (constant exotropia). Control levels 3-5 were assigned based on the duration of manifest exotropia during a 30-second period before any dissociation. If no exotropia was observed, control levels 0-2 were assigned based on the longest time to reestablishing fusion after 3 consecutive 10-second periods of dissociation. Control was measured at the beginning, middle, and end (3 tests) of a 20- to 40-minute office examination, and the mean was used. The change in distance control from baseline to 8 weeks will be calculated. A negative value indicates improvement. (NCT03998670)
Timeframe: 8 Weeks

Intervention	units on a scale (Mean)
Prism Group	0.1
Non-Prism Group	-0.2

Exotropia Control Score at Distance, Continuous Score

The primary analysis will be an intent-to-treat comparison of mean 8-week control of the distance exodeviation (average of 3 measurements) between treatment groups using an analysis of covariance (ANCOVA) model, which adjusts for baseline distance control. Distance control scores range from 0 to 5 with higher scores indicating a worse outcome. (NCT03998670)
Timeframe: 8 weeks

Intervention	units on a scale (Mean)
Prism Group	3.6
Non-Prism Group	3.3

Exotropia Control Score at Near, Continuous Score

Near control will be evaluated similarly to the primary outcome and outcome measures 2-4. Near control scores range from 0 to 5 with higher scores indicating a worse outcome. (NCT03998670)
Timeframe: 8 Weeks

Intervention	units on a scale (Mean)
Prism Group	1.7
Non-Prism Group	1.7

Fusional Convergence - Continuous Break Point

As an exploratory analysis, the distribution of fusional convergence amplitude (break point, blur point, and recovery) at 8 weeks will be summarized for each treatment group. Fusional amplitudes are a measure of how well a participant can converge their eyes using fusional vergence. It is measured by increasing base-out prism to the point that the participant is no longer able to control the deviation. The total amount of fusion is the magnitude of the base-out prism the participant was able to overcome plus the magnitude of the deviation. A higher number of prism diopters for break point is better than a lower number. A lower number for recovery point is better than a higher number. (NCT03998670)
Timeframe: 8 Weeks

Intervention	prism diopters (Mean)
Prism Group	17.8
Non-Prism Group	17.5

Fusional Convergence - Continuous Recovery Point

As an exploratory analysis, the distribution of fusional convergence amplitude (break point, blur point, and recovery) at 8 weeks will be summarized for each treatment group. Fusional amplitudes are a measure of how well a participant can converge their eyes using fusional vergence. It is measured by increasing base-out prism to the point that the participant is no longer able to control the deviation. The total amount of fusion is the magnitude of the base-out prism the participant was able to overcome plus the magnitude of the deviation. A higher number of prism diopters for break point is better than a lower number. A lower number for recovery is better than a higher number. (NCT03998670)
Timeframe: 8 Weeks

Intervention	prism diopters (Mean)
Prism Group	9.4
Non-Prism Group	10.6

Randot Preschool Stereoacuity at Near, Continuous

Randot® Preschool Stereoacuity test (Stereo Optical Co., Inc., Chicago, IL). For analysis, stereoacuity was converted from seconds of arc scores to log arcsec values (in parentheses) as follows: 40 (1.60), 60 (1.78), 100 (2.00), 200 (2.30), 400 (2.60), 800 (2.90); participants with no detectable (nil) stereoacuity were assigned the value of 1600 (3.20). The measure of Randot Preschool Stereoacuity at near will be summarized at 8 weeks for each treatment group. A lower score is better. (NCT03998670)
Timeframe: 8 Weeks

Intervention	log arc seconds (Mean)
Prism Group	2.2
Non-Prism Group	1.9

Child Assessment of Symptoms - Do You Have Double Vision?

Adverse symptoms of intermittent exotropia will be summarized at the 8-week outcome exam using a symptom survey that is administered to the child. Response options are based on frequency of observations: never, sometimes, and always. The distribution of scores on each survey item will be tabulated by treatment group after 8-weeks. (NCT03998670)
Timeframe: 8 Weeks

Intervention	Participants (Count of Participants)
	Never	Sometimes	Almost Always
Non-Prism Group	17	7	1
Prism Group	17	8	0

Child Assessment of Symptoms - Do You Have Problems With Your Eyes in the Sun?

Intervention	Participants (Count of Participants)
	Never	Sometimes	Almost Always
Non-Prism Group	14	5	6
Prism Group	11	8	6

Child Assessment of Symptoms - Do Your Eyes Feel Funny?

Intervention	Participants (Count of Participants)
	Never	Sometimes	Almost Always
Non-Prism Group	20	3	2
Prism Group	17	7	1

Child Assessment of Symptoms - Do Your Eyes go in and Out?

Intervention	Participants (Count of Participants)
	Never	Sometimes	Almost Always
Non-Prism Group	19	3	3
Prism Group	20	2	3

Child Assessment of Symptoms - Do Your Eyes Hurt?

Intervention	Participants (Count of Participants)
	Never	Sometimes	Almost Always
Non-Prism Group	22	3	0
Prism Group	15	6	4

Child Assessment of Symptoms - Is it Hard for You to Stare at Things?

Intervention	Participants (Count of Participants)
	Never	Sometimes	Almost Always
Non-Prism Group	15	8	2
Prism Group	16	7	2

Child Assessment of Symptoms - Is it Hard to Focus Your Eyes?

Intervention	Participants (Count of Participants)
	Never	Sometimes	Almost Always
Non-Prism Group	12	11	2
Prism Group	16	5	4

Compliance of Spectacle Wear

"Parents will be asked to complete a compliance calendar by recording the percentage of time their child has worn the study-prescribed spectacle correction each day. Proportion of time worn each day will be described as excellent (76% to 100%), good (51% to 75%), fair (26% to 50%), poor (1 to 25%), or none (0%). Based on review of the calendars and discussion with parents at the 8-week outcome exam, the investigator will record the total proportion of time worn as excellent (76% to 100%), good (51% to 75%), fair (26% to 50%), poor (1 to 25%), or none (0%: did not fill prescription or never picked up spectacles).~The distribution of compliance will be assessed for each treatment group at the outcome exam." (NCT03998670)
Timeframe: 8 weeks

Intervention	Participants (Count of Participants)
	Excellent (76% to 100%)	Good (51% to 75%)	Fair (26% to 50%)	Poor (1% to 25%)	None (0%)
Non-Prism Group	22	2	1	0	0
Prism Group	22	3	0	0	0

Distance Visual Acuity (Snellen Equivalent)

Distance visual acuity will be assessed at the 8-week outcome exam. Any optotype method can be used for testing. The distribution of distance visual acuity Snellen Equivalents will be tabulated for each treatment group. A lower Snellen Equivalent is best. (NCT03998670)
Timeframe: 8 Weeks

Intervention	Participants (Count of Participants)
	20/16 (best)	20/20	20/25	20/32	20/40
Non-Prism Group	1	9	8	3	4
Prism Group	3	10	9	2	1

Parent Assessment of Symptoms and Spectacle Wear - Has Your Child Avoided Reading or Doing Things up Close?

"Adverse symptoms of intermittent exotropia and spectacle wear will be summarized at the 8-week outcome exam using a symptom survey that is administered to the parent.~Response options are based on frequency of observations: never, almost never, sometimes, often, and almost always. The distribution of scores on each survey item will be tabulated by treatment group after 8-weeks." (NCT03998670)
Timeframe: 8 Weeks

Intervention	Participants (Count of Participants)
	Never	Almost Never	Sometimes	Often	Almost Always
Non-Prism Group	15	6	3	1	0
Prism Group	22	2	0	1	0

Parent Assessment of Symptoms and Spectacle Wear - Has Your Child Complained That the Spectacles Hurt His/Her Ears and/or Nose?

Intervention	Participants (Count of Participants)
	Never	Almost Never	Sometimes	Often	Almost Always
Non-Prism Group	14	5	5	1	0
Prism Group	17	3	5	0	0

Parent Assessment of Symptoms and Spectacle Wear - Has Your Child Had Eyestrain?

Intervention	Participants (Count of Participants)
	Never	Almost Never	Sometimes	Often	Almost Always
Non-Prism Group	11	4	9	1	0
Prism Group	16	5	4	0	0

Parent Assessment of Symptoms and Spectacle Wear - Has Your Child Had Headaches?

Intervention	Participants (Count of Participants)
	Never	Almost Never	Sometimes	Often	Almost Always
Non-Prism Group	14	6	5	0	0
Prism Group	15	8	2	0	0

Parent Assessment of Symptoms and Spectacle Wear - Has Your Child Looked Over His or Her Spectacles?

Intervention	Participants (Count of Participants)
	Never	Almost Never	Sometimes	Often	Almost Always
Non-Prism Group	14	3	5	3	0
Prism Group	12	7	5	0	1

Parent Assessment of Symptoms and Spectacle Wear - Has Your Child Reported Blurry Vision?

Intervention	Participants (Count of Participants)
	Never	Almost Never	Sometimes	Often	Almost Always
Non-Prism Group	21	3	1	0	0
Prism Group	21	2	1	1	0

Parent Assessment of Symptoms and Spectacle Wear - Has Your Child Taken His/Her Spectacles Off When he/She Should be Wearing Them?

Intervention	Participants (Count of Participants)
	Never	Almost Never	Sometimes	Often	Almost Always
Non-Prism Group	10	5	8	1	1
Prism Group	5	11	6	3	0

Suppression

"The suppression assessment is a standardized method of assessing the depth of suppression experienced while the participant is tropic (NOT aligned). Scoring is reported on an ordinal scale from 0 (no suppression) to 3 (dense suppression). Missing refers to cases in which participants were unable to understand the test and/or gave unreliable responses. As an exploratory analysis, the distribution of suppression level (none, mild, moderate, severe, missing) will be tabulated after 8 weeks by treatment group." (NCT03998670)
Timeframe: 8 Weeks

Intervention	Participants (Count of Participants)
	None (0 suppression)	Mild (1 suppression)	Moderate (2 suppression)	Dense (3 suppression)	Missing
Non-Prism Group	5	3	4	10	3
Prism Group	1	5	6	12	1

Substance	Description	Relationhip Strength	Studies	Trials	Classes	Roles
chlorpromazine	[no description available]	medium	133	0	organochlorine compound; phenothiazines; tertiary amine	anticoronaviral agent; antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; phenothiazine antipsychotic drug
chlorpromazine	[no description available]	medium	133	3	organochlorine compound; phenothiazines; tertiary amine	anticoronaviral agent; antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; phenothiazine antipsychotic drug
oxolinic acid	[no description available]	medium	1	0	aromatic carboxylic acid; organic heterotricyclic compound; oxacycle; quinolinemonocarboxylic acid; quinolone antibiotic	antibacterial drug; antifungal agent; antiinfective agent; antimicrobial agent; enzyme inhibitor
temafloxacin	[no description available]	medium	1	0	amino acid; monocarboxylic acid; N-arylpiperazine; organofluorine compound; quinolone antibiotic; quinolone; secondary amino compound; tertiary amino compound
sk&f 10047	[no description available]	medium	2	0
amphetamine	[no description available]	medium	876	0	primary amine
amphetamine	[no description available]	medium	876	19	primary amine
stenopril	[no description available]	medium	1	0
l-amphetamine	[no description available]	medium	4	0	1-phenylpropan-2-amine
d-n-propylamphetamine	[no description available]	medium	2	0
dextroamphetamine	[no description available]	high	176	11	1-phenylpropan-2-amine	adrenergic agent; adrenergic uptake inhibitor; dopamine uptake inhibitor; dopaminergic agent; neurotoxin; sympathomimetic agent
dextroamphetamine	[no description available]	high	176	0	1-phenylpropan-2-amine	adrenergic agent; adrenergic uptake inhibitor; dopamine uptake inhibitor; dopaminergic agent; neurotoxin; sympathomimetic agent
1-phenethylamine, (s)-isomer	[no description available]	medium	1	0	1-phenylethylamine
1-phenethylamine, (r)-isomer	[no description available]	medium	1	0	1-phenylethylamine
choline	[no description available]	medium	22	0	cholines	allergen; Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; neurotransmitter; nutrient; plant metabolite; Saccharomyces cerevisiae metabolite
cimetidine	[no description available]	medium	9	0	aliphatic sulfide; guanidines; imidazoles; nitrile	adjuvant; analgesic; anti-ulcer drug; H2-receptor antagonist; P450 inhibitor
guanidine	[no description available]	medium	4	0	carboxamidine; guanidines; one-carbon compound
procainamide	[no description available]	medium	8	0	benzamides	anti-arrhythmia drug; platelet aggregation inhibitor; sodium channel blocker
1-methyl-4-phenylpyridinium	[no description available]	high	16	0	pyridinium ion	apoptosis inducer; herbicide; human xenobiotic metabolite; neurotoxin
nicotine	[no description available]	high	111	1	3-(1-methylpyrrolidin-2-yl)pyridine	anxiolytic drug; biomarker; immunomodulator; mitogen; neurotoxin; nicotinic acetylcholine receptor agonist; peripheral nervous system drug; phytogenic insecticide; plant metabolite; psychotropic drug; teratogenic agent; xenobiotic
nicotine	[no description available]	high	111	0	3-(1-methylpyrrolidin-2-yl)pyridine	anxiolytic drug; biomarker; immunomodulator; mitogen; neurotoxin; nicotinic acetylcholine receptor agonist; peripheral nervous system drug; phytogenic insecticide; plant metabolite; psychotropic drug; teratogenic agent; xenobiotic
desipramine	[no description available]	medium	36	0	dibenzoazepine; secondary amino compound	adrenergic uptake inhibitor; alpha-adrenergic antagonist; antidepressant; cholinergic antagonist; drug allergen; EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; serotonin uptake inhibitor
desipramine	[no description available]	medium	36	1	dibenzoazepine; secondary amino compound	adrenergic uptake inhibitor; alpha-adrenergic antagonist; antidepressant; cholinergic antagonist; drug allergen; EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; serotonin uptake inhibitor
corticosterone	[no description available]	medium	66	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone	human metabolite; mouse metabolite
corticosterone	[no description available]	medium	66	1	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone	human metabolite; mouse metabolite
desoxycorticosterone	[no description available]	medium	3	0	20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; mineralocorticoid; primary alpha-hydroxy ketone	human metabolite; mouse metabolite
desoxycorticosterone	[no description available]	medium	3	1	20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; mineralocorticoid; primary alpha-hydroxy ketone	human metabolite; mouse metabolite
betaine	[no description available]	medium	4	0	amino-acid betaine; glycine derivative	fundamental metabolite
carnitine	[no description available]	medium	7	0	amino-acid betaine	human metabolite; mouse metabolite
thiamine	[no description available]	medium	9	0	primary alcohol; vitamin B1	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	[no description available]	high	39	0	methylpyridines; phenylpyridine; tetrahydropyridine	neurotoxin
clonidine	[no description available]	medium	21	0	clonidine; imidazoline
tetraethylammonium	[no description available]	medium	5	0	quaternary ammonium ion
tetramethylammonium chloride	[no description available]	medium	1	0	organic molecular entity
tetrahexylammonium	[no description available]	medium	1	0
propionylcarnitine	[no description available]	medium	1	0	O-acylcarnitine	analgesic; antirheumatic drug; cardiotonic drug; human metabolite; peripheral nervous system drug
acetylcarnitine	[no description available]	medium	2	0	O-acetylcarnitine; saturated fatty acyl-L-carnitine	human metabolite; Saccharomyces cerevisiae metabolite
4-hydroxybenzoic acid	[no description available]	medium	1	0	monohydroxybenzoic acid	algal metabolite; plant metabolite
acetic acid	[no description available]	medium	6	0	monocarboxylic acid	antimicrobial food preservative; Daphnia magna metabolite; food acidity regulator; protic solvent
acetone	[no description available]	medium	17	0	ketone body; methyl ketone; propanones; volatile organic compound	EC 3.5.1.4 (amidase) inhibitor; human metabolite; polar aprotic solvent
benzaldehyde	[no description available]	medium	3	0	benzaldehydes	EC 3.1.1.3 (triacylglycerol lipase) inhibitor; EC 3.5.5.1 (nitrilase) inhibitor; flavouring agent; fragrance; odorant receptor agonist; plant metabolite
benzene	[no description available]	high	2	0	aromatic annulene; benzenes; volatile organic compound	carcinogenic agent; environmental contaminant; non-polar solvent
benzoic acid	[no description available]	medium	2	0	benzoic acids	algal metabolite; antimicrobial food preservative; drug allergen; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 3.1.1.3 (triacylglycerol lipase) inhibitor; human xenobiotic metabolite; plant metabolite
benzyl alcohol	[no description available]	medium	2	0	benzyl alcohols	antioxidant; fragrance; metabolite; solvent
1-butanol	[no description available]	medium	1	0	alkyl alcohol; primary alcohol; short-chain primary fatty alcohol	human metabolite; mouse metabolite; protic solvent
butyric acid	[no description available]	medium	3	0	fatty acid 4:0; straight-chain saturated fatty acid	human urinary metabolite; Mycoplasma genitalium metabolite
chloroacetic acid	[no description available]	medium	1	0	chlorocarboxylic acid; haloacetic acid	alkylating agent; herbicide
2-cresol	[no description available]	medium	1	0	cresol	human xenobiotic metabolite
salicylic acid	[no description available]	medium	12	0	monohydroxybenzoic acid	algal metabolite; antifungal agent; antiinfective agent; EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor; keratolytic drug; plant hormone; plant metabolite
3-cresol	[no description available]	medium	1	0	cresol	human xenobiotic metabolite
guaiacol	[no description available]	medium	2	0	guaiacols	disinfectant; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; expectorant; plant metabolite
indole	[no description available]	medium	1	0	indole; polycyclic heteroarene	Escherichia coli metabolite
methanol	[no description available]	medium	7	0	alkyl alcohol; one-carbon compound; primary alcohol; volatile organic compound	amphiprotic solvent; Escherichia coli metabolite; fuel; human metabolite; mouse metabolite; Mycoplasma genitalium metabolite
acetanilide	[no description available]	medium	1	0	acetamides; anilide	analgesic
n,n-dimethylaniline	[no description available]	medium	1	0	dimethylaniline; tertiary amine
4-nitrophenol	[no description available]	medium	1	0	4-nitrophenols	human xenobiotic metabolite; mouse metabolite
phenol	[no description available]	medium	2	0	phenols	antiseptic drug; disinfectant; human xenobiotic metabolite; mouse metabolite
phenylacetic acid	[no description available]	medium	2	0	benzenes; monocarboxylic acid; phenylacetic acids	allergen; Aspergillus metabolite; auxin; EC 6.4.1.1 (pyruvate carboxylase) inhibitor; Escherichia coli metabolite; human metabolite; plant growth retardant; plant metabolite; Saccharomyces cerevisiae metabolite; toxin
1-propanol	[no description available]	medium	9	0	propan-1-ols; short-chain primary fatty alcohol	metabolite; protic solvent
propionic acid	[no description available]	medium	2	0	saturated fatty acid; short-chain fatty acid	antifungal drug
pyridine	[no description available]	medium	3	0	azaarene; mancude organic heteromonocyclic parent; monocyclic heteroarene; pyridines	environmental contaminant; NMR chemical shift reference compound
dimethyl sulfide	[no description available]	medium	1	0	aliphatic sulfide	algal metabolite; bacterial xenobiotic metabolite; EC 3.5.1.4 (amidase) inhibitor; Escherichia coli metabolite; marine metabolite
thiophane	[no description available]	medium	1	0	saturated organic heteromonocyclic parent; tetrahydrothiophenes
toluene	[no description available]	high	11	0	methylbenzene; toluenes; volatile organic compound	cholinergic antagonist; fuel additive; neurotoxin; non-polar solvent
phenytoin	[no description available]	medium	17	0	imidazolidine-2,4-dione	anticonvulsant; drug allergen; sodium channel blocker; teratogenic agent
phenytoin	[no description available]	medium	17	1	imidazolidine-2,4-dione	anticonvulsant; drug allergen; sodium channel blocker; teratogenic agent
alprenolol	[no description available]	medium	4	0	secondary alcohol; secondary amino compound	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent
theophylline	[no description available]	medium	19	0	dimethylxanthine	adenosine receptor antagonist; anti-asthmatic drug; anti-inflammatory agent; bronchodilator agent; drug metabolite; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; fungal metabolite; human blood serum metabolite; immunomodulator; muscle relaxant; vasodilator agent
antipyrine	[no description available]	high	3	0	pyrazolone	antipyretic; cyclooxygenase 3 inhibitor; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
astemizole	[no description available]	medium	1	0	benzimidazoles; piperidines	anti-allergic agent; anticoronaviral agent; H1-receptor antagonist
atenolol	[no description available]	high	6	0	ethanolamines; monocarboxylic acid amide; propanolamine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; environmental contaminant; sympatholytic agent; xenobiotic
barbital	[no description available]	medium	8	0	barbiturates	drug allergen
benzamide	[no description available]	medium	7	0	benzamides
verapamil	[no description available]	medium	9	0	aromatic ether; nitrile; polyether; tertiary amino compound
chlorpheniramine	[no description available]	medium	15	0	monochlorobenzenes; pyridines; tertiary amino compound	anti-allergic agent; antidepressant; antipruritic drug; H1-receptor antagonist; histamine antagonist; serotonin uptake inhibitor
chlorpheniramine	[no description available]	medium	15	1	monochlorobenzenes; pyridines; tertiary amino compound	anti-allergic agent; antidepressant; antipruritic drug; H1-receptor antagonist; histamine antagonist; serotonin uptake inhibitor
ciprofloxacin	[no description available]	medium	6	0	aminoquinoline; cyclopropanes; fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone; zwitterion	antibacterial drug; antiinfective agent; antimicrobial agent; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; environmental contaminant; topoisomerase IV inhibitor; xenobiotic
4-cresol	[no description available]	medium	1	0	cresol	Escherichia coli metabolite; human metabolite; uremic toxin
nordazepam	[no description available]	medium	5	0	1,4-benzodiazepinone; organochlorine compound	anticonvulsant; anxiolytic drug; GABA modulator; human metabolite; sedative
diazepam	[no description available]	high	67	1	1,4-benzodiazepinone; organochlorine compound	anticonvulsant; anxiolytic drug; environmental contaminant; sedative; xenobiotic
diazepam	[no description available]	high	67	0	1,4-benzodiazepinone; organochlorine compound	anticonvulsant; anxiolytic drug; environmental contaminant; sedative; xenobiotic
diphenhydramine	[no description available]	medium	16	0	ether; tertiary amino compound	anti-allergic agent; antidyskinesia agent; antiemetic; antiparkinson drug; antipruritic drug; antitussive; H1-receptor antagonist; local anaesthetic; muscarinic antagonist; oneirogen; sedative
diphenhydramine	[no description available]	medium	16	1	ether; tertiary amino compound	anti-allergic agent; antidyskinesia agent; antiemetic; antiparkinson drug; antipruritic drug; antitussive; H1-receptor antagonist; local anaesthetic; muscarinic antagonist; oneirogen; sedative
epinastine	[no description available]	medium	1	0	benzazepine; guanidines	anti-allergic agent; H1-receptor antagonist; histamine antagonist; ophthalmology drug
flumequine	[no description available]	medium	2	0	3-oxo monocarboxylic acid; organofluorine compound; pyridoquinoline; quinolone antibiotic
fluoxetine	[no description available]	medium	33	0	(trifluoromethyl)benzenes; aromatic ether; secondary amino compound
fluoxetine	[no description available]	medium	33	1	(trifluoromethyl)benzenes; aromatic ether; secondary amino compound
flurbiprofen	[no description available]	medium	4	0	fluorobiphenyl; monocarboxylic acid	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
furosemide	[no description available]	medium	7	0	chlorobenzoic acid; furans; sulfonamide	environmental contaminant; loop diuretic; xenobiotic
haloperidol	[no description available]	medium	192	0	aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol	antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist
haloperidol	[no description available]	medium	192	3	aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol	antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist
hexobarbital	[no description available]	medium	21	0	barbiturates
hydroxyzine	[no description available]	medium	7	0	hydroxyether; monochlorobenzenes; N-alkylpiperazine	anticoronaviral agent; antipruritic drug; anxiolytic drug; dermatologic drug; H1-receptor antagonist
hydroxyzine	[no description available]	medium	7	1	hydroxyether; monochlorobenzenes; N-alkylpiperazine	anticoronaviral agent; antipruritic drug; anxiolytic drug; dermatologic drug; H1-receptor antagonist
ibuprofen	[no description available]	high	8	0	monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; radical scavenger; xenobiotic
lidocaine	[no description available]	high	12	0	benzenes; monocarboxylic acid amide; tertiary amino compound	anti-arrhythmia drug; drug allergen; environmental contaminant; local anaesthetic; xenobiotic
imipramine	[no description available]	medium	89	0	dibenzoazepine	adrenergic uptake inhibitor; antidepressant; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
imipramine	[no description available]	medium	89	1	dibenzoazepine	adrenergic uptake inhibitor; antidepressant; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
indomethacin	[no description available]	high	11	0	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic
2-propanol	[no description available]	medium	5	0	secondary alcohol; secondary fatty alcohol	protic solvent
ketoprofen	[no description available]	high	7	0	benzophenones; oxo monocarboxylic acid	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-steroidal anti-inflammatory drug; xenobiotic
loratadine	[no description available]	medium	4	0	benzocycloheptapyridine; ethyl ester; N-acylpiperidine; organochlorine compound; tertiary carboxamide	anti-allergic agent; cholinergic antagonist; geroprotector; H1-receptor antagonist
metolazone	[no description available]	medium	3	0	organochlorine compound; quinazolines; sulfonamide	antihypertensive agent; diuretic; ion transport inhibitor
metoprolol	[no description available]	high	9	0	aromatic ether; propanolamine; secondary alcohol; secondary amino compound	antihypertensive agent; beta-adrenergic antagonist; environmental contaminant; geroprotector; xenobiotic
oxazepam	[no description available]	high	14	0	1,4-benzodiazepinone; organochlorine compound	anxiolytic drug; environmental contaminant; xenobiotic
oxprenolol	[no description available]	medium	3	0	aromatic ether
papaverine	[no description available]	medium	6	0	benzylisoquinoline alkaloid; dimethoxybenzene; isoquinolines	antispasmodic drug; vasodilator agent
4-chlorophenol	[no description available]	medium	1	0	monochlorophenol
pentobarbital	[no description available]	medium	76	0	barbiturates	GABAA receptor agonist
pentobarbital	[no description available]	medium	76	4	barbiturates	GABAA receptor agonist
phenazopyridine	[no description available]	medium	1	0	diaminopyridine; monoazo compound	anticoronaviral agent; carcinogenic agent; local anaesthetic; non-narcotic analgesic
phenobarbital	[no description available]	medium	52	0	barbiturates	anticonvulsant; drug allergen; excitatory amino acid antagonist; sedative
phenobarbital	[no description available]	medium	52	1	barbiturates	anticonvulsant; drug allergen; excitatory amino acid antagonist; sedative
pindolol	[no description available]	medium	4	0	indoles; secondary amine	antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist; serotonergic antagonist; vasodilator agent
practolol	[no description available]	medium	2	0	acetamides; ethanolamines; propanolamine; secondary alcohol; secondary amino compound	anti-arrhythmia drug; beta-adrenergic antagonist
procaine	[no description available]	medium	6	0	benzoate ester; substituted aniline; tertiary amino compound	central nervous system depressant; drug allergen; local anaesthetic; peripheral nervous system drug
propranolol	[no description available]	high	41	1	naphthalenes; propanolamine; secondary amine	anti-arrhythmia drug; antihypertensive agent; anxiolytic drug; beta-adrenergic antagonist; environmental contaminant; human blood serum metabolite; vasodilator agent; xenobiotic
propranolol	[no description available]	high	41	0	naphthalenes; propanolamine; secondary amine	anti-arrhythmia drug; antihypertensive agent; anxiolytic drug; beta-adrenergic antagonist; environmental contaminant; human blood serum metabolite; vasodilator agent; xenobiotic
pyrilamine	[no description available]	medium	7	0	aromatic ether; ethylenediamine derivative	H1-receptor antagonist
secobarbital	[no description available]	medium	8	0	barbiturates	anaesthesia adjuvant; GABA modulator; sedative
secobarbital	[no description available]	medium	8	2	barbiturates	anaesthesia adjuvant; GABA modulator; sedative
sulfasalazine	[no description available]	medium	5	0
sulpiride	[no description available]	medium	52	0	benzamides; N-alkylpyrrolidine; sulfonamide	antidepressant; antiemetic; antipsychotic agent; dopaminergic antagonist
terfenadine	[no description available]	medium	3	0	diarylmethane
tetracaine	[no description available]	medium	3	0	benzoate ester; tertiary amino compound	local anaesthetic
ultram	[no description available]	medium	4	0	aromatic ether; tertiary alcohol; tertiary amino compound
tranexamic acid	[no description available]	medium	4	0	amino acid
estriol	[no description available]	medium	3	0	16alpha-hydroxy steroid; 17beta-hydroxy steroid; 3-hydroxy steroid	estrogen; human metabolite; human xenobiotic metabolite; mouse metabolite
aldosterone	[no description available]	medium	2	0	11beta-hydroxy steroid; 18-oxo steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid hormone; mineralocorticoid; primary alpha-hydroxy ketone; steroid aldehyde	human metabolite; mouse metabolite
estrone	[no description available]	medium	3	0	17-oxo steroid; 3-hydroxy steroid; phenolic steroid; phenols	antineoplastic agent; bone density conservation agent; estrogen; human metabolite; mouse metabolite
physostigmine	[no description available]	medium	39	0	carbamate ester; indole alkaloid	antidote to curare poisoning; EC 3.1.1.8 (cholinesterase) inhibitor; miotic
physostigmine	[no description available]	medium	39	1	carbamate ester; indole alkaloid	antidote to curare poisoning; EC 3.1.1.8 (cholinesterase) inhibitor; miotic
aminopyrine	[no description available]	high	7	0	pyrazolone; tertiary amino compound	antipyretic; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
aniline	[no description available]	medium	1	0	anilines; primary arylamine
chloroform	[no description available]	medium	9	0	chloromethanes; one-carbon compound	carcinogenic agent; central nervous system drug; inhalation anaesthetic; non-polar solvent; refrigerant
mannitol	[no description available]	medium	4	0	mannitol	allergen; antiglaucoma drug; compatible osmolytes; Escherichia coli metabolite; food anticaking agent; food bulking agent; food humectant; food stabiliser; food thickening agent; hapten; metabolite; osmotic diuretic; sweetening agent
n-pentanol	[no description available]	medium	3	0	pentanol; short-chain primary fatty alcohol	human metabolite; plant metabolite
1,1,1-trichloroethane	[no description available]	medium	1	0	chloroethanes	polar solvent
ethylamine	[no description available]	medium	2	0	primary aliphatic amine	human metabolite
tert-butyl alcohol	[no description available]	medium	1	0	tertiary alcohol	human xenobiotic metabolite
trichloroacetic acid	[no description available]	medium	5	0	monocarboxylic acid; organochlorine compound	carcinogenic agent; metabolite; mouse metabolite
isobutyl alcohol	[no description available]	medium	1	0	alkyl alcohol; primary alcohol	Saccharomyces cerevisiae metabolite
methylethyl ketone	[no description available]	medium	3	0	butanone; dialkyl ketone; methyl ketone; volatile organic compound	bacterial metabolite; polar aprotic solvent
methyl acetate	[no description available]	medium	1	0	acetate ester; methyl ester; volatile organic compound	EC 3.4.19.3 (pyroglutamyl-peptidase I) inhibitor; fragrance; polar aprotic solvent
dichloroacetic acid	[no description available]	medium	2	0	monocarboxylic acid; organochlorine compound	astringent; marine metabolite
2,6-dichlorophenol	[no description available]	medium	1	0	dichlorophenol
2-tert-butylphenol	[no description available]	medium	1	0	alkylbenzene
2-isopropylphenol	[no description available]	medium	1	0	phenols
2-nitroaniline	[no description available]	medium	1	0
2-nitrophenol	[no description available]	medium	1	0	2-nitrophenols
thymol	[no description available]	medium	1	0	monoterpenoid; phenols	volatile oil component
1-naphthol	[no description available]	medium	1	0	naphthol	genotoxin; human xenobiotic metabolite
quinoline	[no description available]	medium	1	0	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinolines
diphenyl	[no description available]	medium	1	0	aromatic fungicide; benzenes; biphenyls	antifungal agrochemical; antimicrobial food preservative
methyl benzoate	[no description available]	medium	1	0	benzoate ester; methyl ester	insect attractant; metabolite
2-toluidine	[no description available]	medium	1	0	aminotoluene	carcinogenic agent
2-bromophenol	[no description available]	medium	1	0	bromophenol	marine metabolite
2-chlorophenol	[no description available]	medium	1	0	2-halophenol; monochlorophenol
3,4-dimethylphenol	[no description available]	medium	1	0	phenols
2,5-xylenol	[no description available]	medium	1	0	phenols	animal metabolite; volatile oil component
butylphen	[no description available]	medium	1	0	phenols	allergen
acetophenone	[no description available]	medium	1	0	acetophenones	animal metabolite; photosensitizing agent; xenobiotic
nitrobenzene	[no description available]	medium	1	0	nitroarene; nitrobenzenes
3-nitroaniline	[no description available]	medium	1	0
4-nitroaniline	[no description available]	medium	1	0	nitroaniline	bacterial xenobiotic metabolite
4-anisic acid	[no description available]	medium	1	0	methoxybenzoic acid	plant metabolite
benzylamine	[no description available]	medium	1	0	aralkylamine; primary amine	allergen; EC 3.5.5.1 (nitrilase) inhibitor; plant metabolite
benzonitrile	[no description available]	medium	1	0	benzenes; nitrile
methylaniline	[no description available]	medium	1	0	methylaniline; phenylalkylamine; secondary amine
anisole	[no description available]	medium	1	0	monomethoxybenzene	plant metabolite
methylphenylsulfide	[no description available]	medium	1	0	aryl sulfide; benzenes
2,4-dimethylphenol	[no description available]	medium	1	0	aromatic fungicide; phenols	disinfectant; volatile oil component
4-bromophenol	[no description available]	medium	1	0	bromophenol	human urinary metabolite; human xenobiotic metabolite; marine metabolite; mouse metabolite; persistent organic pollutant; rat metabolite
4-chloroaniline	[no description available]	medium	1	0	chloroaniline; monochlorobenzenes
4-toluidine	[no description available]	medium	1	0	aminotoluene
propylamine	[no description available]	medium	1	0	alkylamines
2-pentanone	[no description available]	medium	1	0	methyl ketone; pentanone	plant metabolite
3-chloroaniline	[no description available]	medium	1	0
3-chlorophenol	[no description available]	medium	1	0	monochlorophenol
3,5-xylenol	[no description available]	medium	1	0	phenols	xenobiotic metabolite
bromobenzene	[no description available]	medium	1	0	bromoarene; bromobenzenes; volatile organic compound	hepatotoxic agent; mouse metabolite; non-polar solvent
chlorobenzene	[no description available]	medium	1	0	monochlorobenzenes	solvent
propyl acetate	[no description available]	medium	1	0	acetate ester	fragrance; plant metabolite
pentane	[no description available]	medium	2	0	alkane; volatile organic compound	non-polar solvent; refrigerant
n-butylamine	[no description available]	medium	2	0	primary aliphatic amine
1-hexanol	[no description available]	medium	1	0	hexanol; primary alcohol	alarm pheromone; antibacterial agent; fragrance; plant metabolite
heptanol	[no description available]	medium	1	0	heptanol; primary alcohol	flavouring agent; fragrance; gap junctional intercellular communication inhibitor; plant metabolite
isoquinoline	[no description available]	medium	1	0	azaarene; isoquinolines; mancude organic heterobicyclic parent; ortho-fused heteroarene
3-nitrobenzoic acid	[no description available]	medium	1	0
2-naphthol	[no description available]	medium	2	0	naphthol	antinematodal drug; genotoxin; human urinary metabolite; human xenobiotic metabolite; mouse metabolite; radical scavenger
ethyl acetate	[no description available]	medium	2	0	acetate ester; ethyl ester; volatile organic compound	EC 3.4.19.3 (pyroglutamyl-peptidase I) inhibitor; metabolite; polar aprotic solvent; Saccharomyces cerevisiae metabolite
hexanoic acid	[no description available]	medium	1	0	medium-chain fatty acid; straight-chain saturated fatty acid	human metabolite; plant metabolite
pregnenolone	[no description available]	medium	2	0	20-oxo steroid; 3beta-hydroxy-Delta(5)-steroid; C21-steroid	human metabolite; mouse metabolite
3-hydroxyanisole	[no description available]	medium	1	0	monomethoxybenzene; phenols
mequinol	[no description available]	medium	2	0	methoxybenzenes; phenols	metabolite
ephedrine	[no description available]	high	200	0	phenethylamine alkaloid; phenylethanolamines	bacterial metabolite; environmental contaminant; nasal decongestant; plant metabolite; sympathomimetic agent; vasoconstrictor agent; xenobiotic
3-fluorophenol	[no description available]	medium	1	0
fluorobenzenes	[no description available]	medium	5	0	monofluorobenzenes	NMR chemical shift reference compound
3-nitrophenol	[no description available]	medium	1	0	3-nitrophenols
lactulose	[no description available]	medium	3	0	glycosylfructose	gastrointestinal drug; laxative
2,6-xylenol	[no description available]	medium	1	0	hydroxytoluene
2-methoxybenzoic acid	[no description available]	medium	1	0	methoxybenzoic acid	flavouring agent; non-steroidal anti-inflammatory drug
3,5-dichlorophenol	[no description available]	medium	1	0	dichlorophenol
iodobenzene	[no description available]	medium	1	0
methyl n-butyl ketone	[no description available]	medium	1	0	ketone
2-cyanophenol	[no description available]	medium	1	0	benzenes; nitrile
4-cyanophenol	[no description available]	medium	1	0	phenols	EC 1.4.3.4 (monoamine oxidase) inhibitor
4-phenylpyridine	[no description available]	medium	1	0	phenylpyridine
diphenyl sulfoxide	[no description available]	medium	1	0	sulfoxide
methyl phenyl sulfoxide	[no description available]	medium	1	0	benzenes; sulfoxide
azatadine	[no description available]	medium	1	0	benzocycloheptapyridine; tertiary amine	anti-allergic agent; H1-receptor antagonist
dimethindene	[no description available]	medium	1	0	indene
olsalazine	[no description available]	medium	3	0	azobenzenes; dicarboxylic acid	non-steroidal anti-inflammatory drug; prodrug
timolol	[no description available]	medium	5	0	timolol	anti-arrhythmia drug; antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist
penbutolol	[no description available]	medium	2	0	ethanolamines
diltiazem	[no description available]	medium	9	0	5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate	antihypertensive agent; calcium channel blocker; vasodilator agent
foscarnet sodium	[no description available]	medium	2	0	one-carbon compound; organic sodium salt	antiviral drug
cicletanine	[no description available]	medium	1	0	organochlorine compound
temelastine	[no description available]	medium	1	0	pyrimidone
4-trifluoromethylphenol	[no description available]	medium	1	0	(trifluoromethyl)benzenes; phenols	drug metabolite; marine xenobiotic metabolite
naproxen	[no description available]	high	7	0	methoxynaphthalene; monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; gout suppressant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
cortisone	[no description available]	medium	3	0	11-oxo steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	human metabolite; mouse metabolite
raffinose	[no description available]	medium	1	0	raffinose family oligosaccharide; trisaccharide	mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
cortodoxone	[no description available]	medium	1	0	deoxycortisol; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	human metabolite; mouse metabolite
thiopental	[no description available]	high	16	1	barbiturates	anticonvulsant; drug allergen; environmental contaminant; intravenous anaesthetic; sedative; xenobiotic
thiopental	[no description available]	high	16	0	barbiturates	anticonvulsant; drug allergen; environmental contaminant; intravenous anaesthetic; sedative; xenobiotic
quinine	[no description available]	medium	17	0	cinchona alkaloid	antimalarial; muscle relaxant; non-narcotic analgesic
diclofenac sodium	[no description available]	medium	1	0	organic sodium salt
guanabenz	[no description available]	medium	1	0	dichlorobenzene
nifuroxime	[no description available]	medium	1	0
warfarin	[no description available]	medium	10	0	benzenes; hydroxycoumarin; methyl ketone
quinacrine	[no description available]	medium	5	0	acridines; aromatic ether; organochlorine compound; tertiary amino compound	antimalarial; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor
aminocaproic acid	[no description available]	medium	3	0	amino acid zwitterion; epsilon-amino acid; omega-amino fatty acid	antifibrinolytic drug; hematologic agent; metabolite
1-(3-chlorophenyl)piperazine	[no description available]	medium	6	0	monochlorobenzenes; N-arylpiperazine	drug metabolite; environmental contaminant; serotonergic agonist; xenobiotic
enprofylline	[no description available]	medium	1	0	oxopurine	anti-arrhythmia drug; anti-asthmatic drug; bronchodilator agent; non-steroidal anti-inflammatory drug
tacrine	[no description available]	medium	5	0	acridines; aromatic amine	EC 3.1.1.7 (acetylcholinesterase) inhibitor
acebutolol	[no description available]	medium	4	0	aromatic amide; ethanolamines; ether; monocarboxylic acid amide; propanolamine; secondary amino compound	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympathomimetic agent
acetaminophen	[no description available]	high	9	0	acetamides; phenols	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; cyclooxygenase 3 inhibitor; environmental contaminant; ferroptosis inducer; geroprotector; hepatotoxic agent; human blood serum metabolite; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
acetazolamide	[no description available]	medium	5	0	monocarboxylic acid amide; sulfonamide; thiadiazoles	anticonvulsant; diuretic; EC 4.2.1.1 (carbonic anhydrase) inhibitor
albuterol	[no description available]	high	5	0	phenols; phenylethanolamines; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; environmental contaminant; xenobiotic
alfuzosin	[no description available]	medium	3	0	monocarboxylic acid amide; quinazolines; tetrahydrofuranol	alpha-adrenergic antagonist; antihypertensive agent; antineoplastic agent
alosetron	[no description available]	medium	2	0	imidazoles; pyridoindole	antiemetic; gastrointestinal drug; serotonergic antagonist
alprazolam	[no description available]	high	11	2	organochlorine compound; triazolobenzodiazepine	anticonvulsant; anxiolytic drug; GABA agonist; muscle relaxant; sedative; xenobiotic
alprazolam	[no description available]	high	11	0	organochlorine compound; triazolobenzodiazepine	anticonvulsant; anxiolytic drug; GABA agonist; muscle relaxant; sedative; xenobiotic
amantadine	[no description available]	medium	14	0	adamantanes; primary aliphatic amine	analgesic; antiparkinson drug; antiviral drug; dopaminergic agent; NMDA receptor antagonist; non-narcotic analgesic
diatrizoic acid	[no description available]	medium	2	0	acetamides; benzoic acids; organoiodine compound	environmental contaminant; radioopaque medium; xenobiotic
amiodarone	[no description available]	medium	5	0	1-benzofurans; aromatic ketone; organoiodine compound; tertiary amino compound	cardiovascular drug
amitriptyline	[no description available]	high	30	0	carbotricyclic compound; tertiary amine	adrenergic uptake inhibitor; antidepressant; environmental contaminant; tropomyosin-related kinase B receptor agonist; xenobiotic
amlodipine	[no description available]	medium	5	0	dihydropyridine; ethyl ester; methyl ester; monochlorobenzenes; primary amino compound	antihypertensive agent; calcium channel blocker; vasodilator agent
amsacrine	[no description available]	medium	3	0	acridines; aromatic ether; sulfonamide	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
aspirin	[no description available]	medium	14	0	benzoic acids; phenyl acetates; salicylates	anticoagulant; antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; EC 1.1.1.188 (prostaglandin-F synthase) inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; plant activator; platelet aggregation inhibitor; prostaglandin antagonist; teratogenic agent
azelastine	[no description available]	medium	2	0	monochlorobenzenes; phthalazines; tertiary amino compound	anti-allergic agent; anti-asthmatic drug; bronchodilator agent; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; H1-receptor antagonist; platelet aggregation inhibitor
betaxolol	[no description available]	medium	3	0	propanolamine	antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent
bevantolol	[no description available]	medium	1	0	propanolamine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; calcium channel blocker
biperiden	[no description available]	medium	8	0	piperidines; tertiary alcohol; tertiary amino compound	antidote to sarin poisoning; antidyskinesia agent; antiparkinson drug; muscarinic antagonist; parasympatholytic
bisoprolol	[no description available]	medium	4	0	secondary alcohol; secondary amine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent
bromazepam	[no description available]	medium	3	0	organic molecular entity
bromopride	[no description available]	medium	1	0	benzamides
brotizolam	[no description available]	medium	2	0	organic molecular entity
buflomedil	[no description available]	medium	3	0	aromatic ketone
bumetanide	[no description available]	medium	4	0	amino acid; benzoic acids; sulfonamide	diuretic; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor
bunazosin	[no description available]	medium	1	0	quinazolines
bupivacaine	[no description available]	medium	2	0	aromatic amide; piperidinecarboxamide; tertiary amino compound
busulfan	[no description available]	medium	4	0	methanesulfonate ester	alkylating agent; antineoplastic agent; carcinogenic agent; insect sterilant; teratogenic agent
caffeine	[no description available]	high	104	4	purine alkaloid; trimethylxanthine	adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic
caffeine	[no description available]	high	104	0	purine alkaloid; trimethylxanthine	adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic
metrizoate	[no description available]	medium	1	0	monocarboxylic acid	radioopaque medium
carmustine	[no description available]	medium	3	0	N-nitrosoureas; organochlorine compound	alkylating agent; antineoplastic agent
carvedilol	[no description available]	medium	6	0	carbazoles; secondary alcohol; secondary amino compound	alpha-adrenergic antagonist; antihypertensive agent; beta-adrenergic antagonist; cardiovascular drug; vasodilator agent
chlorambucil	[no description available]	medium	3	0	aromatic amine; monocarboxylic acid; nitrogen mustard; organochlorine compound; tertiary amino compound	alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent
chlordiazepoxide	[no description available]	medium	42	0	benzodiazepine
chlordiazepoxide	[no description available]	medium	42	1	benzodiazepine
chloroquine	[no description available]	medium	6	0	aminoquinoline; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; autophagy inhibitor; dermatologic drug
chlorpropamide	[no description available]	medium	6	0	monochlorobenzenes; N-sulfonylurea	hypoglycemic agent; insulin secretagogue
chlorthalidone	[no description available]	medium	2	0	isoindoles; monochlorobenzenes; sulfonamide
cifenline	[no description available]	medium	1	0	diarylmethane
citalopram	[no description available]	medium	16	0	2-benzofurans; cyclic ether; nitrile; organofluorine compound; tertiary amino compound
clomipramine	[no description available]	medium	16	0	dibenzoazepine	anticoronaviral agent; antidepressant; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; serotonergic antagonist; serotonergic drug; serotonin uptake inhibitor
clonazepam	[no description available]	medium	12	0	1,4-benzodiazepinone; monochlorobenzenes	anticonvulsant; anxiolytic drug; GABA modulator
clonazepam	[no description available]	medium	12	1	1,4-benzodiazepinone; monochlorobenzenes	anticonvulsant; anxiolytic drug; GABA modulator
chlorazepate	[no description available]	medium	2	0	1,4-benzodiazepinone	anticonvulsant; anxiolytic drug; GABA modulator; prodrug
dapsone	[no description available]	medium	4	0	substituted aniline; sulfone	anti-inflammatory drug; antiinfective agent; antimalarial; leprostatic drug
diazoxide	[no description available]	medium	3	0	benzothiadiazine; organochlorine compound; sulfone	antihypertensive agent; beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; diuretic; K-ATP channel agonist; sodium channel blocker; sympathomimetic agent; vasodilator agent
diclofenac	[no description available]	high	9	0	amino acid; aromatic amine; dichlorobenzene; monocarboxylic acid; secondary amino compound	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
diflunisal	[no description available]	medium	4	0	monohydroxybenzoic acid; organofluorine compound	non-narcotic analgesic; non-steroidal anti-inflammatory drug
disopyramide	[no description available]	medium	4	0	monocarboxylic acid amide; pyridines; tertiary amino compound	anti-arrhythmia drug
valproic acid	[no description available]	high	19	1	branched-chain fatty acid; branched-chain saturated fatty acid	anticonvulsant; antimanic drug; EC 3.5.1.98 (histone deacetylase) inhibitor; GABA agent; neuroprotective agent; psychotropic drug; teratogenic agent
valproic acid	[no description available]	high	19	0	branched-chain fatty acid; branched-chain saturated fatty acid	anticonvulsant; antimanic drug; EC 3.5.1.98 (histone deacetylase) inhibitor; GABA agent; neuroprotective agent; psychotropic drug; teratogenic agent
domperidone	[no description available]	medium	3	0	benzimidazoles; heteroarylpiperidine	antiemetic; dopaminergic antagonist
domperidone	[no description available]	medium	3	1	benzimidazoles; heteroarylpiperidine	antiemetic; dopaminergic antagonist
doxapram	[no description available]	high	3	0	morpholines; pyrrolidin-2-ones	central nervous system stimulant
doxazosin	[no description available]	medium	2	0	aromatic amine; benzodioxine; monocarboxylic acid amide; N-acylpiperazine; N-arylpiperazine; quinazolines	alpha-adrenergic antagonist; antihyperplasia drug; antihypertensive agent; antineoplastic agent; vasodilator agent
doxepin	[no description available]	medium	4	0	dibenzooxepine; tertiary amino compound	antidepressant
dyphylline	[no description available]	medium	2	0	oxopurine; propane-1,2-diols	bronchodilator agent; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; muscle relaxant; vasodilator agent
enoxacin	[no description available]	medium	2	0	1,8-naphthyridine derivative; amino acid; fluoroquinolone antibiotic; monocarboxylic acid; N-arylpiperazine; quinolone antibiotic	antibacterial drug; DNA synthesis inhibitor
ethacrynic acid	[no description available]	medium	4	0	aromatic ether; aromatic ketone; dichlorobenzene; monocarboxylic acid	EC 2.5.1.18 (glutathione transferase) inhibitor; ion transport inhibitor; loop diuretic
etilefrine	[no description available]	medium	3	0	phenols
felodipine	[no description available]	medium	3	0	dichlorobenzene; dihydropyridine; ethyl ester; methyl ester	anti-arrhythmia drug; antihypertensive agent; calcium channel blocker; vasodilator agent
berotek	[no description available]	medium	2	0	resorcinols; secondary alcohol; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; sympathomimetic agent; tocolytic agent
fenspiride	[no description available]	medium	1	0	azaspiro compound
fentanyl	[no description available]	medium	52	0	anilide; monocarboxylic acid amide; piperidines	adjuvant; anaesthesia adjuvant; anaesthetic; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic
flecainide	[no description available]	medium	4	0	aromatic ether; monocarboxylic acid amide; organofluorine compound; piperidines	anti-arrhythmia drug
fleroxacin	[no description available]	medium	2	0	difluorobenzene; fluoroquinolone antibiotic; monocarboxylic acid; N-alkylpiperazine; quinolines	antibacterial drug; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; topoisomerase IV inhibitor
fluconazole	[no description available]	medium	4	0	conazole antifungal drug; difluorobenzene; tertiary alcohol; triazole antifungal drug	environmental contaminant; P450 inhibitor; xenobiotic
flucytosine	[no description available]	medium	3	0	aminopyrimidine; nucleoside analogue; organofluorine compound; pyrimidine antifungal drug; pyrimidone	prodrug
flumazenil	[no description available]	medium	10	0	ethyl ester; imidazobenzodiazepine; organofluorine compound	antidote to benzodiazepine poisoning; GABA antagonist
flumazenil	[no description available]	medium	10	1	ethyl ester; imidazobenzodiazepine; organofluorine compound	antidote to benzodiazepine poisoning; GABA antagonist
flunitrazepam	[no description available]	medium	15	0	1,4-benzodiazepinone; C-nitro compound; monofluorobenzenes	anxiolytic drug; GABAA receptor agonist; sedative
fluorescite	[no description available]	medium	2	0	benzoic acids; cyclic ketone; hydroxy monocarboxylic acid; organic heterotricyclic compound; phenols; xanthene dye	fluorescent dye; radioopaque medium
fluorouracil	[no description available]	medium	3	0	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
foscarnet	[no description available]	medium	2	0	carboxylic acid; one-carbon compound; phosphonic acids	antiviral drug; geroprotector; HIV-1 reverse transcriptase inhibitor; sodium-dependent Pi-transporter inhibitor
gabapentin	[no description available]	high	10	2	gamma-amino acid	anticonvulsant; calcium channel blocker; environmental contaminant; xenobiotic
gabapentin	[no description available]	high	10	0	gamma-amino acid	anticonvulsant; calcium channel blocker; environmental contaminant; xenobiotic
glimepiride	[no description available]	medium	2	0	sulfonamide
glipizide	[no description available]	medium	2	0	aromatic amide; monocarboxylic acid amide; N-sulfonylurea; pyrazines	EC 2.7.1.33 (pantothenate kinase) inhibitor; hypoglycemic agent; insulin secretagogue
glyburide	[no description available]	medium	5	0	monochlorobenzenes; N-sulfonylurea	anti-arrhythmia drug; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor; hypoglycemic agent
granisetron	[no description available]	medium	2	0	aromatic amide; indazoles
guanfacine	[no description available]	medium	3	0	acetamides
hydralazine	[no description available]	medium	4	0	azaarene; hydrazines; ortho-fused heteroarene; phthalazines	antihypertensive agent; vasodilator agent
hydroflumethiazide	[no description available]	medium	2	0	benzothiadiazine; thiazide	antihypertensive agent; diuretic
hydroxychloroquine	[no description available]	medium	3	0	aminoquinoline; organochlorine compound; primary alcohol; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; dermatologic drug
hydroxyurea	[no description available]	medium	3	0	one-carbon compound; ureas	antimetabolite; antimitotic; antineoplastic agent; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; genotoxin; immunomodulator; radical scavenger; teratogenic agent
hypericin	[no description available]	medium	1	0
ifosfamide	[no description available]	medium	3	0	ifosfamides	alkylating agent; antineoplastic agent; environmental contaminant; immunosuppressive agent; xenobiotic
amrinone	[no description available]	medium	3	0	bipyridines	EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
iohexol	[no description available]	medium	2	0	benzenedicarboxamide; organoiodine compound	environmental contaminant; radioopaque medium; xenobiotic
iopromide	[no description available]	medium	1	0	dicarboxylic acid diamide; organoiodine compound	environmental contaminant; nephrotoxic agent; radioopaque medium; xenobiotic
iothalamic acid	[no description available]	medium	2	0	organic molecular entity
avapro	[no description available]	medium	3	0	azaspiro compound; biphenylyltetrazole	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
isoniazid	[no description available]	medium	6	0	carbohydrazide	antitubercular agent; drug allergen
isoproterenol	[no description available]	medium	30	0	catechols; secondary alcohol; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; sympathomimetic agent
isradipine	[no description available]	medium	10	0	benzoxadiazole; dihydropyridine; isopropyl ester; methyl ester
isradipine	[no description available]	medium	10	5	benzoxadiazole; dihydropyridine; isopropyl ester; methyl ester
itraconazole	[no description available]	medium	3	0	piperazines
ketamine	[no description available]	high	105	1	cyclohexanones; monochlorobenzenes; secondary amino compound	analgesic; environmental contaminant; intravenous anaesthetic; neurotoxin; NMDA receptor antagonist; xenobiotic
ketamine	[no description available]	high	105	0	cyclohexanones; monochlorobenzenes; secondary amino compound	analgesic; environmental contaminant; intravenous anaesthetic; neurotoxin; NMDA receptor antagonist; xenobiotic
ketanserin	[no description available]	medium	14	0	aromatic ketone; organofluorine compound; piperidines; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; cardiovascular drug; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; serotonergic antagonist
ketorolac	[no description available]	medium	3	0	amino acid; aromatic ketone; monocarboxylic acid; pyrrolizines; racemate	analgesic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
labetalol	[no description available]	medium	7	0	benzamides; benzenes; phenols; primary carboxamide; salicylamides; secondary alcohol; secondary amino compound
lansoprazole	[no description available]	medium	3	0	benzimidazoles; pyridines; sulfoxide	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
letrozole	[no description available]	medium	2	0	nitrile; triazoles	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
lorazepam	[no description available]	medium	13	0	benzodiazepine
lorazepam	[no description available]	medium	13	3	benzodiazepine
losartan	[no description available]	medium	5	0	biphenylyltetrazole; imidazoles	angiotensin receptor antagonist; anti-arrhythmia drug; antihypertensive agent; endothelin receptor antagonist
maprotiline	[no description available]	medium	7	0	anthracenes
mebendazole	[no description available]	medium	3	0	aromatic ketone; benzimidazoles; carbamate ester	antinematodal drug; microtubule-destabilising agent; tubulin modulator
meperidine	[no description available]	medium	20	0	ethyl ester; piperidinecarboxylate ester; tertiary amino compound	antispasmodic drug; kappa-opioid receptor agonist; mu-opioid receptor agonist; opioid analgesic
mepivacaine	[no description available]	medium	5	0	piperidinecarboxamide	drug allergen; local anaesthetic
meprobamate	[no description available]	medium	15	0	organic molecular entity
meprobamate	[no description available]	medium	15	1	organic molecular entity
mesalamine	[no description available]	medium	3	0	amino acid; aromatic amine; monocarboxylic acid; monohydroxybenzoic acid; phenols	non-steroidal anti-inflammatory drug
metformin	[no description available]	high	7	0	guanidines	environmental contaminant; geroprotector; hypoglycemic agent; xenobiotic
methadone	[no description available]	medium	91	0	benzenes; diarylmethane; ketone; tertiary amino compound
methadone	[no description available]	medium	91	6	benzenes; diarylmethane; ketone; tertiary amino compound
methapyrilene	[no description available]	medium	1	0	ethylenediamine derivative	anti-allergic agent; carcinogenic agent; H1-receptor antagonist; sedative
methylphenidate	[no description available]	medium	140	0	beta-amino acid ester; methyl ester; piperidines
methylphenidate	[no description available]	medium	140	7	beta-amino acid ester; methyl ester; piperidines
metoclopramide	[no description available]	medium	4	0	benzamides; monochlorobenzenes; substituted aniline; tertiary amino compound	antiemetic; dopaminergic antagonist; environmental contaminant; gastrointestinal drug; xenobiotic
metronidazole	[no description available]	medium	3	0	C-nitro compound; imidazoles; primary alcohol	antiamoebic agent; antibacterial drug; antimicrobial agent; antiparasitic agent; antitrichomonal drug; environmental contaminant; prodrug; radiosensitizing agent; xenobiotic
mexiletine	[no description available]	medium	3	0	aromatic ether; primary amino compound	anti-arrhythmia drug
midazolam	[no description available]	medium	13	0	imidazobenzodiazepine; monofluorobenzenes; organochlorine compound	anticonvulsant; antineoplastic agent; anxiolytic drug; apoptosis inducer; central nervous system depressant; GABAA receptor agonist; general anaesthetic; muscle relaxant; sedative
midazolam	[no description available]	medium	13	1	imidazobenzodiazepine; monofluorobenzenes; organochlorine compound	anticonvulsant; antineoplastic agent; anxiolytic drug; apoptosis inducer; central nervous system depressant; GABAA receptor agonist; general anaesthetic; muscle relaxant; sedative
milrinone	[no description available]	medium	3	0	bipyridines; nitrile; pyridone	cardiotonic drug; EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor; platelet aggregation inhibitor; vasodilator agent
mirtazapine	[no description available]	medium	18	0	benzazepine; tetracyclic antidepressant	alpha-adrenergic antagonist; anxiolytic drug; H1-receptor antagonist; histamine antagonist; oneirogen; serotonergic antagonist
mirtazapine	[no description available]	medium	18	4	benzazepine; tetracyclic antidepressant	alpha-adrenergic antagonist; anxiolytic drug; H1-receptor antagonist; histamine antagonist; oneirogen; serotonergic antagonist
mitoxantrone	[no description available]	medium	3	0	dihydroxyanthraquinone	analgesic; antineoplastic agent
moclobemide	[no description available]	medium	1	0	benzamides; monochlorobenzenes; morpholines	antidepressant; environmental contaminant; xenobiotic
acecainide	[no description available]	medium	1	0	acetamides; benzamides	anti-arrhythmia drug
naratriptan	[no description available]	medium	2	0	heteroarylpiperidine; sulfonamide; tryptamines	serotonergic agonist; vasoconstrictor agent
nefazodone	[no description available]	medium	5	0	aromatic ether; monochlorobenzenes; N-alkylpiperazine; N-arylpiperazine; triazoles	alpha-adrenergic antagonist; analgesic; antidepressant; serotonergic antagonist; serotonin uptake inhibitor
nefopam	[no description available]	medium	1	0	benzoxazocine; tertiary amino compound
nevirapine	[no description available]	medium	5	0	cyclopropanes; dipyridodiazepine	antiviral drug; HIV-1 reverse transcriptase inhibitor
nicardipine	[no description available]	medium	4	0	benzenes; C-nitro compound; diester; dihydropyridine; methyl ester; tertiary amino compound
nifedipine	[no description available]	medium	12	0	C-nitro compound; dihydropyridine; methyl ester	calcium channel blocker; human metabolite; tocolytic agent; vasodilator agent
nimodipine	[no description available]	medium	7	0	2-methoxyethyl ester; C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; isopropyl ester	antihypertensive agent; calcium channel blocker; cardiovascular drug; vasodilator agent
nisoldipine	[no description available]	medium	4	0	C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; methyl ester
nitrazepam	[no description available]	medium	6	0	1,4-benzodiazepinone; C-nitro compound	anticonvulsant; antispasmodic drug; drug metabolite; GABA modulator; sedative
nitrendipine	[no description available]	medium	2	0	C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; ethyl ester; methyl ester	antihypertensive agent; calcium channel blocker; geroprotector; vasodilator agent
nizatidine	[no description available]	medium	3	0	1,3-thiazoles; C-nitro compound; carboxamidine; organic sulfide; tertiary amino compound	anti-ulcer drug; cholinergic drug; H2-receptor antagonist
nomifensine	[no description available]	medium	21	0	isoquinolines	dopamine uptake inhibitor
nomifensine	[no description available]	medium	21	1	isoquinolines	dopamine uptake inhibitor
nortriptyline	[no description available]	high	5	0	organic tricyclic compound; secondary amine	adrenergic uptake inhibitor; analgesic; antidepressant; antineoplastic agent; apoptosis inducer; drug metabolite
ofloxacin	[no description available]	medium	4	0	3-oxo monocarboxylic acid; N-arylpiperazine; N-methylpiperazine; organofluorine compound; oxazinoquinoline
omeprazole	[no description available]	medium	5	0	aromatic ether; benzimidazoles; pyridines; sulfoxide
omeprazole	[no description available]	medium	5	1	aromatic ether; benzimidazoles; pyridines; sulfoxide
ondansetron	[no description available]	medium	7	0	carbazoles
ondansetron	[no description available]	medium	7	1	carbazoles
oxiracetam	[no description available]	medium	2	0	organonitrogen compound; organooxygen compound
oxybutynin	[no description available]	medium	3	0	acetylenic compound; carboxylic ester; racemate; tertiary alcohol; tertiary amino compound	antispasmodic drug; calcium channel blocker; local anaesthetic; muscarinic antagonist; muscle relaxant; parasympatholytic
pamidronate	[no description available]	medium	3	0	phosphonoacetic acid
pantoprazole	[no description available]	medium	3	0	aromatic ether; benzimidazoles; organofluorine compound; pyridines; sulfoxide	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; environmental contaminant; xenobiotic
pentamidine	[no description available]	high	3	0	aromatic ether; carboxamidine; diether	anti-inflammatory agent; antifungal agent; calmodulin antagonist; chemokine receptor 5 antagonist; EC 2.3.1.48 (histone acetyltransferase) inhibitor; NMDA receptor antagonist; S100 calcium-binding protein B inhibitor; trypanocidal drug; xenobiotic
pentoxifylline	[no description available]	medium	4	0	oxopurine
perphenazine	[no description available]	medium	14	0	N-(2-hydroxyethyl)piperazine; N-alkylpiperazine; organochlorine compound; phenothiazines	antiemetic; dopaminergic antagonist; phenothiazine antipsychotic drug
perphenazine	[no description available]	medium	14	1	N-(2-hydroxyethyl)piperazine; N-alkylpiperazine; organochlorine compound; phenothiazines	antiemetic; dopaminergic antagonist; phenothiazine antipsychotic drug
phenacetin	[no description available]	medium	6	0	acetamides; aromatic ether	cyclooxygenase 3 inhibitor; non-narcotic analgesic; peripheral nervous system drug
moxonidine	[no description available]	medium	2	0	organohalogen compound; pyrimidines
pimobendan	[no description available]	medium	1	0	benzimidazoles; pyridazinone	cardiotonic drug; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; vasodilator agent
piretanide	[no description available]	medium	1	0	aromatic ether
prazosin	[no description available]	medium	12	0	aromatic ether; furans; monocarboxylic acid amide; piperazines; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
prilocaine	[no description available]	medium	1	0	amino acid amide; monocarboxylic acid amide	anticonvulsant; local anaesthetic
primaquine	[no description available]	medium	4	0	aminoquinoline; aromatic ether; N-substituted diamine	antimalarial
probenecid	[no description available]	medium	7	0	benzoic acids; sulfonamide	uricosuric drug
prochlorperazine	[no description available]	medium	5	0	N-alkylpiperazine; N-methylpiperazine; organochlorine compound; phenothiazines	alpha-adrenergic antagonist; antiemetic; cholinergic antagonist; dopamine receptor D2 antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; first generation antipsychotic
procyclidine	[no description available]	medium	2	0	pyrrolidines; tertiary alcohol	antidyskinesia agent; antiparkinson drug; muscarinic antagonist
promazine	[no description available]	medium	7	0	phenothiazines; tertiary amine	antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; muscarinic antagonist; phenothiazine antipsychotic drug; serotonergic antagonist
promethazine	[no description available]	medium	13	0	phenothiazines; tertiary amine	anti-allergic agent; anticoronaviral agent; antiemetic; antipruritic drug; H1-receptor antagonist; local anaesthetic; sedative
propafenone	[no description available]	medium	4	0	aromatic ketone; secondary alcohol; secondary amino compound	anti-arrhythmia drug
propofol	[no description available]	medium	4	0	phenols	anticonvulsant; antiemetic; intravenous anaesthetic; radical scavenger; sedative
pyridostigmine	[no description available]	medium	3	0	pyridinium ion
pyrimethamine	[no description available]	medium	4	0	aminopyrimidine; monochlorobenzenes	antimalarial; antiprotozoal drug; EC 1.5.1.3 (dihydrofolate reductase) inhibitor
rabeprazole	[no description available]	medium	2	0	benzimidazoles; pyridines; sulfoxide	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
ranitidine	[no description available]	medium	4	0	aralkylamine
risperidone	[no description available]	high	25	3	1,2-benzoxazoles; heteroarylpiperidine; organofluorine compound; pyridopyrimidine	alpha-adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; psychotropic drug; second generation antipsychotic; serotonergic antagonist
risperidone	[no description available]	high	25	0	1,2-benzoxazoles; heteroarylpiperidine; organofluorine compound; pyridopyrimidine	alpha-adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; psychotropic drug; second generation antipsychotic; serotonergic antagonist
rizatriptan	[no description available]	medium	2	0	tryptamines	anti-inflammatory drug; serotonergic agonist; vasoconstrictor agent
sulfadiazine	[no description available]	medium	3	0	pyrimidines; substituted aniline; sulfonamide antibiotic; sulfonamide	antiinfective agent; antimicrobial agent; antiprotozoal drug; coccidiostat; drug allergen; EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; xenobiotic
risedronic acid	[no description available]	medium	3	0	pyridines
sotalol	[no description available]	high	6	0	ethanolamines; secondary alcohol; secondary amino compound; sulfonamide	anti-arrhythmia drug; beta-adrenergic antagonist; environmental contaminant; xenobiotic
imatinib	[no description available]	medium	2	0	aromatic amine; benzamides; N-methylpiperazine; pyridines; pyrimidines	antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
vorinostat	[no description available]	medium	3	0	dicarboxylic acid diamide; hydroxamic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
sulfamethoxazole	[no description available]	medium	2	0	isoxazoles; substituted aniline; sulfonamide antibiotic; sulfonamide	antibacterial agent; antiinfective agent; antimicrobial agent; drug allergen; EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; epitope; P450 inhibitor; xenobiotic
sulfinpyrazone	[no description available]	medium	2	0	pyrazolidines; sulfoxide	uricosuric drug
sulfisoxazole	[no description available]	medium	1	0	isoxazoles; sulfonamide antibiotic; sulfonamide	antibacterial drug; drug allergen
sumatriptan	[no description available]	medium	3	0	sulfonamide; tryptamines	serotonergic agonist; vasoconstrictor agent
suprofen	[no description available]	medium	3	0	aromatic ketone; monocarboxylic acid; thiophenes	antirheumatic drug; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; peripheral nervous system drug
suramin	[no description available]	medium	2	0	naphthalenesulfonic acid; phenylureas; secondary carboxamide	angiogenesis inhibitor; antinematodal drug; antineoplastic agent; apoptosis inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; GABA antagonist; GABA-gated chloride channel antagonist; purinergic receptor P2 antagonist; ryanodine receptor agonist; trypanocidal drug
gatifloxacin	[no description available]	medium	3	0	N-arylpiperazine; organofluorine compound; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antiinfective agent; antimicrobial agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
temozolomide	[no description available]	medium	4	0	imidazotetrazine; monocarboxylic acid amide; triazene derivative	alkylating agent; antineoplastic agent; prodrug
terazosin	[no description available]	medium	3	0	furans; piperazines; primary amino compound; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; antineoplastic agent
terbutaline	[no description available]	medium	6	0	phenylethanolamines; resorcinols	anti-asthmatic drug; beta-adrenergic agonist; bronchodilator agent; EC 3.1.1.7 (acetylcholinesterase) inhibitor; hypoglycemic agent; sympathomimetic agent; tocolytic agent
thalidomide	[no description available]	medium	4	0	phthalimides; piperidones
thiotepa	[no description available]	medium	2	0	aziridines
tinidazole	[no description available]	medium	2	0	imidazoles	antiamoebic agent; antibacterial drug; antiparasitic agent; antiprotozoal drug
tizanidine	[no description available]	medium	4	0	benzothiadiazole; imidazoles	alpha-adrenergic agonist; muscle relaxant
tolbutamide	[no description available]	medium	4	0	N-sulfonylurea	human metabolite; hypoglycemic agent; insulin secretagogue; potassium channel blocker
trazodone	[no description available]	medium	6	0	monochlorobenzenes; N-alkylpiperazine; N-arylpiperazine; triazolopyridine	adrenergic antagonist; antidepressant; anxiolytic drug; H1-receptor antagonist; sedative; serotonin uptake inhibitor
triamterene	[no description available]	medium	2	0	pteridines	diuretic; sodium channel blocker
triazolam	[no description available]	medium	3	0	triazolobenzodiazepine	sedative
trimethoprim	[no description available]	medium	4	0	aminopyrimidine; methoxybenzenes	antibacterial drug; diuretic; drug allergen; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; environmental contaminant; xenobiotic
trimetrexate	[no description available]	medium	2	0
trimipramine	[no description available]	high	5	0	dibenzoazepine; tertiary amino compound	antidepressant; environmental contaminant; xenobiotic
urapidil	[no description available]	medium	1	0	piperazines
venlafaxine	[no description available]	medium	5	0	cyclohexanols; monomethoxybenzene; tertiary alcohol; tertiary amino compound	adrenergic uptake inhibitor; analgesic; antidepressant; dopamine uptake inhibitor; environmental contaminant; serotonin uptake inhibitor; xenobiotic
viloxazine	[no description available]	medium	1	0	aromatic ether
zaleplon	[no description available]	medium	2	0	nitrile; pyrazolopyrimidine	anticonvulsant; anxiolytic drug; central nervous system depressant; sedative
zolpidem	[no description available]	medium	8	0	imidazopyridine	central nervous system depressant; GABA agonist; sedative
zolpidem	[no description available]	medium	8	1	imidazopyridine	central nervous system depressant; GABA agonist; sedative
zopiclone	[no description available]	medium	2	0	monochloropyridine; pyrrolopyrazine	central nervous system depressant; sedative
prednisolone	[no description available]	high	5	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; drug metabolite; environmental contaminant; immunosuppressive agent; xenobiotic
cephaloridine	[no description available]	medium	2	0	beta-lactam antibiotic allergen; cephalosporin; semisynthetic derivative	antibacterial drug
prednisone	[no description available]	medium	9	0	11-oxo steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; immunosuppressive agent; prodrug
prednisone	[no description available]	medium	9	1	11-oxo steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; immunosuppressive agent; prodrug
penicillin g	[no description available]	medium	4	0	penicillin allergen; penicillin	antibacterial drug; drug allergen; epitope
chloramphenicol	[no description available]	medium	3	0	C-nitro compound; carboxamide; diol; organochlorine compound	antibacterial drug; antimicrobial agent; Escherichia coli metabolite; geroprotector; Mycoplasma genitalium metabolite; protein synthesis inhibitor
vincristine	[no description available]	medium	3	0	acetate ester; formamides; methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; tertiary alcohol; tertiary amino compound; vinca alkaloid	antineoplastic agent; drug; microtubule-destabilising agent; plant metabolite; tubulin modulator
ethinyl estradiol	[no description available]	medium	3	0	17-hydroxy steroid; 3-hydroxy steroid; terminal acetylenic compound	xenoestrogen
apomorphine	[no description available]	medium	161	0	aporphine alkaloid	alpha-adrenergic drug; antidyskinesia agent; antiparkinson drug; dopamine agonist; emetic; serotonergic drug
cephalothin	[no description available]	medium	2	0	azabicycloalkene; beta-lactam antibiotic allergen; carboxylic acid; cephalosporin; semisynthetic derivative; thiophenes	antibacterial drug; antimicrobial agent
kanamycin a	[no description available]	medium	3	0	kanamycins	bacterial metabolite
levodopa	[no description available]	high	59	1	amino acid zwitterion; dopa; L-tyrosine derivative; non-proteinogenic L-alpha-amino acid	allelochemical; antidyskinesia agent; antiparkinson drug; dopaminergic agent; hapten; human metabolite; mouse metabolite; neurotoxin; plant growth retardant; plant metabolite; prodrug
levodopa	[no description available]	high	59	0	amino acid zwitterion; dopa; L-tyrosine derivative; non-proteinogenic L-alpha-amino acid	allelochemical; antidyskinesia agent; antiparkinson drug; dopaminergic agent; hapten; human metabolite; mouse metabolite; neurotoxin; plant growth retardant; plant metabolite; prodrug
methicillin	[no description available]	medium	1	0	penicillin allergen; penicillin	antibacterial drug
colchicine	[no description available]	medium	11	0	alkaloid; colchicine	anti-inflammatory agent; gout suppressant; mutagen
oxacillin	[no description available]	medium	2	0	penicillin	antibacterial agent; antibacterial drug
ampicillin	[no description available]	medium	4	0	beta-lactam antibiotic; penicillin allergen; penicillin	antibacterial drug
triamcinolone acetonide	[no description available]	medium	2	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; cyclic ketal; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone	anti-allergic agent; anti-inflammatory drug
phencyclidine	[no description available]	high	92	0	benzenes; piperidines	anaesthetic; neurotoxin; NMDA receptor antagonist; psychotropic drug
methylprednisolone	[no description available]	high	4	0	6-methylprednisolone; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antiemetic; environmental contaminant; neuroprotective agent; xenobiotic
penicillin v	[no description available]	medium	3	0	penicillin allergen; penicillin
isosorbide dinitrate	[no description available]	medium	4	0	glucitol derivative; nitrate ester	nitric oxide donor; vasodilator agent
ergotamine	[no description available]	medium	7	0	peptide ergot alkaloid	alpha-adrenergic agonist; mycotoxin; non-narcotic analgesic; oxytocic; serotonergic agonist; vasoconstrictor agent
neostigmine bromide	[no description available]	medium	3	0	bromide salt
nafcillin	[no description available]	medium	2	0	penicillin allergen; penicillin	antibacterial drug
methohexital	[no description available]	medium	2	0	acetylenic compound; barbiturates	drug allergen; intravenous anaesthetic
pirinitramide	[no description available]	medium	1	0	nitrile
edrophonium bromide	[no description available]	medium	1	0
azacitidine	[no description available]	medium	5	0	N-glycosyl-1,3,5-triazine; nucleoside analogue	antineoplastic agent
galantamine	[no description available]	medium	6	0	benzazepine alkaloid fundamental parent; benzazepine alkaloid; organic heterotetracyclic compound; tertiary amino compound	antidote to curare poisoning; cholinergic drug; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; plant metabolite
betamethasone	[no description available]	medium	2	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	anti-asthmatic agent; anti-inflammatory drug; immunosuppressive agent
dextropropoxyphene	[no description available]	medium	4	0	1-benzyl-3-(dimethylamino)-2-methyl-1-phenylpropyl propanoate	mu-opioid receptor agonist; opioid analgesic
ketobemidone	[no description available]	medium	1	0	piperidines
chlormethiazole	[no description available]	medium	5	0	thiazoles
lithium carbonate	[no description available]	medium	4	0	carbonate salt; lithium salt	antimanic drug
lithium carbonate	[no description available]	medium	4	1	carbonate salt; lithium salt	antimanic drug
acetylcysteine	[no description available]	medium	18	0	acetylcysteine; L-cysteine derivative; N-acetyl-L-amino acid	antidote to paracetamol poisoning; antiinfective agent; antioxidant; antiviral drug; ferroptosis inhibitor; geroprotector; human metabolite; mucolytic; radical scavenger; vulnerary
acetylcysteine	[no description available]	medium	18	3	acetylcysteine; L-cysteine derivative; N-acetyl-L-amino acid	antidote to paracetamol poisoning; antiinfective agent; antioxidant; antiviral drug; ferroptosis inhibitor; geroprotector; human metabolite; mucolytic; radical scavenger; vulnerary
erythromycin	[no description available]	medium	5	0	cyclic ketone; erythromycin
levonorgestrel	[no description available]	medium	3	0	17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; terminal acetylenic compound	contraceptive drug; female contraceptive drug; progestin; synthetic oral contraceptive
levonorgestrel	[no description available]	medium	3	1	17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; terminal acetylenic compound	contraceptive drug; female contraceptive drug; progestin; synthetic oral contraceptive
lormetazepam	[no description available]	medium	2	0	1,4-benzodiazepinone; organochlorine compound	sedative
vinblastine	[no description available]	medium	2	0
ethambutol	[no description available]	high	3	0	ethanolamines; ethylenediamine derivative	antitubercular agent; environmental contaminant; xenobiotic
vancomycin	[no description available]	medium	5	0	glycopeptide	antibacterial drug; antimicrobial agent; bacterial metabolite
metylperon	[no description available]	medium	1	0	aromatic ketone
spectinomycin	[no description available]	medium	2	0	cyclic acetal; cyclic hemiketal; cyclic ketone; pyranobenzodioxin; secondary alcohol; secondary amino compound	antibacterial drug; antimicrobial agent; bacterial metabolite
dronabinol	[no description available]	medium	71	0	benzochromene; diterpenoid; phytocannabinoid; polyketide	cannabinoid receptor agonist; epitope; hallucinogen; metabolite; non-narcotic analgesic
dronabinol	[no description available]	medium	71	1	benzochromene; diterpenoid; phytocannabinoid; polyketide	cannabinoid receptor agonist; epitope; hallucinogen; metabolite; non-narcotic analgesic
benperidol	[no description available]	medium	2	0	aromatic ketone
chlordesmethyldiazepam	[no description available]	medium	1	0	benzodiazepine
stavudine	[no description available]	medium	5	0	dihydrofuran; nucleoside analogue; organic molecular entity	antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
doxifluridine	[no description available]	medium	2	0	organofluorine compound; pyrimidine 5'-deoxyribonucleoside	antimetabolite; antineoplastic agent; prodrug
dicloxacillin	[no description available]	medium	2	0	dichlorobenzene; penicillin	antibacterial drug
streptomycin	[no description available]	medium	3	0	antibiotic antifungal drug; antibiotic fungicide; streptomycins	antibacterial drug; antifungal agrochemical; antimicrobial agent; antimicrobial drug; bacterial metabolite; protein synthesis inhibitor
cladribine	[no description available]	medium	3	0	organochlorine compound; purine 2'-deoxyribonucleoside	antineoplastic agent; immunosuppressive agent
carbenicillin	[no description available]	medium	2	0	penicillin allergen; penicillin	antibacterial drug
floxacillin	[no description available]	medium	2	0	penicillin allergen; penicillin	antibacterial drug
beclomethasone dipropionate	[no description available]	medium	1	0	11beta-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(1),Delta(4)-steroid; chlorinated steroid; corticosteroid; enone; glucocorticoid; propanoate ester; steroid ester	anti-arrhythmia drug; anti-asthmatic drug; anti-inflammatory drug; prodrug
terodiline	[no description available]	medium	1	0	diarylmethane
1-(4-carboxyphenyl)-3,3-dimethyltriazene	[no description available]	medium	1	0
zalcitabine	[no description available]	medium	2	0	pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor
metocurine iodide	[no description available]	medium	1	0	aromatic ether
apazone	[no description available]	medium	1	0	benzotriazines	non-steroidal anti-inflammatory drug; uricosuric drug
selegiline	[no description available]	medium	91	0	selegiline; terminal acetylenic compound	geroprotector
selegiline	[no description available]	medium	91	12	selegiline; terminal acetylenic compound	geroprotector
cephalexin	[no description available]	medium	3	0	beta-lactam antibiotic allergen; cephalosporin; semisynthetic derivative	antibacterial drug
isosorbide-5-mononitrate	[no description available]	medium	2	0	glucitol derivative; nitrate ester	nitric oxide donor; vasodilator agent
cephapirin	[no description available]	medium	1	0	cephalosporin	antibacterial drug
pregnanolone	[no description available]	medium	3	0	3-hydroxy-5beta-pregnan-20-one; 3alpha-hydroxy steroid	human metabolite; intravenous anaesthetic; sedative
du-21220	[no description available]	medium	1	0	benzyl alcohols; polyphenol; secondary alcohol; secondary amino compound
ribostamycin	[no description available]	medium	1	0	amino cyclitol glycoside; aminoglycoside antibiotic	antibacterial drug; antimicrobial agent; metabolite
cefazolin	[no description available]	medium	3	0	beta-lactam antibiotic allergen; cephalosporin; tetrazoles; thiadiazoles	antibacterial drug
amoxicillin	[no description available]	medium	5	0	penicillin allergen; penicillin	antibacterial drug
indoramin	[no description available]	medium	1	0	tryptamines
toloxatone	[no description available]	medium	1	0	oxazolidinone; primary alcohol; toluenes
zidovudine	[no description available]	medium	5	0	azide; pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor
sisomicin	[no description available]	medium	1	0	amino cyclitol glycoside; aminoglycoside antibiotic; beta-L-arabinoside; monosaccharide derivative
amdinocillin	[no description available]	medium	1	0	penicillin	antibacterial drug; antiinfective agent
tobramycin	[no description available]	medium	2	0	amino cyclitol glycoside	antibacterial agent; antimicrobial agent; toxin
paclitaxel	[no description available]	medium	3	0	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
etoposide	[no description available]	medium	5	0	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
ticarcillin	[no description available]	medium	1	0	penicillin allergen; penicillin	antibacterial drug
trimazosin	[no description available]	medium	1	0	N-arylpiperazine
ribavirin	[no description available]	medium	3	0	1-ribosyltriazole; aromatic amide; monocarboxylic acid amide; primary carboxamide	anticoronaviral agent; antiinfective agent; antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
adinazolam	[no description available]	medium	1	0	triazolobenzodiazepine	anticonvulsant; antidepressant; anxiolytic drug; sedative
amikacin	[no description available]	medium	3	0	alpha-D-glucoside; amino cyclitol glycoside; aminoglycoside; carboxamide	antibacterial drug; antimicrobial agent; nephrotoxin
tolamolol	[no description available]	medium	2	0
cephradine	[no description available]	medium	2	0	beta-lactam antibiotic allergen; cephalosporin	antibacterial drug
methyldopa	[no description available]	medium	10	0	L-tyrosine derivative; non-proteinogenic L-alpha-amino acid	alpha-adrenergic agonist; antihypertensive agent; hapten; peripheral nervous system drug; sympatholytic agent
tocainide	[no description available]	medium	1	0	monocarboxylic acid amide	anti-arrhythmia drug; local anaesthetic; sodium channel blocker
sulbenicillin	[no description available]	medium	1	0	penicillin
sq-11725	[no description available]	medium	3	0
vecuronium bromide	[no description available]	medium	1	0	organic bromide salt; quaternary ammonium salt	muscle relaxant; neuromuscular agent; nicotinic antagonist
meptazinol	[no description available]	medium	1	0	azepanes
sufentanil	[no description available]	medium	3	0	anilide; ether; piperidines; thiophenes	anaesthesia adjuvant; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic
torsemide	[no description available]	medium	3	0	aminopyridine; N-sulfonylurea; secondary amino compound	antihypertensive agent; loop diuretic
medroxalol	[no description available]	medium	1	0	salicylamides
epirubicin	[no description available]	medium	3	0	aminoglycoside; anthracycline antibiotic; anthracycline; deoxy hexoside; monosaccharide derivative; p-quinones; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	antimicrobial agent; antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
cefmetazole	[no description available]	medium	1	0	cephalosporin	antibacterial drug
lorcainide	[no description available]	medium	1	0	acetamides
idarubicin	[no description available]	medium	2	0	anthracycline antibiotic; deoxy hexoside; monosaccharide derivative
ceforanide	[no description available]	medium	1	0	cephalosporin	antibacterial drug
piperacillin	[no description available]	medium	3	0	penicillin allergen; penicillin	antibacterial drug
paroxetine	[no description available]	medium	15	0	aromatic ether; benzodioxoles; organofluorine compound; piperidines	antidepressant; anxiolytic drug; hepatotoxic agent; P450 inhibitor; serotonin uptake inhibitor
paroxetine	[no description available]	medium	15	1	aromatic ether; benzodioxoles; organofluorine compound; piperidines	antidepressant; anxiolytic drug; hepatotoxic agent; P450 inhibitor; serotonin uptake inhibitor
captopril	[no description available]	medium	4	0	alkanethiol; L-proline derivative; N-acylpyrrolidine; pyrrolidinemonocarboxylic acid	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
cefoperazone	[no description available]	medium	4	0	cephalosporin	antibacterial drug
atracurium	[no description available]	medium	2	0	diester; quaternary ammonium ion	muscle relaxant; nicotinic antagonist
moxalactam	[no description available]	medium	2	0	cephalosporin; oxacephem	antibacterial drug
endralazine	[no description available]	medium	1	0	benzamides
cefadroxil anhydrous	[no description available]	medium	3	0	cephalosporin	antibacterial drug
encainide	[no description available]	medium	2	0	benzamides; piperidines	anti-arrhythmia drug; sodium channel blocker
pefloxacin	[no description available]	medium	1	0	fluoroquinolone antibiotic; monocarboxylic acid; N-alkylpiperazine; N-arylpiperazine; quinolone antibiotic; quinolone	antibacterial drug; antiinfective agent; DNA synthesis inhibitor
alfentanil	[no description available]	medium	2	0	monocarboxylic acid amide; piperidines	central nervous system depressant; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic; peripheral nervous system drug
cefotetan	[no description available]	medium	3	0
recainam	[no description available]	medium	1	0
lovastatin	[no description available]	medium	4	0	delta-lactone; fatty acid ester; hexahydronaphthalenes; polyketide; statin (naturally occurring)	anticholesteremic drug; antineoplastic agent; Aspergillus metabolite; prodrug
flupirtine	[no description available]	medium	2	0	aminopyridine
enoximone	[no description available]	medium	2	0	aromatic ketone
idazoxan	[no description available]	medium	2	0	benzodioxine; imidazolines	alpha-adrenergic antagonist
remoxipride	[no description available]	medium	3	0	dimethoxybenzene
pravastatin	[no description available]	medium	4	0	3-hydroxy carboxylic acid; carbobicyclic compound; carboxylic ester; hydroxy monocarboxylic acid; secondary alcohol; statin (semi-synthetic)	anticholesteremic drug; environmental contaminant; metabolite; xenobiotic
bambuterol	[no description available]	medium	1	0	carbamate ester; phenylethanolamines	anti-asthmatic drug; beta-adrenergic agonist; bronchodilator agent; EC 3.1.1.7 (acetylcholinesterase) inhibitor; prodrug; sympathomimetic agent; tocolytic agent
atomoxetine	[no description available]	medium	3	0	aromatic ether; secondary amino compound; toluenes	adrenergic uptake inhibitor; antidepressant; environmental contaminant; xenobiotic
trospectomycin	[no description available]	medium	1	0	dioxanes
finasteride	[no description available]	medium	3	0	3-oxo steroid; aza-steroid; delta-lactam	androgen antagonist; antihyperplasia drug; EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor
sematilide	[no description available]	medium	1	0
esmolol	[no description available]	medium	2	0	aromatic ether; ethanolamines; methyl ester; secondary alcohol; secondary amino compound
clinafloxacin	[no description available]	medium	1	0	quinolines
adefovir	[no description available]	medium	2	0	6-aminopurines; ether; phosphonic acids	antiviral drug; DNA synthesis inhibitor; drug metabolite; HIV-1 reverse transcriptase inhibitor; nephrotoxic agent
loxiglumide	[no description available]	medium	1	0	organic molecular entity
sparfloxacin	[no description available]	medium	2	0	fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone
cidofovir anhydrous	[no description available]	medium	3	0	phosphonic acids; pyrimidone	anti-HIV agent; antineoplastic agent; antiviral drug; photosensitizing agent
tiagabine	[no description available]	medium	2	0	beta-amino acid; piperidinemonocarboxylic acid; tertiary amino compound; thiophenes	anticonvulsant; GABA reuptake inhibitor
mibefradil	[no description available]	medium	1	0	tetralins	T-type calcium channel blocker
topotecan	[no description available]	medium	2	0	pyranoindolizinoquinoline	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor
bromfenac	[no description available]	medium	4	0	aromatic amino acid; benzophenones; organobromine compound; substituted aniline	non-narcotic analgesic; non-steroidal anti-inflammatory drug
gemcitabine	[no description available]	medium	2	0	organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; environmental contaminant; immunosuppressive agent; photosensitizing agent; prodrug; radiosensitizing agent; xenobiotic
ibutilide	[no description available]	medium	2	0	benzenes; organic amino compound
aripiprazole	[no description available]	medium	17	0	aromatic ether; delta-lactam; dichlorobenzene; N-alkylpiperazine; N-arylpiperazine; quinolone	drug metabolite; H1-receptor antagonist; second generation antipsychotic; serotonergic agonist
aripiprazole	[no description available]	medium	17	3	aromatic ether; delta-lactam; dichlorobenzene; N-alkylpiperazine; N-arylpiperazine; quinolone	drug metabolite; H1-receptor antagonist; second generation antipsychotic; serotonergic agonist
remifentanil	[no description available]	medium	3	0	alpha-amino acid ester; anilide; monocarboxylic acid amide; piperidinecarboxylate ester	intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic; sedative
lamivudine	[no description available]	medium	3	0	monothioacetal; nucleoside analogue; oxacycle; primary alcohol	allergen; anti-HBV agent; antiviral drug; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor; HIV-1 reverse transcriptase inhibitor; prodrug
irinotecan	[no description available]	medium	4	0	carbamate ester; delta-lactone; N-acylpiperidine; pyranoindolizinoquinoline; ring assembly; tertiary alcohol; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 5.99.1.2 (DNA topoisomerase) inhibitor; prodrug
valsartan	[no description available]	medium	4	0	biphenylyltetrazole; monocarboxylic acid amide; monocarboxylic acid	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
ibandronic acid	[no description available]	medium	2	0
ziprasidone	[no description available]	medium	2	0	1,2-benzisothiazole; indolones; organochlorine compound; piperazines	antipsychotic agent; dopaminergic antagonist; histamine antagonist; muscarinic antagonist; psychotropic drug; serotonergic antagonist
zanamivir	[no description available]	medium	1	0	guanidines	antiviral agent; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor
zolmitriptan	[no description available]	medium	3	0	oxazolidinone; tryptamines	anti-inflammatory drug; serotonergic agonist; vasoconstrictor agent
tirofiban	[no description available]	medium	2	0	L-tyrosine derivative; piperidines; sulfonamide	anticoagulant; fibrin modulating drug; platelet glycoprotein-IIb/IIIa receptor antagonist
cisatracurium	[no description available]	medium	1	0	diester; quaternary ammonium ion	muscle relaxant; nicotinic antagonist
fosinoprilat	[no description available]	medium	1	0	L-proline derivative; phosphinic acids	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
trovafloxacin	[no description available]	medium	3	0
cefprozil	[no description available]	medium	3	0	cephalosporin; semisynthetic derivative	antibacterial drug
iopamidol	[no description available]	medium	1	0	benzenedicarboxamide; organoiodine compound; pentol	environmental contaminant; radioopaque medium; xenobiotic
imipramine n-oxide	[no description available]	medium	1	0	dibenzooxazepine
dexloxiglumide	[no description available]	medium	1	0	glutamic acid derivative
intoplicine	[no description available]	medium	2	0	pyridoindole
repaglinide	[no description available]	medium	2	0	piperidines
telmisartan	[no description available]	high	4	0	benzimidazoles; biphenyls; carboxybiphenyl	angiotensin receptor antagonist; antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; environmental contaminant; xenobiotic
dexfenfluramine	[no description available]	medium	2	0	fenfluramine	appetite depressant; serotonergic agonist; serotonin uptake inhibitor
ethinyl estradiol-17-sulfate	[no description available]	medium	1	0
ethinylestradiol-3-sulfate	[no description available]	medium	1	0	17beta-hydroxy steroid; steroid sulfate	antineoplastic agent; estrogen
cefcanel	[no description available]	medium	1	0
zoledronic acid	[no description available]	medium	2	0	1,1-bis(phosphonic acid); imidazoles	bone density conservation agent
epristeride	[no description available]	medium	1	0	steroid acid
talinolol	[no description available]	medium	1	0	ureas
denaverine	[no description available]	medium	1	0	diarylmethane
diprafenone	[no description available]	medium	1	0	aromatic compound
nebivolol	[no description available]	medium	3	0	chromanes; diol; organofluorine compound; secondary alcohol; secondary amino compound
uk 68798	[no description available]	medium	3	0	aromatic ether; sulfonamide; tertiary amino compound	anti-arrhythmia drug; potassium channel blocker
ljc 10627	[no description available]	medium	1	0	carbapenems; organic sulfide; pyrazolotriazole	antibacterial drug
dexrazoxane	[no description available]	medium	3	0	razoxane	antineoplastic agent; cardiovascular drug; chelator; immunosuppressive agent
voriconazole	[no description available]	medium	3	0	conazole antifungal drug; difluorobenzene; pyrimidines; tertiary alcohol; triazole antifungal drug	P450 inhibitor
betamipron	[no description available]	medium	1	0	organonitrogen compound; organooxygen compound
bufuralol	[no description available]	medium	2	0	benzofurans
panipenem	[no description available]	medium	1	0	organic molecular entity
perindoprilat	[no description available]	medium	1	0	dicarboxylic acid; dipeptide; L-alanine derivative; organic heterobicyclic compound	antihypertensive agent; drug metabolite; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
7-hydroxystaurosporine	[no description available]	medium	1	0
methotrimeprazine	[no description available]	medium	5	0	phenothiazines; tertiary amine	anticoronaviral agent; cholinergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; non-narcotic analgesic; phenothiazine antipsychotic drug; serotonergic antagonist
9-aminocamptothecin	[no description available]	medium	1	0	pyranoindolizinoquinoline
sch 34343	[no description available]	medium	1	0
squalamine	[no description available]	medium	1	0	bile acid
atovaquone	[no description available]	medium	2	0	hydroxy-1,2-naphthoquinone
rivastigmine	[no description available]	medium	8	0	carbamate ester; tertiary amino compound	cholinergic drug; EC 3.1.1.8 (cholinesterase) inhibitor; neuroprotective agent
rivastigmine	[no description available]	medium	8	5	carbamate ester; tertiary amino compound	cholinergic drug; EC 3.1.1.8 (cholinesterase) inhibitor; neuroprotective agent
frovatriptan	[no description available]	medium	2	0	carbazoles
eletriptan	[no description available]	medium	2	0	indoles; N-alkylpyrrolidine; sulfone	non-steroidal anti-inflammatory drug; serotonergic agonist; vasoconstrictor agent
rosiglitazone	[no description available]	medium	6	0	aminopyridine; thiazolidinediones	EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; insulin-sensitizing drug
clarithromycin	[no description available]	medium	5	0	macrolide antibiotic	antibacterial drug; environmental contaminant; protein synthesis inhibitor; xenobiotic
mci 9038	[no description available]	medium	2	0	peptide
imipenem, anhydrous	[no description available]	medium	1	0	beta-lactam antibiotic allergen; carbapenems; zwitterion	antibacterial drug
bosentan anhydrous	[no description available]	medium	3	0	primary alcohol; pyrimidines; sulfonamide	antihypertensive agent; endothelin receptor antagonist
asulacrine	[no description available]	medium	1	0	acridines
hydroxycotinine	[no description available]	medium	1	0	N-alkylpyrrolidine; pyridines; pyrrolidin-2-ones; pyrrolidine alkaloid
quinaprilat	[no description available]	medium	1	0	dicarboxylic acid; isoquinolines; tertiary carboxamide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; vasodilator agent
2-hydroxyimipramine	[no description available]	medium	1	0	dibenzoazepine
ecteinascidin 743	[no description available]	medium	2	0	acetate ester; azaspiro compound; bridged compound; hemiaminal; isoquinoline alkaloid; lactone; organic heteropolycyclic compound; organic sulfide; oxaspiro compound; polyphenol; tertiary amino compound	alkylating agent; angiogenesis modulating agent; anti-inflammatory agent; antineoplastic agent; marine metabolite
almotriptan	[no description available]	medium	2	0	indoles; sulfonamide; tertiary amine	non-steroidal anti-inflammatory drug; serotonergic agonist; vasoconstrictor agent
mk 0663	[no description available]	medium	1	0	bipyridines; organochlorine compound; sulfone	cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
gefitinib	[no description available]	medium	3	0	aromatic ether; monochlorobenzenes; monofluorobenzenes; morpholines; quinazolines; secondary amino compound; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist
methotrexate	[no description available]	medium	6	0	dicarboxylic acid; monocarboxylic acid amide; pteridines	abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent
tamsulosin	[no description available]	medium	2	0	5-(2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl)-2-methoxybenzenesulfonamide	alpha-adrenergic antagonist; antineoplastic agent
sulbactam	[no description available]	medium	2	0	penicillanic acids
dilevalol	[no description available]	medium	1	0	2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide
docetaxel	[no description available]	medium	2	0	hydrate; secondary alpha-hydroxy ketone	antineoplastic agent
irofulven	[no description available]	medium	1	0	cyclohexenones
ym 872	[no description available]	medium	1	0
levofloxacin	[no description available]	medium	5	0	9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; fluoroquinolone antibiotic; quinolone antibiotic	antibacterial drug; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; topoisomerase IV inhibitor
ertapenem	[no description available]	medium	2	0	carbapenemcarboxylic acid; pyrrolidinecarboxamide	antibacterial drug
dx 8951	[no description available]	medium	1	0	pyranoindolizinoquinoline
cilomilast	[no description available]	medium	1	0	methoxybenzenes
conivaptan	[no description available]	medium	2	0	benzazepine	aquaretic; vasopressin receptor antagonist
tezosentan	[no description available]	medium	2	0
sabarubicin	[no description available]	medium	1	0
moxifloxacin	[no description available]	medium	4	0	aromatic ether; cyclopropanes; fluoroquinolone antibiotic; pyrrolidinopiperidine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antibacterial drug
clevidipine	[no description available]	medium	2	0	dihydropyridine
solifenacin	[no description available]	medium	2	0	isoquinolines
xamoterol	[no description available]	medium	1	0	morpholines
abanoquil	[no description available]	medium	1	0
anidulafungin	[no description available]	medium	2	0	antibiotic antifungal drug; azamacrocycle; echinocandin; heterodetic cyclic peptide; semisynthetic derivative
atropine	[no description available]	medium	44	0
ropivacaine	[no description available]	medium	1	0	piperidinecarboxamide; ropivacaine	local anaesthetic
melagatran	[no description available]	medium	1	0	azetidines; carboxamidine; dicarboxylic acid monoamide; non-proteinogenic alpha-amino acid; secondary amino compound	anticoagulant; EC 3.4.21.5 (thrombin) inhibitor; serine protease inhibitor
tesaglitazar	[no description available]	medium	1	0
bms204352	[no description available]	medium	1	0
fosfluconazole	[no description available]	medium	1	0	conazole antifungal drug; triazole antifungal drug; triazoles	prodrug
cp 101,606	[no description available]	medium	1	0
nsc-89199	[no description available]	medium	1	0	carbamate ester; organochlorine compound; steroid phosphate
phenethicillin	[no description available]	medium	2	0	penicillin allergen; penicillin
acivicin	[no description available]	medium	1	0	isoxazoles; non-proteinogenic L-alpha-amino acid; organochlorine compound	antileishmanial agent; antimetabolite; antimicrobial agent; antineoplastic agent; EC 2.3.2.2 (gamma-glutamyltransferase) inhibitor; glutamine antagonist; metabolite
bortezomib	[no description available]	medium	3	0	amino acid amide; L-phenylalanine derivative; pyrazines	antineoplastic agent; antiprotozoal drug; protease inhibitor; proteasome inhibitor
quinidine	[no description available]	medium	15	0	cinchona alkaloid	alpha-adrenergic antagonist; anti-arrhythmia drug; antimalarial; drug allergen; EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor; EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor; muscarinic antagonist; P450 inhibitor; potassium channel blocker; sodium channel blocker
meropenem	[no description available]	medium	4	0	alpha,beta-unsaturated monocarboxylic acid; carbapenemcarboxylic acid; organic sulfide; pyrrolidinecarboxamide	antibacterial agent; antibacterial drug; drug allergen
cefoxitin	[no description available]	medium	2	0	beta-lactam antibiotic allergen; cephalosporin; cephamycin; semisynthetic derivative	antibacterial drug
digitoxin	[no description available]	medium	2	0	cardenolide glycoside	EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor
saquinavir	[no description available]	medium	5	0	L-asparagine derivative; quinolines	antiviral drug; HIV protease inhibitor
pancuronium	[no description available]	medium	3	0	acetate ester; steroid ester	cholinergic antagonist; muscle relaxant; nicotinic antagonist
rocuronium	[no description available]	medium	2	0	3alpha-hydroxy steroid; acetate ester; androstane; morpholines; quaternary ammonium ion; tertiary amino compound	drug allergen; muscle relaxant; neuromuscular agent
abacavir	[no description available]	medium	2	0	2,6-diaminopurines	antiviral drug; drug allergen; HIV-1 reverse transcriptase inhibitor
netilmicin	[no description available]	medium	2	0
miglitol	[no description available]	medium	2	0	piperidines
linezolid	[no description available]	medium	2	0	acetamides; morpholines; organofluorine compound; oxazolidinone	antibacterial drug; protein synthesis inhibitor
tolterodine	[no description available]	medium	4	0	tertiary amine	antispasmodic drug; muscarinic antagonist; muscle relaxant
darifenacin	[no description available]	medium	2	0	1-benzofurans; monocarboxylic acid amide; pyrrolidines	antispasmodic drug; muscarinic antagonist
fluticasone propionate	[no description available]	medium	1	0	11beta-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; corticosteroid; fluorinated steroid; propanoate ester; steroid ester; thioester	adrenergic agent; anti-allergic agent; anti-asthmatic drug; anti-inflammatory drug; bronchodilator agent; dermatologic drug
acarbose	[no description available]	medium	2	0	amino cyclitol; glycoside
tacrolimus	[no description available]	medium	6	0	macrolide lactam	bacterial metabolite; immunosuppressive agent
cerivastatin	[no description available]	medium	2	0	dihydroxy monocarboxylic acid; pyridines; statin (synthetic)
rosuvastatin	[no description available]	medium	3	0	dihydroxy monocarboxylic acid; monofluorobenzenes; pyrimidines; statin (synthetic); sulfonamide	anti-inflammatory agent; antilipemic drug; cardioprotective agent; CETP inhibitor; environmental contaminant; xenobiotic
cocaine	[no description available]	high	788	17	benzoate ester; methyl ester; tertiary amino compound; tropane alkaloid	adrenergic uptake inhibitor; central nervous system stimulant; dopamine uptake inhibitor; environmental contaminant; local anaesthetic; mouse metabolite; plant metabolite; serotonin uptake inhibitor; sodium channel blocker; sympathomimetic agent; vasoconstrictor agent; xenobiotic
cocaine	[no description available]	high	788	0	benzoate ester; methyl ester; tertiary amino compound; tropane alkaloid	adrenergic uptake inhibitor; central nervous system stimulant; dopamine uptake inhibitor; environmental contaminant; local anaesthetic; mouse metabolite; plant metabolite; serotonin uptake inhibitor; sodium channel blocker; sympathomimetic agent; vasoconstrictor agent; xenobiotic
clindamycin	[no description available]	medium	3	0
fosfomycin	[no description available]	medium	3	0	epoxide; phosphonic acids	antimicrobial agent; EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor
zithromax	[no description available]	medium	4	0	macrolide antibiotic	antibacterial drug; environmental contaminant; xenobiotic
bms 214662	[no description available]	medium	1	0	benzenes; benzodiazepine; imidazoles; nitrile; sulfonamide; thiophenes	antineoplastic agent; apoptosis inducer; EC 2.5.1.58 (protein farnesyltransferase) inhibitor
eptifibatide	[no description available]	medium	2	0	homodetic cyclic peptide; macrocycle; organic disulfide	anticoagulant; platelet aggregation inhibitor
gs 4071	[no description available]	medium	1	0	acetate ester; amino acid; cyclohexenecarboxylic acid; primary amino compound	antiviral drug; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor; marine xenobiotic metabolite
decitabine	[no description available]	medium	4	0	2'-deoxyribonucleoside
sm 8668	[no description available]	medium	1	0
teniposide	[no description available]	medium	3	0	aromatic ether; beta-D-glucoside; cyclic acetal; furonaphthodioxole; gamma-lactone; monosaccharide derivative; phenols; thiophenes	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
troxacitabine	[no description available]	medium	1	0	carbohydrate derivative; nucleobase-containing molecular entity
cefamandole	[no description available]	medium	2	0	cephalosporin; semisynthetic derivative	antibacterial drug
tiazofurin	[no description available]	medium	2	0	1,3-thiazoles; C-glycosyl compound; monocarboxylic acid amide	antineoplastic agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; prodrug
melphalan	[no description available]	medium	3	0	L-phenylalanine derivative; nitrogen mustard; non-proteinogenic L-alpha-amino acid; organochlorine compound	alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent
sitafloxacin	[no description available]	medium	1	0	fluoroquinolone antibiotic; quinolines; quinolone antibiotic
tenofovir	[no description available]	medium	4	0	nucleoside analogue; phosphonic acids	antiviral drug; drug metabolite; HIV-1 reverse transcriptase inhibitor
tenofovir	[no description available]	medium	4	1	nucleoside analogue; phosphonic acids	antiviral drug; drug metabolite; HIV-1 reverse transcriptase inhibitor
dibekacin	[no description available]	medium	1	0	kanamycins	antibacterial agent; protein synthesis inhibitor
micafungin	[no description available]	medium	3	0	antibiotic antifungal drug; echinocandin	antiinfective agent
mezlocillin	[no description available]	medium	1	0	penicillin allergen; penicillin	antibacterial drug
tropisetron	[no description available]	medium	5	0	indolyl carboxylic acid
leuprolide	[no description available]	medium	2	0	oligopeptide	anti-estrogen; antineoplastic agent; gonadotropin releasing hormone agonist
fludarabine	[no description available]	medium	1	0	purine nucleoside
propylthiouracil	[no description available]	medium	4	0	pyrimidinethione	antidote to paracetamol poisoning; antimetabolite; antioxidant; antithyroid drug; carcinogenic agent; EC 1.14.13.39 (nitric oxide synthase) inhibitor; hormone antagonist
etomidate	[no description available]	medium	3	0	ethyl ester; imidazoles	intravenous anaesthetic; sedative
mercaptopurine	[no description available]	medium	5	0	aryl thiol; purines; thiocarbonyl compound	anticoronaviral agent; antimetabolite; antineoplastic agent
cotinine	[no description available]	medium	3	0	N-alkylpyrrolidine; pyridines; pyrrolidin-2-ones; pyrrolidine alkaloid	antidepressant; biomarker; human xenobiotic metabolite; plant metabolite
methimazole	[no description available]	medium	7	0	1,3-dihydroimidazole-2-thiones	antithyroid drug
drotaverin	[no description available]	medium	1	0	isoquinolines
digoxin	[no description available]	medium	5	0	cardenolide glycoside; steroid saponin	anti-arrhythmia drug; cardiotonic drug; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; epitope
cancidas	[no description available]	medium	2	0
lincomycin	[no description available]	medium	3	0	carbohydrate-containing antibiotic; L-proline derivative; monocarboxylic acid amide; pyrrolidinecarboxamide; S-glycosyl compound	antimicrobial agent; bacterial metabolite
hmr 3647	[no description available]	medium	3	0
nelarabine	[no description available]	medium	2	0	beta-D-arabinoside; monosaccharide derivative; purine nucleoside	antineoplastic agent; DNA synthesis inhibitor; prodrug
2-[(2-ethoxyphenoxy)-phenylmethyl]morpholine	[no description available]	medium	1	0	aromatic ether
dolasetron	[no description available]	medium	2	0	indolyl carboxylic acid
or 1259	[no description available]	medium	2	0	hydrazone; nitrile; pyridazinone	anti-arrhythmia drug; cardiotonic drug; EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor; vasodilator agent
gestodene	[no description available]	medium	2	0	steroid	estrogen
isepamicin	[no description available]	medium	1	0
ifetroban	[no description available]	medium	1	0	benzenes; monocarboxylic acid
lamifiban	[no description available]	medium	1	0	N-acylglycine
telavancin	[no description available]	medium	1	0	glycopeptide	antibacterial drug; antimicrobial agent
sitagliptin	[no description available]	medium	2	0	triazolopyrazine; trifluorobenzene	EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; environmental contaminant; hypoglycemic agent; serine proteinase inhibitor; xenobiotic
tolcapone	[no description available]	medium	3	0	2-nitrophenols; benzophenones; catechols	antiparkinson drug; EC 2.1.1.6 (catechol O-methyltransferase) inhibitor
quercetin	[no description available]	medium	1	0	7-hydroxyflavonol; pentahydroxyflavone	antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger
clavulanic acid	[no description available]	medium	4	0	oxapenam	antibacterial drug; anxiolytic drug; bacterial metabolite; EC 3.5.2.6 (beta-lactamase) inhibitor
pulmicort	[no description available]	medium	5	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; cyclic acetal; glucocorticoid; primary alpha-hydroxy ketone	anti-inflammatory drug; bronchodilator agent; drug allergen
pulmicort	[no description available]	medium	5	1	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; cyclic acetal; glucocorticoid; primary alpha-hydroxy ketone	anti-inflammatory drug; bronchodilator agent; drug allergen
eprosartan	[no description available]	medium	2	0	dicarboxylic acid; imidazoles; thiophenes	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
montelukast	[no description available]	medium	4	0	aliphatic sulfide; monocarboxylic acid; quinolines	anti-arrhythmia drug; anti-asthmatic drug; leukotriene antagonist
mivacurium	[no description available]	medium	2	0	isoquinolines
entacapone	[no description available]	medium	3	0	2-nitrophenols; catechols; monocarboxylic acid amide; nitrile	antidyskinesia agent; antiparkinson drug; central nervous system drug; EC 2.1.1.6 (catechol O-methyltransferase) inhibitor
paricalcitol	[no description available]	medium	2	0	hydroxy seco-steroid; seco-cholestane	antiparathyroid drug
sdz psc 833	[no description available]	medium	3	0	homodetic cyclic peptide
indocyanine green	[no description available]	medium	2	0	1,1-diunsubstituted alkanesulfonate; benzoindole; cyanine dye
codeine	[no description available]	high	41	0	morphinane alkaloid; organic heteropentacyclic compound	antitussive; drug allergen; environmental contaminant; opioid analgesic; opioid receptor agonist; prodrug; xenobiotic
cyclosporine	[no description available]	medium	4	0	homodetic cyclic peptide	anti-asthmatic drug; anticoronaviral agent; antifungal agent; antirheumatic drug; carcinogenic agent; dermatologic drug; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; geroprotector; immunosuppressive agent; metabolite
hydromorphone	[no description available]	medium	7	0	morphinane alkaloid; organic heteropentacyclic compound	mu-opioid receptor agonist; opioid analgesic
nalmefene	[no description available]	medium	2	0	morphinane alkaloid
naloxone	[no description available]	medium	29	0	morphinane alkaloid; organic heteropentacyclic compound; tertiary alcohol	antidote to opioid poisoning; central nervous system depressant; mu-opioid receptor antagonist
oxycodone	[no description available]	medium	16	0	organic heteropentacyclic compound; semisynthetic derivative	antitussive; mu-opioid receptor agonist; opioid analgesic
alvocidib	[no description available]	medium	2	0	dihydroxyflavone; hydroxypiperidine; monochlorobenzenes; tertiary amino compound	antineoplastic agent; antirheumatic drug; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
morphine	[no description available]	high	235	0	morphinane alkaloid; organic heteropentacyclic compound; tertiary amino compound	anaesthetic; drug allergen; environmental contaminant; geroprotector; mu-opioid receptor agonist; opioid analgesic; plant metabolite; vasodilator agent; xenobiotic
cicaprost	[no description available]	medium	1	0	monoterpenoid
dexmedetomidine	[no description available]	medium	4	0	medetomidine	alpha-adrenergic agonist; analgesic; non-narcotic analgesic; sedative
iloprost	[no description available]	medium	2	0	carbobicyclic compound; monocarboxylic acid; secondary alcohol	platelet aggregation inhibitor; vasodilator agent
nalbuphine	[no description available]	medium	3	0	organic heteropentacyclic compound	mu-opioid receptor antagonist; opioid analgesic
nateglinide	[no description available]	medium	3	0	phenylalanine derivative
vinorelbine	[no description available]	medium	3	0	acetate ester; methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; ring assembly; vinca alkaloid	antineoplastic agent; photosensitizing agent
romidepsin	[no description available]	medium	1	0	cyclodepsipeptide; heterocyclic antibiotic; organic disulfide	antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor
(6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid	[no description available]	medium	4	0	dihydroxy monocarboxylic acid; indoles; organofluorine compound
naltrexone	[no description available]	high	43	12	cyclopropanes; morphinane-like compound; organic heteropentacyclic compound	antidote to opioid poisoning; central nervous system depressant; environmental contaminant; mu-opioid receptor antagonist; xenobiotic
naltrexone	[no description available]	high	43	0	cyclopropanes; morphinane-like compound; organic heteropentacyclic compound	antidote to opioid poisoning; central nervous system depressant; environmental contaminant; mu-opioid receptor antagonist; xenobiotic
morphine-6-glucuronide	[no description available]	medium	2	0	morphinane alkaloid
butorphanol	[no description available]	medium	4	0	morphinane alkaloid	antitussive; kappa-opioid receptor agonist; mu-opioid receptor agonist; opioid analgesic
cefodizime	[no description available]	medium	1	0	1,3-thiazoles; cephalosporin; oxime O-ether	antibacterial drug; EC 1.14.18.1 (tyrosinase) inhibitor
methylnaltrexone	[no description available]	medium	2	0	phenanthrenes
cefixime	[no description available]	medium	3	0	cephalosporin	antibacterial drug; drug allergen
lisinopril	[no description available]	medium	3	0	dipeptide	EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
indinavir sulfate	[no description available]	medium	4	0	dicarboxylic acid diamide; N-(2-hydroxyethyl)piperazine; piperazinecarboxamide	HIV protease inhibitor
enalaprilat anhydrous	[no description available]	medium	4	0	dicarboxylic acid; dipeptide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
cefuroxime	[no description available]	medium	2	0	3-(carbamoyloxymethyl)cephalosporin; furans; oxime O-ether	drug allergen
ceftriaxone	[no description available]	medium	4	0	1,2,4-triazines; 1,3-thiazoles; cephalosporin; oxime O-ether	antibacterial drug; drug allergen; EC 3.5.2.6 (beta-lactamase) inhibitor
cefepime	[no description available]	medium	2	0	cephalosporin; oxime O-ether	antibacterial drug
hr 810	[no description available]	medium	1	0	cephalosporin; cyclopentapyridine
ceftazidime	[no description available]	medium	3	0	cephalosporin; oxime O-ether	antibacterial drug; drug allergen; EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
cefetamet	[no description available]	medium	1	0	cephalosporin
famotidine	[no description available]	medium	3	0	1,3-thiazoles; guanidines; sulfonamide	anti-ulcer drug; H2-receptor antagonist; P450 inhibitor
cefotaxime	[no description available]	medium	3	0	1,3-thiazoles; cephalosporin; oxime O-ether	antibacterial drug; drug allergen
aztreonam	[no description available]	medium	4	0	beta-lactam antibiotic allergen; monobactam	antibacterial drug; drug allergen; EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
ginkgolide b	[no description available]	medium	1	0
palonosetron	[no description available]	medium	2	0	azabicycloalkane; delta-lactam; organic heterotricyclic compound	antiemetic; serotonergic antagonist
cefatrizine	[no description available]	medium	1	0	amino acid amide; carboxylic acid; cephalosporin; phenols; semisynthetic derivative; triazoles	antibacterial drug; EC 2.7.11.20 (elongation factor 2 kinase) inhibitor
eniporide	[no description available]	medium	1	0
cilastatin	[no description available]	medium	1	0	carboxamide; L-cysteine derivative; non-proteinogenic L-alpha-amino acid; organic sulfide	EC 3.4.13.19 (membrane dipeptidase) inhibitor; environmental contaminant; protease inhibitor; xenobiotic
ixabepilone	[no description available]	medium	3	0	1,3-thiazoles; beta-hydroxy ketone; epoxide; lactam; macrocycle	antineoplastic agent; microtubule-destabilising agent
azlocillin	[no description available]	medium	2	0	penicillin allergen; penicillin; semisynthetic derivative	antibacterial drug
verlukast	[no description available]	medium	1	0
ceftizoxime	[no description available]	medium	2	0	cephalosporin	antibacterial drug
carumonam	[no description available]	medium	1	0	monobactam	antibacterial drug
nitrofurantoin	[no description available]	medium	5	0	imidazolidine-2,4-dione; nitrofuran antibiotic; organonitrogen heterocyclic antibiotic; organooxygen heterocyclic antibiotic	antibacterial drug; antiinfective agent; hepatotoxic agent
eritoran	[no description available]	medium	1	0	lipid As
dantrolene	[no description available]	medium	4	0
artesunate	[no description available]	medium	1	0	artemisinin derivative; cyclic acetal; dicarboxylic acid monoester; hemisuccinate; semisynthetic derivative; sesquiterpenoid	antimalarial; antineoplastic agent; ferroptosis inducer
dexniguldipine	[no description available]	medium	1	0	diarylmethane
napsagatran	[no description available]	medium	1	0
temsirolimus	[no description available]	medium	2	0	macrolide lactam
bms188797	[no description available]	medium	1	0
azimilide	[no description available]	medium	1	0	imidazolidine-2,4-dione
tomopenem	[no description available]	medium	1	0
bb-83698	[no description available]	medium	1	0
zotarolimus	[no description available]	medium	1	0	lactam; macrolide
gentamicin sulfate	[no description available]	medium	3	0
bn 52020	[no description available]	medium	1	0
vindesine	[no description available]	medium	1	0
scopolamine hydrobromide	[no description available]	medium	66	0
scopolamine hydrobromide	[no description available]	medium	66	1
bisaramil	[no description available]	medium	1	0
teicoplanin	[no description available]	medium	1	0
ly-146032	[no description available]	medium	2	0	heterodetic cyclic peptide; lipopeptide antibiotic; lipopeptide; macrocycle; macrolide	antibacterial drug; bacterial metabolite; calcium-dependent antibiotics
dalbavancin	[no description available]	medium	1	0	carbohydrate acid derivative; glycopeptide; monosaccharide derivative; semisynthetic derivative	antibacterial drug; antimicrobial agent
cetrorelix	[no description available]	medium	2	0	oligopeptide	antineoplastic agent; GnRH antagonist
tetracycline	[no description available]	medium	5	0
chlortetracycline	[no description available]	medium	3	0
oxytetracycline, anhydrous	[no description available]	medium	3	0
minocycline	[no description available]	medium	18	0
roquinimex	[no description available]	medium	1	0	aromatic amide
mobic	[no description available]	medium	3	0	1,3-thiazoles; benzothiazine; monocarboxylic acid amide	analgesic; antirheumatic drug; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
mobiflex	[no description available]	medium	2	0	heteroaryl hydroxy compound; monocarboxylic acid amide; pyridines; thienothiazine	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
isoxicam	[no description available]	medium	1	0	benzothiazine; isoxazoles; monocarboxylic acid amide	antirheumatic drug; non-steroidal anti-inflammatory drug
demeclocycline	[no description available]	medium	2	0
rolitetracycline	[no description available]	medium	2	0
tigecycline	[no description available]	medium	2	0
acyclovir	[no description available]	medium	4	0	2-aminopurines; oxopurine	antimetabolite; antiviral drug
rifampin	[no description available]	medium	4	0	cyclic ketal; hydrazone; N-iminopiperazine; N-methylpiperazine; rifamycins; semisynthetic derivative; zwitterion	angiogenesis inhibitor; antiamoebic agent; antineoplastic agent; antitubercular agent; DNA synthesis inhibitor; EC 2.7.7.6 (RNA polymerase) inhibitor; Escherichia coli metabolite; geroprotector; leprostatic drug; neuroprotective agent; pregnane X receptor agonist; protein synthesis inhibitor
clozapine	[no description available]	high	32	0	benzodiazepine; N-arylpiperazine; N-methylpiperazine; organochlorine compound	adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; GABA antagonist; histamine antagonist; muscarinic antagonist; second generation antipsychotic; serotonergic antagonist; xenobiotic
dacarbazine	[no description available]	medium	4	0	dacarbazine
didanosine	[no description available]	medium	4	0	purine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor; geroprotector; HIV-1 reverse transcriptase inhibitor
ganciclovir	[no description available]	medium	3	0	2-aminopurines; oxopurine	antiinfective agent; antiviral drug
sildenafil	[no description available]	medium	3	0	piperazines; pyrazolopyrimidine; sulfonamide	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent
penciclovir	[no description available]	medium	2	0	2-aminopurines; propane-1,3-diols	antiviral drug
vardenafil	[no description available]	medium	2	0	imidazotriazine; N-alkylpiperazine; N-sulfonylpiperazine	EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; vasodilator agent
allopurinol	[no description available]	medium	7	0	nucleobase analogue; organic heterobicyclic compound	antimetabolite; EC 1.17.3.2 (xanthine oxidase) inhibitor; gout suppressant; radical scavenger
leucovorin	[no description available]	medium	3	0	formyltetrahydrofolic acid	Escherichia coli metabolite; mouse metabolite
tegaserod	[no description available]	medium	2	0	carboxamidine; guanidines; hydrazines; indoles	gastrointestinal drug; serotonergic agonist
tirapazamine	[no description available]	medium	2	0	aromatic amine; benzotriazines; N-oxide	antibacterial agent; antineoplastic agent; apoptosis inducer
aprepitant	[no description available]	medium	2	0	(trifluoromethyl)benzenes; cyclic acetal; morpholines; triazoles	antidepressant; antiemetic; neurokinin-1 receptor antagonist; peripheral nervous system drug; substance P receptor antagonist
ceftobiprole	[no description available]	medium	1	0	cephalosporin; thiadiazoles	antimicrobial agent
rifabutin	[no description available]	medium	3	0
acetamide	[no description available]	medium	1	0	acetamides; carboximidic acid; monocarboxylic acid amide; N-acylammonia
adenine	[no description available]	medium	1	0	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
allantoin	[no description available]	medium	1	0	imidazolidine-2,4-dione; ureas	Escherichia coli metabolite; human metabolite; Saccharomyces cerevisiae metabolite; vulnerary
citric acid, anhydrous	[no description available]	medium	3	0	tricarboxylic acid	antimicrobial agent; chelator; food acidity regulator; fundamental metabolite
bupropion	[no description available]	high	54	19	aromatic ketone; monochlorobenzenes; secondary amino compound	antidepressant; environmental contaminant; xenobiotic
bupropion	[no description available]	high	54	0	aromatic ketone; monochlorobenzenes; secondary amino compound	antidepressant; environmental contaminant; xenobiotic
creatine	[no description available]	medium	15	0	glycine derivative; guanidines; zwitterion	geroprotector; human metabolite; mouse metabolite; neuroprotective agent; nutraceutical
lactic acid	[no description available]	medium	7	0	2-hydroxy monocarboxylic acid	algal metabolite; Daphnia magna metabolite
dimethyl sulfoxide	[no description available]	medium	4	0	sulfoxide; volatile organic compound	alkylating agent; antidote; Escherichia coli metabolite; geroprotector; MRI contrast agent; non-narcotic analgesic; polar aprotic solvent; radical scavenger
formaldehyde	[no description available]	high	13	0	aldehyde; one-carbon compound	allergen; carcinogenic agent; disinfectant; EC 3.5.1.4 (amidase) inhibitor; environmental contaminant; Escherichia coli metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
glycine	[no description available]	medium	10	0	alpha-amino acid; amino acid zwitterion; proteinogenic amino acid; serine family amino acid	EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor; fundamental metabolite; hepatoprotective agent; micronutrient; neurotransmitter; NMDA receptor agonist; nutraceutical
glycerol	[no description available]	medium	1	0	alditol; triol	algal metabolite; detergent; Escherichia coli metabolite; geroprotector; human metabolite; mouse metabolite; osmolyte; Saccharomyces cerevisiae metabolite; solvent
hydroquinone	[no description available]	medium	1	0	benzenediol; hydroquinones	antioxidant; carcinogenic agent; cofactor; Escherichia coli metabolite; human xenobiotic metabolite; mouse metabolite; skin lightening agent
inositol	[no description available]	medium	9	0	cyclitol; hexol
niacinamide	[no description available]	medium	7	0	pyridine alkaloid; pyridinecarboxamide; vitamin B3	anti-inflammatory agent; antioxidant; cofactor; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; Escherichia coli metabolite; geroprotector; human urinary metabolite; metabolite; mouse metabolite; neuroprotective agent; Saccharomyces cerevisiae metabolite; Sir2 inhibitor
niacin	[no description available]	medium	6	0	pyridine alkaloid; pyridinemonocarboxylic acid; vitamin B3	antidote; antilipemic drug; EC 3.5.1.19 (nicotinamidase) inhibitor; Escherichia coli metabolite; human urinary metabolite; metabolite; mouse metabolite; plant metabolite; vasodilator agent
orotic acid	[no description available]	medium	2	0	pyrimidinemonocarboxylic acid	Escherichia coli metabolite; metabolite; mouse metabolite
4-aminobenzoic acid	[no description available]	medium	2	0	aminobenzoic acid; aromatic amino-acid zwitterion	allergen; Escherichia coli metabolite; plant metabolite
pyrazinamide	[no description available]	medium	3	0	monocarboxylic acid amide; N-acylammonia; pyrazines	antitubercular agent; prodrug
pyridoxal phosphate	[no description available]	medium	1	0	methylpyridines; monohydroxypyridine; pyridinecarbaldehyde; vitamin B6 phosphate	coenzyme; cofactor; EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
pyridoxine	[no description available]	medium	2	0	hydroxymethylpyridine; methylpyridines; monohydroxypyridine; vitamin B6	cofactor; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
uracil	[no description available]	medium	2	0	pyrimidine nucleobase; pyrimidone	allergen; Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; prodrug; Saccharomyces cerevisiae metabolite
urea	[no description available]	medium	6	0	isourea; monocarboxylic acid amide; one-carbon compound	Daphnia magna metabolite; Escherichia coli metabolite; fertilizer; flour treatment agent; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
catechin	[no description available]	medium	1	0	hydroxyflavan
menthol	[no description available]	medium	3	0	p-menthane monoterpenoid; secondary alcohol	volatile oil component
acetohexamide	[no description available]	medium	1	0	acetophenones; N-sulfonylurea	hypoglycemic agent; insulin secretagogue
acetohydroxamic acid	[no description available]	medium	2	0	acetohydroxamic acids; carbohydroximic acid	algal metabolite; EC 3.5.1.5 (urease) inhibitor
albendazole	[no description available]	medium	2	0	aryl sulfide; benzimidazoles; benzimidazolylcarbamate fungicide; carbamate ester	anthelminthic drug; microtubule-destabilising agent; tubulin modulator
ambroxol	[no description available]	medium	1	0	aromatic amine
aminoglutethimide	[no description available]	medium	1	0	dicarboximide; piperidones; substituted aniline	adrenergic agent; anticonvulsant; antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
pimagedine	[no description available]	medium	1	0	guanidines; one-carbon compound	EC 1.14.13.39 (nitric oxide synthase) inhibitor; EC 1.4.3.4 (monoamine oxidase) inhibitor
amobarbital	[no description available]	medium	34	0	barbiturates
amobarbital	[no description available]	medium	34	6	barbiturates
anastrozole	[no description available]	medium	2	0	nitrile; triazoles	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
anethole trithione	[no description available]	medium	1	0	methoxybenzenes
anthralin	[no description available]	medium	1	0	anthracenes	antipsoriatic
azathioprine	[no description available]	medium	3	0	aryl sulfide; C-nitro compound; imidazoles; thiopurine	antimetabolite; antineoplastic agent; carcinogenic agent; DNA synthesis inhibitor; hepatotoxic agent; immunosuppressive agent; prodrug
baclofen	[no description available]	medium	15	0	amino acid zwitterion; gamma-amino acid; monocarboxylic acid; monochlorobenzenes; primary amino compound	central nervous system depressant; GABA agonist; muscle relaxant
baclofen	[no description available]	medium	15	1	amino acid zwitterion; gamma-amino acid; monocarboxylic acid; monochlorobenzenes; primary amino compound	central nervous system depressant; GABA agonist; muscle relaxant
bendazac	[no description available]	medium	2	0	indazoles; monocarboxylic acid	non-steroidal anti-inflammatory drug; radical scavenger
benzbromarone	[no description available]	medium	3	0	1-benzofurans; aromatic ketone	uricosuric drug
bicalutamide	[no description available]	medium	2	0	(trifluoromethyl)benzenes; monocarboxylic acid amide; monofluorobenzenes; nitrile; sulfone; tertiary alcohol
bay h 4502	[no description available]	medium	1	0	biphenyls; imidazoles
bromisovalum	[no description available]	medium	2	0	N-acylurea; organobromine compound
buspirone	[no description available]	medium	10	0	azaspiro compound; N-alkylpiperazine; N-arylpiperazine; organic heteropolycyclic compound; piperidones; pyrimidines	anxiolytic drug; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; sedative; serotonergic agonist
buspirone	[no description available]	medium	10	1	azaspiro compound; N-alkylpiperazine; N-arylpiperazine; organic heteropolycyclic compound; piperidones; pyrimidines	anxiolytic drug; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; sedative; serotonergic agonist
butalbital	[no description available]	medium	1	0	barbiturates	analgesic; sedative
candesartan cilexetil	[no description available]	medium	2	0	biphenyls
carbamazepine	[no description available]	high	10	0	dibenzoazepine; ureas	analgesic; anticonvulsant; antimanic drug; drug allergen; EC 3.5.1.98 (histone deacetylase) inhibitor; environmental contaminant; glutamate transporter activator; mitogen; non-narcotic analgesic; sodium channel blocker; xenobiotic
carisoprodol	[no description available]	medium	4	0	carbamate ester	muscle relaxant
carprofen	[no description available]	medium	1	0	carbazoles; organochlorine compound	EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug; photosensitizing agent
celecoxib	[no description available]	medium	3	0	organofluorine compound; pyrazoles; sulfonamide; toluenes	cyclooxygenase 2 inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug
cetirizine	[no description available]	high	3	1	ether; monocarboxylic acid; monochlorobenzenes; piperazines	anti-allergic agent; environmental contaminant; H1-receptor antagonist; xenobiotic
cetirizine	[no description available]	high	3	0	ether; monocarboxylic acid; monochlorobenzenes; piperazines	anti-allergic agent; environmental contaminant; H1-receptor antagonist; xenobiotic
chloral hydrate	[no description available]	high	2	0	aldehyde hydrate; ethanediol; organochlorine compound	general anaesthetic; mouse metabolite; sedative; xenobiotic
chlormezanone	[no description available]	medium	2	0	1,3-thiazine; lactam; monochlorobenzenes; sulfone	antipsychotic agent; anxiolytic drug; muscle relaxant
chloroxylenol	[no description available]	medium	1	0	monochlorobenzenes; phenols	antiseptic drug; disinfectant; molluscicide
chlorzoxazone	[no description available]	medium	2	0	1,3-benzoxazoles; heteroaryl hydroxy compound; organochlorine compound	muscle relaxant; sedative
cinoxacin	[no description available]	medium	2	0	cinnolines; oxacycle; oxo carboxylic acid	antibacterial drug; antiinfective agent
ciprofibrate	[no description available]	medium	1	0	cyclopropanes; monocarboxylic acid; organochlorine compound	antilipemic drug
cisapride	[no description available]	medium	2	0	benzamides
clioquinol	[no description available]	medium	1	0	monohydroxyquinoline; organochlorine compound; organoiodine compound	antibacterial agent; antifungal agent; antimicrobial agent; antineoplastic agent; antiprotozoal drug; chelator; copper chelator
clobazam	[no description available]	medium	1	0	1,4-benzodiazepinone; organochlorine compound	anticonvulsant; anxiolytic drug; GABA modulator
clofazimine	[no description available]	medium	1	0	monochlorobenzenes; phenazines	dye; leprostatic drug; non-steroidal anti-inflammatory drug
clofibrate	[no description available]	medium	3	0	aromatic ether; ethyl ester; monochlorobenzenes	anticholesteremic drug; antilipemic drug; geroprotector; PPARalpha agonist
clomiphene	[no description available]	medium	2	0	tertiary amine	estrogen antagonist; estrogen receptor modulator
clotiazepam	[no description available]	medium	1	0	organic molecular entity
clotrimazole	[no description available]	medium	3	0	conazole antifungal drug; imidazole antifungal drug; imidazoles; monochlorobenzenes	antiinfective agent; environmental contaminant; xenobiotic
cyclandelate	[no description available]	medium	1	0	carboxylic ester; secondary alcohol	vasodilator agent
cyproheptadine	[no description available]	medium	8	0	piperidines; tertiary amine	anti-allergic agent; antipruritic drug; gastrointestinal drug; H1-receptor antagonist; serotonergic antagonist
danthron	[no description available]	medium	1	0	dihydroxyanthraquinone	apoptosis inducer; plant metabolite
deferoxamine	[no description available]	medium	4	0	acyclic desferrioxamine	bacterial metabolite; ferroptosis inhibitor; iron chelator; siderophore
eflornithine	[no description available]	medium	1	0	alpha-amino acid; fluoroamino acid	trypanocidal drug
ddt	[no description available]	medium	1	0	benzenoid aromatic compound; chlorophenylethane; monochlorobenzenes; organochlorine insecticide	bridged diphenyl acaricide; carcinogenic agent; endocrine disruptor; persistent organic pollutant
dipyridamole	[no description available]	medium	2	0	piperidines; pyrimidopyrimidine; tertiary amino compound; tetrol	adenosine phosphodiesterase inhibitor; EC 3.5.4.4 (adenosine deaminase) inhibitor; platelet aggregation inhibitor; vasodilator agent
disulfiram	[no description available]	medium	12	0	organic disulfide; organosulfur acaricide	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor; EC 3.1.1.1 (carboxylesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 5.99.1.2 (DNA topoisomerase) inhibitor; ferroptosis inducer; fungicide; NF-kappaB inhibitor
droperidol	[no description available]	medium	8	0	aromatic ketone; benzimidazoles; organofluorine compound	anaesthesia adjuvant; antiemetic; dopaminergic antagonist; first generation antipsychotic
droperidol	[no description available]	medium	8	2	aromatic ketone; benzimidazoles; organofluorine compound	anaesthesia adjuvant; antiemetic; dopaminergic antagonist; first generation antipsychotic
econazole	[no description available]	medium	1	0	dichlorobenzene; ether; imidazoles; monochlorobenzenes
enflurane	[no description available]	medium	1	0	ether; organochlorine compound; organofluorine compound	anaesthetic
estazolam	[no description available]	medium	3	0	triazoles; triazolobenzodiazepine	anticonvulsant; anxiolytic drug; GABA modulator
ethoxzolamide	[no description available]	medium	1	0	aromatic ether; benzothiazoles; sulfonamide	antiglaucoma drug; diuretic; EC 4.2.1.1 (carbonic anhydrase) inhibitor
etodolac	[no description available]	medium	2	0	monocarboxylic acid; organic heterotricyclic compound	antipyretic; cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
brl 42810	[no description available]	medium	2	0	2-aminopurines; acetate ester	antiviral drug; prodrug
felbamate	[no description available]	medium	3	0	carbamate ester	anticonvulsant; neuroprotective agent
fenofibrate	[no description available]	medium	3	0	aromatic ether; chlorobenzophenone; isopropyl ester; monochlorobenzenes	antilipemic drug; environmental contaminant; geroprotector; xenobiotic
flufenamic acid	[no description available]	medium	2	0	aromatic amino acid; organofluorine compound	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
flutamide	[no description available]	medium	3	0	(trifluoromethyl)benzenes; monocarboxylic acid amide	androgen antagonist; antineoplastic agent
fomepizole	[no description available]	medium	2	0	pyrazoles	antidote; EC 1.1.1.1 (alcohol dehydrogenase) inhibitor; protective agent
gemfibrozil	[no description available]	medium	3	0	aromatic ether	antilipemic drug
glafenine	[no description available]	medium	3	0	aminoquinoline; carboxylic ester; glycol; organochlorine compound; secondary amino compound	inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
gliclazide	[no description available]	medium	1	0	N-sulfonylurea	hypoglycemic agent; insulin secretagogue; radical scavenger
glutethimide	[no description available]	medium	6	0	piperidines
gossypol	[no description available]	medium	1	0
guaiazulene	[no description available]	medium	1	0	sesquiterpene
fasudil	[no description available]	medium	2	0	isoquinolines; N-sulfonyldiazepane	antihypertensive agent; calcium channel blocker; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; geroprotector; neuroprotective agent; nootropic agent; vasodilator agent
halothane	[no description available]	medium	7	0	haloalkane; organobromine compound; organochlorine compound; organofluorine compound	inhalation anaesthetic
hexachlorophene	[no description available]	medium	1	0	bridged diphenyl fungicide; polyphenol; trichlorobenzene	acaricide; antibacterial agent; antifungal agrochemical; antiseptic drug
miltefosine	[no description available]	medium	1	0	phosphocholines; phospholipid	anti-inflammatory agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antiprotozoal drug; apoptosis inducer; immunomodulator; protein kinase inhibitor
hexestrol	[no description available]	medium	1	0	stilbenoid
hexetidine	[no description available]	medium	1	0	organic heteromonocyclic compound; organonitrogen heterocyclic compound
hydrochlorothiazide	[no description available]	high	4	0	benzothiadiazine; organochlorine compound; sulfonamide	antihypertensive agent; diuretic; environmental contaminant; xenobiotic
phenelzine	[no description available]	medium	9	0	primary amine
alverine	[no description available]	medium	1	0	tertiary amine	antispasmodic drug
idebenone	[no description available]	medium	1	0	1,4-benzoquinones; primary alcohol	antioxidant; ferroptosis inhibitor
indapamide	[no description available]	medium	2	0	indoles; organochlorine compound; sulfonamide	antihypertensive agent; diuretic
iodipamide	[no description available]	medium	1	0	benzoic acids; organoiodine compound; secondary carboxamide	radioopaque medium
iproniazid	[no description available]	medium	18	0	carbohydrazide; pyridines
isoflurane	[no description available]	medium	2	0	organofluorine compound	inhalation anaesthetic
isoxsuprine	[no description available]	medium	3	0	alkylbenzene
ketoconazole	[no description available]	medium	6	0	dichlorobenzene; dioxolane; ether; imidazoles; N-acylpiperazine; N-arylpiperazine
khellin	[no description available]	medium	1	0	furanochromone; organic heterotricyclic compound; oxacycle	anti-asthmatic agent; bronchodilator agent; cardiovascular drug; vasodilator agent
lamotrigine	[no description available]	high	7	0	1,2,4-triazines; dichlorobenzene; primary arylamine	anticonvulsant; antidepressant; antimanic drug; calcium channel blocker; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; excitatory amino acid antagonist; geroprotector; non-narcotic analgesic; xenobiotic
beta-lapachone	[no description available]	medium	1	0	benzochromenone; orthoquinones	anti-inflammatory agent; antineoplastic agent; plant metabolite
leflunomide	[no description available]	medium	2	0	(trifluoromethyl)benzenes; isoxazoles; monocarboxylic acid amide	antineoplastic agent; antiparasitic agent; EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; hepatotoxic agent; immunosuppressive agent; non-steroidal anti-inflammatory drug; prodrug; pyrimidine synthesis inhibitor; tyrosine kinase inhibitor
lofepramine	[no description available]	medium	1	0	aromatic ketone; dibenzoazepine; monochlorobenzenes; tertiary amino compound	antidepressant
lomustine	[no description available]	medium	2	0	N-nitrosoureas; organochlorine compound	alkylating agent; antineoplastic agent
loperamide	[no description available]	medium	2	0	monocarboxylic acid amide; monochlorobenzenes; piperidines; tertiary alcohol	anticoronaviral agent; antidiarrhoeal drug; mu-opioid receptor agonist
malathion	[no description available]	medium	2	0	diester; ethyl ester; organic thiophosphate
diisopropyl 1,3-dithiol-2-ylidenemalonate	[no description available]	medium	1	0	isopropyl ester
mazindol	[no description available]	medium	23	0	organic molecular entity
meclizine	[no description available]	medium	4	0	diarylmethane
meclofenoxate	[no description available]	medium	3	0	monocarboxylic acid
meclofenoxate	[no description available]	medium	3	1	monocarboxylic acid
mefenamic acid	[no description available]	medium	4	0	aminobenzoic acid; secondary amino compound	analgesic; antipyretic; antirheumatic drug; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-steroidal anti-inflammatory drug; xenobiotic
vitamin k 3	[no description available]	medium	1	0	1,4-naphthoquinones; vitamin K	angiogenesis inhibitor; antineoplastic agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; human urinary metabolite; nutraceutical
mephenytoin	[no description available]	medium	2	0	imidazolidine-2,4-dione	anticonvulsant
methoxsalen	[no description available]	medium	2	0	aromatic ether; psoralens	antineoplastic agent; cross-linking reagent; dermatologic drug; photosensitizing agent; plant metabolite
methoxyflurane	[no description available]	medium	1	0	ether; organochlorine compound; organofluorine compound	hepatotoxic agent; inhalation anaesthetic; nephrotoxic agent; non-narcotic analgesic
methyl salicylate	[no description available]	medium	1	0	benzoate ester; methyl ester; salicylates	flavouring agent; insect attractant; metabolite
methyprylon	[no description available]	medium	1	0	organic molecular entity
metyrapone	[no description available]	medium	7	0	aromatic ketone	antimetabolite; diagnostic agent; EC 1.14.15.4 (steroid 11beta-monooxygenase) inhibitor
metyrapone	[no description available]	medium	7	1	aromatic ketone	antimetabolite; diagnostic agent; EC 1.14.15.4 (steroid 11beta-monooxygenase) inhibitor
mianserin	[no description available]	medium	14	0	dibenzoazepine	adrenergic uptake inhibitor; alpha-adrenergic antagonist; antidepressant; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; geroprotector; H1-receptor antagonist; histamine agonist; sedative; serotonergic antagonist
mianserin	[no description available]	medium	14	3	dibenzoazepine	adrenergic uptake inhibitor; alpha-adrenergic antagonist; antidepressant; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; geroprotector; H1-receptor antagonist; histamine agonist; sedative; serotonergic antagonist
miconazole	[no description available]	medium	1	0	dichlorobenzene; ether; imidazoles
minoxidil	[no description available]	medium	3	0	dialkylarylamine; tertiary amino compound
mitotane	[no description available]	medium	2	0	diarylmethane
modafinil	[no description available]	medium	42	0	monocarboxylic acid amide; sulfoxide
modafinil	[no description available]	medium	42	8	monocarboxylic acid amide; sulfoxide
moxisylyte	[no description available]	medium	3	0	monoterpenoid
deet	[no description available]	medium	1	0	benzamides; monocarboxylic acid amide	environmental contaminant; insect repellent; xenobiotic
nabumetone	[no description available]	medium	2	0	methoxynaphthalene; methyl ketone	cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug
nalidixic acid	[no description available]	medium	10	0	1,8-naphthyridine derivative; monocarboxylic acid; quinolone antibiotic	antibacterial drug; antimicrobial agent; DNA synthesis inhibitor
nialamide	[no description available]	medium	14	0	organonitrogen compound; organooxygen compound
niceritrol	[no description available]	medium	1	0	organic molecular entity
niflumic acid	[no description available]	medium	1	0	aromatic carboxylic acid; pyridines
nilutamide	[no description available]	medium	3	0	(trifluoromethyl)benzenes; C-nitro compound; imidazolidinone	androgen antagonist; antineoplastic agent
nimesulide	[no description available]	medium	4	0	aromatic ether; C-nitro compound; sulfonamide	cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
nitroglycerin	[no description available]	high	4	0	nitroglycerol	explosive; muscle relaxant; nitric oxide donor; prodrug; tocolytic agent; vasodilator agent; xenobiotic
masoprocol	[no description available]	medium	1	0	catechols; lignan; tetrol	antioxidant; ferroptosis inhibitor; geroprotector; plant metabolite
norfloxacin	[no description available]	medium	3	0	fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antibacterial drug; DNA synthesis inhibitor; environmental contaminant; xenobiotic
orphenadrine	[no description available]	medium	3	0	ether; tertiary amino compound	antidyskinesia agent; antiparkinson drug; H1-receptor antagonist; muscarinic antagonist; muscle relaxant; NMDA receptor antagonist; parasympatholytic
oxamniquine	[no description available]	medium	1	0	aromatic primary alcohol; C-nitro compound; quinolines; secondary amino compound
oxaprozin	[no description available]	medium	2	0	1,3-oxazoles; monocarboxylic acid	analgesic; non-steroidal anti-inflammatory drug
oxethazaine	[no description available]	medium	1	0	amino acid amide
oxybenzone	[no description available]	medium	1	0	hydroxybenzophenone; monomethoxybenzene	dermatologic drug; environmental contaminant; protective agent; ultraviolet filter; xenobiotic
oxyphenbutazone	[no description available]	medium	3	0	phenols; pyrazolidines	antimicrobial agent; antineoplastic agent; antipyretic; drug metabolite; gout suppressant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic metabolite
aminosalicylic acid	[no description available]	medium	4	0	aminobenzoic acid; phenols	antitubercular agent
pemoline	[no description available]	high	19	3	1,3-oxazoles	central nervous system stimulant
pemoline	[no description available]	high	19	0	1,3-oxazoles	central nervous system stimulant
perazine	[no description available]	medium	1	0	N-alkylpiperazine; N-methylpiperazine; phenothiazines	dopaminergic antagonist; phenothiazine antipsychotic drug
phenolphthalein	[no description available]	medium	1	0	phenols
phenoxybenzamine	[no description available]	medium	16	0	aromatic amine
phenylbutazone	[no description available]	medium	2	0	pyrazolidines	antirheumatic drug; EC 1.1.1.184 [carbonyl reductase (NADPH)] inhibitor; metabolite; non-narcotic analgesic; non-steroidal anti-inflammatory drug; peripheral nervous system drug
pinacidil	[no description available]	medium	1	0	pyridines
pipemidic acid	[no description available]	medium	1	0	amino acid; monocarboxylic acid; N-arylpiperazine; pyridopyrimidine; quinolone antibiotic	antibacterial drug; DNA synthesis inhibitor
piperazine	[no description available]	medium	2	0	azacycloalkane; piperazines; saturated organic heteromonocyclic parent	anthelminthic drug
praziquantel	[no description available]	medium	2	0	isoquinolines
primidone	[no description available]	high	4	0	pyrimidone	anticonvulsant; environmental contaminant; xenobiotic
probucol	[no description available]	medium	1	0	dithioketal; polyphenol	anti-inflammatory drug; anticholesteremic drug; antilipemic drug; antioxidant; cardiovascular drug
procarbazine	[no description available]	medium	2	0	benzamides; hydrazines	antineoplastic agent
pyridinolcarbamate	[no description available]	medium	1	0	pyridines
opc 12759	[no description available]	medium	1	0	secondary carboxamide
riluzole	[no description available]	medium	6	0	benzothiazoles
riluzole	[no description available]	medium	6	1	benzothiazoles
rofecoxib	[no description available]	medium	1	0	butenolide; sulfone	analgesic; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
salicylamide	[no description available]	medium	1	0	phenols; salicylamides	antirheumatic drug; non-narcotic analgesic
sevoflurane	[no description available]	medium	4	0	ether; organofluorine compound	central nervous system depressant; inhalation anaesthetic; platelet aggregation inhibitor
sibutramine	[no description available]	medium	4	0	organochlorine compound; tertiary amino compound	anti-obesity agent; serotonin uptake inhibitor
4-phenylbutyric acid, sodium salt	[no description available]	medium	1	0	organic sodium salt	EC 3.5.1.98 (histone deacetylase) inhibitor; geroprotector; neuroprotective agent; orphan drug; prodrug
sulfadimethoxine	[no description available]	medium	1	0	aromatic ether; pyrimidines; substituted aniline; sulfonamide antibiotic; sulfonamide	antiinfective agent; antimicrobial agent; drug allergen; environmental contaminant; xenobiotic
sulfamerazine	[no description available]	medium	1	0	pyrimidines; sulfonamide antibiotic; sulfonamide	antiinfective agent; drug allergen
sulfameter	[no description available]	medium	1	0	pyrimidines; sulfonamide antibiotic; sulfonamide	antiinfective agent; leprostatic drug; renal agent
sulfamethazine	[no description available]	medium	1	0	pyrimidines; sulfonamide antibiotic; sulfonamide	antibacterial drug; antiinfective agent; antimicrobial agent; carcinogenic agent; drug allergen; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; ligand; xenobiotic
sulfamethizole	[no description available]	medium	2	0	sulfonamide antibiotic; sulfonamide; thiadiazoles	antiinfective agent; antimicrobial agent; drug allergen; EC 2.5.1.15 (dihydropteroate synthase) inhibitor
sulfanilamide	[no description available]	medium	1	0	substituted aniline; sulfonamide antibiotic; sulfonamide	antibacterial agent; drug allergen; EC 4.2.1.1 (carbonic anhydrase) inhibitor
sulfaphenazole	[no description available]	medium	2	0	primary amino compound; pyrazoles; substituted aniline; sulfonamide antibiotic; sulfonamide	antibacterial drug; EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor; EC 1.14.13.67 (quinine 3-monooxygenase) inhibitor; P450 inhibitor
sulfapyridine	[no description available]	medium	1	0	pyridines; substituted aniline; sulfonamide antibiotic; sulfonamide	antiinfective agent; dermatologic drug; drug allergen; environmental contaminant; xenobiotic
2-(octylamino)-1-[4-(propan-2-ylthio)phenyl]-1-propanol	[no description available]	medium	2	0	alkylbenzene
tegafur	[no description available]	medium	1	0	organohalogen compound; pyrimidines
temazepam	[no description available]	medium	3	0	benzodiazepine
thiabendazole	[no description available]	medium	2	0	1,3-thiazoles; benzimidazole fungicide; benzimidazoles	antifungal agrochemical; antinematodal drug
thioridazine	[no description available]	medium	6	0	phenothiazines; piperidines	alpha-adrenergic antagonist; dopaminergic antagonist; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; first generation antipsychotic; H1-receptor antagonist; serotonergic antagonist
tiaprofenic acid	[no description available]	medium	1	0	aromatic ketone; monocarboxylic acid; thiophenes	drug allergen; non-steroidal anti-inflammatory drug
ticlopidine	[no description available]	medium	3	0	monochlorobenzenes; thienopyridine	anticoagulant; fibrin modulating drug; hematologic agent; P2Y12 receptor antagonist; platelet aggregation inhibitor
tiopronin	[no description available]	medium	2	0	N-acyl-amino acid
tolazamide	[no description available]	medium	2	0	N-sulfonylurea	hypoglycemic agent; potassium channel blocker
tolperisone	[no description available]	medium	1	0	aromatic ketone
triclosan	[no description available]	medium	1	0	aromatic ether; dichlorobenzene; monochlorobenzenes; phenols	antibacterial agent; antimalarial; drug allergen; EC 1.3.1.9 [enoyl-[acyl-carrier-protein] reductase (NADH)] inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; fungicide; persistent organic pollutant; xenobiotic
triflupromazine	[no description available]	medium	2	0	organofluorine compound; phenothiazines; tertiary amine	anticoronaviral agent; antiemetic; dopaminergic antagonist; first generation antipsychotic
trimethadione	[no description available]	medium	5	0	oxazolidinone	anticonvulsant; geroprotector
troglitazone	[no description available]	medium	3	0	chromanes; thiazolidinone	anticoagulant; anticonvulsant; antineoplastic agent; antioxidant; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; hypoglycemic agent; platelet aggregation inhibitor; vasodilator agent
vesnarinone	[no description available]	medium	1	0	organic molecular entity
vigabatrin	[no description available]	medium	7	0	gamma-amino acid	anticonvulsant; EC 2.6.1.19 (4-aminobutyrate--2-oxoglutarate transaminase) inhibitor
vigabatrin	[no description available]	medium	7	2	gamma-amino acid	anticonvulsant; EC 2.6.1.19 (4-aminobutyrate--2-oxoglutarate transaminase) inhibitor
ici 204,219	[no description available]	medium	3	0	carbamate ester; indoles; N-sulfonylcarboxamide	anti-asthmatic agent; leukotriene antagonist
guanidine hydrochloride	[no description available]	medium	1	0	one-carbon compound; organic chloride salt	protein denaturant
hydrocortisone acetate	[no description available]	medium	1	0	cortisol ester; tertiary alpha-hydroxy ketone
cortisone acetate	[no description available]	medium	2	0	corticosteroid hormone
mitomycin	[no description available]	medium	3	0	mitomycin	alkylating agent; antineoplastic agent
reserpine	[no description available]	high	142	0	alkaloid ester; methyl ester; yohimban alkaloid	adrenergic uptake inhibitor; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; first generation antipsychotic; plant metabolite; xenobiotic
phentolamine	[no description available]	medium	25	0	imidazoles; phenols; substituted aniline; tertiary amino compound	alpha-adrenergic antagonist; vasodilator agent
sorbitol	[no description available]	medium	2	0	glucitol	cathartic; Escherichia coli metabolite; food humectant; human metabolite; laxative; metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite; sweetening agent
floxuridine	[no description available]	medium	2	0	nucleoside analogue; organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; radiosensitizing agent
piperonyl butoxide	[no description available]	medium	1	0	benzodioxoles	pesticide synergist
bromouracil	[no description available]	medium	1	0	nucleobase analogue; pyrimidines	mutagen
3,3',5-triiodothyroacetic acid	[no description available]	medium	1	0
histamine dihydrochloride	[no description available]	medium	1	0
thyroxine	[no description available]	medium	7	0	2-halophenol; iodophenol; L-phenylalanine derivative; non-proteinogenic L-alpha-amino acid; thyroxine zwitterion; thyroxine	antithyroid drug; human metabolite; mouse metabolite; thyroid hormone
carbachol	[no description available]	medium	6	0	ammonium salt; carbamate ester	cardiotonic drug; miotic; muscarinic agonist; nicotinic acetylcholine receptor agonist; non-narcotic analgesic
norethindrone acetate	[no description available]	medium	1	0	3-oxo-Delta(4) steroid; acetate ester; terminal acetylenic compound	progestin; synthetic oral contraceptive
spironolactone	[no description available]	medium	2	0	3-oxo-Delta(4) steroid; oxaspiro compound; steroid lactone; thioester	aldosterone antagonist; antihypertensive agent; diuretic; environmental contaminant; xenobiotic
cyclobarbital	[no description available]	medium	1	0	barbiturates
allobarbital	[no description available]	medium	1	0	barbiturates
penicillamine	[no description available]	medium	3	0	non-proteinogenic alpha-amino acid; penicillamine	antirheumatic drug; chelator; copper chelator; drug allergen
trichlorfon	[no description available]	medium	1	0	organic phosphonate; organochlorine compound; phosphonic ester	agrochemical; anthelminthic drug; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; insecticide
oxandrolone	[no description available]	medium	2	0	17beta-hydroxy steroid; 3-oxo steroid; anabolic androgenic steroid; oxa-steroid	anabolic agent; androgen
dehydroepiandrosterone	[no description available]	medium	3	0	17-oxo steroid; 3beta-hydroxy-Delta(5)-steroid; androstanoid	androgen; human metabolite; mouse metabolite
dehydroepiandrosterone	[no description available]	medium	3	2	17-oxo steroid; 3beta-hydroxy-Delta(5)-steroid; androstanoid	androgen; human metabolite; mouse metabolite
nad	[no description available]	medium	1	0	NAD	geroprotector
pilocarpine	[no description available]	medium	12	0	pilocarpine	antiglaucoma drug
triiodothyronine	[no description available]	medium	5	0	2-halophenol; amino acid zwitterion; iodophenol; iodothyronine	human metabolite; mouse metabolite; thyroid hormone
glutamine	[no description available]	medium	13	0	amino acid zwitterion; glutamine family amino acid; glutamine; L-alpha-amino acid; polar amino acid zwitterion; proteinogenic amino acid	EC 1.14.13.39 (nitric oxide synthase) inhibitor; Escherichia coli metabolite; human metabolite; metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
cetrimonium bromide	[no description available]	medium	1	0	organic bromide salt; quaternary ammonium salt	detergent; surfactant
sucrose	[no description available]	medium	19	0	glycosyl glycoside	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; osmolyte; Saccharomyces cerevisiae metabolite; sweetening agent
testosterone propionate	[no description available]	medium	3	0	steroid ester
methyltestosterone	[no description available]	medium	2	0	17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; enone	anabolic agent; androgen; antineoplastic agent
tetrabenazine	[no description available]	medium	43	0	benzoquinolizine; cyclic ketone; tertiary amino compound
uridine	[no description available]	medium	4	0	uridines	drug metabolite; fundamental metabolite; human metabolite
phenylephrine	[no description available]	medium	23	0	phenols; phenylethanolamines; secondary amino compound	alpha-adrenergic agonist; cardiotonic drug; mydriatic agent; nasal decongestant; protective agent; sympathomimetic agent; vasoconstrictor agent
niridazole	[no description available]	medium	1	0	1,3-thiazoles; C-nitro compound
carbaryl	[no description available]	medium	1	0	carbamate ester; naphthalenes	acaricide; agrochemical; carbamate insecticide; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; plant growth retardant
lactose	[no description available]	medium	3	0	lactose
methionine	[no description available]	medium	5	0	aspartate family amino acid; L-alpha-amino acid; methionine zwitterion; methionine; proteinogenic amino acid	antidote to paracetamol poisoning; human metabolite; micronutrient; mouse metabolite; nutraceutical
Mebutamate	[no description available]	medium	1	0	organic molecular entity
norethindrone	[no description available]	medium	1	0	17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; terminal acetylenic compound; tertiary alcohol	progestin; synthetic oral contraceptive
norethynodrel	[no description available]	medium	2	0	oxo steroid
benziodarone	[no description available]	medium	2	0	aromatic ketone
cytarabine	[no description available]	medium	3	0	beta-D-arabinoside; monosaccharide derivative; pyrimidine nucleoside	antimetabolite; antineoplastic agent; antiviral agent; immunosuppressive agent
medroxyprogesterone acetate	[no description available]	medium	1	0	20-oxo steroid; 3-oxo-Delta(4) steroid; acetate ester; corticosteroid; steroid ester	adjuvant; androgen; antineoplastic agent; antioxidant; female contraceptive drug; inhibitor; progestin; synthetic oral contraceptive
mestranol	[no description available]	medium	2	0	17beta-hydroxy steroid; aromatic ether; terminal acetylenic compound	prodrug; xenoestrogen
methaqualone	[no description available]	medium	4	0	quinazolines	GABA agonist; sedative
trypan blue	[no description available]	medium	1	0
cordycepin	[no description available]	medium	1	0	3'-deoxyribonucleoside; adenosines	antimetabolite; nucleoside antibiotic
tryptophan	[no description available]	medium	27	0	erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid; tryptophan zwitterion; tryptophan	antidepressant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
tryptophan	[no description available]	medium	27	1	erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid; tryptophan zwitterion; tryptophan	antidepressant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
arginine	[no description available]	medium	11	0	arginine; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	biomarker; Escherichia coli metabolite; micronutrient; mouse metabolite; nutraceutical
allylpropymal	[no description available]	medium	1	0	barbiturates
butobarbital	[no description available]	medium	1	0	barbiturates
trichloroethylene	[no description available]	medium	1	0	chloroethenes	inhalation anaesthetic; mouse metabolite
dehydrocholic acid	[no description available]	medium	1	0	12-oxo steroid; 3-oxo-5beta-steroid; 7-oxo steroid; oxo-5beta-cholanic acid	gastrointestinal drug
synephrine	[no description available]	medium	12	0	ethanolamines; phenethylamine alkaloid; phenols	alpha-adrenergic agonist; plant metabolite
benzoyl peroxide	[no description available]	medium	1	0	carbonyl compound
furan	[no description available]	medium	1	0	furans; mancude organic heteromonocyclic parent; monocyclic heteroarene	carcinogenic agent; hepatotoxic agent; Maillard reaction product
phenformin	[no description available]	medium	1	0	biguanides	antineoplastic agent; geroprotector; hypoglycemic agent
mephobarbital	[no description available]	medium	1	0	barbiturates	anticonvulsant
hexachlorobenzene	[no description available]	medium	1	0	aromatic fungicide; chlorobenzenes	antifungal agrochemical; carcinogenic agent; persistent organic pollutant
trinitrotoluene	[no description available]	medium	1	0	trinitrotoluene	explosive
framycetin	[no description available]	medium	2	0	aminoglycoside	allergen; antibacterial drug; Escherichia coli metabolite
pyrazolanthrone	[no description available]	medium	5	0	anthrapyrazole; aromatic ketone; cyclic ketone	antineoplastic agent; c-Jun N-terminal kinase inhibitor; geroprotector
meglumine	[no description available]	medium	2	0	hexosamine; secondary amino compound
cinchophen	[no description available]	medium	2	0	quinolines
yohimbine	[no description available]	medium	13	0	methyl 17-hydroxy-20xi-yohimban-16-carboxylate	alpha-adrenergic antagonist; dopamine receptor D2 antagonist; serotonergic antagonist
quinestrol	[no description available]	medium	1	0	17-hydroxy steroid; terminal acetylenic compound	xenoestrogen
dydrogesterone	[no description available]	medium	1	0	20-oxo steroid; 3-oxo-Delta(4) steroid	progestin
chlormadinone acetate	[no description available]	medium	1	0	corticosteroid hormone
2,3-dimercaptosuccinic acid	[no description available]	medium	1	0
evans blue	[no description available]	medium	5	0	organic sodium salt	fluorochrome; histological dye; sodium channel blocker; teratogenic agent
testosterone enanthate	[no description available]	medium	1	0	heptanoate ester; sterol ester	androgen
aminophylline	[no description available]	medium	6	0	mixture	bronchodilator agent; cardiotonic drug
aminophylline	[no description available]	medium	6	1	mixture	bronchodilator agent; cardiotonic drug
phenyramidol	[no description available]	medium	1	0	aminopyridine
carbutamide	[no description available]	medium	1	0	benzenes; sulfonamide
nandrolone decanoate	[no description available]	medium	2	0	steroid ester
bucladesine	[no description available]	medium	1	0	3',5'-cyclic purine nucleotide; butanamides; butyrate ester	agonist; cardiotonic drug; vasodilator agent
perflubron	[no description available]	medium	1	0	haloalkane; organobromine compound; perfluorinated compound	blood substitute; radioopaque medium
cyproterone acetate	[no description available]	medium	1	0	20-oxo steroid; 3-oxo-Delta(4) steroid; acetate ester; chlorinated steroid; steroid ester	androgen antagonist; geroprotector; progestin
glycyrrhetinic acid	[no description available]	medium	2	0	cyclic terpene ketone; hydroxy monocarboxylic acid; pentacyclic triterpenoid	immunomodulator; plant metabolite
chenodeoxycholic acid	[no description available]	medium	2	0	bile acid; C24-steroid; dihydroxy-5beta-cholanic acid	human metabolite; mouse metabolite
dihydralazine	[no description available]	medium	1	0	phthalazines
phenylpropanolamine	[no description available]	high	37	0	amphetamines; phenethylamine alkaloid	plant metabolite
dihydroergotamine	[no description available]	medium	2	0	ergot alkaloid; semisynthetic derivative	dopamine agonist; non-narcotic analgesic; serotonergic agonist; sympatholytic agent; vasoconstrictor agent
podophyllotoxin	[no description available]	medium	2	0	furonaphthodioxole; lignan; organic heterotetracyclic compound	antimitotic; antineoplastic agent; keratolytic drug; microtubule-destabilising agent; plant metabolite; tubulin modulator
hesperidin	[no description available]	medium	1	0	3'-hydroxyflavanones; 4'-methoxyflavanones; dihydroxyflavanone; disaccharide derivative; flavanone glycoside; monomethoxyflavanone; rutinoside	mutagen
gentian violet	[no description available]	medium	2	0	organic chloride salt	anthelminthic drug; antibacterial agent; antifungal agent; antiseptic drug; histological dye
hematoporphyrin	[no description available]	medium	1	0
megestrol acetate	[no description available]	medium	1	0	20-oxo steroid; 3-oxo-Delta(4) steroid; acetate ester; steroid ester	antineoplastic agent; appetite enhancer; contraceptive drug; progestin; synthetic oral contraceptive
erythromycin stearate	[no description available]	medium	1	0	aminoglycoside
estradiol valerate	[no description available]	medium	1	0	steroid ester
d-alpha tocopherol	[no description available]	medium	12	0	alpha-tocopherol	algal metabolite; antiatherogenic agent; anticoagulant; antioxidant; antiviral agent; EC 2.7.11.13 (protein kinase C) inhibitor; immunomodulator; micronutrient; nutraceutical; plant metabolite
d-alpha tocopherol	[no description available]	medium	12	1	alpha-tocopherol	algal metabolite; antiatherogenic agent; anticoagulant; antioxidant; antiviral agent; EC 2.7.11.13 (protein kinase C) inhibitor; immunomodulator; micronutrient; nutraceutical; plant metabolite
amiloride	[no description available]	medium	4	0	aromatic amine; guanidines; organochlorine compound; pyrazines	diuretic; sodium channel blocker
pimozide	[no description available]	medium	11	0	benzimidazoles; heteroarylpiperidine; organofluorine compound	antidyskinesia agent; dopaminergic antagonist; first generation antipsychotic; H1-receptor antagonist; serotonergic antagonist
sulfadoxine	[no description available]	medium	2	0	pyrimidines; sulfonamide	antibacterial drug; antimalarial
acadesine	[no description available]	medium	1	0	1-ribosylimidazolecarboxamide; aminoimidazole; nucleoside analogue	antineoplastic agent; platelet aggregation inhibitor
iproclozide	[no description available]	medium	1	0	aromatic ether
carbenicillin disodium	[no description available]	medium	1	0	organic sodium salt
dehydroemetine	[no description available]	medium	1	0	aromatic ether; isoquinolines; pyridoisoquinoline	antileishmanial agent; antimalarial; antiprotozoal drug
benorilate	[no description available]	medium	1	0	carbonyl compound
trimetazidine	[no description available]	medium	1	0	aromatic amine
vidarabine	[no description available]	medium	1	0	beta-D-arabinoside; purine nucleoside	antineoplastic agent; bacterial metabolite; nucleoside antibiotic
tiadenol	[no description available]	medium	1	0	aliphatic sulfide
camptothecin	[no description available]	medium	1	0	delta-lactone; pyranoindolizinoquinoline; quinoline alkaloid; tertiary alcohol	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; genotoxin; plant metabolite
stanozolol	[no description available]	medium	1	0	17beta-hydroxy steroid; anabolic androgenic steroid; organic heteropentacyclic compound; tertiary alcohol	anabolic agent; androgen
clodronic acid	[no description available]	medium	1	0	1,1-bis(phosphonic acid); one-carbon compound; organochlorine compound	antineoplastic agent; bone density conservation agent
xipamide	[no description available]	medium	1	0	benzamides
levamisole	[no description available]	medium	3	0	6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole	antinematodal drug; antirheumatic drug; EC 3.1.3.1 (alkaline phosphatase) inhibitor; immunological adjuvant; immunomodulator
thiamphenicol	[no description available]	medium	1	0	monocarboxylic acid amide; sulfone	antimicrobial agent; immunosuppressive agent
pizotyline	[no description available]	medium	2	0	benzocycloheptathiophene	histamine antagonist; muscarinic antagonist; serotonergic antagonist
danazol	[no description available]	medium	3	0	17beta-hydroxy steroid; terminal acetylenic compound	anti-estrogen; estrogen antagonist; geroprotector
daunorubicin	[no description available]	medium	3	0	aminoglycoside antibiotic; anthracycline; p-quinones; tetracenequinones	antineoplastic agent; bacterial metabolite
carbimazole	[no description available]	medium	2	0	1,3-dihydroimidazole-2-thiones; carbamate ester	antithyroid drug; prodrug
bromocriptine	[no description available]	medium	8	0	indole alkaloid	antidyskinesia agent; antiparkinson drug; dopamine agonist; hormone antagonist
triamcinolone	[no description available]	medium	2	0	11beta-hydroxy steroid; 16alpha-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid hormone; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	anti-allergic agent; anti-inflammatory drug
oxyphenisatin	[no description available]	medium	2	0	indoles
tetrachloroethylene	[no description available]	medium	1	0	chlorocarbon; chloroethenes	nephrotoxic agent
ursodeoxycholic acid	[no description available]	medium	3	0	bile acid; C24-steroid; dihydroxy-5beta-cholanic acid	human metabolite; mouse metabolite
butachlor	[no description available]	medium	1	0	aromatic amide; organochlorine compound; tertiary carboxamide	environmental contaminant; herbicide; xenobiotic
rose bengal b disodium salt	[no description available]	medium	1	0
glutamic acid	[no description available]	medium	116	0	glutamic acid; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; ferroptosis inducer; micronutrient; mouse metabolite; neurotransmitter; nutraceutical
nicergoline	[no description available]	medium	1	0	organic heterotetracyclic compound; organonitrogen heterocyclic compound
oxcarbazepine	[no description available]	medium	2	0	cyclic ketone; dibenzoazepine	anticonvulsant; drug allergen
amineptin	[no description available]	medium	3	0	amino acid; carbocyclic fatty acid; carbotricyclic compound; secondary amino compound	antidepressant; dopamine uptake inhibitor
pirprofen	[no description available]	medium	3	0	pyrroline
dobutamine	[no description available]	high	3	0	catecholamine; secondary amine	beta-adrenergic agonist; cardiotonic drug; sympathomimetic agent
ticrynafen	[no description available]	medium	3	0	aromatic ether; aromatic ketone; dichlorobenzene; monocarboxylic acid; thiophenes	antihypertensive agent; hepatotoxic agent; loop diuretic
bezafibrate	[no description available]	medium	1	0	aromatic ether; monocarboxylic acid amide; monocarboxylic acid; monochlorobenzenes	antilipemic drug; environmental contaminant; geroprotector; xenobiotic
benoxaprofen	[no description available]	medium	3	0	1,3-benzoxazoles; monocarboxylic acid; monochlorobenzenes	antipsoriatic; antipyretic; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; hepatotoxic agent; nephrotoxin; non-narcotic analgesic; non-steroidal anti-inflammatory drug; protein kinase C agonist
permethrin	[no description available]	medium	1	0	cyclopropanecarboxylate ester; cyclopropanes	agrochemical; ectoparasiticide; pyrethroid ester acaricide; pyrethroid ester insecticide; scabicide
pirfenidone	[no description available]	medium	1	0	pyridone	antipyretic; non-narcotic analgesic; non-steroidal anti-inflammatory drug
desogestrel	[no description available]	medium	1	0	17beta-hydroxy steroid; terminal acetylenic compound	contraceptive drug; progestin; synthetic oral contraceptive
muzolimine	[no description available]	medium	1	0	dichlorobenzene
desflurane	[no description available]	medium	1	0	organofluorine compound	inhalation anaesthetic
nicorandil	[no description available]	medium	1	0	nitrate ester; pyridinecarboxamide	potassium channel opener; vasodilator agent
cefaclor anhydrous	[no description available]	medium	2	0	cephalosporin	antibacterial drug; drug allergen
miglustat	[no description available]	medium	2	0	piperidines; tertiary amino compound	anti-HIV agent; EC 2.4.1.80 (ceramide glucosyltransferase) inhibitor
piritrexim	[no description available]	medium	1	0
simvastatin	[no description available]	medium	4	0	delta-lactone; fatty acid ester; hexahydronaphthalenes; statin (semi-synthetic)	EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor; EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor; ferroptosis inducer; geroprotector; prodrug
atomoxetine hydrochloride	[no description available]	medium	9	0	hydrochloride	adrenergic uptake inhibitor; antidepressant
atomoxetine hydrochloride	[no description available]	medium	9	2	hydrochloride	adrenergic uptake inhibitor; antidepressant
quinapril	[no description available]	medium	2	0	dicarboxylic acid monoester; ethyl ester; isoquinolines; tertiary carboxamide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
gepirone	[no description available]	medium	1	0	N-arylpiperazine
mifepristone	[no description available]	medium	5	0	3-oxo-Delta(4) steroid; acetylenic compound; tertiary amino compound	abortifacient; contraceptive drug; hormone antagonist; synthetic oral contraceptive
zileuton	[no description available]	medium	3	0	1-benzothiophenes; ureas	anti-asthmatic drug; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; ferroptosis inhibitor; leukotriene antagonist; non-steroidal anti-inflammatory drug
clopidogrel	[no description available]	medium	2	0	methyl ester; monochlorobenzenes; thienopyridine	anticoagulant; P2Y12 receptor antagonist; platelet aggregation inhibitor
atorvastatin	[no description available]	high	5	0	aromatic amide; dihydroxy monocarboxylic acid; monofluorobenzenes; pyrroles; statin (synthetic)	environmental contaminant; xenobiotic
duloxetine	[no description available]	medium	2	0	duloxetine
adefovir dipivoxil	[no description available]	medium	1	0	6-aminopurines; carbonate ester; ether; organic phosphonate	antiviral drug; DNA synthesis inhibitor; HIV-1 reverse transcriptase inhibitor; nephrotoxic agent; prodrug
capecitabine	[no description available]	medium	2	0	carbamate ester; cytidines; organofluorine compound	antimetabolite; antineoplastic agent; prodrug
adenosine	[no description available]	medium	14	0	adenosines; purines D-ribonucleoside	analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent
halofuginone	[no description available]	medium	1	0	quinazolines
ortho-cept	[no description available]	medium	1	0
4-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol	[no description available]	medium	1	0	stilbenoid
efavirenz	[no description available]	medium	3	0	acetylenic compound; benzoxazine; cyclopropanes; organochlorine compound; organofluorine compound	antiviral drug; HIV-1 reverse transcriptase inhibitor
nelfinavir	[no description available]	medium	4	0	aryl sulfide; benzamides; organic heterobicyclic compound; phenols; secondary alcohol; tertiary amino compound	antineoplastic agent; HIV protease inhibitor
doxapram hydrochloride	[no description available]	medium	1	0	hydrochloride	central nervous system stimulant
1,5-anhydroglucitol	[no description available]	medium	1	0	anhydro sugar	human metabolite
betulinic acid	[no description available]	medium	2	0	hydroxy monocarboxylic acid; pentacyclic triterpenoid	anti-HIV agent; anti-inflammatory agent; antimalarial; antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; plant metabolite
amprenavir	[no description available]	medium	2	0	carbamate ester; sulfonamide; tetrahydrofuryl ester	antiviral drug; HIV protease inhibitor
glutathione disulfide	[no description available]	medium	4	0	glutathione derivative; organic disulfide	Escherichia coli metabolite; mouse metabolite
bendamustine	[no description available]	medium	2	0	benzimidazoles
erdosteine	[no description available]	medium	1	0	N-acyl-amino acid
mizolastine	[no description available]	medium	1	0	benzimidazoles
2-methoxyestradiol	[no description available]	medium	1	0	17beta-hydroxy steroid; 3-hydroxy steroid	angiogenesis modulating agent; antimitotic; antineoplastic agent; human metabolite; metabolite; mouse metabolite
medetomidine	[no description available]	medium	1	0	imidazoles
sertraline	[no description available]	medium	7	0	dichlorobenzene; secondary amino compound; tetralins	antidepressant; serotonin uptake inhibitor
sertraline	[no description available]	medium	7	2	dichlorobenzene; secondary amino compound; tetralins	antidepressant; serotonin uptake inhibitor
picosulfate sodium	[no description available]	medium	1	0	aryl sulfate; pyridines
dienogest	[no description available]	medium	1	0	17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; aliphatic nitrile; steroid hormone	progesterone receptor agonist; progestin; synthetic oral contraceptive
morphazinamide	[no description available]	medium	1	0	morpholines; pyrazines; secondary carboxamide
cyclobutyrol	[no description available]	medium	1	0	hydroxy monocarboxylic acid	bile therapy drug
terlipressin	[no description available]	medium	1	0	polypeptide
isoflavone	[no description available]	medium	1	0	isoflavones
clevudine	[no description available]	medium	1	0
tetrandrine	[no description available]	medium	1	0	bisbenzylisoquinoline alkaloid; isoquinolines
lopinavir	[no description available]	high	3	0	amphetamines; dicarboxylic acid diamide	anticoronaviral agent; antiviral drug; HIV protease inhibitor
sr141716	[no description available]	medium	10	0	amidopiperidine; carbohydrazide; dichlorobenzene; monochlorobenzenes; pyrazoles	anti-obesity agent; appetite depressant; CB1 receptor antagonist
selenomethionine	[no description available]	medium	1	0	amino acid zwitterion; selenomethionine	plant metabolite
perindopril	[no description available]	medium	3	0	alpha-amino acid ester; dicarboxylic acid monoester; ethyl ester; organic heterobicyclic compound	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
perindopril	[no description available]	medium	3	1	alpha-amino acid ester; dicarboxylic acid monoester; ethyl ester; organic heterobicyclic compound	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
fingolimod	[no description available]	medium	1	0	aminodiol; primary amino compound	antineoplastic agent; CB1 receptor antagonist; immunosuppressive agent; prodrug; sphingosine-1-phosphate receptor agonist
nitisinone	[no description available]	medium	2	0	(trifluoromethyl)benzenes; C-nitro compound; cyclohexanones; mesotrione	EC 1.13.11.27 (4-hydroxyphenylpyruvate dioxygenase) inhibitor
marimastat	[no description available]	medium	1	0	hydroxamic acid; secondary carboxamide	antineoplastic agent; matrix metalloproteinase inhibitor
clofarabine	[no description available]	medium	2	0	adenosines; organofluorine compound	antimetabolite; antineoplastic agent
mitiglinide	[no description available]	medium	1	0	benzenes; monocarboxylic acid
imatinib mesylate	[no description available]	medium	2	0	methanesulfonate salt	anticoronaviral agent; antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine	[no description available]	medium	1	0	adenosines; monocarboxylic acid amide; organoiodine compound	adenosine A3 receptor agonist
antiprimod	[no description available]	medium	1	0
olmesartan medoxomil	[no description available]	medium	2	0	biphenyls
ilomastat	[no description available]	medium	1	0	hydroxamic acid; L-tryptophan derivative; N-acyl-amino acid	anti-inflammatory agent; antibacterial agent; antineoplastic agent; EC 3.4.24.24 (gelatinase A) inhibitor; neuroprotective agent
atazanavir	[no description available]	medium	2	0	carbohydrazide	antiviral drug; HIV protease inhibitor
ezetimibe	[no description available]	medium	2	0	azetidines; beta-lactam; organofluorine compound	anticholesteremic drug; antilipemic drug; antimetabolite
cariporide	[no description available]	medium	1	0
jtt 501	[no description available]	medium	1	0
cyc 202	[no description available]	medium	1	0	2,6-diaminopurines	antiviral drug; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
paromomycin	[no description available]	medium	2	0	amino cyclitol glycoside; aminoglycoside antibiotic	anthelminthic drug; antibacterial drug; antiparasitic agent; antiprotozoal drug
avasimibe	[no description available]	medium	1	0	monoterpenoid
biotin	[no description available]	medium	2	0	biotins; vitamin B7	coenzyme; cofactor; Escherichia coli metabolite; fundamental metabolite; human metabolite; mouse metabolite; nutraceutical; prosthetic group; Saccharomyces cerevisiae metabolite
troleandomycin	[no description available]	medium	2	0	acetate ester; epoxide; macrolide antibiotic; monosaccharide derivative; polyketide; semisynthetic derivative	EC 1.14.13.97 (taurochenodeoxycholate 6alpha-hydroxylase) inhibitor; xenobiotic
deferasirox	[no description available]	medium	2	0	benzoic acids; monocarboxylic acid; phenols; triazoles	iron chelator
tbc-11251	[no description available]	medium	2	0	benzodioxoles
sitosterol, (3beta)-isomer	[no description available]	medium	1	0	3beta-hydroxy-Delta(5)-steroid; 3beta-sterol; C29-steroid; phytosterols; stigmastane sterol	anticholesteremic drug; antioxidant; mouse metabolite; plant metabolite; sterol methyltransferase inhibitor
benzarone	[no description available]	medium	2	0	1-benzofurans
estramustine	[no description available]	medium	2	0	17beta-hydroxy steroid; carbamate ester; organochlorine compound	alkylating agent; antineoplastic agent; radiation protective agent
noscapine	[no description available]	medium	3	0	aromatic ether; benzylisoquinoline alkaloid; cyclic acetal; isobenzofuranone; organic heterobicyclic compound; organic heterotricyclic compound; tertiary amino compound	antineoplastic agent; antitussive; apoptosis inducer; plant metabolite
noscapine	[no description available]	medium	3	1	aromatic ether; benzylisoquinoline alkaloid; cyclic acetal; isobenzofuranone; organic heterobicyclic compound; organic heterotricyclic compound; tertiary amino compound	antineoplastic agent; antitussive; apoptosis inducer; plant metabolite
homoharringtonine	[no description available]	medium	1	0	alkaloid ester; enol ether; organic heteropentacyclic compound; tertiary alcohol	anticoronaviral agent; antineoplastic agent; apoptosis inducer; protein synthesis inhibitor
o-(chloroacetylcarbamoyl)fumagillol	[no description available]	medium	1	0	carbamate ester; organochlorine compound; semisynthetic derivative; sesquiterpenoid; spiro-epoxide	angiogenesis inhibitor; antineoplastic agent; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; methionine aminopeptidase 2 inhibitor; retinoic acid receptor alpha antagonist
ritonavir	[no description available]	high	6	0	1,3-thiazoles; carbamate ester; carboxamide; L-valine derivative; ureas	antiviral drug; environmental contaminant; HIV protease inhibitor; xenobiotic
nexavar	[no description available]	medium	1	0	organosulfonate salt
glucosamine	[no description available]	medium	1	0	D-glucosamine	Escherichia coli metabolite; geroprotector; mouse metabolite
griseofulvin	[no description available]	medium	2	0	1-benzofurans; antibiotic antifungal drug; benzofuran antifungal drug; organochlorine compound; oxaspiro compound	antibacterial agent; Penicillium metabolite
trimethaphan camsylate	[no description available]	medium	1	0
erythromycin estolate	[no description available]	medium	1	0	aminoglycoside sulfate salt; erythromycin derivative	enzyme inhibitor
cyclopamine	[no description available]	medium	1	0	piperidines	glioma-associated oncogene inhibitor
devazepide	[no description available]	medium	1	0	1,4-benzodiazepinone; indolecarboxamide	antineoplastic agent; apoptosis inducer; cholecystokinin antagonist; gastrointestinal drug
doxorubicin hydrochloride	[no description available]	medium	1	0	anthracycline
erythromycin ethylsuccinate	[no description available]	medium	1	0	cyclic ketone; erythromycin derivative; ethyl ester; succinate ester
ao 128	[no description available]	medium	1	0	organic molecular entity
tretinoin	[no description available]	medium	5	0	retinoic acid; vitamin A	anti-inflammatory agent; antineoplastic agent; antioxidant; AP-1 antagonist; human metabolite; keratolytic drug; retinoic acid receptor agonist; retinoid X receptor agonist; signalling molecule
retinol	[no description available]	medium	3	0	retinol; vitamin A	human metabolite; mouse metabolite; plant metabolite
alpha-D-fructofuranose 1,6-bisphosphate	[no description available]	medium	1	0	D-fructofuranose 1,6-bisphosphate
docosahexaenoate	[no description available]	medium	1	0	docosahexaenoic acid; omega-3 fatty acid	algal metabolite; antineoplastic agent; Daphnia tenebrosa metabolite; human metabolite; mouse metabolite; nutraceutical
oleic acid	[no description available]	medium	1	0	octadec-9-enoic acid	antioxidant; Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; Escherichia coli metabolite; mouse metabolite; plant metabolite; solvent
eicosapentaenoic acid	[no description available]	medium	1	0	icosapentaenoic acid; omega-3 fatty acid	anticholesteremic drug; antidepressant; antineoplastic agent; Daphnia galeata metabolite; fungal metabolite; micronutrient; mouse metabolite; nutraceutical
mycophenolic acid	[no description available]	medium	2	0	2-benzofurans; gamma-lactone; monocarboxylic acid; phenols	anticoronaviral agent; antimicrobial agent; antineoplastic agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; environmental contaminant; immunosuppressive agent; mycotoxin; Penicillium metabolite; xenobiotic
drf 2725	[no description available]	medium	1	0
diethylstilbestrol	[no description available]	medium	2	0	olefinic compound; polyphenol	antifungal agent; antineoplastic agent; autophagy inducer; calcium channel blocker; carcinogenic agent; EC 1.1.1.146 (11beta-hydroxysteroid dehydrogenase) inhibitor; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; endocrine disruptor; xenoestrogen
alitretinoin	[no description available]	medium	2	0	retinoic acid	antineoplastic agent; keratolytic drug; metabolite; retinoid X receptor agonist
dactinomycin	[no description available]	medium	5	0	actinomycin	mutagen
rubitecan	[no description available]	medium	1	0	C-nitro compound; delta-lactone; pyranoindolizinoquinoline; semisynthetic derivative; tertiary alcohol	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; prodrug
riboflavin	[no description available]	medium	4	0	flavin; vitamin B2	anti-inflammatory agent; antioxidant; cofactor; Escherichia coli metabolite; food colouring; fundamental metabolite; human urinary metabolite; mouse metabolite; photosensitizing agent; plant metabolite
riboflavin	[no description available]	medium	4	1	flavin; vitamin B2	anti-inflammatory agent; antioxidant; cofactor; Escherichia coli metabolite; food colouring; fundamental metabolite; human urinary metabolite; mouse metabolite; photosensitizing agent; plant metabolite
sodium bicarbonate	[no description available]	medium	2	0	one-carbon compound; organic sodium salt	antacid; food anticaking agent
sodium acetate, anhydrous	[no description available]	medium	1	0	organic sodium salt	NMR chemical shift reference compound
sodium benzoate	[no description available]	medium	1	0	organic sodium salt	algal metabolite; antimicrobial food preservative; drug allergen; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 3.1.1.3 (triacylglycerol lipase) inhibitor; human xenobiotic metabolite; plant metabolite
dipyrone	[no description available]	medium	3	0	organic sodium salt	anti-inflammatory agent; antipyretic; antirheumatic drug; cyclooxygenase 3 inhibitor; non-narcotic analgesic; peripheral nervous system drug; prodrug
ditiocarb sodium	[no description available]	medium	1	0	organic molecular entity
carbenoxolone	[no description available]	medium	1	0
discodermolide	[no description available]	medium	1	0	diterpenoid
cannabidiol	[no description available]	medium	21	0	olefinic compound; phytocannabinoid; resorcinols	antimicrobial agent; plant metabolite
prothionamide	[no description available]	medium	1	0	pyridines
sulindac	[no description available]	medium	3	0	monocarboxylic acid; organofluorine compound; sulfoxide	analgesic; antineoplastic agent; antipyretic; apoptosis inducer; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug; tocolytic agent
capsaicin	[no description available]	medium	2	0	capsaicinoid	non-narcotic analgesic; TRPV1 agonist; voltage-gated sodium channel blocker
terbinafine	[no description available]	medium	3	0	acetylenic compound; allylamine antifungal drug; enyne; naphthalenes; tertiary amine	EC 1.14.13.132 (squalene monooxygenase) inhibitor; P450 inhibitor; sterol biosynthesis inhibitor
thioguanine anhydrous	[no description available]	medium	2	0	2-aminopurines	anticoronaviral agent; antimetabolite; antineoplastic agent
tacrine hydrochloride	[no description available]	medium	1	0
sodium propionate	[no description available]	medium	1	0	organic sodium salt	antifungal drug; food preservative
streptozocin	[no description available]	medium	2	0
tamoxifen	[no description available]	medium	14	0	stilbenoid; tertiary amino compound	angiogenesis inhibitor; antineoplastic agent; bone density conservation agent; EC 1.2.3.1 (aldehyde oxidase) inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; estrogen antagonist; estrogen receptor antagonist; estrogen receptor modulator
ethionamide	[no description available]	medium	2	0	pyridines; thiocarboxamide	antilipemic drug; antitubercular agent; fatty acid synthesis inhibitor; leprostatic drug; prodrug
fusidic acid	[no description available]	medium	1	0	11alpha-hydroxy steroid; 3alpha-hydroxy steroid; alpha,beta-unsaturated monocarboxylic acid; steroid acid; steroid antibiotic; sterol ester	EC 2.7.1.33 (pantothenate kinase) inhibitor; Escherichia coli metabolite; protein synthesis inhibitor
estrone sulfate	[no description available]	medium	1	0	17-oxo steroid; steroid sulfate	human metabolite; mouse metabolite
toremifene	[no description available]	medium	2	0	aromatic ether; organochlorine compound; tertiary amine	antineoplastic agent; bone density conservation agent; estrogen antagonist; estrogen receptor modulator
telaprevir	[no description available]	medium	1	0	cyclopentapyrrole; cyclopropanes; oligopeptide; pyrazines	antiviral drug; hepatitis C protease inhibitor; peptidomimetic
droloxifene	[no description available]	medium	1	0	stilbenoid
orlistat	[no description available]	medium	2	0	beta-lactone; carboxylic ester; formamides; L-leucine derivative	anti-obesity agent; bacterial metabolite; EC 2.3.1.85 (fatty acid synthase) inhibitor; EC 3.1.1.3 (triacylglycerol lipase) inhibitor
idoxifene	[no description available]	medium	1	0	stilbenoid
zd 6474	[no description available]	medium	1	0	aromatic ether; organobromine compound; organofluorine compound; piperidines; quinazolines; secondary amine	antineoplastic agent; tyrosine kinase inhibitor
silybin	[no description available]	medium	1	0
chloramine-t	[no description available]	medium	1	0	organic sodium salt	allergen; antifouling biocide; disinfectant
flosequinan	[no description available]	medium	1	0	quinolines
dinoprostone	[no description available]	medium	3	0	prostaglandins E	human metabolite; mouse metabolite; oxytocic
dinoprost	[no description available]	medium	2	0	monocarboxylic acid; prostaglandins Falpha	human metabolite; mouse metabolite
calcitriol	[no description available]	medium	4	0	D3 vitamins; hydroxycalciol; triol	antineoplastic agent; antipsoriatic; bone density conservation agent; calcium channel agonist; calcium channel modulator; hormone; human metabolite; immunomodulator; metabolite; mouse metabolite; nutraceutical
beta carotene	[no description available]	medium	1	0	carotenoid beta-end derivative; cyclic carotene	antioxidant; biological pigment; cofactor; ferroptosis inhibitor; human metabolite; mouse metabolite; plant metabolite; provitamin A
alprostadil	[no description available]	medium	3	0	prostaglandins E	anticoagulant; human metabolite; platelet aggregation inhibitor; vasodilator agent
cholecalciferol	[no description available]	medium	2	0	D3 vitamins; hydroxy seco-steroid; seco-cholestane; secondary alcohol; steroid hormone	geroprotector; human metabolite
amphotericin b	[no description available]	medium	3	0	antibiotic antifungal drug; macrolide antibiotic; polyene antibiotic	antiamoebic agent; antiprotozoal drug; bacterial metabolite
oxymetholone	[no description available]	medium	2	0
mycophenolate mofetil	[no description available]	medium	2	0	carboxylic ester; ether; gamma-lactone; phenols; tertiary amino compound	anticoronaviral agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; immunosuppressive agent; prodrug
astaxanthine	[no description available]	medium	1	0	carotenol; carotenone	animal metabolite; anticoagulant; antioxidant; food colouring; plant metabolite
diosmin	[no description available]	medium	1	0	dihydroxyflavanone; disaccharide derivative; glycosyloxyflavone; monomethoxyflavone; rutinoside	anti-inflammatory agent; antioxidant
cynarine	[no description available]	medium	1	0	alkyl caffeate ester; quinic acid	plant metabolite
coenzyme q10	[no description available]	medium	4	0	ubiquinones	antioxidant; ferroptosis inhibitor; human metabolite
tranilast	[no description available]	medium	1	0	amidobenzoic acid; cinnamamides; dimethoxybenzene; secondary carboxamide	anti-allergic agent; anti-asthmatic drug; antineoplastic agent; aryl hydrocarbon receptor agonist; calcium channel blocker; hepatoprotective agent; nephroprotective agent
etretinate	[no description available]	medium	1	0	enoate ester; ethyl ester; retinoid	keratolytic drug
isotretinoin	[no description available]	medium	4	0	retinoic acid	antineoplastic agent; keratolytic drug; teratogenic agent
misoprostol	[no description available]	medium	1	0
ozagrel	[no description available]	medium	1	0	cinnamic acids
pitavastatin	[no description available]	medium	2	0	cyclopropanes; dihydroxy monocarboxylic acid; monofluorobenzenes; quinolines; statin (synthetic)	antioxidant
alatrofloxacin mesylate	[no description available]	medium	2	0
natamycin	[no description available]	medium	1	0	antibiotic antifungal drug; dicarboxylic acid monoester; epoxide; macrolide antibiotic; monosaccharide derivative; polyene antibiotic	antifungal agrochemical; antimicrobial food preservative; apoptosis inducer; bacterial metabolite; ophthalmology drug
acitretin	[no description available]	medium	2	0	acitretin; alpha,beta-unsaturated monocarboxylic acid; retinoid	keratolytic drug
dothiepin	[no description available]	medium	1	0	dothiepin
levetiracetam	[no description available]	high	3	0	pyrrolidin-2-ones	anticonvulsant; environmental contaminant; xenobiotic
nalorphine	[no description available]	medium	2	0	morphinane alkaloid
oxymorphone	[no description available]	medium	8	0	morphinane alkaloid
sirolimus	[no description available]	medium	7	0	antibiotic antifungal drug; cyclic acetal; cyclic ketone; ether; macrolide lactam; organic heterotricyclic compound; secondary alcohol	antibacterial drug; anticoronaviral agent; antineoplastic agent; bacterial metabolite; geroprotector; immunosuppressive agent; mTOR inhibitor
topiramate	[no description available]	medium	13	0	cyclic ketal; ketohexose derivative; sulfamate ester	anticonvulsant; sodium channel blocker
topiramate	[no description available]	medium	13	6	cyclic ketal; ketohexose derivative; sulfamate ester	anticonvulsant; sodium channel blocker
seocalcitol	[no description available]	medium	1	0
fenretinide	[no description available]	medium	1	0	monocarboxylic acid amide; retinoid	antineoplastic agent; antioxidant
geldanamycin	[no description available]	medium	1	0	1,4-benzoquinones; ansamycin; carbamate ester; organic heterobicyclic compound	antimicrobial agent; antineoplastic agent; antiviral agent; cysteine protease inhibitor; Hsp90 inhibitor
demycarosylturimycin h	[no description available]	medium	1	0
furazolidone	[no description available]	medium	2	0
fluvoxamine	[no description available]	medium	9	0	(trifluoromethyl)benzenes; 5-methoxyvalerophenone O-(2-aminoethyl)oxime	antidepressant; anxiolytic drug; serotonin uptake inhibitor
semaxinib	[no description available]	medium	1	0	olefinic compound; oxindoles; pyrroles	angiogenesis modulating agent; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; vascular endothelial growth factor receptor antagonist
orantinib	[no description available]	medium	1	0
molsidomine	[no description available]	medium	1	0	ethyl ester; morpholines; oxadiazole; zwitterion	antioxidant; apoptosis inhibitor; cardioprotective agent; nitric oxide donor; vasodilator agent
dextromethorphan	[no description available]	high	18	0	6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene	antitussive; environmental contaminant; neurotoxin; NMDA receptor antagonist; oneirogen; prodrug; xenobiotic
ramipril	[no description available]	medium	2	0	azabicycloalkane; cyclopentapyrrole; dicarboxylic acid monoester; dipeptide; ethyl ester	bradykinin receptor B2 agonist; cardioprotective agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; matrix metalloproteinase inhibitor; prodrug
enalapril	[no description available]	medium	3	0	dicarboxylic acid monoester; dipeptide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; geroprotector; prodrug
nitrofurazone	[no description available]	medium	2	0
bleomycin	[no description available]	medium	2	0	bleomycin	antineoplastic agent; metabolite
imidapril	[no description available]	medium	1	0	dicarboxylic acid monoester; dipeptide; ethyl ester; imidazolidines; N-acylurea; secondary amino compound	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
sulindac sulfone	[no description available]	medium	1	0	monocarboxylic acid; organofluorine compound; sulfone	apoptosis inducer; cyclooxygenase 2 inhibitor; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor
ximelagatran	[no description available]	medium	2	0	amidoxime; azetidines; carboxamide; ethyl ester; hydroxylamines; secondary amino compound; secondary carboxamide; tertiary carboxamide	anticoagulant; EC 3.4.21.5 (thrombin) inhibitor; prodrug; serine protease inhibitor
trandolapril	[no description available]	medium	2	0	dicarboxylic acid monoester; dipeptide; ethyl ester; organic heterobicyclic compound; secondary amino compound; tertiary carboxamide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
guanabenz acetate	[no description available]	medium	1	0	dichlorobenzene	geroprotector
proguanil	[no description available]	medium	1	0	biguanides; monochlorobenzenes	antimalarial; antiprotozoal drug; EC 1.5.1.3 (dihydrofolate reductase) inhibitor
rifamycin sv	[no description available]	medium	1	0	acetate ester; cyclic ketal; lactam; macrocycle; organic heterotetracyclic compound; polyphenol; rifamycins	antimicrobial agent; antitubercular agent; bacterial metabolite
epoprostenol sodium	[no description available]	medium	1	0	prostanoid
dantrolene sodium	[no description available]	medium	1	0
nifurtimox	[no description available]	medium	1	0	nitrofuran antibiotic
roxithromycin	[no description available]	medium	2	0	roxithromycin	environmental contaminant; xenobiotic
beraprost	[no description available]	medium	2	0	enyne; monocarboxylic acid; organic heterotricyclic compound; secondary alcohol; secondary allylic alcohol	anti-inflammatory agent; antihypertensive agent; platelet aggregation inhibitor; prostaglandin receptor agonist; vasodilator agent
lanreotide	[no description available]	medium	1	0
lu 208075	[no description available]	medium	2	0	diarylmethane
nifurtoinol	[no description available]	medium	1	0	hydrazone; imidazolidine-2,4-dione; nitrofuran antibiotic; organonitrogen heterocyclic antibiotic	antibacterial drug; antiinfective agent; hepatotoxic agent
fosinopril	[no description available]	medium	2	0
eflucimibe	[no description available]	medium	1	0
etomoxir	[no description available]	medium	1	0	aromatic ether
pentagastrin	[no description available]	medium	2	0	organic molecular entity
azd 6244	[no description available]	medium	1	0	benzimidazoles; bromobenzenes; hydroxamic acid ester; monochlorobenzenes; organofluorine compound; secondary amino compound	anticoronaviral agent; antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
vinflunine	[no description available]	medium	1	0	acetate ester; methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; semisynthetic derivative; vinca alkaloid	antineoplastic agent
baci-im	[no description available]	medium	2	0	homodetic cyclic peptide; polypeptide; zwitterion	antibacterial agent; antimicrobial agent
pf 03491390	[no description available]	medium	1	0
amodiaquine hydrochloride	[no description available]	medium	2	0
tannins	[no description available]	medium	1	0	tannin
mesna	[no description available]	medium	2	0	organosulfonic acid
cerivastatin sodium	[no description available]	medium	1	0	organic sodium salt; statin (synthetic)
monensin	[no description available]	medium	1	0
oxacillin sodium	[no description available]	medium	1	0	organic sodium salt
sodium diatrizoate	[no description available]	medium	1	0	organic sodium salt; organoiodine compound	radioopaque medium
ascorbic acid	[no description available]	medium	14	0	ascorbic acid; vitamin C	coenzyme; cofactor; flour treatment agent; food antioxidant; food colour retention agent; geroprotector; plant metabolite; skin lightening agent
novobiocin	[no description available]	medium	1	0	carbamate ester; ether; hexoside; hydroxycoumarin; monocarboxylic acid amide; monosaccharide derivative; phenols	antibacterial agent; antimicrobial agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; Escherichia coli metabolite; hepatoprotective agent
dicumarol	[no description available]	medium	2	0	hydroxycoumarin	anticoagulant; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor; Hsp90 inhibitor; vitamin K antagonist
piroxicam	[no description available]	medium	3	0	benzothiazine; monocarboxylic acid amide; pyridines	analgesic; antirheumatic drug; cyclooxygenase 1 inhibitor; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug
acenocoumarol	[no description available]	medium	1	0	C-nitro compound; hydroxycoumarin; methyl ketone	anticoagulant; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor
phenprocoumon	[no description available]	medium	1	0	hydroxycoumarin	anticoagulant; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor
lornoxicam	[no description available]	medium	1	0	heteroaryl hydroxy compound; monocarboxylic acid amide; organochlorine compound; pyridines; thienothiazine	antipyretic; non-narcotic analgesic; non-steroidal anti-inflammatory drug
ajmaline	[no description available]	medium	1	0
entecavir	[no description available]	medium	2	0	2-aminopurines; oxopurine; primary alcohol; secondary alcohol	antiviral drug; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
inosine	[no description available]	medium	2	0	inosines; purines D-ribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
folic acid	[no description available]	medium	4	0	folic acids; N-acyl-amino acid	human metabolite; mouse metabolite; nutrient
olanzapine	[no description available]	medium	16	0	benzodiazepine; N-arylpiperazine; N-methylpiperazine	antiemetic; dopaminergic antagonist; histamine antagonist; muscarinic antagonist; second generation antipsychotic; serotonergic antagonist; serotonin uptake inhibitor
olanzapine	[no description available]	medium	16	1	benzodiazepine; N-arylpiperazine; N-methylpiperazine	antiemetic; dopaminergic antagonist; histamine antagonist; muscarinic antagonist; second generation antipsychotic; serotonergic antagonist; serotonin uptake inhibitor
oxypurinol	[no description available]	medium	1	0	pyrazolopyrimidine	drug metabolite; EC 1.17.3.2 (xanthine oxidase) inhibitor
raltitrexed	[no description available]	medium	1	0	N-acyl-amino acid
alanosine	[no description available]	medium	1	0
phenethylamine	[no description available]	medium	22	0	alkaloid; aralkylamine; phenylethylamine	Escherichia coli metabolite; human metabolite; mouse metabolite
phenethylamine	[no description available]	medium	22	2	alkaloid; aralkylamine; phenylethylamine	Escherichia coli metabolite; human metabolite; mouse metabolite
n-methyl-3,4-methylenedioxyamphetamine	[no description available]	high	478	10	amphetamines; benzodioxoles	neurotoxin
n-methyl-3,4-methylenedioxyamphetamine	[no description available]	high	478	0	amphetamines; benzodioxoles	neurotoxin
p-hydroxyamphetamine	[no description available]	high	22	0	amphetamines
norfenfluramine	[no description available]	medium	1	0	amphetamines
3-iodothyronamine	[no description available]	medium	2	0	aromatic ether
2,5-dimethoxy-4-methylamphetamine, (r)-isomer	[no description available]	medium	1	0
2,5-dimethoxy-4-bromoamphetamine, (r)-isomer	[no description available]	medium	2	0
2,5-dimethoxy-4-bromoamphetamine, (s)-isomer	[no description available]	medium	1	0
coumarin	[no description available]	medium	1	0	coumarins	fluorescent dye; human metabolite; plant metabolite
cilostazol	[no description available]	medium	2	0	lactam; tetrazoles	anticoagulant; bronchodilator agent; EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor; fibrin modulating drug; neuroprotective agent; platelet aggregation inhibitor; vasodilator agent
cromolyn	[no description available]	medium	1	0	chromones; dicarboxylic acid	anti-asthmatic drug; calcium channel blocker
donepezil	[no description available]	medium	7	0	aromatic ether; indanones; piperidines; racemate	EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; nootropic agent
etidronate	[no description available]	medium	2	0	1,1-bis(phosphonic acid)	antineoplastic agent; bone density conservation agent; chelator
guaifenesin	[no description available]	medium	2	0	methoxybenzenes
hycanthone	[no description available]	medium	1	0	thioxanthenes	mutagen; schistosomicide drug
mecamylamine	[no description available]	medium	12	0	primary aliphatic amine
methocarbamol	[no description available]	medium	2	0	aromatic ether; carbamate ester; secondary alcohol
midodrine	[no description available]	medium	2	0	amino acid amide; aromatic ether; secondary alcohol	alpha-adrenergic agonist; prodrug; sympathomimetic agent; vasoconstrictor agent
perhexiline	[no description available]	medium	2	0	piperidines	cardiovascular drug
phentermine	[no description available]	high	32	1	primary amine	adrenergic agent; appetite depressant; central nervous system drug; central nervous system stimulant; dopaminergic agent; sympathomimetic agent
phentermine	[no description available]	high	32	0	primary amine	adrenergic agent; appetite depressant; central nervous system drug; central nervous system stimulant; dopaminergic agent; sympathomimetic agent
pioglitazone	[no description available]	high	4	0	aromatic ether; pyridines; thiazolidinediones	antidepressant; cardioprotective agent; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; geroprotector; hypoglycemic agent; insulin-sensitizing drug; PPARgamma agonist; xenobiotic
raloxifene	[no description available]	medium	2	0	1-benzothiophenes; aromatic ketone; N-oxyethylpiperidine; phenols	bone density conservation agent; estrogen antagonist; estrogen receptor modulator
zomepirac	[no description available]	medium	1	0	aromatic ketone; monocarboxylic acid; monochlorobenzenes; pyrroles	cardiovascular drug; non-steroidal anti-inflammatory drug
metaraminol	[no description available]	medium	17	0	phenylethanolamines	alpha-adrenergic agonist; sympathomimetic agent; vasoconstrictor agent
zoxazolamine	[no description available]	medium	1	0	benzoxazole
leucine	[no description available]	medium	2	0	amino acid zwitterion; L-alpha-amino acid; leucine; proteinogenic amino acid; pyruvate family amino acid	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
phendimetrazine	[no description available]	medium	3	0
beclomethasone	[no description available]	medium	1	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; chlorinated steroid; corticosteroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	anti-asthmatic drug; anti-inflammatory drug
clemastine	[no description available]	medium	2	0	monochlorobenzenes; N-alkylpyrrolidine	anti-allergic agent; antipruritic drug; H1-receptor antagonist; muscarinic antagonist
butylated hydroxytoluene	[no description available]	medium	1	0	phenols	antioxidant; ferroptosis inhibitor; food additive; geroprotector
alpidem	[no description available]	medium	2	0	imidazoles
flunisolide	[no description available]	medium	1	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; cyclic ketal; fluorinated steroid; primary alpha-hydroxy ketone	anti-asthmatic drug; anti-inflammatory drug; immunosuppressive agent
hyoscyamine	[no description available]	medium	1	0	tropane alkaloid
olmesartan	[no description available]	medium	1	0	biphenylyltetrazole	angiotensin receptor antagonist; antihypertensive agent
menthofuran	[no description available]	medium	1	0	1-benzofurans; monoterpenoid	nematicide; plant metabolite
metyrosine	[no description available]	medium	2	0	L-tyrosine derivative; non-proteinogenic L-alpha-amino acid	antihypertensive agent; EC 1.14.16.2 (tyrosine 3-monooxygenase) inhibitor
ipratropium	[no description available]	medium	1	0
cyproterone	[no description available]	medium	1	0	17alpha-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(4) steroid; chlorinated steroid; tertiary alpha-hydroxy ketone	androgen antagonist
hydrocodone	[no description available]	medium	7	0	morphinane-like compound; organic heteropentacyclic compound	antitussive; mu-opioid receptor agonist; opioid analgesic
homatropine methylbromide	[no description available]	medium	1	0
lobelane	[no description available]	medium	5	0
gamma-aminobutyric acid	[no description available]	medium	73	0	amino acid zwitterion; gamma-amino acid; monocarboxylic acid	human metabolite; neurotransmitter; Saccharomyces cerevisiae metabolite; signalling molecule
gamma-aminobutyric acid	[no description available]	medium	73	2	amino acid zwitterion; gamma-amino acid; monocarboxylic acid	human metabolite; neurotransmitter; Saccharomyces cerevisiae metabolite; signalling molecule
beta-alanine	[no description available]	medium	1	0	amino acid zwitterion; beta-amino acid	agonist; fundamental metabolite; human metabolite; inhibitor; neurotransmitter
formic acid	[no description available]	medium	2	0	monocarboxylic acid	antibacterial agent; astringent; metabolite; protic solvent; solvent
gallic acid	[no description available]	medium	1	0	trihydroxybenzoic acid	antineoplastic agent; antioxidant; apoptosis inducer; astringent; cyclooxygenase 2 inhibitor; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; geroprotector; human xenobiotic metabolite; plant metabolite
histamine	[no description available]	medium	29	0	aralkylamino compound; imidazoles	human metabolite; mouse metabolite; neurotransmitter
dihydroxyphenylalanine	[no description available]	medium	39	0	hydroxyphenylalanine; non-proteinogenic alpha-amino acid; tyrosine derivative	human metabolite
picolinic acid	[no description available]	medium	1	0	pyridinemonocarboxylic acid	human metabolite; MALDI matrix material
pyridoxamine	[no description available]	medium	1	0	aminoalkylpyridine; hydroxymethylpyridine; monohydroxypyridine; vitamin B6	Escherichia coli metabolite; human metabolite; iron chelator; mouse metabolite; nephroprotective agent; plant metabolite; Saccharomyces cerevisiae metabolite
trimethylamine	[no description available]	medium	1	0	methylamines; tertiary amine	Escherichia coli metabolite; human xenobiotic metabolite
tryptophan	[no description available]	medium	1	0	alpha-amino acid; amino acid zwitterion; aminoalkylindole; aromatic amino acid; polar amino acid	Daphnia magna metabolite
2,4-dichlorophenoxyacetic acid	[no description available]	medium	1	0	chlorophenoxyacetic acid; dichlorobenzene	agrochemical; defoliant; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; environmental contaminant; phenoxy herbicide; synthetic auxin
dan 2163	[no description available]	high	4	0	aromatic amide; aromatic amine; benzamides; pyrrolidines; sulfone	environmental contaminant; second generation antipsychotic; xenobiotic
amoxapine	[no description available]	medium	2	0	dibenzooxazepine	adrenergic uptake inhibitor; antidepressant; dopaminergic antagonist; geroprotector; serotonin uptake inhibitor
arecoline	[no description available]	medium	3	0	enoate ester; methyl ester; pyridine alkaloid; tetrahydropyridine	metabolite; muscarinic agonist
carbidopa	[no description available]	medium	1	0	benzenes; monocarboxylic acid
celiprolol	[no description available]	medium	1	0	aromatic ketone
cyclobenzaprine	[no description available]	medium	2	0	carbotricyclic compound	antidepressant; muscle relaxant; tranquilizing drug
dyclonine	[no description available]	medium	1	0	aromatic ketone; piperidines	topical anaesthetic
fendiline	[no description available]	medium	2	0	diarylmethane
fluspirilene	[no description available]	medium	1	0	diarylmethane
mephentermine	[no description available]	high	19	0	amphetamines
lomefloxacin	[no description available]	medium	2	0	fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antimicrobial agent; antitubercular agent; photosensitizing agent
loxapine	[no description available]	medium	2	0	dibenzooxazepine	antipsychotic agent; dopaminergic antagonist
mesoridazine	[no description available]	medium	2	0	phenothiazines; sulfoxide; tertiary amino compound	dopaminergic antagonist; first generation antipsychotic
methoxyphenamine	[no description available]	medium	53	0	amphetamines	beta-adrenergic agonist; bronchodilator agent
methoxyphenamine	[no description available]	medium	53	1	amphetamines	beta-adrenergic agonist; bronchodilator agent
3-Hydroxy-alpha-methyl-DL-tyrosine	[no description available]	medium	1	0	benzenes; monocarboxylic acid
oxotremorine	[no description available]	medium	8	0	N-alkylpyrrolidine
periciazine	[no description available]	medium	1	0	hydroxypiperidine; nitrile; phenothiazines	adrenergic antagonist; first generation antipsychotic; sedative
tolmetin	[no description available]	medium	2	0	aromatic ketone; monocarboxylic acid; pyrroles	EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug
trimeprazine	[no description available]	medium	1	0	phenothiazines
isonicotinic acid	[no description available]	medium	1	0	pyridinemonocarboxylic acid	algal metabolite; human metabolite
aspartic acid	[no description available]	medium	28	0	aspartate family amino acid; aspartic acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; mouse metabolite; neurotransmitter
aspartic acid	[no description available]	medium	28	1	aspartate family amino acid; aspartic acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; mouse metabolite; neurotransmitter
tyrosine	[no description available]	medium	27	0	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; proteinogenic amino acid; tyrosine	EC 1.3.1.43 (arogenate dehydrogenase) inhibitor; fundamental metabolite; micronutrient; nutraceutical
tyrosine	[no description available]	medium	27	1	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; proteinogenic amino acid; tyrosine	EC 1.3.1.43 (arogenate dehydrogenase) inhibitor; fundamental metabolite; micronutrient; nutraceutical
phenylalanine	[no description available]	medium	9	0	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; phenylalanine; proteinogenic amino acid	algal metabolite; EC 3.1.3.1 (alkaline phosphatase) inhibitor; Escherichia coli metabolite; human xenobiotic metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
tromethamine	[no description available]	medium	2	0	primary amino compound; triol	buffer
brompheniramine	[no description available]	medium	4	0	organobromine compound; pyridines	anti-allergic agent; H1-receptor antagonist
phenylpiperazine	[no description available]	medium	1	0
2-naphthoic acid	[no description available]	medium	1	0	naphthoic acid	mouse metabolite; xenobiotic metabolite
mecoprop	[no description available]	medium	1	0	aromatic ether; monocarboxylic acid; monochlorobenzenes
deanol	[no description available]	medium	4	0	ethanolamines; tertiary amine	curing agent; radical scavenger
4-methylmorpholine	[no description available]	medium	2	0
piperidine	[no description available]	medium	1	0	azacycloalkane; piperidines; saturated organic heteromonocyclic parent; secondary amine	base; catalyst; human metabolite; non-polar solvent; plant metabolite; protic solvent; reagent
morpholine	[no description available]	medium	1	0	morpholines; saturated organic heteromonocyclic parent	NMR chemical shift reference compound
hexahydroazepine	[no description available]	medium	1	0	azacycloalkane; azepanes; saturated organic heteromonocyclic parent
n-methylpyrrolidine	[no description available]	medium	1	0
triethylamine	[no description available]	medium	2	0	tertiary amine
chloroprocaine	[no description available]	medium	1	0	benzoate ester; monochlorobenzenes	central nervous system depressant; local anaesthetic; peripheral nervous system drug
aziridine	[no description available]	medium	1	0	azacycloalkane; aziridines; saturated organic heteromonocyclic parent	alkylating agent
dibenzepin	[no description available]	medium	1	0	dibenzodiazepine
trifluoroethylamine	[no description available]	medium	1	0
2-fluoroethylamine	[no description available]	medium	1	0
arecaidine	[no description available]	medium	1	0	citraconoyl group
azetidine	[no description available]	medium	1	0	azacycloalkane; azetidines; saturated organic heteromonocyclic parent
gluconic acid	[no description available]	medium	2	0	gluconic acid	chelator; Penicillium metabolite
aminopenicillanic acid	[no description available]	medium	1	0	amino acid zwitterion; penicillanic acids	allergen
glycyl-glycyl-glycine	[no description available]	medium	1	0	tripeptide zwitterion; tripeptide
n,n-dimethylethylamine	[no description available]	medium	1	0
diethylmethylamine	[no description available]	medium	1	0
glycine ethyl ester	[no description available]	medium	1	0
n-methylpiperidine	[no description available]	medium	1	0
benzydamine	[no description available]	high	2	0	aromatic ether; indazoles; tertiary amino compound	analgesic; central nervous system stimulant; hallucinogen; local anaesthetic; non-steroidal anti-inflammatory drug
tempidon	[no description available]	medium	1	0	piperidones
clopyralid	[no description available]	medium	1	0	organochlorine pesticide; pyridines	herbicide
dimethylaminopropionitrile	[no description available]	medium	1	0
5-phenylvaleric acid	[no description available]	medium	1	0	benzenes; monocarboxylic acid
cyclacillin	[no description available]	medium	1	0	penicillin	antibacterial drug
pyrrolidine	[no description available]	medium	2	0	azacycloalkane; pyrrolidines; saturated organic heteromonocyclic parent
metipranolol	[no description available]	medium	1	0	acetate ester; aromatic ether; propanolamine; secondary amino compound	anti-arrhythmia drug; antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist
propamocarb	[no description available]	medium	1	0	carbamate ester; carbamate fungicide; tertiary amino compound	antifungal agrochemical; environmental contaminant; xenobiotic
phenyl-2-aminoethyl sulfide	[no description available]	medium	1	0
Flamprop	[no description available]	medium	1	0	benzamides
d-lactic acid	[no description available]	medium	1	0	2-hydroxypropanoic acid	Escherichia coli metabolite; human metabolite
thiamorpholine	[no description available]	medium	1	0	saturated organic heteromonocyclic parent; thiomorpholines
glycyl-glycyl-glycyl-glycine	[no description available]	medium	1	0
carazolol	[no description available]	medium	1	0	carbazoles
oleandomycin	[no description available]	medium	1	0	oleandomycins
phenylalanyl-phenylalanyl-phenylalanine	[no description available]	medium	1	0	oligopeptide
3-(4-methoxybenzoyl)propionic acid	[no description available]	medium	1	0
dimethylaminopropanol	[no description available]	medium	1	0
4-phenylbutylamine	[no description available]	medium	1	0	benzenes; phenylalkylamine; primary amino compound
glycinexylidide	[no description available]	medium	1	0	amino acid amide	drug metabolite
Trp-Trp	[no description available]	medium	1	0	dipeptide	Mycoplasma genitalium metabolite
kampirone	[no description available]	medium	1	0	N-arylpiperazine
isopelletierine	[no description available]	medium	1	0	citraconoyl group
fenpropimorph	[no description available]	medium	1	0	alkylbenzene
1-(2-pyridinyl)piperazine	[no description available]	medium	1	0
l-lactic acid	[no description available]	medium	1	0	(2S)-2-hydroxy monocarboxylic acid; 2-hydroxypropanoic acid	Escherichia coli metabolite; human metabolite
ibuprofen, (r)-isomer	[no description available]	medium	1	0	ibuprofen
deramciclane	[no description available]	medium	1	0
aspartame	[no description available]	medium	1	0	carboxylic acid; dipeptide zwitterion; dipeptide; methyl ester	apoptosis inhibitor; EC 3.1.3.1 (alkaline phosphatase) inhibitor; environmental contaminant; micronutrient; nutraceutical; sweetening agent; xenobiotic
norpseudoephedrine	[no description available]	high	5	0	amphetamines; phenethylamine alkaloid	central nervous system stimulant; plant metabolite; psychotropic drug
vinpocetine	[no description available]	medium	2	0	alkaloid	geroprotector
e-z cinnamic acid	[no description available]	medium	1	0	cinnamic acid	plant metabolite
sorbic acid	[no description available]	medium	1	0	alpha,beta-unsaturated monocarboxylic acid; sorbic acid
doxepin hydrochloride	[no description available]	medium	1	0
4-methylumbelliferyl glucoside	[no description available]	medium	1	0	beta-D-glucoside; coumarins; monosaccharide derivative	chromogenic compound
tylosin	[no description available]	medium	1	0	aldehyde; disaccharide derivative; enone; leucomycin; macrolide antibiotic; monosaccharide derivative	allergen; bacterial metabolite; environmental contaminant; xenobiotic
triprolidine	[no description available]	medium	2	0	N-alkylpyrrolidine; olefinic compound; pyridines	H1-receptor antagonist
dihydrocodeine	[no description available]	medium	3	0	morphinane alkaloid
codeine phosphate	[no description available]	medium	1	0
dihydromorphine	[no description available]	medium	1	0	morphinane alkaloid
heroin	[no description available]	medium	166	0	morphinane alkaloid	mu-opioid receptor agonist; opioid analgesic; prodrug
heroin	[no description available]	medium	166	5	morphinane alkaloid	mu-opioid receptor agonist; opioid analgesic; prodrug
normorphine	[no description available]	medium	1	0	morphinane alkaloid
morphine-3-glucuronide	[no description available]	medium	1	0	morphinane alkaloid
1,2-dielaidoylphosphatidylethanolamine	[no description available]	medium	1	0
rosaramicin	[no description available]	medium	1	0	aldehyde; enone; epoxide; macrolide antibiotic; monosaccharide derivative	bacterial metabolite
cefdinir	[no description available]	medium	2	0	cephalosporin; ketoxime	antibacterial drug
phenylalanylphenylalanine	[no description available]	medium	1	0	dipeptide; L-aminoacyl-L-amino acid zwitterion	human blood serum metabolite; Mycoplasma genitalium metabolite
norcodeine	[no description available]	medium	1	0	morphinane alkaloid
4-n-butyl-1-(4-(2-methylphenyl)-4-oxo-1-butyl)-piperidine hydrogen chloride	[no description available]	medium	1	0
decanoylcarnitine	[no description available]	medium	1	0	decanoate ester; O-acylcarnitine	human urinary metabolite
norclozapine	[no description available]	medium	1	0	dibenzodiazepine; organochlorine compound; piperazines	delta-opioid receptor agonist; metabolite; serotonergic antagonist
tyramine	[no description available]	medium	50	0	monoamine molecular messenger; primary amino compound; tyramines	EC 3.1.1.8 (cholinesterase) inhibitor; Escherichia coli metabolite; human metabolite; mouse metabolite; neurotransmitter
alaproclate	[no description available]	medium	1	0	alpha-amino acid ester
alendronate	[no description available]	medium	1	0	1,1-bis(phosphonic acid); primary amino compound	bone density conservation agent; EC 2.5.1.1 (dimethylallyltranstransferase) inhibitor
altretamine	[no description available]	medium	1	0	triamino-1,3,5-triazine
ambenonium	[no description available]	medium	1	0	quaternary ammonium ion	EC 3.1.1.8 (cholinesterase) inhibitor
amifostine anhydrous	[no description available]	medium	1	0	diamine; organic thiophosphate	antioxidant; prodrug; radiation protective agent
p-aminohippuric acid	[no description available]	medium	2	0	N-acylglycine	Daphnia magna metabolite
bendroflumethiazide	[no description available]	medium	1	0	benzothiadiazine; sulfonamide	antihypertensive agent; diuretic
bethanechol	[no description available]	medium	2	0	carbamate ester; quaternary ammonium ion	muscarinic agonist
bisacodyl	[no description available]	medium	1	0	diarylmethane
secbutabarbital	[no description available]	medium	1	0	barbiturates
candesartan	[no description available]	medium	1	0	benzimidazolecarboxylic acid; biphenylyltetrazole	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
carbinoxamine	[no description available]	medium	1	0	monochlorobenzenes; pyridines; tertiary amino compound	anti-allergic agent; antiparkinson drug; H1-receptor antagonist; muscarinic antagonist
chlorcyclizine	[no description available]	medium	1	0	diarylmethane
chlorothiazide	[no description available]	medium	3	0	benzothiadiazine	antihypertensive agent; diuretic
cyclofenil	[no description available]	medium	1	0	organic molecular entity
dichlorphenamide	[no description available]	medium	1	0	dichlorobenzene; sulfonamide	antiglaucoma drug; EC 4.2.1.1 (carbonic anhydrase) inhibitor; ophthalmology drug
dicyclomine	[no description available]	medium	2	0	carboxylic ester; tertiary amine	antispasmodic drug; muscarinic antagonist; parasympatholytic
pentetic acid	[no description available]	medium	1	0	pentacarboxylic acid	copper chelator
dimercaprol	[no description available]	medium	1	0	dithiol; primary alcohol	chelator
doxylamine	[no description available]	medium	3	0	pyridines; tertiary amine	anti-allergic agent; antiemetic; antitussive; cholinergic antagonist; H1-receptor antagonist; histamine antagonist; sedative
edrophonium	[no description available]	medium	1	0	phenols; quaternary ammonium ion	antidote; diagnostic agent; EC 3.1.1.8 (cholinesterase) inhibitor
ethosuximide	[no description available]	medium	4	0	dicarboximide; pyrrolidinone	anticonvulsant; geroprotector; T-type calcium channel blocker
ethotoin	[no description available]	medium	1	0	imidazolidine-2,4-dione	anticonvulsant
fenoldopam	[no description available]	medium	1	0	benzazepine	alpha-adrenergic agonist; antihypertensive agent; dopamine agonist; dopaminergic antagonist; vasodilator agent
fenoprofen	[no description available]	medium	1	0	monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; non-narcotic analgesic; non-steroidal anti-inflammatory drug
fexofenadine	[no description available]	medium	1	0	piperidines; tertiary amine	anti-allergic agent; H1-receptor antagonist
fipexide	[no description available]	medium	1	0	benzodioxoles
flavoxate	[no description available]	medium	1	0	carboxylic ester; flavones; piperidines; tertiary amino compound	antispasmodic drug; muscarinic antagonist; parasympatholytic
fluphenazine	[no description available]	medium	9	0	N-alkylpiperazine; organofluorine compound; phenothiazines	anticoronaviral agent; dopaminergic antagonist; phenothiazine antipsychotic drug
flurazepam	[no description available]	medium	1	0	1,4-benzodiazepinone; monofluorobenzenes; organochlorine compound; tertiary amino compound	anticonvulsant; anxiolytic drug; GABAA receptor agonist; sedative
2-cyclopentyl-2-hydroxy-2-phenylacetic acid (1,1-dimethyl-3-pyrrolidin-1-iumyl) ester	[no description available]	medium	1	0	benzenes
guanethidine	[no description available]	medium	15	0	azocanes; guanidines	adrenergic antagonist; antihypertensive agent; sympatholytic agent
ioversol	[no description available]	medium	1	0	amidobenzoic acid
isocarboxazid	[no description available]	medium	1	0	benzenes
mechlorethamine	[no description available]	medium	2	0	nitrogen mustard; organochlorine compound	alkylating agent
meclofenamic acid	[no description available]	medium	1	0	aminobenzoic acid; organochlorine compound; secondary amino compound	analgesic; anticonvulsant; antineoplastic agent; antipyretic; antirheumatic drug; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug
memantine	[no description available]	medium	6	0	adamantanes; primary aliphatic amine	antidepressant; antiparkinson drug; dopaminergic agent; neuroprotective agent; NMDA receptor antagonist
memantine	[no description available]	medium	6	1	adamantanes; primary aliphatic amine	antidepressant; antiparkinson drug; dopaminergic agent; neuroprotective agent; NMDA receptor antagonist
mepenzolate	[no description available]	medium	1	0	diarylmethane
metaproterenol	[no description available]	medium	4	0	aralkylamino compound; phenylethanolamines; resorcinols; secondary alcohol; secondary amino compound
methazolamide	[no description available]	medium	1	0	sulfonamide; thiadiazoles
methyclothiazide	[no description available]	medium	1	0	benzothiadiazine
nadolol	[no description available]	medium	1	0	tetralins
4-phenylbutyric acid	[no description available]	medium	1	0	monocarboxylic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor; prodrug
polythiazide	[no description available]	medium	1	0	benzothiadiazine
duodote	[no description available]	medium	1	0	pyridinium ion	antidote to organophosphate poisoning; antidote to sarin poisoning; cholinergic drug; cholinesterase reactivator
propantheline	[no description available]	medium	1	0	xanthenes
protriptyline	[no description available]	medium	1	0	carbotricyclic compound	antidepressant
sch 16134	[no description available]	medium	1	0	benzodiazepine
quetiapine	[no description available]	medium	1	0	dibenzothiazepine; N-alkylpiperazine; N-arylpiperazine	adrenergic antagonist; dopaminergic antagonist; histamine antagonist; second generation antipsychotic; serotonergic antagonist
rimantadine	[no description available]	medium	1	0	alkylamine
ropinirole	[no description available]	medium	2	0	indolones; tertiary amine	antidyskinesia agent; antiparkinson drug; central nervous system drug; dopamine agonist
salicylsalicylic acid	[no description available]	medium	1	0	benzoate ester; benzoic acids; phenols; salicylates	antineoplastic agent; antirheumatic drug; EC 3.5.2.6 (beta-lactamase) inhibitor; hypoglycemic agent; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug
succinylcholine	[no description available]	medium	4	0	quaternary ammonium ion; succinate ester	drug allergen; muscle relaxant; neuromuscular agent
sulfathiazole	[no description available]	medium	1	0	1,3-thiazoles; substituted aniline; sulfonamide antibiotic; sulfonamide	antiinfective agent; drug allergen; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; xenobiotic
trifluoperazine	[no description available]	medium	3	0	N-alkylpiperazine; N-methylpiperazine; organofluorine compound; phenothiazines	antiemetic; calmodulin antagonist; dopaminergic antagonist; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor; phenothiazine antipsychotic drug
trihexyphenidyl	[no description available]	medium	8	0	amine
trimethobenzamide	[no description available]	medium	3	0	benzamides; tertiary amino compound	antiemetic
delavirdine	[no description available]	medium	1	0	aminopyridine; indolecarboxamide; N-acylpiperazine; sulfonamide	antiviral drug; HIV-1 reverse transcriptase inhibitor
zonisamide	[no description available]	medium	1	0	1,2-benzoxazoles; sulfonamide	anticonvulsant; antioxidant; central nervous system drug; protective agent; T-type calcium channel blocker
cysteine	[no description available]	medium	1	0	cysteine zwitterion; cysteine; L-alpha-amino acid; proteinogenic amino acid; serine family amino acid	EC 4.3.1.3 (histidine ammonia-lyase) inhibitor; flour treatment agent; human metabolite
edetic acid	[no description available]	medium	2	0	ethylenediamine derivative; polyamino carboxylic acid; tetracarboxylic acid	anticoagulant; antidote; chelator; copper chelator; geroprotector
cysteamine	[no description available]	medium	3	0	amine; thiol	geroprotector; human metabolite; mouse metabolite; radiation protective agent
acetylcholine chloride	[no description available]	medium	1	0	quaternary ammonium salt
mepazine	[no description available]	medium	1	0	phenothiazines
cloxacillin	[no description available]	medium	1	0	penicillin allergen; penicillin; semisynthetic derivative	antibacterial agent; antibacterial drug
calcium acetate	[no description available]	medium	1	0	calcium salt	chelator
mebanazine	[no description available]	medium	1	0	benzenes
cycloserine	[no description available]	medium	3	0	4-amino-1,2-oxazolidin-3-one; organonitrogen heterocyclic antibiotic; organooxygen heterocyclic antibiotic; zwitterion	antiinfective agent; antimetabolite; antitubercular agent; metabolite; NMDA receptor agonist
perflutren	[no description available]	medium	1	0	fluoroalkane; fluorocarbon
fluoxymesterone	[no description available]	medium	1	0	11beta-hydroxy steroid; 17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; anabolic androgenic steroid; fluorinated steroid	anabolic agent; antineoplastic agent
methsuximide	[no description available]	medium	3	0	organic molecular entity
pseudoephedrine	[no description available]	high	50	0	phenylethanolamines; secondary alcohol; secondary amino compound	anti-asthmatic drug; bronchodilator agent; central nervous system drug; nasal decongestant; plant metabolite; sympathomimetic agent; vasoconstrictor agent; xenobiotic
diethylpropion	[no description available]	medium	15	0	aromatic ketone; tertiary amine	appetite depressant
benzonatate	[no description available]	medium	1	0	benzoate ester; secondary amino compound; substituted aniline	anaesthetic; antitussive
methylergonovine	[no description available]	medium	1	0	ergoline alkaloid
4-hydroxybutyric acid	[no description available]	medium	5	0	4-hydroxy monocarboxylic acid; hydroxybutyric acid	general anaesthetic; GHB receptor agonist; neurotoxin; sedative
medroxyprogesterone	[no description available]	medium	1	0	17alpha-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(4) steroid; tertiary alpha-hydroxy ketone	contraceptive drug; progestin; synthetic oral contraceptive
dimenhydrinate	[no description available]	medium	1	0	diarylmethane
levocarnitine	[no description available]	medium	1	0	carnitine	antilipemic drug; nootropic agent; nutraceutical; Saccharomyces cerevisiae metabolite; water-soluble vitamin (role)
sulfanilylurea	[no description available]	medium	1	0	benzenes; sulfonamide
pamabrom	[no description available]	medium	1	0
diphenoxylate	[no description available]	medium	2	0	ethyl ester; nitrile; piperidinecarboxylate ester; tertiary amine	antidiarrhoeal drug
ibufenac	[no description available]	medium	1	0	monocarboxylic acid	EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; hepatotoxic agent; non-narcotic analgesic; non-steroidal anti-inflammatory drug
metaxalone	[no description available]	medium	1	0	aromatic ether
dexbrompheniramine	[no description available]	medium	1	0	brompheniramine	anti-allergic agent; H1-receptor antagonist
megestrol	[no description available]	medium	1	0	17alpha-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(4) steroid; tertiary alpha-hydroxy ketone	antineoplastic agent; appetite enhancer; contraceptive drug; progestin; synthetic oral contraceptive
clomacran	[no description available]	medium	1	0	acridines
methenamine hippurate	[no description available]	medium	1	0	N-acylglycine
sodium thiosulfate	[no description available]	medium	1	0	inorganic sodium salt	antidote to cyanide poisoning; antifungal drug; nephroprotective agent
fenclozic acid	[no description available]	medium	1	0
laxagetten 4,4'-diacetoxydiphenylpyridylemethane	[no description available]	medium	1	0
fludarabine phosphate	[no description available]	medium	1	0	nucleoside analogue; organofluorine compound; purine arabinonucleoside monophosphate	antimetabolite; antineoplastic agent; antiviral agent; DNA synthesis inhibitor; immunosuppressive agent; prodrug
alclofenac	[no description available]	medium	1	0	aromatic ether; monocarboxylic acid; monochlorobenzenes	drug allergen; non-narcotic analgesic; non-steroidal anti-inflammatory drug
fludrocortisone	[no description available]	medium	1	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; fluorinated steroid; mineralocorticoid	adrenergic agent; anti-inflammatory drug
dexchlorpheniramine	[no description available]	medium	1	0	chlorphenamine
clometacin	[no description available]	medium	1	0	N-acylindole
carbidopa	[no description available]	medium	1	0	catechols; hydrazines; monocarboxylic acid	antiparkinson drug; dopaminergic agent; EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor
moricizine	[no description available]	medium	1	0	carbamate ester; morpholines; phenothiazines	anti-arrhythmia drug
vecuronium	[no description available]	medium	1	0	acetate ester; androstane; quaternary ammonium ion	drug allergen; muscle relaxant; neuromuscular agent; nicotinic antagonist
exifone	[no description available]	medium	1	0	benzophenones
mefloquine	[no description available]	medium	1	0	[2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol	antimalarial
nitazoxanide	[no description available]	medium	1	0	benzamides; carboxylic ester
acarbose	[no description available]	medium	1	0	tetrasaccharide derivative	EC 3.2.1.1 (alpha-amylase) inhibitor; EC 3.2.1.20 (alpha-glucosidase) inhibitor; geroprotector; hypoglycemic agent
pergolide	[no description available]	medium	3	0	diamine; methyl sulfide; organic heterotetracyclic compound	antiparkinson drug; dopamine agonist
fialuridine	[no description available]	medium	1	0
haloperidol decanoate	[no description available]	medium	2	0	organic molecular entity
tolrestat	[no description available]	medium	1	0	naphthalenes	EC 1.1.1.21 (aldehyde reductase) inhibitor
balsalazide	[no description available]	medium	1	0
cabergoline	[no description available]	medium	3	0	N-acylurea	antineoplastic agent; antiparkinson drug; dopamine agonist
cabergoline	[no description available]	medium	3	2	N-acylurea	antineoplastic agent; antiparkinson drug; dopamine agonist
fosphenytoin	[no description available]	medium	1	0	imidazolidine-2,4-dione
ranolazine	[no description available]	medium	1	0	aromatic amide; monocarboxylic acid amide; monomethoxybenzene; N-alkylpiperazine; secondary alcohol
aromasil	[no description available]	medium	1	0	17-oxo steroid; 3-oxo-Delta(1),Delta(4)-steroid	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor; environmental contaminant; xenobiotic
emtricitabine	[no description available]	medium	2	0	monothioacetal; nucleoside analogue; organofluorine compound; pyrimidone	antiviral drug; HIV-1 reverse transcriptase inhibitor
tasosartan	[no description available]	medium	1	0	biphenyls
tiludronic acid	[no description available]	medium	1	0	organochlorine compound
fenofibric acid	[no description available]	medium	1	0	aromatic ketone; chlorobenzophenone; monocarboxylic acid	drug metabolite; marine xenobiotic metabolite
plerixafor	[no description available]	medium	1	0	azacycloalkane; azamacrocycle; benzenes; crown amine; secondary amino compound; tertiary amino compound	anti-HIV agent; antineoplastic agent; C-X-C chemokine receptor type 4 antagonist; immunological adjuvant
oseltamivir	[no description available]	medium	1	0	acetamides; amino acid ester; cyclohexenecarboxylate ester; primary amino compound	antiviral drug; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor; environmental contaminant; prodrug; xenobiotic
histamine phosphate	[no description available]	medium	1	0	phosphate salt	histamine agonist
tilbroquinol	[no description available]	medium	1	0	organohalogen compound; quinolines
droxicam	[no description available]	medium	1	0	organic heterotricyclic compound; pyridines	cyclooxygenase 1 inhibitor; hepatotoxic agent; non-narcotic analgesic; non-steroidal anti-inflammatory drug; platelet aggregation inhibitor; prodrug
ebrotidine	[no description available]	medium	1	0	sulfonamide
acamprosate	[no description available]	high	2	0	acetamides; organosulfonic acid	environmental contaminant; neurotransmitter agent; xenobiotic
isaxonine	[no description available]	medium	1	0	aminopyrimidine
hp 873	[no description available]	medium	1	0	1,2-benzoxazoles; aromatic ether; aromatic ketone; methyl ketone; monoamine; organofluorine compound; piperidines; tertiary amino compound	dopaminergic antagonist; second generation antipsychotic; serotonergic antagonist
fenoxypropazine	[no description available]	medium	1	0	aromatic ether
aceclofenac	[no description available]	medium	1	0	amino acid; carboxylic ester; dichlorobenzene; monocarboxylic acid; secondary amino compound	EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
nitrefazole	[no description available]	medium	1	0	imidazoles
doripenem	[no description available]	medium	1	0	carbapenems
bexarotene	[no description available]	medium	1	0	benzoic acids; naphthalenes; retinoid	antineoplastic agent
moexipril	[no description available]	medium	1	0	peptide
fulvestrant	[no description available]	medium	1	0	17beta-hydroxy steroid; 3-hydroxy steroid; organofluorine compound; sulfoxide	antineoplastic agent; estrogen antagonist; estrogen receptor antagonist
tadalafil	[no description available]	medium	2	0	benzodioxoles; pyrazinopyridoindole	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent
paliperidone	[no description available]	medium	1	0	1,2-benzoxazoles; heteroarylpiperidine; organofluorine compound; pyridopyrimidine; secondary alcohol
pramipexole	[no description available]	medium	3	0	benzothiazoles; diamine	antidyskinesia agent; antiparkinson drug; dopamine agonist; radical scavenger
valdecoxib	[no description available]	medium	1	0	isoxazoles; sulfonamide	antipyretic; antirheumatic drug; cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
desloratadine	[no description available]	medium	1	0	benzocycloheptapyridine	anti-allergic agent; cholinergic antagonist; drug metabolite; H1-receptor antagonist
desvenlafaxine	[no description available]	medium	1	0	cyclohexanols; phenols; tertiary amino compound	antidepressant; drug metabolite; marine xenobiotic metabolite
rufinamide	[no description available]	medium	1	0	aromatic amide; heteroarene
dexpanthenol	[no description available]	medium	1	0	amino alcohol; monocarboxylic acid amide	cholinergic drug; provitamin
fosamprenavir	[no description available]	medium	1	0	sulfonamide	prodrug
febuxostat	[no description available]	medium	1	0	1,3-thiazolemonocarboxylic acid; aromatic ether; nitrile	EC 1.17.3.2 (xanthine oxidase) inhibitor
escitalopram	[no description available]	medium	1	0	1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile	antidepressant; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
10-propargyl-10-deazaaminopterin	[no description available]	medium	1	0	N-acyl-L-glutamic acid; pteridines; terminal acetylenic compound	antimetabolite; antineoplastic agent; EC 1.5.1.3 (dihydrofolate reductase) inhibitor
docetaxel anhydrous	[no description available]	medium	1	0	secondary alpha-hydroxy ketone; tetracyclic diterpenoid	antimalarial; antineoplastic agent; photosensitizing agent
cox 189	[no description available]	medium	1	0	amino acid; monocarboxylic acid; organochlorine compound; organofluorine compound; secondary amino compound	cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
pralnacasan	[no description available]	medium	1	0
dexmethylphenidate	[no description available]	medium	1	0	methyl phenyl(piperidin-2-yl)acetate	adrenergic agent
cinacalcet	[no description available]	medium	1	0	(trifluoromethyl)benzenes; naphthalenes; secondary amino compound	calcimimetic; P450 inhibitor
lubiprostone	[no description available]	medium	1	0
telbivudine	[no description available]	medium	1	0	pyrimidine 2'-deoxyribonucleoside	antiviral drug; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
17 alpha-hydroxyprogesterone caproate	[no description available]	medium	1	0	corticosteroid hormone
varenicline	[no description available]	medium	11	0
varenicline	[no description available]	medium	11	3
fiduxosin	[no description available]	medium	1	0
erlotinib	[no description available]	medium	1	0	aromatic ether; quinazolines; secondary amino compound; terminal acetylenic compound	antineoplastic agent; epidermal growth factor receptor antagonist; protein kinase inhibitor
etravirine	[no description available]	medium	1	0	aminopyrimidine; aromatic ether; dinitrile; organobromine compound	antiviral agent; HIV-1 reverse transcriptase inhibitor
dronedarone	[no description available]	medium	1	0	1-benzofurans; aromatic ether; aromatic ketone; sulfonamide; tertiary amino compound	anti-arrhythmia drug; environmental contaminant; xenobiotic
ramelteon	[no description available]	medium	1	0	indanes
lapatinib	[no description available]	medium	1	0	furans; organochlorine compound; organofluorine compound; quinazolines	antineoplastic agent; tyrosine kinase inhibitor
darunavir	[no description available]	medium	1	0	carbamate ester; furofuran; sulfonamide	antiviral drug; HIV protease inhibitor
tolvaptan	[no description available]	medium	1	0	benzazepine; benzenedicarboxamide	aquaretic; vasopressin receptor antagonist
sorafenib	[no description available]	medium	1	0	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; phenylureas; pyridinecarboxamide	angiogenesis inhibitor; anticoronaviral agent; antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; ferroptosis inducer; tyrosine kinase inhibitor
lenalidomide	[no description available]	medium	1	0	aromatic amine; dicarboximide; isoindoles; piperidones	angiogenesis inhibitor; antineoplastic agent; immunomodulator
regadenoson	[no description available]	medium	1	0	purine nucleoside
lacosamide	[no description available]	medium	1	0	N-acyl-amino acid
vincaleukoblastine	[no description available]	medium	1	0	acetate ester; indole alkaloid fundamental parent; methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; tertiary alcohol; tertiary amino compound; vinca alkaloid	antineoplastic agent; immunosuppressive agent; microtubule-destabilising agent; plant metabolite
oxytocin	[no description available]	medium	40	0	heterodetic cyclic peptide; peptide hormone	oxytocic; vasodilator agent
oxytocin	[no description available]	medium	40	5	heterodetic cyclic peptide; peptide hormone	oxytocic; vasodilator agent
pentostatin	[no description available]	medium	2	0	coformycins	antimetabolite; antineoplastic agent; Aspergillus metabolite; bacterial metabolite; EC 3.5.4.4 (adenosine deaminase) inhibitor
clindamycin phosphate	[no description available]	medium	1	0
eplerenone	[no description available]	medium	1	0	3-oxo-Delta(4) steroid; epoxy steroid; gamma-lactone; methyl ester; organic heteropentacyclic compound; oxaspiro compound; steroid acid ester	aldosterone antagonist; antihypertensive agent
octreotide	[no description available]	medium	1	0
posaconazole	[no description available]	medium	1	0	aromatic ether; conazole antifungal drug; N-arylpiperazine; organofluorine compound; oxolanes; triazole antifungal drug; triazoles	trypanocidal drug
arsenic trioxide	[no description available]	medium	1	0	arsenic oxide	antineoplastic agent; insecticide
sr 90107	[no description available]	medium	1	0
meglumine iodipamide	[no description available]	medium	1	0	organoammonium salt	radioopaque medium
thyrotropin-releasing hormone	[no description available]	medium	1	0	peptide hormone; tripeptide	human metabolite
arginine vasopressin	[no description available]	medium	4	0	vasopressin	cardiovascular drug; hematologic agent; mitogen
s 1033	[no description available]	medium	1	0	(trifluoromethyl)benzenes; imidazoles; pyridines; pyrimidines; secondary amino compound; secondary carboxamide	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor
pyrantel	[no description available]	medium	1	0	1,4,5,6-tetrahydropyrimidines; carboxamidine; thiophenes	antinematodal drug
thiothixene	[no description available]	medium	1	0	N-methylpiperazine	anticoronaviral agent
eszopiclone	[no description available]	medium	1	0	zopiclone	central nervous system depressant; sedative
benztropine	[no description available]	medium	5	0	diarylmethane
succimer	[no description available]	medium	1	0	dicarboxylic acid; dithiol; sulfur-containing carboxylic acid	chelator
ranitidine	[no description available]	high	5	0	C-nitro compound; furans; organic sulfide; tertiary amino compound	anti-ulcer drug; drug allergen; environmental contaminant; H2-receptor antagonist; xenobiotic
aplaviroc	[no description available]	medium	1	0
maraviroc	[no description available]	medium	1	0	tropane alkaloid
dermatan sulfate	[no description available]	medium	1	0	amino disaccharide; glycosylgalactose derivative; iduronic acids; oligosaccharide sulfate
fospropofol	[no description available]	medium	1	0	alkylbenzene
rasagiline	[no description available]	medium	8	0	indanes; secondary amine; terminal acetylenic compound	EC 1.4.3.4 (monoamine oxidase) inhibitor; neuroprotective agent
dasatinib	[no description available]	medium	1	0	1,3-thiazoles; aminopyrimidine; monocarboxylic acid amide; N-(2-hydroxyethyl)piperazine; N-arylpiperazine; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor
vitamin d 2	[no description available]	medium	1	0	hydroxy seco-steroid; seco-ergostane; vitamin D	bone density conservation agent; nutraceutical; plant metabolite; rodenticide
hemabate	[no description available]	medium	1	0
7432 s	[no description available]	medium	1	0	cephalosporin; dicarboxylic acid	antibacterial drug
epoprostenol	[no description available]	medium	1	0	prostaglandins I	mouse metabolite
ethamolin	[no description available]	medium	1	0	long-chain fatty acid
estropipate	[no description available]	medium	1	0	piperazinium salt; steroid sulfate
ly 163892	[no description available]	medium	1	0	carbacephem; zwitterion	antibacterial drug; antimicrobial agent
nabilone	[no description available]	medium	1	0
vitamin k 1	[no description available]	medium	1	0	phylloquinones; vitamin K	cofactor; human metabolite; plant metabolite
trospium chloride	[no description available]	medium	1	0
benzphetamine	[no description available]	high	22	0	amphetamines; tertiary amine	adrenergic uptake inhibitor; appetite depressant; dopamine uptake inhibitor; sympathomimetic agent
deamino arginine vasopressin	[no description available]	medium	1	0	heterodetic cyclic peptide	diagnostic agent; renal agent; vasopressin receptor agonist
goserelin	[no description available]	medium	1	0	organic molecular entity
silodosin	[no description available]	medium	2	0	indolecarboxamide
su 11248	[no description available]	medium	1	0	monocarboxylic acid amide; pyrroles	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; immunomodulator; neuroprotective agent; vascular endothelial growth factor receptor antagonist
levorphanol	[no description available]	medium	2	0	morphinane alkaloid
benazepril	[no description available]	medium	2	0	benzazepine; dicarboxylic acid monoester; ethyl ester; lactam	EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
verteporfin	[no description available]	medium	1	0
zimeldine	[no description available]	medium	2	0	styrenes
trientine hydrochloride	[no description available]	medium	1	0
n-methylscopolamine bromide	[no description available]	medium	1	0
pafuramidine	[no description available]	medium	1	0
pregabalin	[no description available]	medium	1	0	gamma-amino acid	anticonvulsant; calcium channel blocker
alvimopan anhydrous	[no description available]	medium	1	0	peptide
aliskiren	[no description available]	medium	1	0	monocarboxylic acid amide; monomethoxybenzene	antihypertensive agent
cefpodoxime	[no description available]	medium	1	0	carboxylic acid; cephalosporin	antibacterial drug
rifaximin	[no description available]	medium	1	0	acetate ester; cyclic ketal; lactam; macrocycle; organic heterohexacyclic compound; rifamycins; semisynthetic derivative	antimicrobial agent; gastrointestinal drug; orphan drug
everolimus	[no description available]	medium	1	0	cyclic acetal; cyclic ketone; ether; macrolide lactam; primary alcohol; secondary alcohol	anticoronaviral agent; antineoplastic agent; geroprotector; immunosuppressive agent; mTOR inhibitor
1-methyl-d-lysergic acid butanolamide	[no description available]	medium	1	0	ergot alkaloid; monocarboxylic acid amide	serotonergic antagonist; sympatholytic agent; vasoconstrictor agent
etonogestrel	[no description available]	medium	1	0	17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; terminal acetylenic compound	contraceptive drug; female contraceptive drug; progestin
dutasteride	[no description available]	medium	1	0	(trifluoromethyl)benzenes; aza-steroid; delta-lactam	antihyperplasia drug; EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor
bibx 1382bs	[no description available]	medium	1	0	substituted aniline
fesoterodine	[no description available]	medium	1	0	diarylmethane
gemifloxacin	[no description available]	medium	1	0	1,8-naphthyridine derivative; fluoroquinolone antibiotic; monocarboxylic acid; quinolone antibiotic	antibacterial drug; antimicrobial agent; topoisomerase IV inhibitor
dexlansoprazole	[no description available]	medium	1	0	benzimidazoles; sulfoxide
armodafinil	[no description available]	medium	1	0	2-[(diphenylmethyl)sulfinyl]acetamide	central nervous system stimulant; eugeroic
sincalide	[no description available]	medium	13	0	oligopeptide
tapentadol	[no description available]	medium	1	0	alkylbenzene
cefditoren	[no description available]	medium	1	0	carboxylic acid; cephalosporin	antibacterial drug
pazopanib	[no description available]	medium	1	0	aminopyrimidine; indazoles; sulfonamide	angiogenesis modulating agent; antineoplastic agent; tyrosine kinase inhibitor; vascular endothelial growth factor receptor antagonist
prasugrel hydrochloride	[no description available]	medium	1	0
bms 477118	[no description available]	medium	1	0	adamantanes; azabicycloalkane; monocarboxylic acid amide; nitrile; tertiary alcohol	EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; hypoglycemic agent
nystatin a1	[no description available]	medium	1	0	nystatins
milnacipran	[no description available]	medium	1	0	acetamides
bivalirudin	[no description available]	medium	1	0	polypeptide	anticoagulant; EC 3.4.21.5 (thrombin) inhibitor
enfuvirtide	[no description available]	medium	1	0
ganirelix	[no description available]	medium	1	0	polypeptide
teriparatide	[no description available]	medium	1	0	polypeptide
salmon calcitonin	[no description available]	medium	1	0	heterodetic cyclic peptide; peptide hormone; polypeptide	bone density conservation agent; metabolite
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ilys-prolyl-alaninamide	[no description available]	medium	1	0	polypeptide
exenatide	[no description available]	medium	1	0
sodium lactate	[no description available]	medium	1	0	lactate salt; organic sodium salt	food acidity regulator; food preservative
sodium iothalamate	[no description available]	medium	1	0
raltegravir	[no description available]	medium	1	0	1,2,4-oxadiazole; dicarboxylic acid amide; hydroxypyrimidine; monofluorobenzenes; pyrimidone; secondary carboxamide	antiviral drug; HIV-1 integrase inhibitor
tipranavir	[no description available]	medium	2	0	sulfonamide	antiviral drug; HIV protease inhibitor
fertinex	[no description available]	medium	1	0
valacyclovir	[no description available]	medium	1	0	L-valyl ester	antiviral drug
citrovorum factor	[no description available]	medium	1	0	tetrahydrofolic acid
rifapentine	[no description available]	medium	1	0	N-alkylpiperazine; N-iminopiperazine; rifamycins	antitubercular agent; leprostatic drug
bl 4162a	[no description available]	medium	1	0	imidazoquinazoline	anticoagulant; antifibrinolytic drug; cardiovascular drug; platelet aggregation inhibitor
pemetrexed	[no description available]	medium	1	0	N-acyl-L-glutamic acid; pyrrolopyrimidine	antimetabolite; antineoplastic agent; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; EC 2.1.1.45 (thymidylate synthase) inhibitor; EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor
valganciclovir	[no description available]	medium	1	0	L-valyl ester; purines	antiviral drug; prodrug
fosaprepitant	[no description available]	medium	1	0	(trifluoromethyl)benzenes; cyclic acetal; morpholines; phosphoramide; triazoles	antiemetic; neurokinin-1 receptor antagonist; prodrug
levomefolate calcium	[no description available]	medium	1	0	organic calcium salt	antidepressant
tramiprosate	[no description available]	medium	1	0	amino sulfonic acid; zwitterion	algal metabolite; anti-inflammatory agent; anticonvulsant; GABA agonist; nootropic agent
4-amino-1,8-naphthalimide	[no description available]	medium	1	0	benzoisoquinoline; dicarboximide
tyrphostin ag 1024	[no description available]	medium	1	0	alkylbenzene
carbonyl cyanide m-chlorophenyl hydrazone	[no description available]	medium	1	0	hydrazone; monochlorobenzenes; nitrile	antibacterial agent; geroprotector; ionophore
ciglitazone	[no description available]	medium	1	0	aromatic ether; thiazolidinone	antineoplastic agent; insulin-sensitizing drug
tyrphostin 8	[no description available]	medium	1	0	phenols
ezogabine	[no description available]	medium	1	0	carbamate ester; organofluorine compound; secondary amino compound; substituted aniline	anticonvulsant; potassium channel modulator
3,5-bis(trifluoromethyl)benzyl n-acetyltryptophan	[no description available]	medium	1	0
pomalidomide	[no description available]	medium	1	0	aromatic amine; dicarboximide; isoindoles; piperidones	angiogenesis inhibitor; antineoplastic agent; immunomodulator
sodium dichloroacetate	[no description available]	medium	1	0
curcumin	[no description available]	medium	5	0	aromatic ether; beta-diketone; diarylheptanoid; enone; polyphenol	anti-inflammatory agent; antifungal agent; antineoplastic agent; biological pigment; contraceptive drug; dye; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor; EC 1.8.1.9 (thioredoxin reductase) inhibitor; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; flavouring agent; food colouring; geroprotector; hepatoprotective agent; immunomodulator; iron chelator; ligand; lipoxygenase inhibitor; metabolite; neuroprotective agent; nutraceutical; radical scavenger
kaempferol	[no description available]	medium	1	0	7-hydroxyflavonol; flavonols; tetrahydroxyflavone	antibacterial agent; geroprotector; human blood serum metabolite; human urinary metabolite; human xenobiotic metabolite; plant metabolite
dorzolamide	[no description available]	medium	1	0	sulfonamide; thiophenes	antiglaucoma drug; antihypertensive agent; EC 4.2.1.1 (carbonic anhydrase) inhibitor
stiripentol	[no description available]	medium	1	0
bosutinib	[no description available]	medium	1	0	aminoquinoline; aromatic ether; dichlorobenzene; N-methylpiperazine; nitrile; tertiary amino compound	antineoplastic agent; tyrosine kinase inhibitor
furaltadon	[no description available]	medium	1	0
3-aminopyridine-2-carboxaldehyde thiosemicarbazone	[no description available]	medium	1	0
tryprostatin a	[no description available]	medium	1	0	aromatic ether; dipeptide; indole alkaloid; indoles; pyrrolopyrazine	breast cancer resistance protein inhibitor
tryptamine	[no description available]	medium	2	0	aminoalkylindole; aralkylamino compound; indole alkaloid; tryptamines	human metabolite; mouse metabolite; plant metabolite
8-hydroxy-2-(di-n-propylamino)tetralin	[no description available]	medium	9	0	phenols; tertiary amino compound; tetralins	serotonergic antagonist
4-iodo-2,5-dimethoxyphenylisopropylamine	[no description available]	medium	5	0	amphetamines; dimethoxybenzene; organoiodine compound
monomethylpropion	[no description available]	medium	34	0	aromatic ketone; secondary amino compound
3,4-methylenedioxyamphetamine	[no description available]	medium	130	0	benzodioxoles
3,4-methylenedioxyamphetamine	[no description available]	medium	130	8	benzodioxoles
fenfluramine	[no description available]	medium	53	0	(trifluoromethyl)benzenes; secondary amino compound	appetite depressant; serotonergic agonist; serotonin uptake inhibitor
fenfluramine	[no description available]	medium	53	1	(trifluoromethyl)benzenes; secondary amino compound	appetite depressant; serotonergic agonist; serotonin uptake inhibitor
octopamine	[no description available]	medium	6	0	phenylethanolamines; tyramines	neurotransmitter
etryptamine	[no description available]	medium	2	0	indoles
indopan	[no description available]	medium	1	0	tryptamines
2,4,5-trimethoxyphenylisopropylamine	[no description available]	medium	1	0
2,5-dimethoxy-4-bromoamphetamine	[no description available]	medium	3	0
cathinone	[no description available]	medium	93	0	2-aminopropiophenone; monoamine alkaloid	central nervous system stimulant; psychotropic drug
cathinone	[no description available]	medium	93	1	2-aminopropiophenone; monoamine alkaloid	central nervous system stimulant; psychotropic drug
2,5-dimethoxyamphetamine	[no description available]	medium	1	0
2-(2,5-dimethoxyphenyl)ethanamine	[no description available]	medium	1	0	dimethoxybenzene
2,5-dimethoxy-4-methylamphetamine	[no description available]	medium	1	0
4-methoxymethamphetamine	[no description available]	medium	32	0
3-methoxyamphetamine	[no description available]	medium	1	0
n-desmethylmethoxyphenamine	[no description available]	medium	5	0
8-methoxy-2-(di-n-propylamino)tetralin	[no description available]	medium	1	0
sk&f 10047	[no description available]	medium	1	0
8-hydroxy-2-(di-n-propylamino)tetralin, (r)-isomer	[no description available]	medium	1	0	tetralins
ms-245	[no description available]	medium	1	0
4-iodo-2,5-dimethoxyphenylisopropylamine, (r)-isomer	[no description available]	medium	1	0
mephedrone	[no description available]	high	364	0	amphetamines; aromatic ketone; secondary amino compound	environmental contaminant; xenobiotic
mephedrone	[no description available]	high	364	3	amphetamines; aromatic ketone; secondary amino compound	environmental contaminant; xenobiotic
pyrophosphate	[no description available]	medium	1	1	diphosphate ion
cytidine	[no description available]	medium	1	1	cytidines	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
cytidine diphosphate choline	[no description available]	medium	3	3	nucleotide-(amino alcohol)s; phosphocholines	human metabolite; mouse metabolite; neuroprotective agent; psychotropic drug; Saccharomyces cerevisiae metabolite
buprenorphine	[no description available]	medium	31	5	morphinane alkaloid	delta-opioid receptor antagonist; kappa-opioid receptor antagonist; mu-opioid receptor agonist; opioid analgesic
alpha-synuclein	[no description available]	medium	34	0
bay-k-8644	[no description available]	medium	4	0	(trifluoromethyl)benzenes; C-nitro compound; dihydropyridine; methyl ester
methane	[no description available]	medium	8	0	alkane; gas molecular entity; mononuclear parent hydride; one-carbon compound	bacterial metabolite; fossil fuel; greenhouse gas
jwh-210	[no description available]	medium	2	0	indolecarboxamide
4-butyrolactone	[no description available]	medium	11	0	butan-4-olide	metabolite; neurotoxin
sodium oxybate	[no description available]	medium	41	1
melatonin	[no description available]	medium	44	0	acetamides; tryptamines	anticonvulsant; central nervous system depressant; geroprotector; hormone; human metabolite; immunological adjuvant; mouse metabolite; radical scavenger
sch 23390	[no description available]	medium	50	0	benzazepine
lactoferrin	[no description available]	medium	1	0
mitragynine	[no description available]	medium	3	0	monoterpenoid indole alkaloid
parthenolide	[no description available]	medium	2	0	germacranolide
sesquiterpenes	[no description available]	medium	2	0
cariprazine	[no description available]	medium	2	0
piracetam	[no description available]	medium	6	0	organonitrogen compound; organooxygen compound
oxidopamine	[no description available]	medium	103	0	benzenetriol; catecholamine; primary amino compound	drug metabolite; human metabolite; neurotoxin
3,4-dihydroxyphenylacetic acid	[no description available]	medium	184	0	catechols; dihydroxyphenylacetic acid	human metabolite
homovanillic acid	[no description available]	medium	98	2	guaiacols; monocarboxylic acid	human metabolite; mouse metabolite
naphyrone	[no description available]	medium	9	0
rotenolone	[no description available]	medium	1	0	organic molecular entity	metabolite
rotenone	[no description available]	medium	6	0	organic heteropentacyclic compound; rotenones	antineoplastic agent; metabolite; mitochondrial NADH:ubiquinone reductase inhibitor; phytogenic insecticide; piscicide; toxin
ruthenium	[no description available]	medium	1	0	iron group element atom; platinum group metal atom
ubiquinone	[no description available]	medium	4	0
piperidines	[no description available]	medium	102	2
ifenprodil	[no description available]	medium	10	2	piperidines
mandrax	[no description available]	medium	1	0	diarylmethane
silver	[no description available]	medium	15	0	copper group element atom; elemental silver	Escherichia coli metabolite
ly 274614	[no description available]	medium	2	0
etizolam	[no description available]	medium	1	0	organic molecular entity
divinyl benzene	[no description available]	medium	1	0	styrenes
n,alpha-diethylphenylethylamine	[no description available]	medium	5	0	amphetamines
baohuoside i	[no description available]	medium	1	0	glycosyloxyflavone	anti-inflammatory agent; antineoplastic agent; apoptosis inducer; plant metabolite
platinum	[no description available]	medium	2	0	elemental platinum; nickel group element atom; platinum group metal atom
cannabidiolic acid	[no description available]	medium	1	0	dihydroxybenzoic acid; phytocannabinoid; polyketide; resorcinols
nitrous oxide	[no description available]	medium	2	0	gas molecular entity; nitrogen oxide	analgesic; bacterial metabolite; food packaging gas; food propellant; general anaesthetic; greenhouse gas; inhalation anaesthetic; NMDA receptor antagonist; raising agent; refrigerant; vasodilator agent
limestone	[no description available]	medium	6	0	calcium salt; carbonate salt; inorganic calcium salt; one-carbon compound	antacid; fertilizer; food colouring; food firming agent
dantrolene	[no description available]	medium	4	0	hydrazone; imidazolidine-2,4-dione	muscle relaxant; neuroprotective agent; ryanodine receptor antagonist
famprofazone	[no description available]	medium	16	1	pyrazoles; ring assembly
ammonium hydroxide	[no description available]	medium	16	0	azane; gas molecular entity; mononuclear parent hydride	EC 3.5.1.4 (amidase) inhibitor; metabolite; mouse metabolite; neurotoxin; NMR chemical shift reference compound; nucleophilic reagent; refrigerant
buprenorphine, naloxone drug combination	[no description available]	medium	1	1
2-methylpentane	[no description available]	medium	2	0	alkane
tramadol	[no description available]	medium	10	1	2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol	adrenergic uptake inhibitor; antitussive; capsaicin receptor antagonist; delta-opioid receptor agonist; kappa-opioid receptor agonist; metabolite; mu-opioid receptor agonist; muscarinic antagonist; nicotinic antagonist; NMDA receptor antagonist; opioid analgesic; serotonergic antagonist; serotonin uptake inhibitor
aminopropionitrile	[no description available]	medium	1	0	aminopropionitrile	antineoplastic agent; antirheumatic drug; collagen cross-linking inhibitor; plant metabolite
elastin	[no description available]	medium	1	0	oligopeptide
psilocybin	[no description available]	medium	16	4	organic phosphate; tertiary amino compound; tryptamine alkaloid	fungal metabolite; hallucinogen; prodrug; serotonergic agonist
racemetirosine	[no description available]	medium	24	0
gold	[no description available]	medium	22	0	copper group element atom; elemental gold
2-ethylammonio-1-(3,4-methylenedioxyphenyl)propane-1-one chloride	[no description available]	medium	4	0
3-methylmethcathinone	[no description available]	medium	16	0
nitrites	[no description available]	medium	5	0	monovalent inorganic anion; nitrogen oxoanion; reactive nitrogen species	human metabolite
acridine orange	[no description available]	medium	1	0	aminoacridines; aromatic amine; tertiary amino compound	fluorochrome; histological dye
ethidium	[no description available]	medium	1	0	phenanthridines	fluorochrome; intercalator
propidium	[no description available]	medium	3	0	phenanthridines; quaternary ammonium ion	fluorochrome; intercalator
losartan potassium	[no description available]	medium	1	0
lysine	[no description available]	medium	3	0	aspartate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; lysine; organic molecular entity; proteinogenic amino acid	algal metabolite; anticonvulsant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
mannans	[no description available]	medium	2	0
kynurenic acid	[no description available]	medium	3	0	monohydroxyquinoline; quinolinemonocarboxylic acid	G-protein-coupled receptor agonist; human metabolite; neuroprotective agent; nicotinic antagonist; NMDA receptor antagonist; Saccharomyces cerevisiae metabolite
kynurenine	[no description available]	medium	2	0	aromatic ketone; non-proteinogenic alpha-amino acid; substituted aniline	human metabolite
fluorescein	[no description available]	medium	4	0	2-benzofurans; gamma-lactone; organic heteropentacyclic compound; oxaspiro compound; polyphenol; xanthene dye	fluorescent dye; radioopaque medium
ninhydrin	[no description available]	medium	1	0	aromatic ketone; beta-diketone; indanones; ketone hydrate	colour indicator; human metabolite
arabitol	[no description available]	medium	1	0	arabinitol
nad	[no description available]	medium	2	0	organophosphate oxoanion	cofactor; human metabolite; hydrogen acceptor; Saccharomyces cerevisiae metabolite
lysergic acid diethylamide	[no description available]	medium	71	2	ergoline alkaloid; monocarboxylic acid amide; organic heterotetracyclic compound	dopamine agonist; hallucinogen; serotonergic agonist
lisdexamfetamine dimesylate	[no description available]	medium	5	5
methylone	[no description available]	medium	105	0	benzodioxoles
dalteparin	[no description available]	medium	1	0
ractopamine	[no description available]	medium	1	0	benzyl alcohols; polyphenol; secondary alcohol; secondary amino compound
4-aminospiroperidol	[no description available]	medium	1	0
gadolinium	[no description available]	medium	4	0	f-block element atom; lanthanoid atom
cytidine monophosphate	[no description available]	medium	1	0	cytidine 5'-phosphate; pyrimidine ribonucleoside 5'-monophosphate	Escherichia coli metabolite; human metabolite; mouse metabolite
sildenafil citrate	[no description available]	medium	16	0	citrate salt	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent
emtricitabine, tenofovir disoproxil fumarate drug combination	[no description available]	medium	2	0
acrylic acid	[no description available]	medium	2	0	alpha,beta-unsaturated monocarboxylic acid	metabolite
diethylaminosulfur trifluoride	[no description available]	medium	1	0
lithium	[no description available]	medium	22	1	alkali metal atom
psilocin	[no description available]	medium	2	0	hydroxyindoles; phenols; tertiary amino compound; tryptamine alkaloid	drug metabolite; fungal metabolite; hallucinogen; human xenobiotic metabolite; serotonergic agonist
clephedrone	[no description available]	medium	2	0
obeticholic acid	[no description available]	medium	1	0	3alpha-hydroxy steroid; 7alpha-hydroxy steroid; dihydroxy-5beta-cholanic acid	farnesoid X receptor agonist; hepatoprotective agent
mdl 100907	[no description available]	medium	10	0
hydroxyethyl methacrylate	[no description available]	medium	1	0	enoate ester	allergen; polymerisation monomer
venlafaxine hydrochloride	[no description available]	medium	2	0	hydrochloride
lignin	[no description available]	medium	1	0
dihydroconiferyl alcohol	[no description available]	medium	1	0	eugenol; primary alcohol	plant metabolite
fenethylline	[no description available]	medium	4	0	oxopurine
rhyncophylline	[no description available]	medium	7	0
vanillic acid	[no description available]	medium	1	0	methoxybenzoic acid; monohydroxybenzoic acid	plant metabolite
dextrorphan	[no description available]	medium	2	0	morphinane alkaloid
vasoactive intestinal peptide	[no description available]	medium	3	0
ginsenoside re	[no description available]	medium	4	0	12beta-hydroxy steroid; 3beta-hydroxy-4,4-dimethylsteroid; 3beta-hydroxy steroid; beta-D-glucoside; disaccharide derivative; ginsenoside; tetracyclic triterpenoid	anti-inflammatory agent; antineoplastic agent; antioxidant; nephroprotective agent; neuroprotective agent; plant metabolite
ginsenosides	[no description available]	medium	10	0
y 27632	[no description available]	medium	2	0	aromatic amide
zinc oxide	[no description available]	medium	1	0	zinc molecular entity
catechin	[no description available]	medium	3	0	catechin	antioxidant; plant metabolite
epigallocatechin gallate	[no description available]	medium	3	0	flavans; gallate ester; polyphenol	antineoplastic agent; antioxidant; apoptosis inducer; geroprotector; Hsp90 inhibitor; neuroprotective agent; plant metabolite
quinone methide	[no description available]	medium	1	0	quinomethane
dynorphins	[no description available]	medium	27	0
phosphorus	[no description available]	medium	10	0	monoatomic phosphorus; nonmetal atom; pnictogen	macronutrient
xylazine	[no description available]	medium	2	0	1,3-thiazine; methylbenzene; secondary amino compound	alpha-adrenergic agonist; analgesic; emetic; muscle relaxant; sedative
lead	[no description available]	medium	6	0	carbon group element atom; elemental lead; metal atom	neurotoxin
metergoline	[no description available]	medium	2	0	carbamate ester; ergoline alkaloid	dopamine agonist; geroprotector; serotonergic antagonist
dizocilpine maleate	[no description available]	medium	110	0	maleate salt; tetracyclic antidepressant	anaesthetic; anticonvulsant; neuroprotective agent; nicotinic antagonist; NMDA receptor antagonist
atrolactic acid	[no description available]	medium	3	0	2-hydroxy monocarboxylic acid
tetrahydropalmatine	[no description available]	medium	9	0
rottlerin	[no description available]	medium	4	0	aromatic ketone; benzenetriol; chromenol; enone; methyl ketone	anti-allergic agent; antihypertensive agent; antineoplastic agent; apoptosis inducer; K-ATP channel agonist; metabolite
pentylone	[no description available]	medium	6	0
sepharose	[no description available]	medium	1	0
benzoylecgonine	[no description available]	medium	38	1	benzoate ester; tropane alkaloid	epitope; human xenobiotic metabolite; marine xenobiotic metabolite; plant metabolite
glucose, (beta-d)-isomer	[no description available]	medium	4	0	D-glucopyranose	epitope; mouse metabolite
lipid a	[no description available]	medium	3	0	dodecanoate ester; lipid A; tetradecanoate ester	Escherichia coli metabolite
ibudilast	[no description available]	medium	10	4	pyrazolopyridine
pituitrin	[no description available]	medium	8	0
hydrogen	[no description available]	medium	2	0	elemental hydrogen; elemental molecule; gas molecular entity	antioxidant; electron donor; food packaging gas; fuel; human metabolite
malondialdehyde	[no description available]	medium	21	0	dialdehyde	biomarker
pyrroles	[no description available]	medium	10	0	pyrrole; secondary amine
thiazolidines	[no description available]	medium	2	0	thiazolidine
carfentanil	[no description available]	medium	1	0	methyl ester; piperidines; tertiary amino compound; tertiary carboxamide	mu-opioid receptor agonist; opioid analgesic; tranquilizing drug
3,4-methylenedioxyethamphetamine	[no description available]	medium	29	3	benzodioxoles; secondary amino compound
cellulose	[no description available]	medium	5	0	glycoside
3-fluoromethcathinone	[no description available]	medium	3	1
4-fluoromethcathinone	[no description available]	medium	8	1
4-methylethcathinone	[no description available]	medium	9	0	aromatic ketone
pentedrone	[no description available]	medium	9	0
gastrodin	[no description available]	medium	2	0	glycoside
6-o-monoacetylmorphine	[no description available]	medium	12	0	morphinane alkaloid
resveratrol	[no description available]	medium	4	0	resveratrol	antioxidant; phytoalexin; plant metabolite; quorum sensing inhibitor; radical scavenger
lb-100	[no description available]	medium	3	0
luteolin	[no description available]	medium	2	0	3'-hydroxyflavonoid; tetrahydroxyflavone	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; c-Jun N-terminal kinase inhibitor; EC 2.3.1.85 (fatty acid synthase) inhibitor; immunomodulator; nephroprotective agent; plant metabolite; radical scavenger; vascular endothelial growth factor receptor antagonist
malachite green	[no description available]	medium	1	0	organic chloride salt	antibacterial agent; antifungal drug; carcinogenic agent; environmental contaminant; fluorochrome; histological dye; teratogenic agent
c.i. 42510	[no description available]	medium	2	0
anthracene	[no description available]	medium	1	0	acene; anthracenes; ortho-fused tricyclic hydrocarbon
adamantane	[no description available]	medium	3	0	adamantanes; polycyclic alkane
thiophenes	[no description available]	medium	25	0	mancude organic heteromonocyclic parent; monocyclic heteroarene; thiophenes; volatile organic compound	non-polar solvent
AKB48	[no description available]	medium	1	0	aromatic amide; indazoles
indazoles	[no description available]	medium	15	0	indazole
lupenone	[no description available]	medium	1	0	triterpenoid	metabolite
atazanavir sulfate	[no description available]	medium	3	0	organic sulfate salt
2-tert-butylhydroquinone	[no description available]	medium	3	0	hydroquinones	food antioxidant
interleukin-8	[no description available]	medium	5	0
3,4-dimethylmethcathinone	[no description available]	medium	1	0	aromatic ketone
hydroxyindoleacetic acid	[no description available]	medium	73	3	indole-3-acetic acids	drug metabolite; human metabolite; mouse metabolite
serine	[no description available]	medium	10	0	L-alpha-amino acid; proteinogenic amino acid; serine family amino acid; serine zwitterion; serine	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
enkephalin, leucine	[no description available]	medium	24	0	pentapeptide; peptide zwitterion	analgesic; delta-opioid receptor agonist; human metabolite; mu-opioid receptor agonist; neurotransmitter; rat metabolite
preproenkephalin	[no description available]	medium	18	0
duloxetine hydrochloride	[no description available]	medium	1	0	duloxetine hydrochloride	antidepressant
benzoxazoles	[no description available]	medium	9	0	1,3-benzoxazoles; mancude organic heterobicyclic parent
sb 334867-a	[no description available]	medium	3	0	naphthyridine derivative
itraconazole	[no description available]	medium	2	1	aromatic ether; conazole antifungal drug; cyclic ketal; dichlorobenzene; dioxolane; N-arylpiperazine; triazole antifungal drug; triazoles	EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor; Hedgehog signaling pathway inhibitor; P450 inhibitor
alanine	[no description available]	medium	8	0	alanine zwitterion; alanine; L-alpha-amino acid; proteinogenic amino acid; pyruvate family amino acid	EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor; fundamental metabolite
safinamide	[no description available]	medium	1	0	amino acid amide
betadex	[no description available]	medium	6	0	cyclodextrin
valine	[no description available]	medium	3	0	L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid; pyruvate family amino acid; valine	algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
ethylphenidate	[no description available]	medium	3	0
cholecystokinin	[no description available]	medium	13	0
ro 25-6981	[no description available]	medium	2	0	benzenes; phenols; piperidines; secondary alcohol; tertiary amino compound	anticonvulsant; antidepressant; neuroprotective agent; NMDA receptor antagonist
neuropeptide y	[no description available]	medium	14	0
neuropeptide y, leu(31)-pro(34)-	[no description available]	medium	1	0
neuropeptide y (13-36)	[no description available]	medium	1	0
l 745870	[no description available]	medium	2	0	piperazines
urb 597	[no description available]	medium	3	0	biphenyls
carbamates	[no description available]	medium	5	0	amino-acid anion
1-phenyl-2-propanone	[no description available]	medium	8	0	methyl ketone; propanones
phenyl-n-tert-butylnitrone	[no description available]	medium	5	0
n-methylphenethylamine	[no description available]	medium	15	0
quetiapine fumarate	[no description available]	medium	10	2	fumarate salt
proline	[no description available]	medium	5	0	amino acid zwitterion; glutamine family amino acid; L-alpha-amino acid; proline; proteinogenic amino acid	algal metabolite; compatible osmolytes; Escherichia coli metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
dimethoxyphenylethylamine	[no description available]	medium	3	0	alkaloid; aromatic ether; phenylethylamine	allergen; plant metabolite
bromochloroacetic acid	[no description available]	medium	1	0	2-bromocarboxylic acid; monocarboxylic acid; organochlorine compound
2-(4-iodo-2,5-dimethoxyphenyl)-n-(2-methoxybenzyl)ethanamine	[no description available]	medium	1	0
taurochenodeoxycholic acid	[no description available]	medium	1	0	bile acid taurine conjugate	human metabolite; mouse metabolite
ursodoxicoltaurine	[no description available]	medium	1	0	bile acid taurine conjugate	anti-inflammatory agent; apoptosis inhibitor; bone density conservation agent; cardioprotective agent; human metabolite; neuroprotective agent
aromadedrin	[no description available]	medium	1	0	4'-hydroxyflavanones; dihydroflavonols; secondary alpha-hydroxy ketone; tetrahydroxyflavanone	metabolite
2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline	[no description available]	medium	5	0	naphthalenes; sulfonic acid derivative
quinoxalines	[no description available]	medium	15	2	mancude organic heterobicyclic parent; naphthyridine; ortho-fused heteroarene
pholedrine	[no description available]	medium	134	0	amphetamines
s-nitrosocysteine	[no description available]	medium	2	0	L-cysteine derivative; nitrosothio compound	hematologic agent; platelet aggregation inhibitor; vasodilator agent
cysteine	[no description available]	medium	3	0	cysteinium	fundamental metabolite
1-phenyl-2-(1-pyrrolidinyl)-1-pentanone	[no description available]	medium	5	0
lorcaserin	[no description available]	medium	2	1	benzazepine; organochlorine compound	anti-obesity agent; appetite depressant
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one	[no description available]	medium	2	0	chromones; morpholines; organochlorine compound	autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector
erythrosine	[no description available]	medium	17	0
6,7-dihydroxyflavone	[no description available]	medium	3	0
methacrylic acid	[no description available]	medium	1	0	alpha,beta-unsaturated monocarboxylic acid
hydroxide ion	[no description available]	medium	1	0	oxygen hydride	mouse metabolite
2,2,2-trifluoroethyl allyl ether	[no description available]	medium	1	0
mosher's acid	[no description available]	medium	1	0
beta-endorphin	[no description available]	medium	1	0
almorexant	[no description available]	medium	1	0	isoquinolines
roflumilast	[no description available]	medium	1	0	aromatic ether; benzamides; chloropyridine; cyclopropanes; organofluorine compound	anti-asthmatic drug; phosphodiesterase IV inhibitor
alpha-aminopyridine	[no description available]	medium	4	0
metoprine	[no description available]	medium	1	0
tiletamine hydrochloride	[no description available]	medium	4	0
2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone	[no description available]	medium	3	0
pifithrin	[no description available]	medium	2	0	aromatic ketone
n-cyclopropyl-5-(thiophen-2-yl)isoxazole-3-carboxamide	[no description available]	medium	1	0	aromatic amide; heteroarene
isoxazoles	[no description available]	medium	3	0	isoxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
am 251	[no description available]	medium	10	0	amidopiperidine; carbohydrazide; dichlorobenzene; organoiodine compound; pyrazoles	antidepressant; antineoplastic agent; apoptosis inducer; CB1 receptor antagonist
u 0126	[no description available]	medium	3	0	aryl sulfide; dinitrile; enamine; substituted aniline	antineoplastic agent; antioxidant; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; osteogenesis regulator; vasoconstrictor agent
methylazoxymethanol acetate	[no description available]	medium	6	0	azoxy compound
methylazoxymethanol	[no description available]	medium	5	0	azoxy compound
cp 94253	[no description available]	medium	2	0	pyrrolopyridine
oxazolidin-2-one	[no description available]	medium	1	0	carbamate ester; oxazolidinone	metabolite
cytochrome c-t	[no description available]	medium	11	0
n-methylalanine	[no description available]	medium	1	0	amino acid zwitterion; methyl-L-alanine
deuterium	[no description available]	medium	15	1	dihydrogen
neurotensin	[no description available]	medium	38	0	peptide hormone	human metabolite; mitogen; neurotransmitter; vulnerary
tranylcypromine	[no description available]	medium	30	0	2-phenylcyclopropan-1-amine
sarcosine	[no description available]	medium	1	0	N-alkylglycine zwitterion; N-alkylglycine; N-methyl-amino acid; N-methylglycines	Escherichia coli metabolite; glycine receptor agonist; glycine transporter 1 inhibitor; human metabolite; mouse metabolite
sarkosyl	[no description available]	medium	1	0
deoxyguanosine	[no description available]	medium	6	0	purine 2'-deoxyribonucleoside; purines 2'-deoxy-D-ribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
8-hydroxy-2'-deoxyguanosine	[no description available]	medium	7	0	guanosines	biomarker
rimcazole	[no description available]	medium	2	0	carbazoles
cystine	[no description available]	medium	3	0
n-monoacetylcystine	[no description available]	medium	1	0
norketamine	[no description available]	medium	4	0	organochlorine compound
glycolipids	[no description available]	medium	1	0
clenbuterol	[no description available]	medium	1	0	amino alcohol; dichlorobenzene; ethanolamines; primary arylamine; secondary amino compound; substituted aniline	beta-adrenergic agonist; bronchodilator agent; sympathomimetic agent
lobeline	[no description available]	medium	26	0
4-fluoroamphetamine	[no description available]	medium	2	0
benzofurans	[no description available]	medium	15	0
threonine	[no description available]	medium	3	0	amino acid zwitterion; aspartate family amino acid; L-alpha-amino acid; proteinogenic amino acid; threonine	algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
oxilofrine	[no description available]	medium	1	0	alkylbenzene
4-methoxyamphetamine	[no description available]	medium	19	0
2-(4-bromo-2,5-dimethoxyphenyl)ethylamine	[no description available]	medium	2	0	2-arylethylamine
4-methoxymethcathinone	[no description available]	medium	3	0
2,5-dimethoxy-4-n-propylthiophenethylamine	[no description available]	medium	1	0
2-(4-chloro-2,5-dimethoxyphenyl)-n-((2-methoxyphenyl)methyl)ethanamine	[no description available]	medium	2	0
marfey's reagent	[no description available]	medium	4	0
dinitrobenzenes	[no description available]	medium	5	0
fg 7142	[no description available]	medium	3	0	beta-carbolines
pexacerfont	[no description available]	medium	1	1	pyrazolopyridine
heparitin sulfate	[no description available]	medium	1	0
nitroarginine	[no description available]	medium	5	0	guanidines; L-arginine derivative; N-nitro compound; non-proteinogenic L-alpha-amino acid
propane	[no description available]	medium	4	0	alkane; gas molecular entity	food propellant
butane	[no description available]	medium	2	0	alkane; gas molecular entity	food propellant; refrigerant
saccharin	[no description available]	medium	10	0	1,2-benzisothiazole; N-sulfonylcarboxamide	environmental contaminant; sweetening agent; xenobiotic
enkephalin, ala(2)-mephe(4)-gly(5)-	[no description available]	medium	8	0
oxazoles	[no description available]	medium	16	1	1,3-oxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
thiobarbituric acid	[no description available]	medium	2	0	barbiturates	allergen; reagent
asiatic acid	[no description available]	medium	1	0	monocarboxylic acid; pentacyclic triterpenoid; triol	angiogenesis modulating agent; metabolite
natriuretic peptide, brain	[no description available]	medium	3	0	polypeptide
relcovaptan	[no description available]	medium	1	0	proline derivative
vasotocin, desgly(nh2)(9)d(ch2)5-tyr(me)(2)-thr(4)-orn(8)-	[no description available]	medium	1	0
2-(2,3-dicarboxycyclopropyl)glycine	[no description available]	medium	1	0
colforsin	[no description available]	medium	6	0	acetate ester; cyclic ketone; labdane diterpenoid; organic heterotricyclic compound; tertiary alpha-hydroxy ketone; triol	adenylate cyclase agonist; anti-HIV agent; antihypertensive agent; plant metabolite; platelet aggregation inhibitor; protein kinase A agonist
tak-063	[no description available]	medium	2	0
ethylamphetamine	[no description available]	medium	4	0	amphetamines
2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine	[no description available]	medium	2	0
gw 1000	[no description available]	medium	1	0
l 733060	[no description available]	medium	3	0	piperidines
substance p	[no description available]	medium	26	0	peptide	neurokinin-1 receptor agonist; neurotransmitter; vasodilator agent
isospaglumic acid	[no description available]	medium	3	0	dipeptide	human metabolite
lactulose	[no description available]	medium	4	0
tetrodotoxin	[no description available]	medium	4	0	azatetracycloalkane; oxatetracycloalkane; quinazoline alkaloid	animal metabolite; bacterial metabolite; marine metabolite; neurotoxin; voltage-gated sodium channel blocker
ginsenoside rb1	[no description available]	medium	1	0	ginsenoside; glycoside; tetracyclic triterpenoid	anti-inflammatory drug; anti-obesity agent; apoptosis inhibitor; neuroprotective agent; plant metabolite; radical scavenger
bafilomycin a1	[no description available]	medium	1	0	cyclic hemiketal; macrolide antibiotic; oxanes	apoptosis inducer; autophagy inhibitor; bacterial metabolite; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; EC 3.6.3.14 (H(+)-transporting two-sector ATPase) inhibitor; ferroptosis inhibitor; fungicide; potassium ionophore; toxin
cobalt	[no description available]	medium	2	0	cobalt group element atom; metal allergen	micronutrient
n-acetylaspartic acid	[no description available]	medium	18	1	N-acetyl-L-amino acid; N-acyl-L-aspartic acid	antioxidant; human metabolite; mouse metabolite; nutraceutical; rat metabolite
dimethylamphetamine	[no description available]	medium	32	0	amphetamines
mocetinostat	[no description available]	medium	3	0	aminopyrimidine; benzamides; pyridines; secondary amino compound; secondary carboxamide; substituted aniline	antineoplastic agent; apoptosis inducer; autophagy inducer; cardioprotective agent; EC 3.5.1.98 (histone deacetylase) inhibitor; hepatotoxic agent
agmatine	[no description available]	medium	5	0	guanidines; primary amino compound	Escherichia coli metabolite; mouse metabolite
estradiol 3-benzoate	[no description available]	medium	3	0	17beta-hydroxy steroid; benzoate ester	estrogen receptor agonist; xenoestrogen
calpastatin	[no description available]	medium	4	0	polypeptide	EC 3.4.22.52 (calpain-1) inhibitor; EC 3.4.22.53 (calpain-2) inhibitor
raclopride	[no description available]	medium	33	1	salicylamides
muscimol	[no description available]	medium	6	0	alkaloid; isoxazoles; primary amino compound	fungal metabolite; GABA agonist; oneirogen; psychotropic drug
blister	[no description available]	medium	5	0	cyclic ketone; pyrroloquinoline; tertiary alcohol; tertiary alpha-hydroxy ketone	inhibitor
crocin	[no description available]	medium	1	0
n-acetylcysteinamide	[no description available]	medium	4	0
triazoles	[no description available]	medium	3	0	1,2,3-triazole
18-crown-6 2,3,11,12-tetracarboxylic acid	[no description available]	medium	1	0
2-methylamino-1-(3,4-methylenedioxyphenyl)butan-1-one	[no description available]	medium	5	0	butanone
(3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid	[no description available]	medium	1	0	(6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
5,6-methylenedioxy-2-aminoindane	[no description available]	medium	4	0	benzodioxoles
ammonium nitrate	[no description available]	medium	1	0	ammonium salt; inorganic molecular entity; inorganic nitrate salt	explosive; fertilizer; oxidising agent
nitrates	[no description available]	medium	11	0	monovalent inorganic anion; nitrogen oxoanion; reactive nitrogen species
jzl 184	[no description available]	medium	2	0	benzodioxoles
sazetidine-a	[no description available]	medium	1	0
desmethylselegiline	[no description available]	medium	21	8
lithium chloride	[no description available]	medium	9	0	inorganic chloride; lithium salt	antimanic drug; geroprotector
stilbenes	[no description available]	medium	3	0	stilbene
ro13-9904	[no description available]	medium	5	0
zeolites	[no description available]	medium	1	0
berberine	[no description available]	medium	3	0	alkaloid antibiotic; berberine alkaloid; botanical anti-fungal agent; organic heteropentacyclic compound	antilipemic drug; antineoplastic agent; antioxidant; EC 1.1.1.141 [15-hydroxyprostaglandin dehydrogenase (NAD(+))] inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.13.11.52 (indoleamine 2,3-dioxygenase) inhibitor; EC 1.21.3.3 (reticuline oxidase) inhibitor; EC 2.1.1.116 [3'-hydroxy-N-methyl-(S)-coclaurine 4'-O-methyltransferase] inhibitor; EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor; EC 2.7.11.10 (IkappaB kinase) inhibitor; EC 3.1.1.4 (phospholipase A2) inhibitor; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor; EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; geroprotector; hypoglycemic agent; metabolite; potassium channel blocker
luminol	[no description available]	medium	2	0
n-methylephedrine	[no description available]	medium	3	0	amphetamines
ozone	[no description available]	medium	1	0	elemental molecule; gas molecular entity; reactive oxygen species; triatomic oxygen	antiseptic drug; disinfectant; electrophilic reagent; greenhouse gas; mutagen; oxidising agent; tracer
stepholidine	[no description available]	medium	1	0
ly 341495	[no description available]	medium	4	0
xanthenes	[no description available]	medium	7	0	xanthene
11-nor-delta(9)-tetrahydrocannabinol-9-carboxylic acid	[no description available]	medium	6	1	1-benzopyran
alpha-hydroxymetoprolol	[no description available]	medium	1	0	aromatic ether
o-demethylmetoprolol	[no description available]	medium	1	0
apelin-13 peptide	[no description available]	medium	1	0	oligopeptide	antihypertensive agent; autophagy inhibitor; biomarker; human metabolite; neuroprotective agent
guanosine 5'-o-(3-thiotriphosphate)	[no description available]	medium	3	0	nucleoside triphosphate analogue
bromodeoxyuridine	[no description available]	medium	10	0	pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent
3-nitrotyrosine	[no description available]	medium	13	0	2-nitrophenols; C-nitro compound; nitrotyrosine; non-proteinogenic alpha-amino acid
amyl nitrate	[no description available]	medium	2	0
n,n-dimethylarginine	[no description available]	medium	1	0	dimethylarginine; guanidines; L-arginine derivative; non-proteinogenic L-alpha-amino acid	EC 1.14.13.39 (nitric oxide synthase) inhibitor
n(g),n(g')-dimethyl-l-arginine	[no description available]	medium	1	0	alpha-amino acid
manganese	[no description available]	medium	3	0	elemental manganese; manganese group element atom	Escherichia coli metabolite; micronutrient
anisomycin	[no description available]	medium	4	0	monohydroxypyrrolidine; organonitrogen heterocyclic antibiotic	anticoronaviral agent; antimicrobial agent; antineoplastic agent; antiparasitic agent; bacterial metabolite; DNA synthesis inhibitor; protein synthesis inhibitor
hydrazine	[no description available]	medium	13	0	azane; hydrazines	EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor
sc 51089	[no description available]	medium	1	0
fti 277	[no description available]	medium	1	0
ethyl glucuronide	[no description available]	medium	1	0	beta-D-glucosiduronic acid	human urinary metabolite
jhw 015	[no description available]	medium	3	0	indolecarboxamide
sodium selenite	[no description available]	medium	1	0	inorganic sodium salt; selenite salt	nutraceutical
beta-funaltrexamine	[no description available]	medium	2	0	morphinane alkaloid
oxalates	[no description available]	medium	5	0
istradefylline	[no description available]	medium	1	0	oxopurine
4-methylthioamphetamine	[no description available]	medium	6	0
trypan blue	[no description available]	medium	4	0
blonanserin	[no description available]	medium	1	0	organic molecular entity
sauchinone	[no description available]	medium	2	0
copper gluconate	[no description available]	medium	1	0	organic molecular entity
norethandrolone	[no description available]	medium	1	0	corticosteroid hormone
1-(3-trifluoromethylphenyl)piperazine	[no description available]	medium	4	0	(trifluoromethyl)benzenes; N-arylpiperazine	environmental contaminant; psychotropic drug; serotonergic agonist; xenobiotic
cuprizone	[no description available]	medium	1	0	organonitrogen compound; organooxygen compound
mk 2866	[no description available]	medium	1	0
jwh 018	[no description available]	medium	3	0	indolecarboxamide
pyrovalerone	[no description available]	medium	7	0	aromatic ketone
chrysin	[no description available]	medium	1	0	7-hydroxyflavonol; dihydroxyflavone	anti-inflammatory agent; antineoplastic agent; antioxidant; EC 2.7.11.18 (myosin-light-chain kinase) inhibitor; hepatoprotective agent; plant metabolite
ly 379268	[no description available]	medium	2	0	amino dicarboxylic acid; bridged compound; organic heterobicyclic compound	antipsychotic agent; anxiolytic drug; metabotropic glutamate receptor agonist; neuroprotective agent
pregnane-20-one	[no description available]	medium	1	0
carbostyril	[no description available]	medium	13	3	monohydroxyquinoline; quinolone	bacterial xenobiotic metabolite
geranylgeranylacetone	[no description available]	medium	1	0
latrunculin a	[no description available]	medium	1	0	cyclic hemiketal; macrolide; oxabicycloalkane; thiazolidinone	actin polymerisation inhibitor; metabolite; toxin
paxilline	[no description available]	medium	2	0	diterpene alkaloid; enone; organic heterohexacyclic compound; terpenoid indole alkaloid; tertiary alcohol	anticonvulsant; Aspergillus metabolite; EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor; genotoxin; geroprotector; mycotoxin; Penicillium metabolite; potassium channel blocker
ns 1619	[no description available]	medium	2	0	(trifluoromethyl)benzenes; benzimidazoles; phenols	potassium channel opener
homocarnosine	[no description available]	medium	1	0	dipeptide zwitterion; dipeptide; homocarnosine; L-histidine derivative; N-acyl-L-alpha-amino acid anion; N-acyl-L-alpha-amino acid	human metabolite
pantothenic acid	[no description available]	medium	4	0	pantothenic acid; vitamin B5	antidote to curare poisoning; geroprotector; human blood serum metabolite
carnosine	[no description available]	medium	2	0	amino acid zwitterion; dipeptide	anticonvulsant; antineoplastic agent; antioxidant; Daphnia magna metabolite; geroprotector; human metabolite; mouse metabolite; neuroprotective agent
4-hydroxy-3-methoxymethamphetamine	[no description available]	medium	36	4
n,n-dimethyltryptamine	[no description available]	medium	2	0	tryptamine alkaloid; tryptamines
alpha-chymotrypsin	[no description available]	medium	2	0
calpain	[no description available]	medium	9	0
paraquat	[no description available]	medium	3	0	organic cation	geroprotector; herbicide
sk&f 81297	[no description available]	medium	5	0	benzazepine
jwh-122	[no description available]	medium	1	0
AM2201	[no description available]	medium	1	0	indolecarboxamide
alpha-methylepinine	[no description available]	medium	12	3
3-o-methyl-alpha-methyldopamine	[no description available]	medium	9	0	amphetamines
deoxyepinephrine	[no description available]	medium	12	3	catecholamine
ferric ferrocyanide	[no description available]	medium	1	0
adenosine monophosphate	[no description available]	medium	2	0	adenosine 5'-phosphate; purine ribonucleoside 5'-monophosphate	adenosine A1 receptor agonist; cofactor; EC 3.1.3.1 (alkaline phosphatase) inhibitor; EC 3.1.3.11 (fructose-bisphosphatase) inhibitor; fundamental metabolite; micronutrient; nutraceutical
nickel	[no description available]	medium	2	0	metal allergen; nickel group element atom	epitope; micronutrient
acetovanillone	[no description available]	medium	2	0	acetophenones; aromatic ketone; methyl ketone	antirheumatic drug; EC 1.6.3.1. [NAD(P)H oxidase (H2O2-forming)] inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; peripheral nervous system drug; plant metabolite
tetraisopropylpyrophosphamide	[no description available]	medium	1	0	phosphoramide
sk&f-38393	[no description available]	medium	13	0	benzazepine; catechols; secondary amino compound
n-((1-allyl-2-pyrrolidinyl)methyl)-5-(3-fluoropropyl)-2,3-dimethoxybenzamide	[no description available]	medium	7	0
limonene	[no description available]	medium	1	0	cycloalkene; p-menthadiene	human metabolite
opipramol	[no description available]	medium	3	0	dibenzoazepine
eticlopride	[no description available]	medium	10	0	salicylamides
4-aminopyridine	[no description available]	medium	1	0	aminopyridine; aromatic amine	avicide; orphan drug; potassium channel blocker
margatoxin	[no description available]	medium	1	0
acid phosphatase	[no description available]	medium	1	0
c.i. direct blue 1	[no description available]	medium	2	0
tucaresol	[no description available]	medium	1	0
ng-nitroarginine methyl ester	[no description available]	medium	14	0	alpha-amino acid ester; L-arginine derivative; methyl ester; N-nitro compound	EC 1.14.13.39 (nitric oxide synthase) inhibitor
potassium chloride	[no description available]	medium	12	0	inorganic chloride; inorganic potassium salt; potassium salt	fertilizer
glyceryl 2-arachidonate	[no description available]	medium	3	0	2-acylglycerol 20:4; endocannabinoid	human metabolite
anandamide	[no description available]	medium	3	0	endocannabinoid; N-acylethanolamine 20:4	human blood serum metabolite; neurotransmitter; vasodilator agent
normetanephrine	[no description available]	medium	4	0	catecholamine
n-n-propylnorapomorphine	[no description available]	medium	1	0
rs 504393	[no description available]	medium	1	0	1,3-oxazoles
rti 121	[no description available]	medium	10	0
gamma-cyclodextrin	[no description available]	medium	1	0	cyclodextrin
dithiothreitol	[no description available]	medium	1	0	1,4-dimercaptobutane-2,3-diol; butanediols; dithiol; glycol; thiol	chelator; human metabolite; reducing agent
cocaethylene	[no description available]	medium	4	0	benzoate ester
quinpirole	[no description available]	medium	16	0	pyrazoloquinoline	dopamine agonist
silicon	[no description available]	medium	2	0	carbon group element atom; metalloid atom; nonmetal atom
perfluorooctanoic acid	[no description available]	medium	3	0	fluoroalkanoic acid	carcinogenic agent; endocrine disruptor; environmental contaminant; surfactant; xenobiotic
caprylates	[no description available]	medium	3	0	fatty acid anion 8:0; straight-chain saturated fatty acid anion	human metabolite; Saccharomyces cerevisiae metabolite
propentofylline	[no description available]	medium	3	0	oxopurine
n,n-dipropyl-2-(4-methoxy-3-(2-phenylethoxy)phenyl)ethylamine monohydrochloride	[no description available]	medium	1	0
phenetidine	[no description available]	medium	1	0	aromatic ether; primary amino compound; substituted aniline	drug metabolite
bucetin, caffeine, dibenzoylthiamine, ethenzamide drug combination	[no description available]	medium	1	0
bismuth	[no description available]	medium	1	0	metal atom; pnictogen
mercury	[no description available]	medium	1	0	elemental mercury; zinc group element atom	neurotoxin
peroxynitrous acid	[no description available]	medium	8	0	nitrogen oxoacid
baicalein	[no description available]	medium	2	0	trihydroxyflavone	angiogenesis inhibitor; anti-inflammatory agent; antibacterial agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antioxidant; apoptosis inducer; EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; EC 4.1.1.17 (ornithine decarboxylase) inhibitor; ferroptosis inhibitor; geroprotector; hormone antagonist; plant metabolite; prostaglandin antagonist; radical scavenger
n-methylaspartate	[no description available]	medium	22	1	amino dicarboxylic acid; D-alpha-amino acid; D-aspartic acid derivative; secondary amino compound	neurotransmitter agent
yqa14	[no description available]	medium	2	0
2-(4-(2-carboxyethyl)phenethylamino)-5'-n-ethylcarboxamidoadenosine	[no description available]	medium	5	0	adenosines; dicarboxylic acid monoamide; monocarboxylic acid	adenosine A2A receptor agonist; anti-inflammatory agent
n(6)-cyclopentyladenosine	[no description available]	medium	5	0
maleimide	[no description available]	medium	2	0	dicarboximide; maleimides	EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
5-APB	[no description available]	medium	4	0	benzofurans
acetylcarnitine	[no description available]	medium	5	0	O-acylcarnitine	human metabolite
benzofuran	[no description available]	medium	2	0	1-benzofurans; benzofuran
17-n,n-diethylcarbamoyl-4-methyl-4-azaandrostane-3-one	[no description available]	medium	1	0
dihydrotestosterone	[no description available]	medium	2	0	17beta-hydroxy steroid; 17beta-hydroxyandrostan-3-one; 3-oxo-5alpha-steroid	androgen; Daphnia magna metabolite; human metabolite; mouse metabolite
oxadiazoles	[no description available]	medium	6	0
D-fructopyranose	[no description available]	medium	11	6	cyclic hemiketal; D-fructose; fructopyranose	sweetening agent
1-aminoindan	[no description available]	medium	2	0
2-aminoindan	[no description available]	medium	2	0
arachidonyl-2-chloroethylamide	[no description available]	medium	1	0	fatty amide; organochlorine compound; secondary carboxamide; synthetic cannabinoid	CB1 receptor agonist; CB2 receptor agonist; neuroprotective agent
chlorine	[no description available]	medium	6	0	halide anion; monoatomic chlorine	cofactor; Escherichia coli metabolite; human metabolite
piperonal	[no description available]	medium	1	0	arenecarbaldehyde; benzodioxoles	fragrance; insect repellent; plant metabolite
benzocaine	[no description available]	medium	2	0	benzoate ester; substituted aniline	allergen; antipruritic drug; sensitiser; topical anaesthetic
tipepidine	[no description available]	medium	1	0	piperidines
titanium	[no description available]	medium	1	0	titanium group element atom
titanium dioxide	[no description available]	medium	1	0	titanium oxides	food colouring
4'-methyl-alpha-pyrrolidinopropiophenone	[no description available]	medium	2	0	aromatic ketone
alpha-pyrrolidinopropiophenone	[no description available]	medium	2	0	aromatic ketone
norbinaltorphimine	[no description available]	medium	2	0	isoquinolines
hispidulin	[no description available]	medium	2	0	monomethoxyflavone; trihydroxyflavone	anti-inflammatory agent; anticonvulsant; antineoplastic agent; antioxidant; apoptosis inducer; plant metabolite
dihydropyridines	[no description available]	medium	3	2
3-methoxy-5-pyridin-2-ylethynylpyridine	[no description available]	medium	1	0
imidazole	[no description available]	medium	1	0	imidazole
phosphocreatine	[no description available]	medium	13	0	phosphagen; phosphoamino acid	human metabolite; mouse metabolite
bd 1047	[no description available]	medium	4	0	primary amine
fluorodeoxyglucose f18	[no description available]	medium	11	0	2-deoxy-2-((18)F)fluoro-D-glucose; 2-deoxy-2-fluoro-aldehydo-D-glucose
nitroxyl	[no description available]	medium	1	0	nitrogen oxoacid
dihydrotetrabenazine	[no description available]	medium	9	0	isoquinolines
erbium	[no description available]	medium	1	0	f-block element atom; lanthanoid atom
yttrium	[no description available]	medium	1	0	d-block element atom; rare earth metal atom; scandium group element atom
ytterbium	[no description available]	medium	1	0	f-block element atom; lanthanoid atom
fluorides	[no description available]	medium	2	0	halide anion; monoatomic fluorine
n-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine	[no description available]	medium	4	0
6-(2-aminopropyl)benzofuran	[no description available]	medium	1	0
acetylcellulose	[no description available]	medium	1	0
tris(2-ethylhexyl)phosphate	[no description available]	medium	1	0	trialkyl phosphate
desomorphine	[no description available]	medium	2	0	morphinane alkaloid
fluo-3	[no description available]	medium	1	0	xanthene dye	fluorochrome
luzindole	[no description available]	medium	2	0	acetamides; indoles	melatonin receptor antagonist
methyllycaconitine	[no description available]	medium	5	0
aconitine	[no description available]	medium	5	0
p-chloroamphetamine	[no description available]	medium	26	0
epibatidine	[no description available]	medium	1	0
discretamine	[no description available]	medium	1	0	alkaloid
desoxyepothilone b	[no description available]	medium	1	0	epothilone	microtubule-stabilising agent
epothilone a	[no description available]	medium	1	0	epothilone; epoxide	antineoplastic agent; metabolite; microtubule-stabilising agent; tubulin modulator
n-(2-methoxybenzyl)-n-(4-phenoxypyridin-3-yl)acetamide	[no description available]	medium	1	0
3,4-methylenedioxyphenethylamine	[no description available]	medium	1	0
succinic acid	[no description available]	medium	1	0	alpha,omega-dicarboxylic acid; C4-dicarboxylic acid	anti-ulcer drug; fundamental metabolite; micronutrient; nutraceutical; radiation protective agent
glutaric acid	[no description available]	medium	1	0	alpha,omega-dicarboxylic acid; dicarboxylic fatty acid	Daphnia magna metabolite; human metabolite
adipic acid	[no description available]	medium	1	0	alpha,omega-dicarboxylic acid; dicarboxylic fatty acid	food acidity regulator; human xenobiotic metabolite
endothelin-1	[no description available]	medium	1	0
pd 145065	[no description available]	medium	1	0
3,4-dimethoxyamphetamine	[no description available]	medium	3	0
pseudoginsenoside f11	[no description available]	medium	2	0
thiazoles	[no description available]	medium	18	0	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid	[no description available]	medium	2	0	non-proteinogenic alpha-amino acid
bicuculline	[no description available]	medium	11	0	benzylisoquinoline alkaloid; isoquinoline alkaloid; isoquinolines	agrochemical; central nervous system stimulant; GABA-gated chloride channel antagonist; GABAA receptor antagonist; neurotoxin
3-cyano-n-(1,3-diphenyl-1h-pyrazol-5-yl)benzamide	[no description available]	medium	1	0
1-benzylpiperazine	[no description available]	medium	8	0	N-alkylpiperazine	environmental contaminant; psychotropic drug; serotonergic agonist; xenobiotic
cyclic gmp	[no description available]	medium	8	0	3',5'-cyclic purine nucleotide; guanyl ribonucleotide	Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
trifluoroacetyl chloride	[no description available]	medium	1	0	acyl chloride
2,2'-dipyridyl	[no description available]	medium	2	0	bipyridine	chelator; ferroptosis inhibitor
fluorosulfonic acid	[no description available]	medium	2	0	sulfur oxoacid	NMR solvent
1-(9-fluorenyl)methyl chloroformate	[no description available]	medium	3	0
quinazolines	[no description available]	medium	2	0	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines
n-(1-adamantyl)-1-(5-fluoropentyl)-1h-indazole-3-carboxamide	[no description available]	medium	1	0	aromatic amide; indazoles
3,4-dihydroxyphenylglycol	[no description available]	medium	1	0	catechols; tetrol	metabolite; mouse metabolite
methoxyhydroxyphenylglycol	[no description available]	medium	11	2	methoxybenzenes; phenols
pimavanserin	[no description available]	medium	1	0	aromatic ether; monofluorobenzenes; piperidines; tertiary amino compound; ureas	5-hydroxytryptamine 2A receptor inverse agonist; antipsychotic agent; serotonergic antagonist
1-naphthylacetylspermine	[no description available]	medium	1	0	naphthalenes
spermine	[no description available]	medium	4	0	polyazaalkane; tetramine	antioxidant; fundamental metabolite; immunosuppressive agent
methyl-thiohydantoin-tryptophan	[no description available]	medium	1	0	organonitrogen compound; organooxygen compound
zd 7288	[no description available]	medium	1	0
cardiovascular agents	[no description available]	medium	3	0
ro 15-4513	[no description available]	medium	1	0	organic heterotricyclic compound; organonitrogen heterocyclic compound
azides	[no description available]	medium	1	0	pseudohalide anion	mitochondrial respiratory-chain inhibitor
cyclohexane	[no description available]	medium	1	0	cycloalkane; volatile organic compound	non-polar solvent
pk 11195	[no description available]	medium	4	0	aromatic amide; isoquinolines; monocarboxylic acid amide; monochlorobenzenes	antineoplastic agent
nimetazepam	[no description available]	medium	1	0	1,4-benzodiazepinone; C-nitro compound	anticonvulsant; antispasmodic drug; GABA modulator; sedative
sodium permanganate	[no description available]	medium	1	0
5-(alpha-methyl-4-bromobenzylamino)phosphonomethyl-1,4-dihydroquinoxaline-2,3-dione	[no description available]	medium	1	0
nadp	[no description available]	medium	7	0
clopenthixol	[no description available]	medium	3	0	N-alkylpiperazine; primary alcohol; thioxanthenes	alpha-adrenergic antagonist; dopaminergic antagonist; first generation antipsychotic; H1-receptor antagonist; serotonergic antagonist
clopenthixol decanoate	[no description available]	medium	1	0
3-n-butylphthalide	[no description available]	medium	1	0	benzofurans
bisphenol a	[no description available]	medium	3	0	bisphenol	endocrine disruptor; environmental contaminant; xenobiotic; xenoestrogen
deoxynivalenol	[no description available]	medium	1	0	cyclic ketone; enone; primary alcohol; secondary alpha-hydroxy ketone; trichothecene; triol	mycotoxin
5-carboxytetramethylrhodamine succinimidyl ester	[no description available]	medium	1	0
buphedrone	[no description available]	medium	1	0
1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine dihydrochloride	[no description available]	medium	4	0
1,3-benzodioxole	[no description available]	medium	1	0	benzodioxole
catechol	[no description available]	medium	3	0	catechols	allelochemical; genotoxin; plant metabolite
spiperone	[no description available]	medium	14	0	aromatic ketone; azaspiro compound; organofluorine compound; piperidines; tertiary amino compound	alpha-adrenergic antagonist; antipsychotic agent; dopaminergic antagonist; psychotropic drug; serotonergic antagonist
5,7-dihydroxytryptamine	[no description available]	medium	4	0
n-pentyl nitrite	[no description available]	medium	4	0	nitrite esters	vasodilator agent
rhodamine 123	[no description available]	medium	2	0	organic cation; xanthene dye	fluorochrome
1-(3,4-methylenedioxyphenyl)-2-butanamine	[no description available]	medium	1	0	benzodioxoles
pentazocine	[no description available]	medium	18	0	benzazocine
transforming growth factor beta	[no description available]	medium	1	0
ferrous sulfate	[no description available]	medium	1	0	iron molecular entity; metal sulfate	reducing agent
acrylamide	[no description available]	medium	2	0	acrylamides; N-acylammonia; primary carboxamide	alkylating agent; carcinogenic agent; Maillard reaction product; mutagen; neurotoxin
neopterin	[no description available]	medium	1	0
ovalbumin	[no description available]	medium	4	0
dopamine quinone	[no description available]	medium	3	0	1,2-benzoquinones; primary amino compound	metabolite
myelin basic protein	[no description available]	medium	1	0
1,1-dimethylheptyl-11-hydroxytetrahydrocannabinol	[no description available]	medium	1	0
thioperamide	[no description available]	medium	7	0	primary aliphatic amine
4-(1h-imidazol-4-ylmethyl)piperidine	[no description available]	medium	3	0	piperidines
u-50488	[no description available]	medium	8	0	dichlorobenzene; monocarboxylic acid amide; N-alkylpyrrolidine	analgesic; antitussive; calcium channel blocker; diuretic; kappa-opioid receptor agonist
ru 43044	[no description available]	medium	1	0
ibogaine	[no description available]	medium	6	0
18-methoxycoronaridine	[no description available]	medium	3	0
15-deoxyprostaglandin j2	[no description available]	medium	1	0
prostaglandin d2	[no description available]	medium	1	0	prostaglandins D	human metabolite; mouse metabolite
pyrazole	[no description available]	medium	1	0	pyrazole
clorgyline	[no description available]	medium	13	0	aromatic ether; dichlorobenzene; terminal acetylenic compound; tertiary amino compound	antidepressant; EC 1.4.3.4 (monoamine oxidase) inhibitor
win 51708	[no description available]	medium	6	0
1-phenylpropene	[no description available]	medium	4	0
puromycin	[no description available]	medium	1	0	puromycins	antiinfective agent; antimicrobial agent; antineoplastic agent; EC 3.4.11.14 (cytosol alanyl aminopeptidase) inhibitor; EC 3.4.14.2 (dipeptidyl-peptidase II) inhibitor; nucleoside antibiotic; protein synthesis inhibitor
cadaverine	[no description available]	medium	1	0	alkane-alpha,omega-diamine	Daphnia magna metabolite; Escherichia coli metabolite; mouse metabolite; plant metabolite
monodansylcadaverine	[no description available]	medium	1	0	aminonaphthalene; primary amino compound; sulfonamide; tertiary amino compound	EC 2.3.2.13 (protein-glutamine gamma-glutamyltransferase) inhibitor; fluorochrome; protective agent
carbon monoxide	[no description available]	medium	1	0	carbon oxide; gas molecular entity; one-carbon compound	biomarker; EC 1.9.3.1 (cytochrome c oxidase) inhibitor; human metabolite; ligand; metabolite; mitochondrial respiratory-chain inhibitor; mouse metabolite; neurotoxin; neurotransmitter; P450 inhibitor; probe; signalling molecule; vasodilator agent
opromazine	[no description available]	medium	1	0	phenothiazines
pf-670462	[no description available]	medium	1	0	hydrochloride	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
2'-hydroxy-5,9-dimethyl-2-allyl-6,7-benzomorphan	[no description available]	medium	3	0
phenazocine	[no description available]	medium	4	0
ketotifen	[no description available]	medium	1	0	cyclic ketone; olefinic compound; organic heterotricyclic compound; organosulfur heterocyclic compound; piperidines; tertiary amino compound	anti-asthmatic drug; H1-receptor antagonist
alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol	[no description available]	medium	6	0	N-arylpiperazine
sm 21	[no description available]	medium	1	0	monocarboxylic acid
thiourea	[no description available]	medium	5	0	one-carbon compound; thioureas; ureas	antioxidant; chromophore
imetit	[no description available]	medium	3	0	imidazoles; imidothiocarbamic ester	H3-receptor agonist; H4-receptor agonist
mitotracker green fm	[no description available]	medium	1	0
bisindolylmaleimide i	[no description available]	medium	2	0
sulfuric acid	[no description available]	medium	2	0	sulfur oxoacid	catalyst
glucuronic acid	[no description available]	medium	1	0	D-glucuronic acid	algal metabolite
2-methoxy-n-n-propylnorapomorphine	[no description available]	medium	1	0
(3h)2-carbomethoxy-3-(4-fluorophenyl)tropane	[no description available]	medium	17	0
osemozotan	[no description available]	medium	4	0
nornicotine	[no description available]	medium	1	0
ethyl chloride	[no description available]	medium	1	0	chloroethanes	antipruritic drug; inhalation anaesthetic; local anaesthetic
pentafluorobenzoyl chloride	[no description available]	medium	2	0	acyl chloride; perfluorinated compound	chromatographic reagent
diadenosine tetraphosphate	[no description available]	medium	1	0	diadenosyl tetraphosphate	Escherichia coli metabolite; mouse metabolite
ritanserin	[no description available]	medium	8	0	organofluorine compound; piperidines; thiazolopyrimidine	antidepressant; antipsychotic agent; anxiolytic drug; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; serotonergic antagonist
3-methoxy-4-hydroxyphenylglycol sulfate	[no description available]	medium	2	1	alcohol; phenols
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid	[no description available]	medium	2	0	chromanol; monocarboxylic acid; phenols	antioxidant; ferroptosis inhibitor; neuroprotective agent; radical scavenger; Wnt signalling inhibitor
substance p, sar(9)-met(o2)(11)-	[no description available]	medium	1	0
dihydro-beta-erythroidine	[no description available]	medium	1	0	delta-lactone; organic heterotetracyclic compound; tertiary amino compound	nicotinic antagonist
tris(2,2'-bipyridine)ruthenium(II)	[no description available]	medium	2	0	ruthenium coordination entity	fluorochrome
isoliquiritigenin	[no description available]	medium	1	0	chalcones	antineoplastic agent; biological pigment; EC 1.14.18.1 (tyrosinase) inhibitor; GABA modulator; geroprotector; metabolite; NMDA receptor antagonist
4-hydroxy-2-nonenal	[no description available]	medium	4	0	4-hydroxynon-2-enal; 4-hydroxynonenal
histidine	[no description available]	medium	10	0	amino acid zwitterion; histidine; L-alpha-amino acid; polar amino acid zwitterion; proteinogenic amino acid	algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
gadolinium dtpa	[no description available]	medium	1	0	gadolinium coordination entity	MRI contrast agent
bemesetron	[no description available]	medium	4	0
phorbol 12,13-dibutyrate	[no description available]	medium	1	0	butyrate ester; phorbol ester; tertiary alpha-hydroxy ketone
dsp 4	[no description available]	medium	13	0
vitamin b 12	[no description available]	medium	1	0
hydroxydione	[no description available]	medium	1	1	20-oxo steroid; 21-hydroxy steroid; 3-oxo-5beta-steroid; primary alpha-hydroxy ketone	human xenobiotic metabolite
phenyl acetate	[no description available]	medium	17	0	benzenes; phenyl acetates
hydrogen carbonate	[no description available]	medium	4	0	carbon oxoanion	cofactor; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
thyronines	[no description available]	medium	1	0	thyronine
oxazolidine	[no description available]	medium	1	0	oxazolidine
vanoxerine	[no description available]	medium	18	0	ether; N-alkylpiperazine; organofluorine compound; tertiary amino compound	dopamine uptake inhibitor
zotepine	[no description available]	medium	2	0	dibenzothiepine; tertiary amino compound	alpha-adrenergic drug; second generation antipsychotic; serotonergic drug
norfentanyl	[no description available]	medium	1	0	anilide; monocarboxylic acid amide; piperidines	drug metabolite; opioid analgesic
acetyl coenzyme a	[no description available]	medium	1	0	acyl-CoA	acyl donor; coenzyme; effector; fundamental metabolite
5-nitroindazole	[no description available]	medium	1	0
mescaline	[no description available]	medium	26	0	methoxybenzenes; phenethylamine alkaloid; primary amino compound	hallucinogen
ciproxifan	[no description available]	medium	3	0	aromatic ketone
pitolisant	[no description available]	medium	1	0	organochlorine compound
benzonitrile, 4-(2-(2-((2r)-2-methyl-1-pyrrolidinyl)ethyl)-5-benzofuranyl)-	[no description available]	medium	2	0
dimethylformamide	[no description available]	medium	2	0	formamides; volatile organic compound	geroprotector; hepatotoxic agent; polar aprotic solvent
n-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-4-(pyridin-2-yl)benzamide	[no description available]	medium	1	0
sulfur	[no description available]	medium	3	0	chalcogen; nonmetal atom	macronutrient
acetonitrile	[no description available]	medium	3	0	aliphatic nitrile; volatile organic compound	EC 3.5.1.4 (amidase) inhibitor; NMR chemical shift reference compound; polar aprotic solvent
ether	[no description available]	medium	4	0	ether; volatile organic compound	inhalation anaesthetic; non-polar solvent; refrigerant
leptin	[no description available]	medium	3	0
epidermal growth factor	[no description available]	medium	2	0
diphenhydramine hydrochloride	[no description available]	medium	3	1	hydrochloride; organoammonium salt	anti-allergic agent; antiemetic; antiparkinson drug; antipruritic drug; H1-receptor antagonist; local anaesthetic; muscarinic antagonist; sedative
nan 190	[no description available]	medium	2	0	N-alkylpiperazine; N-arylpiperazine; phthalimides	serotonergic antagonist
guanine	[no description available]	medium	2	0	2-aminopurines; oxopurine; purine nucleobase	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
8-hydroxyguanine	[no description available]	medium	2	0	oxopurine
kainic acid	[no description available]	medium	14	0	dicarboxylic acid; L-proline derivative; non-proteinogenic L-alpha-amino acid; pyrrolidinecarboxylic acid	antinematodal drug; excitatory amino acid agonist
fenclonine	[no description available]	medium	22	0	phenylalanine derivative
n,n,n',n'-tetrakis(2-pyridylmethyl)ethylenediamine	[no description available]	medium	1	0	N-substituted diamine; pyridines; tertiary amino compound	apoptosis inducer; chelator; copper chelator
tricine	[no description available]	medium	1	0	tricine
2',3'-o-(2,4,6-trinitrophenyl)adenosine 5'-triphosphate	[no description available]	medium	1	0	C-nitro compound; spiroketal	antagonist
cyclopentane	[no description available]	medium	2	0	cycloalkane; cyclopentanes; volatile organic compound	non-polar solvent
cgp 7930	[no description available]	medium	1	0	alkylbenzene
n,n'-dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine	[no description available]	medium	1	0	aryl sulfide
l 451167	[no description available]	medium	1	0
emodin	[no description available]	medium	1	0	trihydroxyanthraquinone	antineoplastic agent; laxative; plant metabolite; tyrosine kinase inhibitor
trifluoroacetic acid	[no description available]	medium	5	0	fluoroalkanoic acid	human xenobiotic metabolite; NMR chemical shift reference compound; reagent
7-hydroxy-2-n,n-dipropylaminotetralin	[no description available]	medium	2	0	tetralins
phosgene	[no description available]	medium	2	0	acyl chloride
trichloroethyl chloroformate	[no description available]	medium	2	0
3,4-dihydroxymandelic acid	[no description available]	medium	2	0	2-hydroxy monocarboxylic acid; catechols	antioxidant; drug metabolite; human metabolite; mouse metabolite
heptafluorobutyric anhydride	[no description available]	medium	5	1	acyclic carboxylic anhydride; organofluorine compound	chromatographic reagent
sb 277011	[no description available]	medium	3	0
mgs 0028	[no description available]	medium	1	0
pentafluoropropionic anhydride	[no description available]	medium	2	0
magadi soda	[no description available]	medium	1	0
trehalose	[no description available]	medium	1	0	trehalose	Escherichia coli metabolite; geroprotector; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
alpha-methylhistamine	[no description available]	medium	2	0	aralkylamino compound; imidazoles	animal metabolite; H3-receptor agonist
fenproporex	[no description available]	medium	3	0	amphetamines
sk&f 82958	[no description available]	medium	3	0	benzazepine
kt 5720	[no description available]	medium	1	0	carboxylic ester; gamma-lactam; hemiaminal; indolocarbazole; organic heterooctacyclic compound; semisynthetic derivative; tertiary alcohol	EC 2.7.11.11 (cAMP-dependent protein kinase) inhibitor
carbodiimides	[no description available]	medium	3	0	carbodiimide
cyclosporine	[no description available]	medium	2	0
n-pentanoic acid	[no description available]	medium	1	0	short-chain fatty acid; straight-chain saturated fatty acid	plant metabolite
phalloidine	[no description available]	medium	1	0	homodetic cyclic peptide
fluorescein-5-isothiocyanate	[no description available]	medium	7	0	fluorescein isothiocyanate
phenmetrazine	[no description available]	medium	37	1	morpholines	metabolite; sympathomimetic agent
ammonium acetate	[no description available]	medium	1	0	acetate salt; ammonium salt	buffer; food acidity regulator
pd 168,077	[no description available]	medium	1	0	piperazines
sulforaphane	[no description available]	medium	1	0	isothiocyanate; sulfoxide	antineoplastic agent; antioxidant; EC 3.5.1.98 (histone deacetylase) inhibitor; plant metabolite
4-phenyl-1,2,3,4-tetrahydroisoquinoline	[no description available]	medium	7	0	isoquinolines
am-356	[no description available]	medium	4	0	fatty amide
quipazine	[no description available]	medium	4	0	piperazines; pyridines
cgp 54626	[no description available]	medium	1	0
n-(3-(aminomethyl)benzyl)acetamidine	[no description available]	medium	1	0	aralkylamine; carboxamidine; primary amino compound	angiogenesis inhibitor; EC 1.14.13.39 (nitric oxide synthase) inhibitor; geroprotector
taurine	[no description available]	medium	6	0	amino sulfonic acid; zwitterion	antioxidant; Escherichia coli metabolite; glycine receptor agonist; human metabolite; mouse metabolite; nutrient; radical scavenger; Saccharomyces cerevisiae metabolite
sc 514	[no description available]	medium	1	0	ring assembly; thiophenes
atosiban	[no description available]	medium	2	0	oligopeptide
vasotocin	[no description available]	medium	2	0
lignans	[no description available]	medium	2	0
naloxonazine	[no description available]	medium	1	0
n-trifluoroacetylprolyl chloride	[no description available]	medium	2	0
arachidonic acid	[no description available]	medium	3	0	icosa-5,8,11,14-tetraenoic acid; long-chain fatty acid; omega-6 fatty acid	Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; human metabolite; mouse metabolite
quinolinic acid	[no description available]	medium	7	0	pyridinedicarboxylic acid	Escherichia coli metabolite; human metabolite; mouse metabolite; NMDA receptor agonist
2-(dibutylamino)ethanol	[no description available]	medium	1	0
chitosan	[no description available]	medium	1	0
hydroiodic acid	[no description available]	medium	2	0	gas molecular entity; hydrogen halide; mononuclear parent hydride	mouse metabolite
sb 242084	[no description available]	medium	1	0
sb 206553	[no description available]	medium	1	0	pyrroloindole
latrepirdine	[no description available]	medium	1	0	methylpyridines; pyridoindole	geroprotector
6-methyl-2-(phenylethynyl)pyridine	[no description available]	medium	4	0	acetylenic compound; methylpyridines	anxiolytic drug; metabotropic glutamate receptor antagonist
atrial natriuretic factor	[no description available]	medium	1	0	polypeptide
fenobam	[no description available]	medium	1	0	ureas
glucaric acid	[no description available]	medium	1	0	glucaric acid	antineoplastic agent
glycogen	[no description available]	medium	10	0
1,3-ditolylguanidine	[no description available]	medium	4	0	toluenes
bibp 3226	[no description available]	medium	1	0
caffeic acid	[no description available]	medium	1	0	caffeic acid	geroprotector; mouse metabolite
gyki 52466	[no description available]	medium	2	0	benzodiazepine
2-aminoethoxydiphenyl borate	[no description available]	medium	1	0	organoboron compound; primary amino compound	calcium channel blocker; IP3 receptor antagonist; potassium channel opener
xestospongin a	[no description available]	medium	1	0
n,n-diisopropyltryptamine	[no description available]	medium	1	0	tryptamines
2-(4-chlorophenyl)cyclopropylamine	[no description available]	medium	1	0
gbr 12935	[no description available]	medium	5	0	ether; N-alkylpiperazine; tertiary amino compound	dopamine uptake inhibitor
podophyllin	[no description available]	medium	1	0
mitopodozide	[no description available]	medium	1	0	lignan
trifluoroacetic anhydride	[no description available]	medium	4	0
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone	[no description available]	medium	4	0
tryptamine-4,5-dione	[no description available]	medium	2	0
rimorphin	[no description available]	medium	1	0
pentylenetetrazole	[no description available]	medium	28	2	organic heterobicyclic compound; organonitrogen heterocyclic compound
picrotoxin	[no description available]	medium	6	0
strychnine	[no description available]	medium	12	0	monoterpenoid indole alkaloid; organic heteroheptacyclic compound	avicide; cholinergic antagonist; glycine receptor antagonist; neurotransmitter agent; rodenticide
barakol	[no description available]	medium	1	0
phosphoserine	[no description available]	medium	2	0	non-proteinogenic alpha-amino acid; O-phosphoamino acid; serine derivative	human metabolite
l 365260	[no description available]	medium	1	0	benzodiazepine
fg 9041	[no description available]	medium	2	0	quinoxaline derivative
2-amino-5-phosphonovalerate	[no description available]	medium	3	0	non-proteinogenic alpha-amino acid	NMDA receptor antagonist
tetradecanoylphorbol acetate	[no description available]	medium	1	0	acetate ester; diester; phorbol ester; tertiary alpha-hydroxy ketone; tetradecanoate ester	antineoplastic agent; apoptosis inducer; carcinogenic agent; mitogen; plant metabolite; protein kinase C agonist; reactive oxygen species generator
ucn 1028 c	[no description available]	medium	1	0
7-hydroxyflavone	[no description available]	medium	1	0	hydroxyflavonoid
pargyline	[no description available]	medium	20	0	aromatic amine
pyrogallol	[no description available]	medium	5	0	benzenetriol; phenolic donor	plant metabolite
guanylyl imidodiphosphate	[no description available]	medium	1	0	nucleoside triphosphate analogue
chlorine	[no description available]	medium	15	1	diatomic chlorine; gas molecular entity	bleaching agent
hydrofluoric acid	[no description available]	medium	1	0	hydrogen halide; mononuclear parent hydride	NMR chemical shift reference compound
o-chlorobenzylidenemalonitrile	[no description available]	medium	1	0	organochlorine compound
u 69593	[no description available]	medium	2	0	monocarboxylic acid amide; N-alkylpyrrolidine; organic heterobicyclic compound; oxaspiro compound	anti-inflammatory agent; diuretic; kappa-opioid receptor agonist
1-hydroxy-1-phenyl-2-propanone	[no description available]	medium	1	0	benzenes; methyl ketone; secondary alpha-hydroxy ketone
talipexole	[no description available]	medium	4	0	azepine
cyclohexanone	[no description available]	medium	1	0	cyclohexanones	human xenobiotic metabolite
metaperiodate	[no description available]	medium	4	0	iodine oxoacid
metaperiodate	[no description available]	medium	2	0	iodine oxoanion; monovalent inorganic anion
salicylates	[no description available]	medium	11	0	monohydroxybenzoate	plant metabolite
iodine	[no description available]	medium	20	0	diatomic iodine	nutrient
iodine	[no description available]	medium	20	2	diatomic iodine	nutrient
phenothiazine	[no description available]	medium	1	0	phenothiazine	ferroptosis inhibitor; plant metabolite; radical scavenger
phenaglycodol	[no description available]	medium	1	0	alkylbenzene
clorprenaline	[no description available]	medium	1	0	ethanolamines; monochlorobenzenes; secondary amino compound
bemegride	[no description available]	medium	4	0	piperidones
beta-escin	[no description available]	medium	5	0
azacyclonol	[no description available]	medium	2	0	diarylmethane
pheniprazine	[no description available]	medium	1	0	amphetamines
pipradrol	[no description available]	medium	1	0	diarylmethane
dibucaine	[no description available]	medium	2	0	aromatic ether; monocarboxylic acid amide; tertiary amino compound	topical anaesthetic
phenylhydrazine	[no description available]	medium	1	0	phenylhydrazines	xenobiotic
5-hydroxytryptophan	[no description available]	medium	24	1	hydroxytryptophan	human metabolite; neurotransmitter
phensuximide	[no description available]	medium	2	0	pyrrolidines
gallamine triethiodide	[no description available]	medium	1	0
trimethaphan	[no description available]	medium	1	0	sulfonium compound	anaesthesia adjuvant; antihypertensive agent; nicotinic antagonist; vasodilator agent
tolazoline	[no description available]	medium	5	0	imidazoles	alpha-adrenergic antagonist; antihypertensive agent; vasodilator agent
norcoralydine	[no description available]	medium	1	0	alkaloid
barium	[no description available]	medium	1	0	alkaline earth metal atom; elemental barium
magnesium sulfate	[no description available]	medium	1	0	magnesium salt; metal sulfate; organic magnesium salt	anaesthetic; analgesic; anti-arrhythmia drug; anticonvulsant; calcium channel blocker; cardiovascular drug; fertilizer; tocolytic agent
barbituric acid	[no description available]	medium	3	0	barbiturates	allergen; xenobiotic
mephenesin	[no description available]	medium	3	0	aromatic ether; glycerol ether
paraldehyde	[no description available]	medium	2	0	trioxane	sedative
hydantoins	[no description available]	medium	4	0	imidazolidine-2,4-dione
methoxamine	[no description available]	medium	10	0	amphetamines	alpha-adrenergic agonist; antihypotensive agent
fluoresone	[no description available]	medium	1	0	sulfonamide
tripelennamine	[no description available]	medium	5	0	aromatic amine
ammonium chloride	[no description available]	medium	3	0	ammonium salt; inorganic chloride	ferroptosis inhibitor
chloralose	[no description available]	medium	3	0
urethane	[no description available]	medium	3	0	carbamate ester	fungal metabolite; mutagen
tubocurarine	[no description available]	medium	3	0	bisbenzylisoquinoline alkaloid	drug allergen; muscle relaxant; nicotinic antagonist
pronethalol	[no description available]	medium	1	0	naphthalenes
cx546	[no description available]	medium	1	0
cx 614	[no description available]	medium	1	0
8-cyclopentyl-1,3-dimethylxanthine	[no description available]	medium	2	0	oxopurine
afimoxifene	[no description available]	medium	2	0	phenols; tertiary amino compound	antineoplastic agent; estrogen receptor antagonist; metabolite
clobenpropit	[no description available]	medium	1	0	imidazoles; imidothiocarbamic ester; organochlorine compound	H3-receptor antagonist; H4-receptor agonist
3-methylglutamic acid	[no description available]	medium	1	0
pyrrolidine-2,4-dicarboxylic acid	[no description available]	medium	1	0
dinobuton	[no description available]	medium	1	0	C-nitro compound
bucladesine	[no description available]	medium	3	0	3',5'-cyclic purine nucleotide
pd 98059	[no description available]	medium	3	0	aromatic amine; monomethoxyflavone	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector
3-aminobenzamide	[no description available]	medium	1	0	benzamides; substituted aniline	EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
uric acid	[no description available]	medium	3	0	uric acid	Escherichia coli metabolite; human metabolite; mouse metabolite
salvinorin a	[no description available]	medium	1	0	organic heterotricyclic compound; organooxygen compound	metabolite; oneirogen
cycloheximide	[no description available]	medium	8	0	antibiotic fungicide; cyclic ketone; dicarboximide; piperidine antibiotic; piperidones; secondary alcohol	anticoronaviral agent; bacterial metabolite; ferroptosis inhibitor; neuroprotective agent; protein synthesis inhibitor
4-bromotoluene	[no description available]	medium	1	0
sodium carbonate	[no description available]	medium	2	0	carbonate salt; organic sodium salt
carbonates	[no description available]	medium	3	0	carbon oxoanion
metallothionein	[no description available]	medium	2	0
hydroxyl radical	[no description available]	medium	12	0	oxygen hydride; oxygen radical; reactive oxygen species
cyclopropane	[no description available]	medium	1	0	cycloalkane; cyclopropanes	inhalation anaesthetic
deserpidine	[no description available]	medium	1	0	alkaloid ester; benzoate ester; methyl ester; organic heteropentacyclic compound; yohimban alkaloid
4-(n-maleimido)benzyltrimethylammonium	[no description available]	medium	1	0
nefiracetam	[no description available]	medium	4	0	organonitrogen compound; organooxygen compound
3-methoxytyramine	[no description available]	medium	10	1	monomethoxybenzene; phenols; phenylethylamine; primary amino compound	biomarker; human blood serum metabolite; human urinary metabolite
arsenic	[no description available]	medium	1	0	metalloid atom; pnictogen	micronutrient
teprotide	[no description available]	medium	1	0	peptide
staurosporine	[no description available]	medium	1	0	ammonium ion derivative
cadmium	[no description available]	medium	1	0	cadmium molecular entity; zinc group element atom
flurothyl	[no description available]	medium	3	0	ether
biocytin	[no description available]	medium	2	0	azabicycloalkane; L-alpha-amino acid zwitterion; L-lysine derivative; monocarboxylic acid amide; non-proteinogenic L-alpha-amino acid; thiabicycloalkane; ureas	mouse metabolite
bms 204756	[no description available]	medium	1	0
ferrous chloride	[no description available]	medium	1	0	iron coordination entity
3,9-bis((ethylthio)methyl)-k-252a	[no description available]	medium	1	0
allylbenzene 2',3'-epoxide	[no description available]	medium	1	0
cinnamyl alcohol	[no description available]	medium	1	0	cinnamyl alcohol	plant metabolite
alkenes	[no description available]	medium	1	0
fluorodopa f 18	[no description available]	medium	2	0	(18)F radiopharmaceutical; 6-fluoro-L-dopa
pentafluorobenzenesulfonyl chloride	[no description available]	medium	1	0
rolipram	[no description available]	medium	7	0	pyrrolidin-2-ones	antidepressant; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
noladin ether	[no description available]	medium	1	0	2-alkylglycerol; endocannabinoid; monoalkylglycerol
3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol	[no description available]	medium	2	0	alkylbenzene; ring assembly
cyclohexanol	[no description available]	medium	2	0	cyclohexanols; secondary alcohol	solvent
arachidonyl dopamine	[no description available]	medium	1	0	catechols; fatty amide; N-(fatty acyl)-dopamine; secondary carboxamide
virodhamine	[no description available]	medium	1	0	fatty acid ester
phosphine	[no description available]	medium	3	0	mononuclear parent hydride; phosphanes; phosphine	carcinogenic agent; fumigant insecticide
hydrochloric acid	[no description available]	medium	7	0	chlorine molecular entity; gas molecular entity; hydrogen halide; mononuclear parent hydride	mouse metabolite
7-nitroindazole	[no description available]	medium	12	0
xenon	[no description available]	medium	1	0	monoatomic xenon; noble gas atom; p-block element atom
motilin	[no description available]	medium	1	0
zinc chloride	[no description available]	medium	1	0	inorganic chloride; zinc molecular entity	astringent; disinfectant; EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor; Lewis acid
europium	[no description available]	medium	2	0	f-block element atom; lanthanoid atom
carbocyanines	[no description available]	medium	1	0	cyanine dye; organic iodide salt	fluorochrome
mcn 5652	[no description available]	medium	1	0	isoquinolines
ag-490	[no description available]	medium	1	0	catechols; enamide; monocarboxylic acid amide; nitrile; secondary carboxamide	anti-inflammatory agent; antioxidant; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; geroprotector; STAT3 inhibitor
clocinnamox	[no description available]	medium	1	0
4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-n,n-diethylbenzamide	[no description available]	medium	1	0	diarylmethane
2-carbomethoxy-8-(3-fluoropropyl)-3-(4-iodophenyl)tropane	[no description available]	medium	1	0
lisuride	[no description available]	medium	2	0	monocarboxylic acid amide	antidyskinesia agent; antiparkinson drug; dopamine agonist; serotonergic agonist
dironyl	[no description available]	medium	1	0	organic molecular entity
edaravone	[no description available]	medium	1	0	pyrazolone	antioxidant; radical scavenger
somatostatin-28	[no description available]	medium	1	0
correolide	[no description available]	medium	1	0	hydroxy steroid
sodium dodecyl sulfate	[no description available]	medium	4	0	organic sodium salt	detergent; protein denaturant
5-methoxy-n-methyl,n-isopropyl tryptamine	[no description available]	medium	1	0
sja 6017	[no description available]	medium	1	0
4-amino-1-(6-chloro-2-pyridyl)piperidine hydrochloride	[no description available]	medium	1	0
gr 65630	[no description available]	medium	1	0
gw9662	[no description available]	medium	1	0	benzamides
5-methoxytryptamine	[no description available]	medium	4	0	aromatic ether; primary amino compound; tryptamines	5-hydroxytryptamine 2A receptor agonist; 5-hydroxytryptamine 2B receptor agonist; 5-hydroxytryptamine 2C receptor agonist; antioxidant; cardioprotective agent; human metabolite; mouse metabolite; neuroprotective agent; radiation protective agent; serotonergic agonist
5-methoxy-n,n-diisopropyltryptamine	[no description available]	medium	4	0	tryptamines	hallucinogen
citrulline	[no description available]	medium	2	0	amino acid zwitterion; citrulline	Daphnia magna metabolite; EC 1.14.13.39 (nitric oxide synthase) inhibitor; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; protective agent; Saccharomyces cerevisiae metabolite
3-nitropropionic acid	[no description available]	medium	3	0	C-nitro compound	antimycobacterial drug; EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitor; mycotoxin; neurotoxin
cp 154526	[no description available]	medium	1	0
1-phenyl-2-propanol	[no description available]	medium	1	0
phenylethyl alcohol	[no description available]	medium	1	0	benzenes; primary alcohol	Aspergillus metabolite; fragrance; plant growth retardant; plant metabolite; Saccharomyces cerevisiae metabolite
ro 32-0432	[no description available]	medium	1	0
vitamin b 6	[no description available]	medium	1	0
diacetyldichlorofluorescein	[no description available]	medium	2	0
3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid	[no description available]	medium	3	0
u 99194a	[no description available]	medium	1	0
3,4,4a,10b-tetrahydro-4-propyl-2h,5h-(1)benzopyrano(4,3-b)-1,4-oxazin-9-ol	[no description available]	medium	1	0
fullerene c60	[no description available]	medium	1	0	fullerene	geroprotector
sodium azide	[no description available]	medium	1	0	inorganic sodium salt	antibacterial agent; explosive; mitochondrial respiratory-chain inhibitor; mutagen
ro 20-1815	[no description available]	medium	1	0	benzodiazepine
dimaprit	[no description available]	medium	1	0	imidothiocarbamic ester
sk&f 91488	[no description available]	medium	1	0
pyrethrins	[no description available]	medium	1	0
cypermethrin	[no description available]	medium	1	0	aromatic ether; cyclopropanecarboxylate ester; nitrile; organochlorine compound	agrochemical; molluscicide; pyrethroid ester acaricide; pyrethroid ester insecticide
cyfluthrin	[no description available]	medium	1	0	aromatic ether; cyclopropanecarboxylate ester; nitrile; organochlorine compound; organofluorine compound	agrochemical; pyrethroid ester insecticide
methylene chloride	[no description available]	medium	1	0	chloromethanes; volatile organic compound	carcinogenic agent; polar aprotic solvent; refrigerant
nisoxetine	[no description available]	medium	1	0	aromatic ether; secondary amino compound	adrenergic uptake inhibitor; antidepressant
sodium fluoride	[no description available]	medium	1	0	fluoride salt	mutagen
aminoindanol	[no description available]	medium	1	0
alpha-tocopherol phosphate	[no description available]	medium	1	0
ascorbate-2-phosphate	[no description available]	medium	1	0	aldonolactone phosphate
iodine	[no description available]	medium	1	0	halide anion; monoatomic iodine	human metabolite
4'-hydroxydiclofenac	[no description available]	medium	1	0	dichlorobenzene; monocarboxylic acid; phenols; secondary amino compound	allergen; drug metabolite
bp 897	[no description available]	medium	1	0	naphthalenecarboxamide
ngb 2904	[no description available]	medium	1	0	fluorenes
muromonab-cd3	[no description available]	medium	1	0	alkaloid; macrocycle; organic heteropentacyclic compound; organonitrogen heterocyclic compound; oxacycle; tertiary amino compound	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; IP3 receptor antagonist; marine metabolite
thiazolyl blue	[no description available]	medium	1	0	organic bromide salt	colorimetric reagent; dye
fusaric acid	[no description available]	medium	1	0	aromatic carboxylic acid; pyridines
chromated copper arsenate	[no description available]	medium	1	0
6-cyano-7-nitroquinoxaline-2,3-dione	[no description available]	medium	2	0	quinoxaline derivative
glycerophosphoinositol 4,5-bisphosphate	[no description available]	medium	1	0
azasetron	[no description available]	medium	1	0	benzoxazine
sb 203580	[no description available]	medium	1	0	imidazoles; monofluorobenzenes; pyridines; sulfoxide	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector; Hsp90 inhibitor; neuroprotective agent
clorazepate dipotassium	[no description available]	medium	1	0	potassium salt	anticonvulsant; anxiolytic drug; GABA modulator; prodrug
pnu-282987	[no description available]	medium	1	0
1h-3-benzazepin-7-ol, 8-bromo-2,3,4,5-tetrahydro-3-methyl-5-phenyl-	[no description available]	medium	2	0	benzazepine
n-(4-amino-2-methylquinolin-6-yl)-2-(4-ethylphenoxymethyl)benzamide	[no description available]	medium	1	0	aminoquinoline
chlorphentermine	[no description available]	medium	16	0	amphetamines
naphazoline	[no description available]	medium	2	0	naphthalenes
ym 09151-2	[no description available]	medium	12	0	N-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-(methylamino)benzamide
timiperone	[no description available]	medium	1	0	aromatic ketone
carpipramine	[no description available]	medium	1	0	dibenzooxazepine
3-chlorocarpipramine	[no description available]	medium	2	0	dibenzooxazepine
debrisoquin	[no description available]	medium	6	1	carboxamidine; isoquinolines	adrenergic agent; antihypertensive agent; human metabolite; sympatholytic agent
4-bromomethamphetamine	[no description available]	medium	5	0
benserazide	[no description available]	medium	4	0	carbohydrazide; catechols; primary alcohol; primary amino compound	antiparkinson drug; dopaminergic agent; EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor
iprindole	[no description available]	medium	4	0	indoles
ru 24926	[no description available]	medium	1	0
2h-benzo(a)quinolizin-2-ol, 2-ethyl-1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy-	[no description available]	medium	4	0
desmethylclomipramine	[no description available]	medium	1	0	dibenzoazepine
ceruletide	[no description available]	medium	9	0	oligopeptide	diagnostic agent; gastrointestinal drug
dn 1417	[no description available]	medium	5	0
dimethophrine	[no description available]	medium	1	0	methoxybenzenes; phenols
n-nitrosoephedrine	[no description available]	medium	2	0
rilmazafone	[no description available]	medium	1	0	benzophenones
bupranolol	[no description available]	medium	1	0	aromatic ether
thiamine pyrophosphate	[no description available]	medium	1	0	organic chloride salt; vitamin B1
thiamine monophosphate	[no description available]	medium	1	0	organic chloride salt; vitamin B1
thiamine pyrophosphate	[no description available]	medium	1	0	organophosphate oxoanion; vitamin B1	human metabolite; Saccharomyces cerevisiae metabolite
pirenperone	[no description available]	medium	2	0	aromatic ketone
carbidopa	[no description available]	medium	5	0
3-hydroxybenzylhydrazine	[no description available]	medium	2	0	phenols
norfenfluramine	[no description available]	medium	3	0	amphetamines
n-methylbenzylamine	[no description available]	medium	1	0
n-methylphenylethanolamine	[no description available]	medium	1	0	alkaloid; phenylethanolamines	human metabolite; plant metabolite
4-hydroxyphenylacetic acid	[no description available]	medium	2	0	monocarboxylic acid; phenols	fungal metabolite; human metabolite; mouse metabolite; plant metabolite
carbidopa, levodopa drug combination	[no description available]	medium	1	0
molindone	[no description available]	medium	1	0	indoles
physostigmine salicylate	[no description available]	medium	1	0	azaheterocycle salicylate salt; salicylates
sodium glutamate	[no description available]	medium	1	0	monosodium glutamate	flavouring agent
alpha-methyltyrosine methyl ester	[no description available]	medium	1	0
ergoline	[no description available]	medium	10	1	diamine; ergoline alkaloid; indole alkaloid fundamental parent; indole alkaloid; organic heterotetracyclic compound
bifemelane	[no description available]	medium	2	0	diarylmethane
afloqualone	[no description available]	medium	1	0	organic molecular entity
schizandrol b	[no description available]	medium	1	0	tannin
schizandrin	[no description available]	medium	1	0
g(m1) ganglioside	[no description available]	medium	1	0	alpha-N-acetylneuraminosyl-(2->3)-[beta-D-galactosyl-(1->3)-N-acetyl-beta-D-galactosaminyl-(1->4)]-beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1')-N-acylsphingosine; sialotetraosylceramide
cp 96345	[no description available]	medium	1	0
butaclamol	[no description available]	medium	2	0
preclamol	[no description available]	medium	3	0
cgp 39653	[no description available]	medium	1	0
adenosine diphosphate ribose	[no description available]	medium	2	0	ADP-sugar	Escherichia coli metabolite; mouse metabolite
1-(9-fluorenyl)ethyl chloroformate	[no description available]	medium	1	0
sertindole	[no description available]	medium	1	0	heteroarylpiperidine; imidazolidinone; organochlorine compound; organofluorine compound; phenylindole	alpha-adrenergic antagonist; H1-receptor antagonist; second generation antipsychotic; serotonergic antagonist
selfotel	[no description available]	medium	3	0	non-proteinogenic alpha-amino acid
3-(2-carboxypiperazine-4-yl)-1-propenyl-1-phosphonic acid	[no description available]	medium	3	0
carbon tetrachloride	[no description available]	medium	4	0	chlorocarbon; chloromethanes	hepatotoxic agent; refrigerant
beta-carboline-3-carboxylic acid ethyl ester	[no description available]	medium	1	0	beta-carbolines
1,2-naphthoquinone	[no description available]	medium	2	0	1,2-naphthoquinones	aryl hydrocarbon receptor agonist; carcinogenic agent
naphthoquinones	[no description available]	medium	4	0
propionaldehyde	[no description available]	medium	1	0	alpha-CH2-containing aldehyde; propanals	Escherichia coli metabolite
sodium borohydride	[no description available]	medium	2	0	inorganic sodium salt; metal tetrahydridoborate
ibotenic acid	[no description available]	medium	4	0	non-proteinogenic alpha-amino acid	neurotoxin
fr 121196	[no description available]	medium	3	0
2,5-dihydroxybenzoic acid	[no description available]	medium	5	0	dihydroxybenzoic acid	EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; fungal metabolite; human metabolite; MALDI matrix material; mouse metabolite
2,3-dihydroxybenzoic acid	[no description available]	medium	7	0	dihydroxybenzoic acid	human xenobiotic metabolite; plant metabolite
4-fluorodeprenyl	[no description available]	medium	2	0
n-(3-phenyl-n-propyl)-1-phenyl-2-aminopropane	[no description available]	medium	1	0
sr 48692	[no description available]	medium	1	0	N-acyl-amino acid
1-hydroxy-3-amino-2-pyrrolidone	[no description available]	medium	1	0
7-chlorokynurenic acid	[no description available]	medium	2	0	organochlorine compound; quinolinemonocarboxylic acid	neuroprotective agent; NMDA receptor antagonist
npc 12626	[no description available]	medium	2	0
n-hydroxyamphetamine	[no description available]	medium	4	0
ethylmaleimide	[no description available]	medium	1	0	maleimides	anticoronaviral agent; EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor; EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor; EC 2.7.1.1 (hexokinase) inhibitor
naltrindole	[no description available]	medium	2	0	isoquinolines
naltrindole benzofuran	[no description available]	medium	2	0	morphinane alkaloid
7-benzylidenenaltrexone	[no description available]	medium	2	0	phenanthrenes
tetrahydrofuran	[no description available]	medium	1	0	cyclic ether; oxolanes; saturated organic heteromonocyclic parent; volatile organic compound	polar aprotic solvent
amfonelic acid	[no description available]	medium	7	0
chiniofon	[no description available]	medium	1	0
sodium hydroxide	[no description available]	medium	2	0	alkali metal hydroxide
1,4-dioxane	[no description available]	medium	1	0	dioxane; volatile organic compound	carcinogenic agent; metabolite; NMR chemical shift reference compound; non-polar solvent
potassium hydroxide	[no description available]	medium	1	0	alkali metal hydroxide
9-fluoreneacetic acid	[no description available]	medium	1	0
salsolinol	[no description available]	medium	1	0	1-methyl-1,2,3,4-tetrahydroisoquinoline-6,7-diol	human urinary metabolite
flunarizine	[no description available]	medium	6	0	diarylmethane
beta-amyrin palmitate	[no description available]	medium	1	0
oleanolic acid	[no description available]	medium	1	0	hydroxy monocarboxylic acid; pentacyclic triterpenoid	plant metabolite
aniracetam	[no description available]	medium	2	0	N-acylpyrrolidine; pyrrolidin-2-ones
3-n-methylspiperone	[no description available]	medium	2	0	aromatic ketone
deoxyglucose	[no description available]	medium	5	0
1-aminocyclopropane-1-carboxylic acid	[no description available]	medium	1	0	amino acid zwitterion; monocarboxylic acid; non-proteinogenic alpha-amino acid	ethylene releasers; plant metabolite
enkephalin, d-penicillamine (2,5)-	[no description available]	medium	2	0	heterodetic cyclic peptide	delta-opioid receptor agonist
n-methyl-n-(tert-butyldimethylsilyl)trifluoroacetamide	[no description available]	medium	1	0	monocarboxylic acid amide; N-silyl compound; trifluoroacetamide	chromatographic reagent
cgs 10746b	[no description available]	medium	1	0
methyl-3-tyrosine	[no description available]	medium	1	0	amino acid zwitterion; L-tyrosine derivative; non-proteinogenic L-alpha-amino acid
6-(6-(4-hydroxypiperidinyl)hexyloxy)-3-methylflavone hydrochloride	[no description available]	medium	1	0
prazepam	[no description available]	medium	2	0	benzodiazepine
spiradoline	[no description available]	medium	1	0
5-methoxy-6-methyl-2-aminoindan	[no description available]	medium	1	0
5,6-dihydroxytryptamine	[no description available]	medium	3	0
2,4,5-trihydroxyamphetamine	[no description available]	medium	2	0
perfluorobutyric acid	[no description available]	medium	2	0	fluoroalkanoic acid	chromatographic reagent; environmental contaminant; xenobiotic
alpha-benzyl-n-methylphenethylamine	[no description available]	medium	6	0
aluminum	[no description available]	medium	2	0	boron group element atom; elemental aluminium; metal atom
1,2-naphthoquinone-4-sulfonate	[no description available]	medium	2	0	arenesulfonic acid; naphthalenone	colorimetric reagent
rexigen	[no description available]	medium	2	0
mefenorex	[no description available]	medium	3	0	amphetamines
malonic acid	[no description available]	medium	2	0	alpha,omega-dicarboxylic acid	human metabolite
epichlorohydrin	[no description available]	medium	1	0	epoxide; organochlorine compound
aluminum sulfate	[no description available]	medium	1	0	aluminium sulfate
alpha-methyldopamine	[no description available]	medium	1	0	amphetamines
alpha-methyldopamine	[no description available]	medium	1	1	amphetamines
dynorphins	[no description available]	medium	2	0
enkephalin, methionine	[no description available]	medium	3	0
3-phenylpropylamine	[no description available]	medium	1	0	benzenes; phenylalkylamine; primary amino compound
n-acetylserotonin	[no description available]	medium	1	0	acetamides; N-acylserotonin; phenols	antioxidant; human metabolite; mouse metabolite; tropomyosin-related kinase B receptor agonist
1-amino-1,3-dicarboxycyclopentane	[no description available]	medium	1	0
cycloleucine	[no description available]	medium	1	0	non-proteinogenic alpha-amino acid	EC 2.5.1.6 (methionine adenosyltransferase) inhibitor
alpha-methyl-4-carboxyphenylglycine	[no description available]	medium	1	0	non-proteinogenic alpha-amino acid	metabotropic glutamate receptor antagonist
alpha-fluoromethylhistidine	[no description available]	medium	1	0
sk&f 95282	[no description available]	medium	3	0	piperidines
tan 67	[no description available]	medium	1	0
technetium tc 99m exametazime	[no description available]	medium	2	1
p-hydroxynorephedrine	[no description available]	medium	3	0
perospirone	[no description available]	medium	2	0	N-arylpiperazine
pentafluorobenzyl bromide	[no description available]	medium	1	0	benzyl bromides; fluorobenzenes
1-(5-isoquinolinesulfonyl)-2-methylpiperazine	[no description available]	medium	1	0	isoquinolines; N-sulfonylpiperazine	EC 2.7.11.13 (protein kinase C) inhibitor
h 89	[no description available]	medium	1	0	N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide
n-methyl-n-(trimethylsilyl)trifluoroacetamide	[no description available]	medium	1	0	monocarboxylic acid amide; N-silyl compound; trifluoroacetamide	chromatographic reagent
4-chloro-7-nitrobenzofurazan	[no description available]	medium	3	0	benzoxadiazole; C-nitro compound; organochlorine compound	EC 1.4.3.4 (monoamine oxidase) inhibitor; EC 3.6.1.3 (adenosinetriphosphatase) inhibitor; fluorescent probe; fluorochrome
7-fluoro-4-nitrobenzo-2-oxa-1,3-diazole	[no description available]	medium	2	0
ginsenoside rg1	[no description available]	medium	1	0	12beta-hydroxy steroid; 3beta-hydroxy-4,4-dimethylsteroid; beta-D-glucoside; ginsenoside; tetracyclic triterpenoid	neuroprotective agent; pro-angiogenic agent
n-ethyl-1-phenylcyclohexylamine	[no description available]	medium	1	0
tenocyclidine	[no description available]	medium	1	0	piperidines; tertiary amino compound; thiophenes	central nervous system stimulant; hallucinogen; neuroprotective agent; NMDA receptor antagonist
ecopipam	[no description available]	medium	2	0	benzazepine
naxagolide	[no description available]	medium	1	0	organic heterotricyclic compound; phenols; tertiary amino compound	anticonvulsant; antiparkinson drug; dopamine agonist
n-(2,6-dimethylergoline-8-yl)-2,2-dimethylpropanamide	[no description available]	medium	1	0
sk&f 77434	[no description available]	medium	1	0	benzazepine; catechols; tertiary amino compound	dopamine agonist
s-adenosylmethionine	[no description available]	medium	1	0	organic cation; sulfonium compound	coenzyme; cofactor; human metabolite; micronutrient; Mycoplasma genitalium metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
4-(4,5-diphenyl-1h-imidazol-2-yl)benzoyl chloride	[no description available]	medium	1	0
omega-agatoxin iva	[no description available]	medium	1	0
dansyl chloride	[no description available]	medium	3	0	aminonaphthalene; sulfonic acid derivative
sapropterin	[no description available]	medium	3	0	5,6,7,8-tetrahydrobiopterin	coenzyme; cofactor; diagnostic agent; human metabolite
zipeprol	[no description available]	medium	1	0	benzyl ether
enkephalin, leucine-2-alanine	[no description available]	medium	5	0
ditiocarb	[no description available]	medium	3	0	dithiocarbamic acids	chelator; copper chelator
sidnocarb	[no description available]	medium	3	0
selenium	[no description available]	medium	4	0	chalcogen; nonmetal atom	micronutrient
bdp 12	[no description available]	medium	1	0	N-acylpiperidine
guanosine monophosphate	[no description available]	medium	1	0	guanosine 5'-phosphate; purine ribonucleoside 5'-monophosphate	biomarker; Escherichia coli metabolite; metabolite; mouse metabolite
guanosine 5'-monophosphorothioate	[no description available]	medium	1	0
ouabain	[no description available]	medium	2	0	11alpha-hydroxy steroid; 14beta-hydroxy steroid; 5beta-hydroxy steroid; alpha-L-rhamnoside; cardenolide glycoside; steroid hormone	anti-arrhythmia drug; cardiotonic drug; EC 2.3.3.1 [citrate (Si)-synthase] inhibitor; EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; ion transport inhibitor; plant metabolite
hexamethonium	[no description available]	medium	1	0	quaternary ammonium salt
peroxynitric acid	[no description available]	medium	6	0	nitrogen oxoacid
bis(2,4,6-trichlorophenyl)oxalate	[no description available]	medium	1	0
1,4-dihydropyridine	[no description available]	medium	2	2
4-methylaminorex	[no description available]	medium	1	0
oleylamide	[no description available]	medium	1	0	primary fatty amide	human metabolite; plant metabolite
1-(3-chlorophenyl)biguanide	[no description available]	medium	1	0	biguanides; monochlorobenzenes
biguanides	[no description available]	medium	1	0	guanidines
conotoxin gv	[no description available]	medium	1	0
indatraline	[no description available]	medium	1	0	indanes
n(6)-cyclohexyladenosine	[no description available]	medium	1	0
furfenorex	[no description available]	medium	2	0	amphetamines
pirenzepine	[no description available]	medium	1	0	pyridobenzodiazepine	anti-ulcer drug; antispasmodic drug; muscarinic antagonist
okadaic acid	[no description available]	medium	2	0	ketal
calyculin a	[no description available]	medium	1	0
furafylline	[no description available]	medium	1	0	oxopurine
fluorexon	[no description available]	medium	1	0	xanthene dye	fluorochrome
acridines	[no description available]	medium	2	0	acridines; mancude organic heterotricyclic parent; polycyclic heteroarene	genotoxin
elacridar	[no description available]	medium	1	0
5-iodotubercidin	[no description available]	medium	1	0	organoiodine compound
tubercidin	[no description available]	medium	1	0	antibiotic antifungal agent; N-glycosylpyrrolopyrimidine; ribonucleoside	antimetabolite; antineoplastic agent; bacterial metabolite
dilazep	[no description available]	medium	1	0	benzoate ester; diazepane; diester; methoxybenzenes	cardioprotective agent; platelet aggregation inhibitor; vasodilator agent
adenosine kinase	[no description available]	medium	1	0
3-bromo-7-nitroindazole	[no description available]	medium	1	0
s-methylthiocitrulline	[no description available]	medium	1	0	imidothiocarbamic ester; L-arginine derivative; L-ornithine derivative; non-proteinogenic L-alpha-amino acid	EC 1.14.13.39 (nitric oxide synthase) inhibitor; neuroprotective agent
benzamidoxime	[no description available]	medium	1	0	amidoxime	bacterial metabolite; genotoxin; mammalian metabolite
oxymatrine	[no description available]	medium	1	0
2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide	[no description available]	medium	1	0
egtazic acid	[no description available]	medium	2	0	diether; tertiary amino compound; tetracarboxylic acid	chelator
trimethyltin	[no description available]	medium	1	0
tetraphenylphosphonium	[no description available]	medium	1	0	heteroorganic entity; phosphorus molecular entity; polyatomic cation
neuromedin n	[no description available]	medium	1	0
methadyl acetate	[no description available]	medium	1	0	diarylmethane
lofexidine	[no description available]	medium	1	0	aromatic ether; carboxamidine; dichlorobenzene; imidazoles	alpha-adrenergic agonist; antihypertensive agent
lubeluzole	[no description available]	medium	1	0	benzothiazoles
veratridine	[no description available]	medium	1	0
proadifen	[no description available]	medium	5	0	diarylmethane
alloxan	[no description available]	medium	1	0	pyrimidone	hyperglycemic agent; metabolite
tert-butylhydroperoxide	[no description available]	medium	1	0	alkyl hydroperoxide	antibacterial agent; oxidising agent
angiotensinogen	[no description available]	medium	1	0
flb 457	[no description available]	medium	1	0
heptaminol	[no description available]	medium	1	0	tertiary alcohol
1,3-dipropyl-8-cyclopentylxanthine	[no description available]	medium	1	0	oxopurine	adenosine A1 receptor antagonist; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
methyl chloride	[no description available]	medium	1	0	chloromethanes; methyl halides	marine metabolite; mutagen; refrigerant
tele-methylhistamine	[no description available]	medium	2	0	imidazoles; primary amino compound	human metabolite; mouse metabolite
indophenol	[no description available]	medium	1	0	quinone imine	dye
sib 1893	[no description available]	medium	1	0
phosphothreonine	[no description available]	medium	1	0	L-threonine derivative; non-proteinogenic L-alpha-amino acid; O-phosphoamino acid	Escherichia coli metabolite
prenylamine	[no description available]	medium	2	0	diarylmethane
an 1	[no description available]	medium	1	0	amphetamines
palmitic acid	[no description available]	medium	1	1	long-chain fatty acid; straight-chain saturated fatty acid	algal metabolite; Daphnia magna metabolite; EC 1.1.1.189 (prostaglandin-E2 9-reductase) inhibitor; plant metabolite
5-s-cysteinyldopamine	[no description available]	medium	1	0	S-conjugate
cysteinyldopa	[no description available]	medium	1	0	catecholamine; zwitterion
5-s-cysteinyl-3,4-dihydroxyphenylacetic acid	[no description available]	medium	1	0
aminorex	[no description available]	medium	1	0	benzenes
3-methoxytyrosine	[no description available]	medium	2	0	tyrosine derivative
diacetylfluorescein	[no description available]	medium	1	0
trifluperidol	[no description available]	medium	2	0	aromatic ketone
indenolol	[no description available]	medium	1	0
uridine diphosphate xylose	[no description available]	medium	1	0	UDP-sugar	fundamental metabolite
trimetozine	[no description available]	medium	1	0	morpholines
procaterol	[no description available]	medium	1	0	quinolines
methysergide	[no description available]	medium	5	0	ergoline alkaloid
gallopamil	[no description available]	medium	1	0	benzenes; organic amino compound
harmaline	[no description available]	medium	5	0	harmala alkaloid	oneirogen
tryptoline	[no description available]	medium	1	0	beta-carbolines
etoperidone	[no description available]	medium	1	0	piperazines
bis(4-methyl-1-homopiperazinylthiocarbonyl)disulfide	[no description available]	medium	3	0
iothalamate meglumine	[no description available]	medium	1	0	amidobenzoic acid
penfluridol	[no description available]	medium	2	0	diarylmethane
tremorine	[no description available]	medium	7	0	N-alkylpyrrolidine
nafronyl	[no description available]	medium	1	0	naphthalenes
adenosine diphosphate	[no description available]	medium	1	0	adenosine 5'-phosphate; purine ribonucleoside 5'-diphosphate	fundamental metabolite; human metabolite
rubidium	[no description available]	medium	2	0	alkali metal atom
phenylthiazolylthiourea	[no description available]	medium	3	0
nikethamide	[no description available]	medium	4	0	pyridinecarboxamide
flupenthixol	[no description available]	medium	3	0	thioxanthenes
spermidine	[no description available]	medium	3	0	polyazaalkane; triamine	autophagy inducer; fundamental metabolite; geroprotector
chlorprothixene	[no description available]	medium	2	0	chlorprothixene
fluorescamine	[no description available]	medium	1	0
diquat	[no description available]	medium	1	0	organic cation	defoliant; herbicide
dexetimide	[no description available]	medium	1	0	piperidines
mr 2266	[no description available]	medium	1	0
perfluorotributylamine	[no description available]	medium	1	0	organofluorine compound	blood substitute; greenhouse gas; solvent
aspirin, butalbital and caffeine drug combination	[no description available]	medium	1	0
iofetamine	[no description available]	medium	2	0
bromperidol	[no description available]	medium	1	0	aromatic ketone
mosapramine	[no description available]	medium	2	0	azaspiro compound; dibenzoazepine; organochlorine compound; tertiary amino compound
theobromine	[no description available]	medium	1	0	dimethylxanthine	adenosine receptor antagonist; bronchodilator agent; food component; human blood serum metabolite; mouse metabolite; plant metabolite; vasodilator agent
4-(n,n-dimethylaminosulfonyl)-7-fluoro-2,1,3-benzoxadiazole	[no description available]	medium	1	0
4-carbethoxyhexafluorobutyryl chloride	[no description available]	medium	2	0
putrescine	[no description available]	medium	1	0	alkane-alpha,omega-diamine	antioxidant; fundamental metabolite
ornithine	[no description available]	medium	1	0	non-proteinogenic L-alpha-amino acid; ornithine	algal metabolite; hepatoprotective agent; mouse metabolite
eliprodil	[no description available]	medium	1	0	monochlorobenzenes; monofluorobenzenes; piperidines; secondary alcohol; tertiary amino compound
3-hexylsalicylic acid	[no description available]	medium	2	0
wb 4101	[no description available]	medium	3	0	aromatic ether; benzodioxine; secondary amino compound	alpha-adrenergic antagonist
ici 118551	[no description available]	medium	1	0	aromatic ether; indanes; secondary alcohol; secondary amino compound	beta-adrenergic antagonist
quisqualic acid	[no description available]	medium	1	0	non-proteinogenic alpha-amino acid
lomerizine	[no description available]	medium	1	0	diarylmethane
azetirelin	[no description available]	medium	2	0
menthyl chloroformate	[no description available]	medium	1	0
15-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic acid	[no description available]	medium	1	0
cytidine diphosphate	[no description available]	medium	1	0	cytidine 5'-phosphate; pyrimidine ribonucleoside 5'-diphosphate	Escherichia coli metabolite; mouse metabolite
setiptiline	[no description available]	medium	1	0	tertiary amino compound; tetracyclic antidepressant	alpha-adrenergic antagonist; serotonergic antagonist
butylscopolammonium bromide	[no description available]	medium	1	0
mergocriptine	[no description available]	medium	1	0
n-n-propyl-n-phenylethyl-4(3-hydroxyphenyl)ethylamine hydrochloride	[no description available]	medium	1	0
benzenaminium, 4,4'-(3-oxo-1,5-pentanediyl)bis(n,n-dimethyl-n-2-propenyl-), dibromide	[no description available]	medium	1	0
6-(n-(4-aminobutyl)-n-ethyl)amino-2,3-dihydrophthalazine-1,4-dione	[no description available]	medium	1	0	phthalazines
potassium carbonate	[no description available]	medium	1	0	carbonate salt; potassium salt	catalyst; fertilizer; flame retardant
neurokinin a	[no description available]	medium	1	0
isomhpg	[no description available]	medium	1	0	methoxybenzenes; phenols
enclomiphene	[no description available]	medium	2	0
cianopramine	[no description available]	medium	1	0
tamolarizine	[no description available]	medium	1	0
n-methyl-bis(trifluoroacetamide)	[no description available]	medium	1	0
etorphine	[no description available]	medium	1	0
propiverine	[no description available]	medium	1	0	diarylmethane
droxidopa	[no description available]	medium	1	0	catechols; L-tyrosine derivative	antihypertensive agent; prodrug; vasoconstrictor agent
ergonovine	[no description available]	medium	2	0	ergot alkaloid; monocarboxylic acid amide; organic heterotetracyclic compound; primary alcohol; secondary amino compound; tertiary amino compound	diagnostic agent; fungal metabolite; oxytocic; toxin
fluorine	[no description available]	medium	7	0	diatomic fluorine; gas molecular entity	NMR chemical shift reference compound
mevalonic acid	[no description available]	medium	1	0	3,5-dihydroxy-3-methylpentanoic acid
pantogab	[no description available]	medium	2	0
3-methylcholanthrene	[no description available]	medium	3	0	ortho- and peri-fused polycyclic arene	aryl hydrocarbon receptor agonist; carcinogenic agent
cesium	[no description available]	medium	1	0	alkali metal atom
cesium chloride	[no description available]	medium	1	0	inorganic caesium salt; inorganic chloride	phase-transfer catalyst; vasoconstrictor agent
methiothepin	[no description available]	medium	1	0	aryl sulfide; dibenzothiepine; N-alkylpiperazine; tertiary amino compound	antipsychotic agent; dopaminergic antagonist; geroprotector; serotonergic antagonist
kaolinite	[no description available]	medium	1	0	aluminosilicate mineral; mixture	antidiarrhoeal drug; excipient
cinanserin	[no description available]	medium	1	0	aryl sulfide; cinnamamides; secondary carboxamide; tertiary amino compound	anticoronaviral agent; antiviral agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor
cannabinol	[no description available]	medium	1	0	dibenzopyran
4-amino-5-hexynoic acid	[no description available]	medium	1	0
dinitrofluorobenzene	[no description available]	medium	1	0	C-nitro compound; organofluorine compound	agrochemical; allergen; chromatographic reagent; EC 2.7.3.2 (creatine kinase) inhibitor; protein-sequencing agent; spectrophotometric reagent
camphor, (+-)-isomer	[no description available]	medium	2	0	bornane monoterpenoid; cyclic monoterpene ketone	plant metabolite
gentamicin	[no description available]	medium	1	0
rhodamine b	[no description available]	medium	1	0	organic chloride salt; xanthene dye	fluorescent probe; fluorochrome; histological dye
rhodamine 6g	[no description available]	medium	1	0
pyronine	[no description available]	medium	1	0	iminium salt; organic chloride salt	histological dye
procaine hydrochloride	[no description available]	medium	1	0	organic molecular entity
harmine	[no description available]	medium	1	0	harmala alkaloid	anti-HIV agent; EC 1.4.3.4 (monoamine oxidase) inhibitor; metabolite
ammonium sulfate	[no description available]	medium	1	0	ammonium salt; inorganic sulfate salt	fertilizer
n-phenylethanolamine	[no description available]	medium	1	0	aralkylamine
skimmianine	[no description available]	medium	1	0	alkaloid antibiotic; organic heterotricyclic compound; organonitrogen heterocyclic compound; oxacycle
dodecyl sulfate	[no description available]	medium	1	0	alkyl sulfate
tetragastrin	[no description available]	medium	1	0	peptidyl amide; tetrapeptide	anxiogenic; human metabolite
proglumide	[no description available]	medium	1	0	benzamides; dicarboxylic acid monoamide; glutamine derivative; racemate	anti-ulcer drug; cholecystokinin antagonist; cholinergic antagonist; delta-opioid receptor agonist; drug metabolite; gastrointestinal drug; opioid analgesic; xenobiotic metabolite
gastrins	[no description available]	medium	1	0
1,3-diphenyl-2-aminopropane	[no description available]	medium	1	0
phenylisothiocyanate	[no description available]	medium	1	0	isothiocyanate	allergen; reagent
osmium	[no description available]	medium	1	0	iron group element atom; platinum group metal atom
dibenzylchlorethamine	[no description available]	medium	2	0
nitrophenols	[no description available]	medium	2	0
morphinans	[no description available]	medium	2	0	isoquinoline alkaloid fundamental parent; morphinane alkaloid
pteridines	[no description available]	medium	1	0	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; pteridines
angiotensin ii	[no description available]	medium	3	0	amino acid zwitterion; angiotensin II	human metabolite
bradykinin	[no description available]	medium	1	0	oligopeptide	human blood serum metabolite; vasodilator agent
neostigmine	[no description available]	medium	3	0	quaternary ammonium ion	antidote to curare poisoning; EC 3.1.1.7 (acetylcholinesterase) inhibitor
glucagon	[no description available]	medium	1	0	peptide hormone
felypressin	[no description available]	medium	1	0	heterodetic cyclic peptide	vasoconstrictor agent; vasopressin receptor agonist
thiothixene	[no description available]	medium	1	0	thioxanthenes
pheniramine	[no description available]	medium	1	0	pyridines; tertiary amino compound
carbon disulfide	[no description available]	medium	1	0	one-carbon compound; organosulfur compound
alphaprodine	[no description available]	medium	1	0	piperidines
cyclazocine	[no description available]	medium	1	0
bromine	[no description available]	medium	2	0	diatomic bromine
tellurium	[no description available]	medium	1	0	chalcogen; metalloid atom
veratrine	[no description available]	medium	1	0	alkaloid
thiethylperazine	[no description available]	medium	1	0	N-methylpiperazine; phenothiazines	antiemetic; dopaminergic antagonist; histamine antagonist; muscarinic antagonist; phenothiazine antipsychotic drug; serotonergic antagonist
furaldehyde	[no description available]	medium	1	0	aldehyde; furans	Maillard reaction product; metabolite
humulene	[no description available]	medium	91	1	alpha-humulene
s,n,n'-tripropylthiocarbamate	[no description available]	medium	237	11	tertiary amine
melamine phosphate	[no description available]	medium	1	0
pica	[no description available]	medium	3	0
exudates	[no description available]	medium	7	0
isomethyleugenol	[no description available]	medium	17	0	isomethyleugenol
sabinene	[no description available]	medium	1	0	thujene	plant metabolite
fomesafen	[no description available]	medium	26	0	aromatic ether; C-nitro compound; monochlorobenzenes; N-sulfonylcarboxamide; organofluorine compound; phenols	agrochemical; EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor; herbicide
eye	[no description available]	medium	5	0
cetylpyridinium chloride anhydrous	[no description available]	medium	1	0	chloride salt; organic chloride salt	antiseptic drug; surfactant
nociceptin	[no description available]	medium	3	0	organic molecular entity; polypeptide	human metabolite; rat metabolite
propiconazole	[no description available]	medium	1	0	conazole fungicide; cyclic ketal; dichlorobenzene; triazole fungicide; triazoles	antifungal agrochemical; EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor; environmental contaminant; xenobiotic
phenylephrine hydrochloride	[no description available]	medium	1	0	hydrochloride
ego	[no description available]	medium	1	0
apnea	[no description available]	medium	1	0	purine nucleoside
diethyl phthalate	[no description available]	low	0	0	diester; ethyl ester; phthalate ester	neurotoxin; plasticiser; teratogenic agent
pseudocumene	[no description available]	low	0	0	trimethylbenzene	neurotoxin
3-dinitrobenzene	[no description available]	low	0	0	dinitrobenzene	neurotoxin
1-bromopropane	[no description available]	low	0	0	bromoalkane; bromohydrocarbon	neurotoxin; solvent
allyl cyanide	[no description available]	low	0	0	aliphatic nitrile; olefinic compound	antifeedant; neurotoxin; plant metabolite
2,5-hexanedione	[no description available]	low	0	0	diketone; methyl ketone	human xenobiotic metabolite; neurotoxin
n-hexane	[no description available]	low	0	0	alkane; volatile organic compound	neurotoxin; non-polar solvent
1,4-butanediol	[no description available]	low	0	0	butanediol; glycol	neurotoxin; prodrug; protic solvent
potassium cyanide	[no description available]	low	0	0	cyanide salt; one-carbon compound; potassium salt	EC 1.15.1.1 (superoxide dismutase) inhibitor; EC 1.9.3.1 (cytochrome c oxidase) inhibitor; neurotoxin
hemimellitene	[no description available]	low	0	0	trimethylbenzene	neurotoxin; plant metabolite
thallium acetate	[no description available]	low	0	0	acetate salt; thallium molecular entity	apoptosis inducer; neurotoxin
decabromobiphenyl ether	[no description available]	low	0	0	polybromodiphenyl ether	neurotoxin
n-butylbenzenesulfonamide	[no description available]	low	0	0	sulfonamide	neurotoxin; plant metabolite
lead chromate	[no description available]	low	0	0	chromium coordination entity; lead coordination entity	carcinogenic agent; nephrotoxin; neurotoxin
edifenphos	[no description available]	low	0	0	organic thiophosphate	antifungal agrochemical; EC 3.1.1.7 (acetylcholinesterase) inhibitor; neurotoxin; phospholipid biosynthesis inhibitor
2-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline	[no description available]	low	0	0	isoquinolinol; tertiary amino compound	human metabolite; neurotoxin; rat metabolite
vx	[no description available]	low	0	0	organic thiophosphate; tertiary amino compound	EC 3.1.1.7 (acetylcholinesterase) inhibitor; neurotoxin
oltipraz	[no description available]	low	0	0	1,2-dithiole; pyrazines	angiogenesis modulating agent; antimutagen; antineoplastic agent; antioxidant; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor; neurotoxin; protective agent; schistosomicide drug
2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine	[no description available]	low	0	0	hydroxylamine; imidazopyridine	carcinogenic agent; genotoxin; human xenobiotic metabolite; mouse metabolite; mutagen; neurotoxin; rat metabolite
beta-n-methylamino-l-alanine	[no description available]	low	0	0	diamino acid; L-alanine derivative; non-proteinogenic L-alpha-amino acid; secondary amino compound	bacterial metabolite; neurotoxin
acromelic acid a	[no description available]	low	0	0	pyridone; pyrrolidinecarboxylic acid; tricarboxylic acid	fungal metabolite; neurotoxin; NMDA receptor agonist
megestrol acetate	[no description available]	low	0	0	bridged compound; organic heterotetracyclic compound; secondary alcohol; sesquiterpene lactone; spiro compound; tertiary alcohol; tetrol	GABA antagonist; neurotoxin; phytogenic insecticide; plant metabolite
3,4-dihydroxyphenylglycolaldehyde	[no description available]	low	0	0	catechols; hydroxyaldehyde	human metabolite; mouse metabolite; neurotoxin
aminochrome 1	[no description available]	low	0	0	indoledione; orthoquinones	neurotoxin
domoic acid	[no description available]	low	0	0	L-proline derivative; non-proteinogenic L-alpha-amino acid; pyrrolidinecarboxylic acid; tricarboxylic acid	algal metabolite; hapten; marine metabolite; neuromuscular agent; neurotoxin
t-2 toxin	[no description available]	low	0	0	acetate ester; organic heterotetracyclic compound; trichothecene	apoptosis inducer; cardiotoxic agent; DNA synthesis inhibitor; environmental contaminant; fungal metabolite; mycotoxin; neurotoxin
resiniferatoxin	[no description available]	low	0	0	carboxylic ester; diterpenoid; enone; monomethoxybenzene; organic heteropentacyclic compound; ortho ester; phenols; tertiary alpha-hydroxy ketone	analgesic; neurotoxin; plant metabolite; TRPV1 agonist
dysiherbaine	[no description available]	low	0	0	amino dicarboxylic acid; furopyran; hydroxy carboxylic acid; secondary amino compound	animal metabolite; excitatory amino acid agonist; marine metabolite; neurotoxin
decarbamylsaxitoxin	[no description available]	low	0	0	alkaloid; guanidines; ketone hydrate; paralytic shellfish toxin; primary alcohol; pyrrolopurine	bacterial metabolite; marine metabolite; neurotoxin; toxin; xenobiotic
saxitoxin	[no description available]	low	0	0	alkaloid; carbamate ester; guanidines; ketone hydrate; paralytic shellfish toxin; pyrrolopurine	cyanotoxin; marine metabolite; neurotoxin; sodium channel blocker; toxin
noribogaine	[no description available]	low	0	0	monoterpenoid indole alkaloid; organic heteropentacyclic compound; secondary amino compound; tertiary amino compound	kappa-opioid receptor agonist; NMDA receptor antagonist; psychotropic drug; serotonin uptake inhibitor
cytidine diphosphate choline	[no description available]	low	0	0	nucleotide-(amino alcohol)s; phosphocholines	human metabolite; mouse metabolite; neuroprotective agent; psychotropic drug; Saccharomyces cerevisiae metabolite
cgs 15943	[no description available]	low	0	0	aromatic amine; biaryl; furans; organochlorine compound; primary amino compound; quinazolines; triazoloquinazoline	adenosine A1 receptor antagonist; adenosine A2A receptor antagonist; antineoplastic agent; central nervous system stimulant
1,7-dimethylxanthine	[no description available]	low	0	0	dimethylxanthine	central nervous system stimulant; human blood serum metabolite; human xenobiotic metabolite; mouse metabolite
8-chlorotheophylline	[no description available]	low	0	0	organochlorine compound; purines	central nervous system stimulant
almitrine	[no description available]	low	0	0	piperazines; triamino-1,3,5-triazine	central nervous system stimulant
cocaine hydrochloride	[no description available]	low	0	0	hydrochloride	central nervous system stimulant; local anaesthetic
almitrine dimesylate	[no description available]	low	0	0	methanesulfonate salt	central nervous system stimulant
octane	[no description available]	low	0	0	alkane	xenobiotic
2-nitropropane	[no description available]	low	0	0	secondary nitroalkane	carcinogenic agent; hepatotoxic agent; polar aprotic solvent; xenobiotic
dibenzofuran	[no description available]	low	0	0	dibenzofurans; mancude organic heterotricyclic parent; polycyclic heteroarene	xenobiotic
acetochlor	[no description available]	low	0	0	aromatic amide; monocarboxylic acid amide; organochlorine compound	environmental contaminant; herbicide; xenobiotic
alachlor	[no description available]	low	0	0	aromatic amide; monocarboxylic acid amide; organochlorine compound	environmental contaminant; herbicide; xenobiotic
antazoline	[no description available]	low	0	0	aromatic amine; imidazolines; tertiary amino compound	cholinergic antagonist; H1-receptor antagonist; xenobiotic
atrazine	[no description available]	low	0	0	chloro-1,3,5-triazine; diamino-1,3,5-triazine	environmental contaminant; herbicide; xenobiotic
bentazone	[no description available]	low	0	0	benzothiadiazine	environmental contaminant; herbicide; xenobiotic
chlorpyrifos	[no description available]	low	0	0	chloropyridine; organic thiophosphate	acaricide; agrochemical; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; environmental contaminant; insecticide; xenobiotic
diazinon	[no description available]	low	0	0	organic thiophosphate; pyrimidines	acaricide; agrochemical; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; environmental contaminant; nematicide; xenobiotic
dicamba	[no description available]	low	0	0	dichlorobenzene; methoxybenzoic acid	agrochemical; environmental contaminant; herbicide; synthetic auxin; xenobiotic
dichlobanil	[no description available]	low	0	0	dichlorobenzene; nitrile	agrochemical; cellulose synthesis inhibitor; environmental contaminant; herbicide; xenobiotic
dimethoate	[no description available]	low	0	0	monocarboxylic acid amide; organic thiophosphate	acaricide; agrochemical; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; environmental contaminant; insecticide; xenobiotic
diuron	[no description available]	low	0	0	3-(3,4-substituted-phenyl)-1,1-dimethylurea; dichlorobenzene	environmental contaminant; mitochondrial respiratory-chain inhibitor; photosystem-II inhibitor; urea herbicide; xenobiotic
iomeprol	[no description available]	low	0	0	benzenedicarboxamide; organoiodine compound	environmental contaminant; radioopaque medium; xenobiotic
tetramisole	[no description available]	low	0	0	imidazothiazole	environmental contaminant; xenobiotic
methomyl	[no description available]	low	0	0	aliphatic sulfide; carbamate ester	acaricide; agrochemical; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; environmental contaminant; insecticide; nematicide; xenobiotic
prometone	[no description available]	low	0	0	diamino-1,3,5-triazine; methoxy-1,3,5-triazine	environmental contaminant; herbicide; xenobiotic
prometryne	[no description available]	low	0	0	diamino-1,3,5-triazine; methylthio-1,3,5-triazine	environmental contaminant; herbicide; xenobiotic
propachlor	[no description available]	low	0	0	anilide; monocarboxylic acid amide; organochlorine compound	environmental contaminant; herbicide; xenobiotic
propazine	[no description available]	low	0	0	chloro-1,3,5-triazine; diamino-1,3,5-triazine	environmental contaminant; herbicide; xenobiotic
simazine	[no description available]	low	0	0	chloro-1,3,5-triazine; diamino-1,3,5-triazine	environmental contaminant; herbicide; xenobiotic
trifluralin	[no description available]	low	0	0	(trifluoromethyl)benzenes; C-nitro compound; substituted aniline	agrochemical; environmental contaminant; herbicide; xenobiotic
2-methyl-4-chlorophenoxy gamma-butyric acid	[no description available]	low	0	0	aromatic ether; monocarboxylic acid; monochlorobenzenes	environmental contaminant; phenoxy herbicide; xenobiotic
benzotriazole	[no description available]	low	0	0	benzotriazoles	environmental contaminant; xenobiotic
benzothiazole	[no description available]	low	0	0	benzothiazoles	environmental contaminant; plant metabolite; xenobiotic
3,4-dichloroaniline	[no description available]	low	0	0	dichloroaniline	epitope; xenobiotic
triclocarban	[no description available]	low	0	0	dichlorobenzene; monochlorobenzenes; phenylureas	antimicrobial agent; antiseptic drug; disinfectant; environmental contaminant; xenobiotic
fenuron	[no description available]	low	0	0	3-(3,4-substituted-phenyl)-1,1-dimethylurea	agrochemical; environmental contaminant; herbicide; photosystem-II inhibitor; xenobiotic
cyanuric acid	[no description available]	low	0	0	1,3,5-triazinanes; 1,3,5-triazines; heteroaryl hydroxy compound	xenobiotic
diglyme	[no description available]	low	0	0	polyether	environmental contaminant; solvent; xenobiotic
propylene	[no description available]	low	0	0	alkene; gas molecular entity	refrigerant; xenobiotic
2-naphthalenesulfonic acid	[no description available]	low	0	0	naphthalenesulfonic acid	environmental contaminant; xenobiotic
4-sulfanilic acid	[no description available]	low	0	0	aminobenzenesulfonic acid	allergen; environmental contaminant; xenobiotic metabolite; xenobiotic
5-tolyltriazole	[no description available]	low	0	0	benzotriazoles	environmental contaminant; xenobiotic
monuron	[no description available]	low	0	0	3-(3,4-substituted-phenyl)-1,1-dimethylurea; monochlorobenzenes	environmental contaminant; herbicide; xenobiotic
linuron	[no description available]	low	0	0	dichlorobenzene; phenylureas	agrochemical; environmental contaminant; herbicide; xenobiotic
perfluorodecanoic acid	[no description available]	low	0	0	fluoroalkanoic acid	environmental contaminant; xenobiotic
triphenylmethane	[no description available]	low	0	0	triarylmethane	environmental contaminant; xenobiotic
3-methylquinoline	[no description available]	low	0	0	methylquinoline	xenobiotic
terbutryne	[no description available]	low	0	0	diamino-1,3,5-triazine; methylthio-1,3,5-triazine	environmental contaminant; herbicide; xenobiotic
metformin hydrochloride	[no description available]	low	0	0	hydrochloride	environmental contaminant; hypoglycemic agent; xenobiotic
ioxynil	[no description available]	low	0	0	iodophenol; nitrile	environmental contaminant; herbicide; xenobiotic
bromoxynil	[no description available]	low	0	0	dibromobenzene; hydroxynitrile; phenols	environmental contaminant; herbicide; xenobiotic
pyrazon	[no description available]	low	0	0	benzenes; organochlorine compound; primary amino compound; pyridazinone	environmental contaminant; herbicide; xenobiotic
methiocarb	[no description available]	low	0	0	aryl sulfide; carbamate ester; methyl sulfide	acaricide; agrochemical; avicide; EC 3.1.1.7 (acetylcholinesterase) inhibitor; environmental contaminant; insecticide; molluscicide; xenobiotic
lenacil	[no description available]	low	0	0	cyclopentapyrimidine	agrochemical; environmental contaminant; herbicide; xenobiotic
fluometuron	[no description available]	low	0	0	(trifluoromethyl)benzenes; 3-(3,4-substituted-phenyl)-1,1-dimethylurea	agrochemical; environmental contaminant; herbicide; photosystem-II inhibitor; xenobiotic
1,2-benzisothiazoline-3-one	[no description available]	low	0	0	organic heterobicyclic compound; organonitrogen heterocyclic compound	disinfectant; drug allergen; environmental contaminant; platelet aggregation inhibitor; sensitiser; xenobiotic
asulam	[no description available]	low	0	0	carbamate ester; primary amino compound; substituted aniline; sulfonamide	agrochemical; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; herbicide; xenobiotic
chlorpyrifos-methyl	[no description available]	low	0	0	chloropyridine; organic thiophosphate	acaricide; agrochemical; EC 3.1.1.7 (acetylcholinesterase) inhibitor; environmental contaminant; insecticide; xenobiotic
terbutylazine	[no description available]	low	0	0	chloro-1,3,5-triazine; diamino-1,3,5-triazine	environmental contaminant; herbicide; xenobiotic
1-indanol	[no description available]	low	0	0	aromatic alcohol; indanes; secondary alcohol	xenobiotic
desmedipham	[no description available]	low	0	0	carbamate ester	agrochemical; environmental contaminant; herbicide; xenobiotic
phenmedipham	[no description available]	low	0	0	carbamate ester	environmental contaminant; herbicide; xenobiotic
chlortoluron	[no description available]	low	0	0	monochlorobenzenes; phenylureas	agrochemical; environmental contaminant; herbicide; xenobiotic
methoxuron	[no description available]	low	0	0	3-(3,4-substituted-phenyl)-1,1-dimethylurea; monochlorobenzenes; monomethoxybenzene	agrochemical; environmental contaminant; herbicide; photosystem-II inhibitor; plant growth regulator; xenobiotic
neohesperidin dihydrochalcone	[no description available]	low	0	0	dihydrochalcones; disaccharide derivative; neohesperidoside	environmental contaminant; plant metabolite; sweetening agent; xenobiotic
metribuzin	[no description available]	low	0	0	1,2,4-triazines; cyclic ketone; organic sulfide	agrochemical; environmental contaminant; herbicide; xenobiotic
cyanazine	[no description available]	low	0	0	1,3,5-triazinylamino nitrile; chloro-1,3,5-triazine	environmental contaminant; herbicide; xenobiotic
pirimicarb	[no description available]	low	0	0	aminopyrimidine; carbamate ester; tertiary amino compound	agrochemical; carbamate insecticide; EC 3.1.1.7 (acetylcholinesterase) inhibitor; environmental contaminant; insecticide; xenobiotic
5-chloro-2-methyl-4-isothiazolin-3-one	[no description available]	low	0	0	1,2-thiazoles; organochlorine compound	antimicrobial agent; environmental contaminant; xenobiotic
2-n-octyl-4-isothiazolin-3-one	[no description available]	low	0	0	1,2-thiazoles	antibacterial agent; antifungal agrochemical; environmental contaminant; xenobiotic
ioxitalamic acid	[no description available]	low	0	0	acetamides; benzoic acids; dicarboxylic acid monoamide; organoiodine compound	environmental contaminant; radioopaque medium; xenobiotic
amitraz	[no description available]	low	0	0	formamidines; tertiary amino compound	acaricide; environmental contaminant; insecticide; xenobiotic
acetosulfame	[no description available]	low	0	0	organic heteromonocyclic compound; organonitrogen heterocyclic compound; oxacycle; sulfamate ester	environmental contaminant; sweetening agent; xenobiotic
isoproturon	[no description available]	low	0	0	3-(3,4-substituted-phenyl)-1,1-dimethylurea	agrochemical; environmental contaminant; herbicide; xenobiotic
metamitron	[no description available]	low	0	0	1,2,4-triazines	environmental contaminant; herbicide; xenobiotic
triclopyr	[no description available]	low	0	0	aromatic ether; chloropyridine; monocarboxylic acid	agrochemical; environmental contaminant; herbicide; xenobiotic
metazachlor	[no description available]	low	0	0	aromatic amide; organochlorine compound; pyrazoles	environmental contaminant; herbicide; xenobiotic
4,5-amino-3,5-dichloro-6-fluoro-2-pyridinyloxyacetic acid	[no description available]	low	0	0	aminopyridine; aromatic ether; monocarboxylic acid; organochlorine compound; organofluorine compound	environmental contaminant; herbicide; xenobiotic
fenoxycarb	[no description available]	low	0	0	aromatic ether; carbamate ester	environmental contaminant; insecticide; juvenile hormone mimic; xenobiotic
metsulfuron methyl	[no description available]	low	0	0	1,3,5-triazines; benzoate ester; N-sulfonylurea	environmental contaminant; herbicide; xenobiotic
clomazone	[no description available]	low	0	0	isoxazolidinone; monochlorobenzenes	agrochemical; carotenoid biosynthesis inhibitor; environmental contaminant; herbicide; xenobiotic
prosulfocarb	[no description available]	low	0	0	benzenes; monothiocarbamic ester	environmental contaminant; herbicide; xenobiotic
3-iodo-2-propynylbutylcarbamate	[no description available]	low	0	0	acetylenic compound; carbamate ester; carbamate fungicide; organoiodine compound	antifungal agrochemical; environmental contaminant; xenobiotic
iobitridol	[no description available]	low	0	0	benzenedicarboxamide; hexol; organoiodine compound	environmental contaminant; radioopaque medium; xenobiotic
perfluorohexanoic acid	[no description available]	low	0	0	fluoroalkanoic acid	environmental contaminant; xenobiotic
perfluoro-n-heptanoic acid	[no description available]	low	0	0	fluoroalkanoic acid	environmental contaminant; xenobiotic
perfluoro-n-nonanoic acid	[no description available]	low	0	0	fluoroalkanoic acid	persistent organic pollutant; surfactant; xenobiotic
trichlorosucrose	[no description available]	low	0	0	disaccharide derivative; organochlorine compound	environmental contaminant; sweetening agent; xenobiotic
nicosulfuron	[no description available]	low	0	0	N-sulfonylurea; pyridines; pyrimidines	environmental contaminant; herbicide; xenobiotic
prochloraz	[no description available]	low	0	0	amide fungicide; aromatic ether; conazole fungicide; imidazole fungicide; imidazoles; trichlorobenzene; ureas	antifungal agrochemical; EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor; environmental contaminant; xenobiotic
thifensulfuron methyl	[no description available]	low	0	0	1,3,5-triazines; methyl ester; N-sulfonylurea; thiophenes	agrochemical; environmental contaminant; herbicide; xenobiotic
flusilazole	[no description available]	low	0	0	conazole fungicide; monofluorobenzenes; organosilicon compound; triazole fungicide; triazoles	antifungal agrochemical; EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor; environmental contaminant; xenobiotic
perfluoropentanoic acid	[no description available]	low	0	0	fluoroalkanoic acid	environmental contaminant; xenobiotic
perfluoroundecanoic acid	[no description available]	low	0	0	fluoroalkanoic acid	environmental contaminant; xenobiotic
sulfluramid	[no description available]	low	0	0	sulfonamide	acaricide; environmental contaminant; insecticide; xenobiotic
spiroxamine	[no description available]	low	0	0	dioxolane; spiroketal; tertiary amino compound	antifungal agrochemical; environmental contaminant; sterol biosynthesis inhibitor; xenobiotic
difenoconazole	[no description available]	low	0	0	aromatic ether; conazole fungicide; cyclic ketal; dioxolane; triazole fungicide; triazoles	antifungal agrochemical; EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor; environmental contaminant; xenobiotic
dimethomorph	[no description available]	low	0	0	mixture; morpholine fungicide	antifungal agrochemical; environmental contaminant; xenobiotic
cyprodinil	[no description available]	low	0	0	aminopyrimidine; anilinopyrimidine fungicide; cyclopropanes; secondary amino compound	antifungal agrochemical; aryl hydrocarbon receptor agonist; environmental contaminant; xenobiotic
imidacloprid	[no description available]	low	0	0	imidacloprid; imidazolidines; monochloropyridine	environmental contaminant; genotoxin; neonicotinoid insectide; nicotinic acetylcholine receptor agonist; xenobiotic
foe 5043	[no description available]	low	0	0	aromatic amide; monofluorobenzenes; thiadiazoles	environmental contaminant; herbicide; xenobiotic
irgarol 1051	[no description available]	low	0	0	aryl sulfide; cyclopropanes; diamino-1,3,5-triazine	antifouling biocide; environmental contaminant; xenobiotic
pyrimethanil	[no description available]	low	0	0	aminopyrimidine; anilinopyrimidine fungicide; secondary amino compound	antifungal agrochemical; aryl hydrocarbon receptor agonist; environmental contaminant; xenobiotic
kathon 930	[no description available]	low	0	0	1,2-thiazoles; organochlorine compound	environmental contaminant; fungicide; xenobiotic
fluazinam	[no description available]	low	0	0	(trifluoromethyl)benzenes; aminopyridine; C-nitro compound; chloropyridine; monochlorobenzenes; secondary amino compound	allergen; antifungal agrochemical; apoptosis inducer; environmental contaminant; xenobiotic
teflubenzuron	[no description available]	low	0	0	dichlorobenzene; difluorobenzene; N-acylurea	environmental contaminant; insecticide; xenobiotic
diflufenican	[no description available]	low	0	0	(trifluoromethyl)benzenes; aromatic ether; pyridinecarboxamide	carotenoid biosynthesis inhibitor; environmental contaminant; herbicide; xenobiotic
sulcotrione	[no description available]	low	0	0	aromatic ketone; beta-triketone; cyclohexanones; sulfone	carotenoid biosynthesis inhibitor; environmental contaminant; herbicide; xenobiotic
tebufenozide	[no description available]	low	0	0	carbohydrazide	ecdysone agonist; environmental contaminant; xenobiotic
dpx e9636	[no description available]	low	0	0	aromatic ether; N-sulfonylurea; pyridines; pyrimidines; sulfone	environmental contaminant; herbicide; xenobiotic
arsenocholine	[no description available]	low	0	0	arsonium ion; organoarsenic compound	human urinary metabolite; marine metabolite; xenobiotic
methoxyfenozide	[no description available]	low	0	0	carbohydrazide; monomethoxybenzene	environmental contaminant; insecticide; xenobiotic
thiamethoxam	[no description available]	low	0	0	1,3-thiazoles; 2-nitroguanidine derivative; organochlorine compound; oxadiazane	antifeedant; carcinogenic agent; environmental contaminant; neonicotinoid insectide; xenobiotic
thiacloprid	[no description available]	low	0	0	monochloropyridine; nitrile; thiazolidines	environmental contaminant; neonicotinoid insectide; xenobiotic
2-ethyl-5-carboxypentyl phthalate	[no description available]	low	0	0	phthalic acid monoester	xenobiotic
carpropamid	[no description available]	low	0	0	amide fungicide; cyclopropylcarboxamide; monochlorobenzenes	antifungal agrochemical; EC 4.2.1.94 (scytalone dehydratase) inhibitor; melanin synthesis inhibitor; xenobiotic
mesotrione	[no description available]	low	0	0	aromatic ketone; beta-triketone; C-nitro compound; sulfone	carotenoid biosynthesis inhibitor; EC 1.13.11.27 (4-hydroxyphenylpyruvate dioxygenase) inhibitor; environmental contaminant; herbicide; xenobiotic
pinoxaden	[no description available]	low	0	0	pivalate ester; pyrazolooxadiazepine	agrochemical; EC 6.4.1.2 (acetyl-CoA carboxylase) inhibitor; environmental contaminant; proherbicide; xenobiotic
2-chloro-n-(4-chlorobiphenyl-2-yl)nicotinamide	[no description available]	low	0	0	anilide fungicide; biphenyls; monochlorobenzenes; pyridinecarboxamide	antifungal agrochemical; EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitor; environmental contaminant; xenobiotic
prizes	[no description available]	low	0	0	carboxamidine; monochloropyridine; nitrile	environmental contaminant; neonicotinoid insectide; xenobiotic
lenticin	[no description available]	low	0	0	amino-acid betaine; indole alkaloid; L-tryptophan derivative	fungal metabolite; plant metabolite; xenobiotic
cyanoginosin lr	[no description available]	low	0	0	microcystin	bacterial metabolite; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; environmental contaminant; xenobiotic
dieldrin	[no description available]	low	0	0	epoxide; organochlorine compound; organochlorine insecticide	carcinogenic agent; xenobiotic
azoxystrobin	[no description available]	low	0	0	aryloxypyrimidine; enoate ester; enol ether; methoxyacrylate strobilurin antifungal agent; methyl ester; nitrile	antifungal agrochemical; environmental contaminant; mitochondrial cytochrome-bc1 complex inhibitor; quinone outside inhibitor; xenobiotic
kresoxim-methyl	[no description available]	low	0	0	aromatic ether; methoxyiminoacetate strobilurin antifungal agent; methyl ester; oxime O-ether	antifungal agrochemical; environmental contaminant; mitochondrial cytochrome-bc1 complex inhibitor; xenobiotic
pyrachlostrobin	[no description available]	low	0	0	aromatic ether; carbamate ester; carbanilate fungicide; methoxycarbanilate strobilurin antifungal agent; monochlorobenzenes; pyrazoles	antifungal agrochemical; environmental contaminant; mitochondrial cytochrome-bc1 complex inhibitor; xenobiotic
microcystin rr	[no description available]	low	0	0	microcystin; organic molecular entity	bacterial metabolite; environmental contaminant; xenobiotic
yunaconitine	[no description available]	low	0	0	acetate ester; aromatic ether; benzoate ester; bridged compound; diterpene alkaloid; organic heteropolycyclic compound; polyether; secondary alcohol; tertiary alcohol; tertiary amino compound	antifeedant; human urinary metabolite; phytotoxin; plant metabolite; xenobiotic
pymetrozine	[no description available]	low	0	0	1,2,4-triazines; pyridines	antifeedant; environmental contaminant; TRPV channel modulator; xenobiotic
neotame	[no description available]	low	0	0	dipeptide	environmental contaminant; sweetening agent; xenobiotic
flonicamid	[no description available]	low	0	0	nitrile; organofluorine compound; pyridinecarboxamide	environmental contaminant; insecticide; xenobiotic
microcystin-lf	[no description available]	low	0	0	microcystin	bacterial metabolite; environmental contaminant; xenobiotic
clothianidin	[no description available]	low	0	0	1,3-thiazoles; 2-nitroguanidine derivative; clothianidin; organochlorine compound	environmental contaminant; neonicotinoid insectide; nicotinic acetylcholine receptor agonist; xenobiotic
naphthalene	[no description available]	low	0	0	naphthalenes; ortho-fused bicyclic arene	apoptosis inhibitor; carcinogenic agent; environmental contaminant; mouse metabolite; plant metabolite; volatile oil component
phenanthrene	[no description available]	low	0	0	ortho-fused polycyclic arene; ortho-fused tricyclic hydrocarbon; phenanthrenes	environmental contaminant; mouse metabolite
2,4,6-tribromophenol	[no description available]	low	0	0	bromophenol	environmental contaminant; fungicide; marine metabolite
4-nonylphenol	[no description available]	low	0	0	phenols	environmental contaminant
dibutyl phthalate	[no description available]	low	0	0	diester; phthalate ester	EC 3.2.1.20 (alpha-glucosidase) inhibitor; environmental contaminant; metabolite; plasticiser; teratogenic agent
ethion	[no description available]	low	0	0	organic thiophosphate	acaricide; agrochemical; EC 3.1.1.7 (acetylcholinesterase) inhibitor; environmental contaminant; insecticide
methyl parathion	[no description available]	low	0	0	C-nitro compound; organic thiophosphate; organothiophosphate insecticide	acaricide; agrochemical; antifungal agent; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; environmental contaminant; genotoxin
bromodichloromethane	[no description available]	low	0	0	halomethane	environmental contaminant; reagent
trichlorofluoromethane	[no description available]	low	0	0	chlorofluorocarbon; halomethane	environmental contaminant; NMR chemical shift reference compound; NMR solvent; refrigerant
tris(2-butoxyethyl) phosphate	[no description available]	low	0	0	trialkyl phosphate	environmental contaminant; flame retardant
cumene hydroperoxide	[no description available]	low	0	0	peroxol	environmental contaminant; Mycoplasma genitalium metabolite; oxidising agent
1-nitronaphthalene	[no description available]	low	0	0	mononitronaphthalene	environmental contaminant; mouse metabolite
2-nitrotoluene	[no description available]	low	0	0	mononitrotoluene	carcinogenic agent; environmental contaminant
2-methyl-4-chlorophenoxyacetic acid	[no description available]	low	0	0	chlorophenoxyacetic acid; monochlorobenzenes	environmental contaminant; phenoxy herbicide; synthetic auxin
benzotrifluoride	[no description available]	low	0	0	(trifluoromethyl)benzenes; fluorohydrocarbon	environmental contaminant; NMR chemical shift reference compound; solvent
n-nitrosopiperidine	[no description available]	low	0	0	nitrosamine; piperidine	apoptosis inducer; carcinogenic agent; environmental contaminant; mutagen
cyclamic acid	[no description available]	low	0	0	sulfamic acids	environmental contaminant; human xenobiotic metabolite
1,3-dichloropropane	[no description available]	low	0	0	chloroalkane; chlorohydrocarbon	environmental contaminant; nematicide
2,6-dimethylnaphthalene	[no description available]	low	0	0	dimethylnaphthalene	environmental contaminant
brilliant green	[no description available]	low	0	0	organic hydrogensulfate salt	antibacterial agent; antiseptic drug; environmental contaminant; fluorochrome; histological dye; poison
ametryne	[no description available]	low	0	0	diamino-1,3,5-triazine; methylthio-1,3,5-triazine	environmental contaminant; herbicide
3-methylfuran	[no description available]	low	0	0	furans; volatile organic compound	Aspergillus metabolite; environmental contaminant; fungal metabolite; Penicillium metabolite; plant metabolite
bpmc	[no description available]	low	0	0	carbamate ester	agrochemical; EC 3.1.1.7 (acetylcholinesterase) inhibitor; environmental contaminant; herbicide; insecticide
pirimiphos methyl	[no description available]	low	0	0	aminopyrimidine; organic thiophosphate	acaricide; agrochemical; EC 3.1.1.7 (acetylcholinesterase) inhibitor; environmental contaminant; insecticide
pendimethalin	[no description available]	low	0	0	C-nitro compound; secondary amino compound; substituted aniline	agrochemical; environmental contaminant; herbicide
isoprothiolane	[no description available]	low	0	0	dithiolanes; isopropyl ester; malonate ester	antifungal agrochemical; environmental contaminant; insecticide; phospholipid biosynthesis inhibitor
perfluorododecanoic acid	[no description available]	low	0	0	fluoroalkanoic acid	environmental contaminant
prolintane	[no description available]	low	0	0	amphetamines
clortermine	[no description available]	low	0	0	amphetamines
cloforex	[no description available]	low	0	0	amphetamines
n-acetylamphetamine	[no description available]	low	0	0	amphetamines
2,5-dimethoxy-4-ethylamphetamine	[no description available]	low	0	0	amphetamines
n-benzoylphenylalanylphenylalinol acetate	[no description available]	low	0	0	amphetamines
desmethylselegiline	[no description available]	low	0	0	amphetamines
phenylalaninol	[no description available]	low	0	0	amino alcohol; amphetamines; primary alcohol; primary amino compound
chloramphenicol succinate	[no description available]	low	0	0	amphetamines; hemisuccinate
N-[1-(1H-benzimidazol-2-yl)-2-phenylethyl]-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-oxo-3-pyrrolidinecarboxamide	[no description available]	low	0	0	amphetamines
N-(5-bromo-2-thiazolyl)-3-phenyl-2-(1-pyrrolyl)propanamide	[no description available]	low	0	0	amphetamines
4-[(2S)-2-[2-(4-ethoxyphenyl)ethylamino]-3-[[(2S)-1-(methylamino)hexan-2-yl]amino]propyl]phenol	[no description available]	low	0	0	amphetamines
afuresertib	[no description available]	low	0	0	amphetamines
brimonidine	[no description available]	low	0	0	imidazoles; quinoxaline derivative; secondary amine	adrenergic agonist; alpha-adrenergic agonist; antihypertensive agent
minaprine	[no description available]	low	0	0	morpholines; pyridazines; secondary amine	antidepressant; antiparkinson drug; cholinergic drug; dopamine uptake inhibitor; serotonin uptake inhibitor
3-phenylamino-1,2-propanediol	[no description available]	low	0	0	glycol; secondary amine
N-methyl-5-pyridin-4-yl-1,3,4-thiadiazol-2-amine	[no description available]	low	0	0	secondary amine
5-(methylamino)-3H-1,3,4-thiadiazole-2-thione	[no description available]	low	0	0	secondary amine
5-methyl-n-(pyridin-3-ylmethyl)isoxazol-3-amine	[no description available]	low	0	0	secondary amine
N-methyl-6-phenyl-3-(2-pyridinyl)-1,2,4-triazin-5-amine	[no description available]	low	0	0	secondary amine
tln 4601	[no description available]	low	0	0	dibenzodiazepine; farnesane sesquiterpenoid; olefinic compound; secondary amine; triol	antineoplastic agent; antioxidant; cathepsin L (EC 3.4.22.15) inhibitor

Article	Year
Emergency department management of methamphetamine toxicity. Emergency medicine practice, Volume: 25, Issue: 11	2023
Proteomic Analysis Reveals the Neurotoxic Effects of Chronic Methamphetamine Self-Administration-Induced Cognitive Impairments and the Role of Melatonin-Enhanced Restorative Process during Methamphetamine Withdrawal. Journal of proteome research, 10-06, Volume: 22, Issue: 10	2023
Tacrine First-Phase Biotransformation and Associated Hepatotoxicity: A Possible Way to Avoid Quinone Methide Formation. ACS chemical biology, 09-15, Volume: 18, Issue: 9	2023
Nrf2 protects against methamphetamine-induced nephrotoxicity by mitigating oxidative stress and autophagy in mice. Toxicology letters, Aug-01, Volume: 384	2023
Vanillic acid alleviates methamphetamine-induced mitochondrial toxicity in cardiac mitochondria via antioxidant activity and inhibition of MPT Pore opening: an in-vitro study. BMC pharmacology & toxicology, 05-19, Volume: 24, Issue: 1	2023
Gut microbiota contribute to Methamphetamine-induced cardiotoxicity in mouse model. Chemico-biological interactions, Jul-01, Volume: 379	2023
The Role of Non-coding RNAs in Methamphetamine-Induced Neurotoxicity. Cellular and molecular neurobiology, Volume: 43, Issue: 6	2023
Neuroprotective effect of thyroid hormones on methamphetamine-induced neurotoxicity via cell surface receptors. Neuroscience letters, 01-18, Volume: 794	2023
Lisdexamfetamine for the treatment of acute methamphetamine withdrawal: A pilot feasibility and safety trial. Drug and alcohol dependence, Dec-01, Volume: 241	2022
Methamphetamine-induced lethal toxicity in zebrafish larvae. Psychopharmacology, Volume: 239, Issue: 12	2022
N-isopropylbenzylamine, a methamphetamine mimics, produces toxicity via increasing nitric oxide in vitro. Toxicology, Volume: 480	2022
Alterations of Mitochondrial Structure in Methamphetamine Toxicity. International journal of molecular sciences, Aug-10, Volume: 23, Issue: 16	2022
"Complexity, safety and challenges: Emergency responders' experience of people affected by methamphetamines". Nursing & health sciences, Volume: 24, Issue: 3	2022
Erythropoietin improve spatial memory impairment following methamphetamine neurotoxicity by inhibition of apoptosis, oxidative stress and neuroinflammation in CA1 area of hippocampus. Journal of chemical neuroanatomy, Volume: 124	2022
3-Methylmethcathinone (3-MMC) Poisonings: Acute Clinical Toxicity and Time Trend Between 2013 and 2021 in the Netherlands. Annals of emergency medicine, Volume: 80, Issue: 3	2022
Potential Effects of Nrf2 in Exercise Intervention of Neurotoxicity Caused by Methamphetamine Oxidative Stress. Oxidative medicine and cellular longevity, Volume: 2022	2022
Dopamine and Methamphetamine Differentially Affect Electron Transport Chain Complexes and Parkin in Rat Striatum: New Insight into Methamphetamine Neurotoxicity. International journal of molecular sciences, Dec-29, Volume: 23, Issue: 1	2021
Effects of methamphetamine-induced neurotoxicity on striatal long-term potentiation. Psychopharmacology, Volume: 239, Issue: 1	2022
Loneliness, Risky Beliefs and Intentions about Practicing Safer Sex among Methamphetamine Dependent Individuals. Substance use & misuse, Volume: 57, Issue: 2	2022
The neuroprotective role of melatonin against methamphetamine toxicity-induced neurotransmission dysregulation and cognitive deficits in rats. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, Volume: 157	2021
Possible repair mechanisms of renin-angiotensin system inhibitors, matrix metalloproteinase-9 inhibitors and protein hormones on methamphetamine-induced neurotoxicity. Molecular biology reports, Volume: 48, Issue: 11	2021
Inhibition of Methamphetamine-Induced Cytotoxicity in the U87-Cell Line by Atorvastatin-Conjugated Carbon Nanotubes. Applied biochemistry and biotechnology, Volume: 194, Issue: 1	2022
Tetrahydropalmatine Regulates BDNF through TrkB/CAM Interaction to Alleviate the Neurotoxicity Induced by Methamphetamine. ACS chemical neuroscience, 09-15, Volume: 12, Issue: 18	2021
Neuroprotective Effects of Anti-high Mobility Group Box-1 Monoclonal Antibody Against Methamphetamine-Induced Dopaminergic Neurotoxicity. Neurotoxicity research, Volume: 39, Issue: 5	2021
Parkin-deficient rats are resistant to neurotoxicity of chronic high-dose methamphetamine. Experimental neurology, Volume: 345	2021
Converging dopaminergic neurotoxicity mechanisms of antipsychotics, methamphetamine and levodopa. European review for medical and pharmacological sciences, Volume: 25, Issue: 13	2021
Methamphetamine-induced dopaminergic neurotoxicity as a model of Parkinson's disease. Archives of pharmacal research, Volume: 44, Issue: 7	2021
Norepinephrine Protects against Methamphetamine Toxicity through β2-Adrenergic Receptors Promoting LC3 Compartmentalization. International journal of molecular sciences, Jul-05, Volume: 22, Issue: 13	2021
Levo-tetrahydropalmatine: A new potential medication for methamphetamine addiction and neurotoxicity. Experimental neurology, Volume: 344	2021
Assessment on chronic and transgenerational toxicity of methamphetamine to Caenorhabditis elegans and associated aquatic risk through toxicity indicator sensitivity distribution (TISD) analysis. Environmental pollution (Barking, Essex : 1987), Nov-01, Volume: 288	2021
Neurotoxicity of methamphetamine: Main effects and mechanisms. Experimental neurology, Volume: 344	2021
Safety and tolerability of oral lisdexamfetamine in adults with methamphetamine dependence: a phase-2 dose-escalation study. BMJ open, 05-18, Volume: 11, Issue: 5	2021
6,7,4'-Trihydroxyflavanone Mitigates Methamphetamine-Induced Neurotoxicity in SH-SY5y Cells via Nrf2/heme Oxyganase-1 and PI3K/Akt/mTOR Signaling Pathways. Molecules (Basel, Switzerland), Apr-22, Volume: 26, Issue: 9	2021
Non-coding RNA: insights into the mechanism of methamphetamine neurotoxicity. Molecular and cellular biochemistry, Volume: 476, Issue: 9	2021
Curcumin attenuates spatial memory impairment by anti-oxidative, anti-apoptosis, and anti-inflammatory mechanism against methamphetamine neurotoxicity in male Wistar rats: Histological and biochemical changes. Neurotoxicology, Volume: 84	2021
Assessment on the adverse effects on different kinds of fish induced by methamphetamine during the natural attenuation process based on adverse outcome pathway. The Science of the total environment, Aug-01, Volume: 780	2021
The Role of α-Synuclein in Methamphetamine-Induced Neurotoxicity. Neurotoxicity research, Volume: 39, Issue: 3	2021
Pediatric Methamphetamine Toxicity: Clinical Manifestations and Therapeutic Use of Antipsychotics-One Institution's Experience. Journal of medical toxicology : official journal of the American College of Medical Toxicology, Volume: 17, Issue: 2	2021
Inhibition of PLCβ1 signaling pathway regulates methamphetamine self-administration and neurotoxicity in rats. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, Volume: 149	2021
Escalating dose-multiple binge methamphetamine treatment elicits neurotoxicity, altering gut microbiota and fecal metabolites in mice. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, Volume: 148	2021
TBHQ-Overview of Multiple Mechanisms against Oxidative Stress for Attenuating Methamphetamine-Induced Neurotoxicity. Oxidative medicine and cellular longevity, Volume: 2020	2020
Methamphetamine-Induced Open Field Behavior and LD50 in Periplaneta americana Cockroaches (Blattodea: Blattidae). Journal of economic entomology, 02-09, Volume: 114, Issue: 1	2021
mTOR-autophagy promotes pulmonary senescence through IMP1 in chronic toxicity of methamphetamine. Journal of cellular and molecular medicine, Volume: 24, Issue: 20	2020
Role of alpha-synuclein phosphorylation at Serine 129 in methamphetamine-induced neurotoxicity in vitro and in vivo. Neuroreport, 08-05, Volume: 31, Issue: 11	2020
The interplay between autophagy and apoptosis mediates toxicity triggered by synthetic cathinones in human kidney cells. Toxicology letters, Oct-01, Volume: 331	2020
TBHQ Attenuates Neurotoxicity Induced by Methamphetamine in the VTA through the Nrf2/HO-1 and PI3K/AKT Signaling Pathways. Oxidative medicine and cellular longevity, Volume: 2020	2020
The induction of Neuron-Glial2 (NG2) expressing cells in methamphetamine toxicity-induced neuroinflammation in rat brain are averted by melatonin. Journal of neuroimmunology, 07-15, Volume: 344	2020
High ambient temperature increases the toxicity and lethality of 3,4-methylenedioxymethamphetamine and methcathinone. Pharmacology, biochemistry, and behavior, Volume: 192	2020
Environmental behavior of methamphetamine and ketamine in aquatic ecosystem: Degradation, bioaccumulation, distribution, and associated shift in toxicity and bacterial community. Water research, May-01, Volume: 174	2020
Epigallocatechin Gallate Mitigates the Methamphetamine-Induced Striatal Dopamine Terminal Toxicity by Preventing Oxidative Stress in the Mouse Brain. Neurotoxicity research, Volume: 37, Issue: 4	2020
Luteolin alleviates methamphetamine-induced neurotoxicity by suppressing PI3K/Akt pathway-modulated apoptosis and autophagy in rats. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, Volume: 137	2020
The effect of α-synuclein and Tau in methamphetamine induced neurotoxicity in vivo and in vitro. Toxicology letters, Feb-01, Volume: 319	2020
Obestatin attenuated methamphetamine-induced PC12 cells neurotoxicity via inhibiting autophagy and apoptosis. Human & experimental toxicology, Volume: 39, Issue: 3	2020
Chronic toxicity of methamphetamine: Oxidative remodeling of pulmonary arteries. Toxicology in vitro : an international journal published in association with BIBRA, Volume: 62	2020
Methamphetamine induces neurotoxicity-associated pathways and stereological changes in prefrontal cortex. Neuroscience letters, 11-01, Volume: 712	2019
Aquatic Phytotoxicity to Lemna minor of Three Commonly Used Drugs of Addiction in Australia. Bulletin of environmental contamination and toxicology, Volume: 103, Issue: 5	2019
Serial exposure to ethanol drinking and methamphetamine enhances glutamate excitotoxicity. Journal of neurochemistry, Volume: 151, Issue: 6	2019
A complicated case of bowel obstruction with sepsis and methamphetamine toxicity in a child with pica. Forensic science, medicine, and pathology, Volume: 15, Issue: 4	2019
Protein kinase Cδ mediates methamphetamine-induced dopaminergic neurotoxicity in mice via activation of microsomal epoxide hydrolase. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, Volume: 133	2019
Adverse effect of catechol-O-methyltransferase (COMT) Val158Met met/met genotype in methamphetamine-related executive dysfunction. Addictive behaviors, Volume: 98	2019
The role of chaperone-mediated autophagy in neurotoxicity induced by alpha-synuclein after methamphetamine exposure. Brain and behavior, Volume: 9, Issue: 8	2019
Research Progress on Chiral Separation Methods and Toxic Effects of Methamphetamine Enantiomers. Fa yi xue za zhi, Volume: 35, Issue: 3	2019
Effects of combined toxicity of methamphetamine and ketamine on apoptosis, oxidative stress and genotoxicity in HepG2 cells. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, Volume: 132	2019
Neurotoxicity to dopamine neurons after the serial exposure to alcohol and methamphetamine: Protection by COX-2 antagonism. Brain, behavior, and immunity, Volume: 81	2019
A study protocol for the N-ICE trial: A randomised double-blind placebo-controlled study of the safety and efficacy of N-acetyl-cysteine (NAC) as a pharmacotherapy for methamphetamine ("ice") dependence. Trials, Jun-04, Volume: 20, Issue: 1	2019
Abuse potential and toxicity of the synthetic cathinones (i.e., "Bath salts"). Neuroscience and biobehavioral reviews, Volume: 110	2020
Methiopropamine, a methamphetamine analogue, produces neurotoxicity via dopamine receptors. Chemico-biological interactions, May-25, Volume: 305	2019
A comparison of mitochondrial toxicity of mephedrone on three separate parts of brain including hippocampus, cortex and cerebellum. Neurotoxicology, Volume: 73	2019
Significance of protein kinase C in the neuropsychotoxicity induced by methamphetamine-like psychostimulants. Neurochemistry international, Volume: 124	2019
mTOR Modulates Methamphetamine-Induced Toxicity through Cell Clearing Systems. Oxidative medicine and cellular longevity, Volume: 2018	2018
Poor Identification of Emergency Department Acute Recreational Drug Toxicity Presentations Using Routine Hospital Coding Systems: the Experience in Denmark, Switzerland and the UK. Journal of medical toxicology : official journal of the American College of Medical Toxicology, Volume: 15, Issue: 2	2019
Methamphetamine neurotoxicity, microglia, and neuroinflammation. Journal of neuroinflammation, Dec-12, Volume: 15, Issue: 1	2018
Cytotoxicity of new psychoactive substances and other drugs of abuse studied in human HepG2 cells using an adopted high content screening assay. Toxicology letters, Volume: 301	2019
Efficacy and safety of naltrexone for amfetamine and methamfetamine use disorder: a systematic review of randomized controlled trials. Clinical toxicology (Philadelphia, Pa.), Volume: 57, Issue: 4	2019
Krill oil protects PC12 cells against methamphetamine-induced neurotoxicity by inhibiting apoptotic response and oxidative stress. Nutrition research (New York, N.Y.), Volume: 58	2018
Crocin Inhibits Apoptosis and Astrogliosis of Hippocampus Neurons Against Methamphetamine Neurotoxicity via Antioxidant and Anti-inflammatory Mechanisms. Neurochemical research, Volume: 43, Issue: 12	2018
Severe neurologic and hepatic toxicity in a newborn prenatally exposed to methamphetamine. A case report. Brain & development, Volume: 41, Issue: 2	2019
Dissociation between hypothermia and neurotoxicity caused by mephedrone and methcathinone in TPH2 knockout mice. Psychopharmacology, Volume: 236, Issue: 3	2019
Concurrence of autophagy with apoptosis in alveolar epithelial cells contributes to chronic pulmonary toxicity induced by methamphetamine. Cell proliferation, Volume: 51, Issue: 5	2018
Methamphetamine toxicity-induced calcineurin activation, nuclear translocation of nuclear factor of activated T-cells and elevation of cyclooxygenase 2 levels are averted by calpastatin overexpression in neuroblastoma SH-SY5Y cells. Neurotoxicology, Volume: 67	2018
Lactulose attenuates METH-induced neurotoxicity by alleviating the impaired autophagy, stabilizing the perturbed antioxidant system and suppressing apoptosis in rat striatum. Toxicology letters, Jun-01, Volume: 289	2018
Protective and restorative effects of the traditional Chinese medicine Jitai tablet against methamphetamine-induced dopaminergic neurotoxicity. BMC complementary and alternative medicine, Feb-23, Volume: 18, Issue: 1	2018
Ginsenoside Re protects methamphetamine-induced dopaminergic neurotoxicity in mice via upregulation of dynorphin-mediated κ-opioid receptor and downregulation of substance P-mediated neurokinin 1 receptor. Journal of neuroinflammation, Feb-21, Volume: 15, Issue: 1	2018
Asiatic acid attenuates methamphetamine-induced neuroinflammation and neurotoxicity through blocking of NF-kB/STAT3/ERK and mitochondria-mediated apoptosis pathway. Journal of neuroinflammation, Dec-11, Volume: 14, Issue: 1	2017
Role of dopamine D1 receptor in 3-fluoromethamphetamine-induced neurotoxicity in mice. Neurochemistry international, Volume: 113	2018
Clinical and Autopsy Characteristics of Fatal Methamphetamine Toxicity in Australia. Journal of forensic sciences, Volume: 63, Issue: 5	2018
Toxicity of new synthetic amphetamine drug mephedrone On Rat Heart mitochondria: a warning for its abuse. Xenobiotica; the fate of foreign compounds in biological systems, Volume: 48, Issue: 12	2018
A Stinging Suspicion Something Was Just Not Right: Methamphetamine Toxicity in Infant Mimics Scorpion Envenomation. Pediatric emergency care, Volume: 33, Issue: 11	2017
Safety, risk, and aggression: Health professionals' experiences of caring for people affected by methamphetamine when presenting for emergency care. International journal of mental health nursing, Volume: 26, Issue: 5	2017
Trace amine-associated receptor 1 regulation of methamphetamine-induced neurotoxicity. Neurotoxicology, Volume: 63	2017
Assessing the role of dopamine in the differential neurotoxicity patterns of methamphetamine, mephedrone, methcathinone and 4-methylmethamphetamine. Neuropharmacology, 05-15, Volume: 134, Issue: Pt A	2018
Corticosterone and exogenous glucose alter blood glucose levels, neurotoxicity, and vascular toxicity produced by methamphetamine. Journal of neurochemistry, Volume: 143, Issue: 2	2017
Rescue extracorporeal membrane oxygenation therapy in methamphetamine toxicity. CJEM, Volume: 20, Issue: S2	2018
Self-administration of methamphetamine alters gut biomarkers of toxicity. The European journal of neuroscience, Volume: 46, Issue: 3	2017
Mechanisms of hepatocellular toxicity associated with new psychoactive synthetic cathinones. Toxicology, 07-15, Volume: 387	2017
Molecular, Behavioral, and Physiological Consequences of Methamphetamine Neurotoxicity: Implications for Treatment. The Journal of pharmacology and experimental therapeutics, Volume: 362, Issue: 3	2017
Methamphetamine causes neurotoxicity by promoting polarization of macrophages and inflammatory response. Human & experimental toxicology, Volume: 37, Issue: 5	2018
Role of Mitochondria in Methamphetamine-Induced Dopaminergic Neurotoxicity: Involvement in Oxidative Stress, Neuroinflammation, and Pro-apoptosis-A Review. Neurochemical research, Volume: 43, Issue: 1	2018
Recombinant AAV8-mediated intrastriatal gene delivery of CDNF protects rats against methamphetamine neurotoxicity. International journal of medical sciences, Volume: 14, Issue: 4	2017
Methylone and MDPV activate autophagy in human dopaminergic SH-SY5Y cells: a new insight into the context of β-keto amphetamines-related neurotoxicity. Archives of toxicology, Volume: 91, Issue: 11	2017
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Article	Year
[Central Administration of p-Hydroxyamphetamine Produces a Behavioral Stimulant Effect in Rodents: Contribution of Dopamine and Serotonin Neurotransmission]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, Volume: 143, Issue: 11	2023
Isradipine, an L-type calcium channel inhibitor, attenuates cue-associated methamphetamine-seeking in mice. Brain research, 11-01, Volume: 1818	2023
Normal Transaminases in Methamphetamine- and Heroin-Associated Hyperammonemic Encephalopathy. Journal of insurance medicine (New York, N.Y.), Jan-01, Volume: 49, Issue: 4	2023
Does chronic use of amphetamine-type stimulants impair interference control? - A meta-analysis. Neuroscience and biobehavioral reviews, Volume: 146	2023
Methamphetamine-associated pulmonary arterial hypertension. Current opinion in pulmonary medicine, 09-01, Volume: 28, Issue: 5	2022
Molecular mechanism behind methamphetamine-induced damages in testicular tissue: Evidences for oxidative stress, autophagy, and apoptosis. Andrologia, Volume: 54, Issue: 10	2022
Resting-state EEG, Substance use and Abstinence After Chronic use: A Systematic Review. Clinical EEG and neuroscience, Volume: 53, Issue: 4	2022
Dysregulation of iron homeostasis and methamphetamine reward behaviors in Clk1-deficient mice. Acta pharmacologica Sinica, Volume: 43, Issue: 7	2022
Is Methamphetamine-Linked Cardiomyopathy an Emerging Epidemic for New Generation? Current problems in cardiology, Volume: 48, Issue: 1	2023
The neuroprotective role of melatonin against methamphetamine toxicity-induced neurotransmission dysregulation and cognitive deficits in rats. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, Volume: 157	2021
Chronic methamphetamine-induced neurodegeneration: Differential vulnerability of ventral tegmental area and substantia nigra pars compacta dopamine neurons. Neuropharmacology, 12-01, Volume: 200	2021
The Relationship Between Brain Metabolites Alterations and Neuropsychological Deficits in Patients with Methamphetamine Use Disorder: A Proton Magnetic Resonance Spectroscopy Study. Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists, Jan-17, Volume: 37, Issue: 1	2022
Melatonin ameliorates methamphetamine-induced cognitive impairments by inhibiting neuroinflammation via suppression of the TLR4/MyD88/NFκB signaling pathway in the mouse hippocampus. Progress in neuro-psychopharmacology & biological psychiatry, 12-20, Volume: 111	2021
RUNX3-dependent oxidative epithelial-to-mesenchymal transition in methamphetamine-induced chronic lung injury. Cell stress & chaperones, Volume: 25, Issue: 5	2020
Differential Responses of LINE-1 in the Dentate Gyrus, Striatum and Prefrontal Cortex to Chronic Neurotoxic Methamphetamine: A Study in Rat Brain. Genes, 03-28, Volume: 11, Issue: 4	2020
Neuroprotective effect of chronic administration of cannabidiol during the abstinence period on methamphetamine-induced impairment of recognition memory in the rats. Behavioural pharmacology, Volume: 31, Issue: 4	2020
Nod-like receptor protein 3 and nod-like receptor protein 1 inflammasome activation in the hippocampal region of postmortem methamphetamine chronic user. Bratislavske lekarske listy, Volume: 120, Issue: 10	2019
Identification of novel risk loci with shared effects on alcoholism, heroin, and methamphetamine dependence. Molecular psychiatry, Volume: 26, Issue: 4	2021
Rodent Models of Methamphetamine Misuse: Mechanisms of Methamphetamine Action and Comparison of Different Rodent Paradigms. Methods in molecular biology (Clifton, N.J.), Volume: 2011	2019
Methamphetamine acutely alters frontostriatal resting state functional connectivity in healthy young adults. Addiction biology, Volume: 25, Issue: 3	2020
Thyroid hormone treatment alleviates the impairments of neurogenesis, mitochondrial biogenesis and memory performance induced by methamphetamine. Neurotoxicology, Volume: 74	2019
Effects of intrastriatal dopamine D1 or D2 antagonists on methamphetamine-induced egocentric and allocentric learning and memory deficits in Sprague-Dawley rats. Psychopharmacology, Volume: 236, Issue: 7	2019
Methamphetamine ("crystal meth") causes induction of DNA damage and chromosomal aberrations in human derived cells. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, Volume: 128	2019
Protective role of metformin against methamphetamine induced anxiety, depression, cognition impairment and neurodegeneration in rat: The role of CREB/BDNF and Akt/GSK3 signaling pathways. Neurotoxicology, Volume: 72	2019
Methamphetamine and its immune-modulating effects. Maturitas, Volume: 121	2019
Mephedrone Impact on Matrix Metalloproteinases Activity - Do they Influence the Memory Processes? Current molecular pharmacology, Volume: 12, Issue: 2	2019
Neurocognitive decision-making processes of casual methamphetamine users. NeuroImage. Clinical, Volume: 21	2019
Methamphetamine use and cognitive function: A systematic review of neuroimaging research. Drug and alcohol dependence, 01-01, Volume: 194	2019
Which individual, social and environmental influences shape key phases in the amphetamine type stimulant use trajectory? A systematic narrative review and thematic synthesis of the qualitative literature. Addiction (Abingdon, England), Volume: 114, Issue: 1	2019
Phenotypic effects of chronic and acute use of methiopropamine in a mouse model. International journal of legal medicine, Volume: 133, Issue: 3	2019
Increasing methamphetamine doses inhibit glycogen synthase kinase 3β activity by stimulating the insulin signaling pathway in substantia nigra. Journal of cellular biochemistry, Volume: 119, Issue: 10	2018
Effects of acute and chronic methamphetamine administration on cynomolgus monkey hippocampus structure and cellular transcriptome. Toxicology and applied pharmacology, 09-15, Volume: 355	2018
Methamphetamine Induces Apoptosis of Microglia via the Intrinsic Mitochondrial-Dependent Pathway. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, Volume: 13, Issue: 3	2018
Abstinence to chronic methamphetamine switches connectivity between striatal, hippocampal and sensorimotor regions and increases cerebral blood volume response. NeuroImage, 07-01, Volume: 174	2018
Intranasal insulin treatment restores cognitive deficits and insulin signaling impairment induced by repeated methamphetamine exposure. Journal of cellular biochemistry, Volume: 119, Issue: 2	2018
Methamphetamine causes neurotoxicity by promoting polarization of macrophages and inflammatory response. Human & experimental toxicology, Volume: 37, Issue: 5	2018
Methamphetamine: Effects on the brain, gut and immune system. Pharmacological research, Volume: 120	2017
Voluntary inhalation of methamphetamine: a novel strategy for studying intake non-invasively. Psychopharmacology, Volume: 234, Issue: 5	2017
Escalating Methamphetamine Regimen Induces Compensatory Mechanisms, Mitochondrial Biogenesis, and GDNF Expression, in Substantia Nigra. Journal of cellular biochemistry, Volume: 118, Issue: 6	2017
Breakdown of Blood-Brain and Blood-Spinal Cord Barriers During Acute Methamphetamine Intoxication: Role of Brain Temperature. CNS & neurological disorders drug targets, Volume: 15, Issue: 9	2016
The Clock Gene Rev-Erbα Regulates Methamphetamine Actions on Circadian Timekeeping in the Mouse Brain. Molecular neurobiology, Volume: 54, Issue: 7	2017
Chronic methamphetamine self-administration disrupts cortical control of cognition. Neuroscience and biobehavioral reviews, Volume: 69	2016
Effect of Methamphetamine Exposure on Expression of Calcium Binding Proteins in Rat Frontal Cortex and Hippocampus. Neurotoxicity research, Volume: 30, Issue: 3	2016
Single nucleotide polymorphism near CREB1, rs7591784, is associated with pretreatment methamphetamine use frequency and outcome of outpatient treatment for methamphetamine use disorder. Journal of psychiatric research, Volume: 74	2016
Drugs of abuse and blood-brain barrier endothelial dysfunction: A focus on the role of oxidative stress. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, Volume: 36, Issue: 3	2016
Neurocognitive Profiles of Methamphetamine Users: Comparison of Those With or Without Concomitant Ketamine Use. Substance use & misuse, Volume: 50, Issue: 14	2015
Drug-induced parkinsonism following chronic methamphetamine use by a patient on haloperidol decanoate. International journal of psychiatry in medicine, Volume: 50, Issue: 4	2015
BDNF-TrkB signaling in the nucleus accumbens shell of mice has key role in methamphetamine withdrawal symptoms. Translational psychiatry, Oct-27, Volume: 5	2015
Chronic methamphetamine treatment reduces the expression of synaptic plasticity genes and changes their DNA methylation status in the mouse brain. Brain research, Dec-10, Volume: 1629	2015
l-Scoulerine attenuates behavioural changes induced by methamphetamine in zebrafish and mice. Behavioural brain research, Feb-01, Volume: 298, Issue: Pt A	2016
Chronic administration of methamphetamine promotes atherosclerosis formation in ApoE-/- knockout mice fed normal diet. Atherosclerosis, Volume: 243, Issue: 1	2015
G protein-coupled receptor kinase 6/β-arrestin 2 system in a rat model of dopamine supersensitivity psychosis. Journal of psychopharmacology (Oxford, England), Volume: 29, Issue: 12	2015
Neuropsychiatric Adverse Effects of Amphetamine and Methamphetamine. International review of neurobiology, Volume: 120	2015
Autophagy inhibition by caffeine increases toxicity of methamphetamine in SH-SY5Y neuroblastoma cell line. Neurotoxicity research, Volume: 27, Issue: 4	2015
Modafinil improves methamphetamine-induced object recognition deficits and restores prefrontal cortex ERK signaling in mice. Neuropharmacology, Volume: 87	2014
The whole is just the sum of its parts: limited polydrug use among the "big three" expensive drugs in the United States. Current drug abuse reviews, Volume: 6, Issue: 2	2013
Induction of mitochondrial permeability transition (MPT) pore opening and ROS formation as a mechanism for methamphetamine-induced mitochondrial toxicity. Naunyn-Schmiedeberg's archives of pharmacology, Volume: 387, Issue: 1	2014
Withdrawal from long-term methamphetamine self-administration 'normalizes' neurometabolites in rhesus monkeys: a (1) H MR spectroscopy study. Addiction biology, Volume: 20, Issue: 1	2015
Neurologic manifestations of chronic methamphetamine abuse. The Psychiatric clinics of North America, Volume: 36, Issue: 2	2013
Experimental evidence for the involvement of PDLIM5 in mood disorders in hetero knockout mice. PloS one, Volume: 8, Issue: 4	2013
Cardiotoxicity of methamphetamine under stress conditions: comparison of single dose and long-term use. Molecular medicine reports, Volume: 7, Issue: 6	2013
The role of the neuropeptide somatostatin on methamphetamine and glutamate-induced neurotoxicity in the striatum of mice. Brain research, May-13, Volume: 1510	2013
Illicit stimulant use is associated with abnormal substantia nigra morphology in humans. PloS one, Volume: 8, Issue: 2	2013
Caffeic acid protects tissue antioxidants and DNA content in methamphetamine induced tissue toxicity in Sprague Dawley rats. Toxicology mechanisms and methods, Volume: 23, Issue: 2	2013
Chronic treatment with curcumin enhances methamphetamine locomotor sensitization and cue-induced reinstatement of methamphetamine self-administration. Pharmacology, biochemistry, and behavior, Volume: 102, Issue: 4	2012
Gender differences in behavioral changes elicited by prenatal methamphetamine exposure and application of the same drug in adulthood. Developmental psychobiology, Volume: 55, Issue: 3	2013
[A new designer drug: methylone related death]. Orvosi hetilap, Feb-19, Volume: 153, Issue: 7	2012
Visual memory in methamphetamine-dependent individuals: deficient strategic control of encoding and retrieval. The Australian and New Zealand journal of psychiatry, Volume: 46, Issue: 2	2012
Methods in drug abuse models: comparison of different models of methamphetamine paradigms. Methods in molecular biology (Clifton, N.J.), Volume: 829	2012
GHB and synthetic cathinones: clinical effects and potential consequences. Drug testing and analysis, Volume: 3, Issue: 9	2011
Differences between dextroamphetamine and methamphetamine: behavioral changes and oxidative damage in brain of Wistar rats. Journal of neural transmission (Vienna, Austria : 1996), Volume: 119, Issue: 1	2012
L-type voltage-dependent calcium channels facilitate acetylation of histone H3 through PKCγ phosphorylation in mice with methamphetamine-induced place preference. Journal of neurochemistry, Volume: 118, Issue: 6	2011
Age and sex effects levels of choline compounds in the anterior cingulate cortex of adolescent methamphetamine users. Drug and alcohol dependence, Dec-15, Volume: 119, Issue: 3	2011
Repeated mirtazapine nullifies the maintenance of previously established methamphetamine-induced conditioned place preference in rats. Behavioural brain research, Nov-20, Volume: 225, Issue: 1	2011
Glycogen synthase kinase 3β in the nucleus accumbens core is critical for methamphetamine-induced behavioral sensitization. Journal of neurochemistry, Volume: 118, Issue: 1	2011
Acute administration of methamphetamine decreases the mRNA expression of diazepam binding inhibitor in rat brain. The Tokai journal of experimental and clinical medicine, Apr-20, Volume: 33, Issue: 1	2008
Chronic administration of methamphetamine increases the mRNA expression of diazepam binding inhibitor in rat brain. The Tokai journal of experimental and clinical medicine, Apr-20, Volume: 33, Issue: 1	2008
Chronic methamphetamine exposure suppresses the striatal expression of members of multiple families of immediate early genes (IEGs) in the rat: normalization by an acute methamphetamine injection. Psychopharmacology, Volume: 215, Issue: 2	2011
[Methamphetamine dependence: Consequences and complications]. Presse medicale (Paris, France : 1983), Volume: 39, Issue: 12	2010
The anthraquinone derivative emodin attenuates methamphetamine-induced hyperlocomotion and startle response in rats. Pharmacology, biochemistry, and behavior, Volume: 97, Issue: 2	2010
Impairments of facial emotion recognition and theory of mind in methamphetamine abusers. Psychiatry research, Mar-30, Volume: 186, Issue: 1	2011
[Molecular mechanism for methamphetamine-induced memory impairment]. Nihon Arukoru Yakubutsu Igakkai zasshi = Japanese journal of alcohol studies & drug dependence, Volume: 45, Issue: 2	2010
Longer term improvement in neurocognitive functioning and affective distress among methamphetamine users who achieve stable abstinence. Journal of clinical and experimental neuropsychology, Volume: 32, Issue: 7	2010
Deterioration of intelligence in methamphetamine-induced psychosis: comparison with alcohol dependence on WAIS-III. Psychiatry and clinical neurosciences, Volume: 64, Issue: 1	2010
Intermittent Dopaminergic stimulation causes behavioral sensitization in the addicted brain and parkinsonism. International review of neurobiology, Volume: 88	2009
C-fos, fos-B, c-jun and dusp-1 expression in the mouse heart after single and repeated methamphetamine administration. Legal medicine (Tokyo, Japan), Volume: 11, Issue: 6	2009
Neurotoxic effects of methamphetamine. Neurochemical research, Volume: 35, Issue: 1	2010
Prenatal methamphetamine exposure affects the mesolimbic dopaminergic system and behavior in adult offspring. International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience, Volume: 27, Issue: 6	2009
Histopathological studies of cardiac lesions after long term administration of methamphetamine in high dosage--Part II. Legal medicine (Tokyo, Japan), Volume: 11 Suppl 1	2009
Myocardial lesions after long-term administration of methamphetamine in rats. Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih, Volume: 23, Issue: 4	2008
Methamphetamine fails to alter the noradrenergic integrity of the heart. Annals of the New York Academy of Sciences, Volume: 1139	2008
Illicit stimulant use in a United States heart failure population presenting to the emergency department (from the Acute Decompensated Heart Failure National Registry Emergency Module). The American journal of cardiology, Nov-01, Volume: 102, Issue: 9	2008
mRNA expression of the Nurr1 and NGFI-B nuclear receptor families following acute and chronic administration of methamphetamine. Progress in neuro-psychopharmacology & biological psychiatry, Dec-12, Volume: 32, Issue: 8	2008
The peroxidative DNA damage and apoptosis in methamphetamine-treated rat brain. The journal of medical investigation : JMI, Volume: 55, Issue: 3-4	2008
Effect of +-methamphetamine on path integration learning, novel object recognition, and neurotoxicity in rats. Psychopharmacology, Volume: 199, Issue: 4	2008
The effects of methamphetamine on core body temperature in the rat--part 1: chronic treatment and ambient temperature. Psychopharmacology, Volume: 198, Issue: 3	2008
The beta-lactam antibiotic ceftriaxone inhibits physical dependence and abstinence-induced withdrawal from cocaine, amphetamine, methamphetamine, and clorazepate in planarians. European journal of pharmacology, Apr-28, Volume: 584, Issue: 2-3	2008
Methamphetamine abuse and impairment of social functioning: a review of the underlying neurophysiological causes and behavioral implications. Psychological bulletin, Volume: 134, Issue: 2	2008
A collaborative model for community action against methamphetamine. Journal of psychoactive drugs, Volume: Suppl 4	2007
Differential neurochemical consequences of an escalating dose-binge regimen followed by single-day multiple-dose methamphetamine challenges. Journal of neurochemistry, Volume: 105, Issue: 5	2008
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Article	Year
Pervitin Intoxication with Two-peak Massive Myoglobinemia, Acute Kidney Injury and Marked Procalcitonin Increase Not Associated with Sepsis. Prague medical report, Volume: 123, Issue: 4	2022
Methamphetamine-mediated dissemination of β-amyloid: Disturbances in endocytosis, transport and clearance of β-amyloid in microglial BV2 cells. Toxicology and applied pharmacology, 07-15, Volume: 447	2022
Radiation Effects on Methamphetamine Pharmacokinetics and Pharmacodynamics in Rats. European journal of drug metabolism and pharmacokinetics, Volume: 47, Issue: 3	2022
Effects of cytidine-5'-diphosphate choline on gray matter volumes in methamphetamine-dependent patients: A randomized, double-blind, placebo-controlled study. Journal of psychiatric research, Volume: 143	2021
Pharmacokinetics of Synthetic Cathinones Found in Bath Salts in Mouse Brain and Plasma Using High-Pressure Liquid Chromatography-Tandem Mass Spectrometry. European journal of drug metabolism and pharmacokinetics, Volume: 46, Issue: 6	2021
Electroacupuncture alleviates spatial memory deficits in METH withdrawal mice by enhancing astrocyte-mediated glutamate clearance in the dCA1. Addiction biology, Volume: 27, Issue: 1	2022
Astrocyte-selective STAT3 knockdown rescues methamphetamine withdrawal-disrupted spatial memory in mice via restoring the astrocytic capacity of glutamate clearance in dCA1. Glia, Volume: 69, Issue: 10	2021
Pharmacokinetics of Mephedrone and Its Metabolites in Whole Blood and Plasma after Controlled Intranasal Administration to Healthy Human Volunteers. Journal of analytical toxicology, Aug-14, Volume: 45, Issue: 7	2021
Effect of bile duct ligation-induced liver dysfunction on methamphetamine pharmacokinetics in male and female rats. Drug and alcohol dependence, 10-01, Volume: 215	2020
Impact of Recent Methamphetamine Use on Vancomycin Clearance. Psychopharmacology bulletin, 07-23, Volume: 50, Issue: 3	2020
Higher impulsivity and lower grey matter volume in the bilateral prefrontal cortex in long-term abstinent individuals with severe methamphetamine use disorder. Drug and alcohol dependence, 07-01, Volume: 212	2020
Comparisons of Voxel-Based Morphometric Brain Volumes of Individuals with Methamphetamine-Induced Psychotic Disorder and Schizophrenia Spectrum Disorder and Healthy Controls. Neuropsychobiology, Volume: 79, Issue: 2	2020
Antibody production and pharmacokinetics of METH in rats following vaccination with the METH vaccine, IXT-v100, adjuvanted with GLA-SE. Drug and alcohol dependence, 11-01, Volume: 204	2019
Effect of Bile Duct Ligation-induced Liver Dysfunction on Methamphetamine Pharmacokinetics and Locomotor Activity in Rats. Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, Volume: 22, Issue: 1	2019
Detection, pharmacokinetics, and selected pharmacodynamic effects of methamphetamine following a single transmucosal and intravenous administration to exercised Thoroughbred horses. Drug testing and analysis, Volume: 11, Issue: 9	2019
Pharmacokinetics of selegiline, R-methamphetamine, R-amphetamine, and desmethylselegiline in oral fluid after a single oral administration of selegiline. Drug testing and analysis, Volume: 11, Issue: 6	2019
Effects of HIV Infection, methamphetamine dependence and age on cortical thickness, area and volume. NeuroImage. Clinical, Volume: 20	2018
Mega-Analysis of Gray Matter Volume in Substance Dependence: General and Substance-Specific Regional Effects. The American journal of psychiatry, 02-01, Volume: 176, Issue: 2	2019
A review of the influence of functional group modifications to the core scaffold of synthetic cathinones on drug pharmacokinetics. Psychopharmacology, Volume: 236, Issue: 3	2019
Abstinence to chronic methamphetamine switches connectivity between striatal, hippocampal and sensorimotor regions and increases cerebral blood volume response. NeuroImage, 07-01, Volume: 174	2018
Gray matter volume showed dynamic alterations in methamphetamine users at 6 and 12months abstinence: A longitudinal voxel-based morphometry study. Progress in neuro-psychopharmacology & biological psychiatry, Feb-02, Volume: 81	2018
Pharmacokinetics of Mephedrone and Its Metabolites in Human by LC-MS/MS. The AAPS journal, Volume: 19, Issue: 6	2017
The pharmacokinetic profile of synthetic cathinones in a pregnancy model. Neurotoxicology and teratology, Volume: 63	2017
Role of d-amphetamine and d-methamphetamine as active metabolites of benzphetamine: Evidence from drug discrimination and pharmacokinetic studies in male rhesus monkeys. Pharmacology, biochemistry, and behavior, Volume: 156	2017
Psychomotor effect differences between l-methamphetamine and d-methamphetamine are independent of murine plasma and brain pharmacokinetics profiles. Journal of neural transmission (Vienna, Austria : 1996), Volume: 124, Issue: 5	2017
Could Google Trends Be Used to Predict Methamphetamine-Related Crime? An Analysis of Search Volume Data in Switzerland, Germany, and Austria. PloS one, Volume: 11, Issue: 11	2016
GC-MS Quantification Method for Mephedrone in Plasma and Urine: Application to Human Pharmacokinetics. Journal of analytical toxicology, Mar-01, Volume: 41, Issue: 2	2017
Development of visual peak selection system based on multi-ISs normalization algorithm to apply to methamphetamine impurity profiling. Forensic science international, Volume: 268	2016
Psychological intervention with working memory training increases basal ganglia volume: A VBM study of inpatient treatment for methamphetamine use. NeuroImage. Clinical, Volume: 12	2016
PEGylation of a High-Affinity Anti-(+)Methamphetamine Single Chain Antibody Fragment Extends Functional Half-Life by Reducing Clearance. Pharmaceutical research, Volume: 33, Issue: 12	2016
Hematocrit-Independent Quantitation of Stimulants in Dried Blood Spots: Pipet versus Microfluidic-Based Volumetric Sampling Coupled with Automated Flow-Through Desorption and Online Solid Phase Extraction-LC-MS/MS Bioanalysis. Analytical chemistry, 07-05, Volume: 88, Issue: 13	2016
Chronic methamphetamine exposure prior to middle cerebral artery occlusion increases infarct volume and worsens cognitive injury in Male mice. Metabolic brain disease, Volume: 31, Issue: 4	2016
Chiral Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine and its Phase I and II Metabolites following Controlled Administration to Humans. Drug metabolism and disposition: the biological fate of chemicals, Volume: 43, Issue: 12	2015
A Nanotechnology-Based Platform for Extending the Pharmacokinetic and Binding Properties of Anti-methamphetamine Antibody Fragments. Scientific reports, Jul-10, Volume: 5	2015
Hippocampal volume reduction in female but not male recent abstinent methamphetamine users. Behavioural brain research, Aug-01, Volume: 289	2015
Gray-matter volume, midbrain dopamine D2/D3 receptors and drug craving in methamphetamine users. Molecular psychiatry, Volume: 20, Issue: 6	2015
3-Methyl-methcathinone: Pharmacokinetic profile evaluation in pigs in relation to pharmacodynamics. Journal of psychopharmacology (Oxford, England), Volume: 29, Issue: 6	2015
The pharmacokinetics of methamphetamine self-administration in male and female rats. Drug and alcohol dependence, May-01, Volume: 150	2015
Sex differences in methamphetamine pharmacokinetics in adult rats and its transfer to pups through the placental membrane and breast milk. Drug and alcohol dependence, Jun-01, Volume: 139	2014
Nonlinear pharmacokinetics of (+/-)3,4-methylenedioxymethamphetamine (MDMA) and its pharmacodynamic consequences in the rat. Drug metabolism and disposition: the biological fate of chemicals, Volume: 42, Issue: 1	2014
Volume reductions in frontopolar and left perisylvian cortices in methamphetamine induced psychosis. Schizophrenia research, Volume: 147, Issue: 2-3	2013
Mephedrone pharmacokinetics after intravenous and oral administration in rats: relation to pharmacodynamics. Psychopharmacology, Volume: 229, Issue: 2	2013
An integrated pharmacokinetic and pharmacodynamic study of a new drug of abuse, methylone, a synthetic cathinone sold as "bath salts". Progress in neuro-psychopharmacology & biological psychiatry, Aug-01, Volume: 45	2013
In vitro metabolism and pharmacokinetic studies on methylone. Drug metabolism and disposition: the biological fate of chemicals, Volume: 41, Issue: 6	2013
Warning against co-administration of 3,4-methylenedioxymethamphetamine (MDMA) with methamphetamine from the perspective of pharmacokinetic and pharmacodynamic evaluations in rat brain. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, Apr-11, Volume: 49, Issue: 1	2013
Estimation of the duration after methamphetamine injection using a pharmacokinetic model in suspects who caused fatal traffic accidents. Legal medicine (Tokyo, Japan), Volume: 14, Issue: 4	2012
Gray-matter volume in methamphetamine dependence: cigarette smoking and changes with abstinence from methamphetamine. Drug and alcohol dependence, Oct-01, Volume: 125, Issue: 3	2012
Reduced amygdala and hippocampal volumes in patients with methamphetamine psychosis. Schizophrenia research, Volume: 132, Issue: 2-3	2011
Gestation time-dependent pharmacokinetics of intravenous (+)-methamphetamine in rats. Drug metabolism and disposition: the biological fate of chemicals, Volume: 39, Issue: 9	2011
Pharmacodynamic interactions between MDMA and concomitants in MDMA tablets on extracellular dopamine and serotonin in the rat brain. European journal of pharmacology, Jun-25, Volume: 660, Issue: 2-3	2011
Behavioral, hyperthermic and pharmacokinetic profile of para-methoxymethamphetamine (PMMA) in rats. Pharmacology, biochemistry, and behavior, Volume: 98, Issue: 1	2011
Distribution and pharmacokinetics of methamphetamine in the human body: clinical implications. PloS one, Dec-07, Volume: 5, Issue: 12	2010
Human methamphetamine pharmacokinetics simulated in the rat: behavioral and neurochemical effects of a 72-h binge. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, Volume: 34, Issue: 11	2009
A processing method enabling the use of peak height for accurate and precise proton NMR quantitation. Magnetic resonance in chemistry : MRC, Volume: 47, Issue: 10	2009
Detox agents do not affect the pharmacokinetics of methamphetamine in the rat. Forensic science international, Apr-15, Volume: 186, Issue: 1-3	2009
Evaluation of a pharmacokinetic hypothesis for reduced locomotor stimulation from methamphetamine and cocaine in adolescent versus adult male C57BL/6J mice. Psychopharmacology, Volume: 201, Issue: 4	2009
Pharmacological manipulations of interval timing using the peak procedure in male C3H mice. Psychopharmacology, Volume: 201, Issue: 1	2008
Nonlinear pharmacokinetics of (+/-)3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") and its major metabolites in squirrel monkeys at plasma concentrations of MDMA that develop after typical psychoactive doses. The Journal of pharmacology and experimental therapeutics, Volume: 327, Issue: 1	2008
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, Volume: 36, Issue: 7	2008
Pharmacokinetic studies of (-)-deprenyl and some of its metabolites in mouse. Journal of neural transmission. Supplementum, Issue: 72	2007
PET studies of d-methamphetamine pharmacokinetics in primates: comparison with l-methamphetamine and ( --)-cocaine. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, Volume: 48, Issue: 10	2007
Methamphetamine blood concentrations in human abusers: application to pharmacokinetic modeling. Synapse (New York, N.Y.), Volume: 61, Issue: 4	2007
Development of an in vitro incubation procedure for screening of CYP2D6 intrinsic clearance. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, May-01, Volume: 850, Issue: 1-2	2007
Single-trials analyses demonstrate that increases in clock speed contribute to the methamphetamine-induced horizontal shifts in peak-interval timing functions. Psychopharmacology, Volume: 188, Issue: 2	2006
Escalating dose pretreatment induces pharmacodynamic and not pharmacokinetic tolerance to a subsequent high-dose methamphetamine binge. Synapse (New York, N.Y.), Volume: 60, Issue: 6	2006
Human methamphetamine pharmacokinetics simulated in the rat: single daily intravenous administration reveals elements of sensitization and tolerance. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, Volume: 31, Issue: 5	2006
Sex- and dose-dependency in the pharmacokinetics and pharmacodynamics of (+)-methamphetamine and its metabolite (+)-amphetamine in rats. Toxicology and applied pharmacology, Dec-15, Volume: 209, Issue: 3	2005
Smaller subcortical volumes and cognitive deficits in children with prenatal methamphetamine exposure. Psychiatry research, Dec-15, Volume: 132, Issue: 2	2004
Urinary pharmacokinetics of methamphetamine and its metabolite, amphetamine following controlled oral administration to humans. Therapeutic drug monitoring, Volume: 26, Issue: 6	2004
Extrapyramidal motor symptoms versus striatal infarction volume after focal ischemia in mongolian gerbils. Neuroscience, Volume: 127, Issue: 2	2004
Development of a liquid chromatography-tandem mass spectrometric method for the determination of methamphetamine and amphetamine using small volumes of rat serum. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, Jul-05, Volume: 806, Issue: 2	2004
Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats. European journal of pharmacology, Feb-14, Volume: 461, Issue: 2-3	2003
Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers. Clinical chemistry, Volume: 49, Issue: 1	2003
Effect of concomitant hormone replacement therapy containing estradiol and levonorgestrel on the pharmacokinetics of selegiline. European journal of clinical pharmacology, Volume: 58, Issue: 4	2002
[Pharmacokinetic behavioral changes of methamphetamine in methamphetamine-sensitized animal model]. Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology, Volume: 21, Issue: 5	2001
[Positron emission tomography (PET) study of the alterations in brain pharmacokinetics of methamphetamine in methamphetamine sensitized animals]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, Volume: 121, Issue: 8	2001
Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole. European journal of clinical pharmacology, Volume: 57, Issue: 1	2001
Relevance of pharmacokinetic parameters in animal models of methamphetamine abuse. Synapse (New York, N.Y.), Volume: 39, Issue: 2	2001
Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. British journal of clinical pharmacology, Volume: 49, Issue: 2	2000
Spontaneous locomotor activity and pharmacokinetics of intravenous methamphetamine and its metabolite amphetamine in the rat. The Journal of pharmacology and experimental therapeutics, Volume: 291, Issue: 3	1999
Effects of pretreatment with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) on methamphetamine pharmacokinetics and striatal dopamine losses. Journal of neurochemistry, Volume: 72, Issue: 2	1999
l-methamphetamine pharmacokinetics and pharmacodynamics for assessment of in vivo deprenyl-derived l-methamphetamine. The Journal of pharmacology and experimental therapeutics, Volume: 288, Issue: 2	1999
Pharmacodynamics of a monoclonal antiphencyclidine Fab with broad selectivity for phencyclidine-like drugs. The Journal of pharmacology and experimental therapeutics, Volume: 285, Issue: 3	1998
Pharmacokinetic evaluation of a selegiline pulsatile oral delivery system. Biopharmaceutics & drug disposition, Volume: 18, Issue: 8	1997
Integrated pharmacokinetic and metabolic modeling of selegiline and metabolites after transdermal administration. Biopharmaceutics & drug disposition, Volume: 18, Issue: 7	1997
p-Hydroxymethamphetamine enantiomer pharmacokinetics and metabolism in rats: absence of N-demethylation. Biopharmaceutics & drug disposition, Volume: 18, Issue: 5	1997
Effects of haloperidol and cocaine pretreatments on brain distribution and kinetics of [11C]methamphetamine in methamphetamine sensitized dog: application of PET to drug pharmacokinetic study. Nuclear medicine and biology, Volume: 24, Issue: 2	1997
Pharmacokinetics and bioequivalence of the main metabolites of selegiline: desmethylselegiline, methamphetamine and amphetamine after oral administration of selegiline. International journal of clinical pharmacology and therapeutics, Volume: 35, Issue: 1	1997
Chronopharmacokinetics and chronopharmacodynamics of dextromethamphetamine in man. Journal of clinical pharmacology, Volume: 36, Issue: 11	1996
Lack of pharmacokinetic interaction between the selective dopamine agonist cabergoline and the MAO-B inhibitor selegiline. Journal of neural transmission. Supplementum, Volume: 45	1995
Detection of a GC/MS artifact peak as methamphetamine. Journal of analytical toxicology, Volume: 17, Issue: 5	1993
Pharmacokinetic and pharmacodynamic analysis of the actions of D-amphetamine and D-methamphetamine on the dopamine terminal. The Journal of pharmacology and experimental therapeutics, Volume: 274, Issue: 1	1995
Influence of ion-pair-formation on the pharmacokinetic properties of drugs. Part 3: Influence of hexylsalicylic acid on the pharmacokinetics of pholedrine. Die Pharmazie, Volume: 43, Issue: 9	1988
Behavioral differentiation between pharmacokinetic and pharmacodynamic components of the interaction of antidepressants or neuroleptics with methamphetamine. Psychopharmacology, Volume: 90, Issue: 1	1986
Disposition and pharmacodynamics of methamphetamine in pregnant sheep. JAMA, Apr-17, Volume: 265, Issue: 15	1991
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Article	Year
COMT val158met genotype alters the effects of methamphetamine dependence on dopamine and dopamine-related executive function: preliminary findings. Psychiatry research, Volume: 292	2020
Methamphetamine administration increases hepatic CYP1A2 but not CYP3A activity in female guinea pigs. PloS one, Volume: 15, Issue: 5	2020
Adverse effect of catechol-O-methyltransferase (COMT) Val158Met met/met genotype in methamphetamine-related executive dysfunction. Addictive behaviors, Volume: 98	2019
Intranasal insulin treatment alleviates methamphetamine induced anxiety-like behavior and neuroinflammation. Neuroscience letters, Nov-01, Volume: 660	2017
GC-MS Quantification Method for Mephedrone in Plasma and Urine: Application to Human Pharmacokinetics. Journal of analytical toxicology, Mar-01, Volume: 41, Issue: 2	2017
Methamphetamine-induced toxicity: The role of autophagy? Chemico-biological interactions, Dec-25, Volume: 260	2016
Adsorption/desorption and bioavailability of methamphetamine in simulated gastrointestinal fluids under the presence of multiwalled carbon nanotubes. Environmental science and pollution research international, Volume: 22, Issue: 12	2015
3-Methyl-methcathinone: Pharmacokinetic profile evaluation in pigs in relation to pharmacodynamics. Journal of psychopharmacology (Oxford, England), Volume: 29, Issue: 6	2015
Liposomal melatonin rescues methamphetamine-elicited mitochondrial burdens, pro-apoptosis, and dopaminergic degeneration through the inhibition PKCδ gene. Journal of pineal research, Volume: 58, Issue: 1	2015
Discovery of N-sulfonyl-7-azaindoline derivatives as potent, orally available and selective M(4) muscarinic acetylcholine receptor agonists. Bioorganic & medicinal chemistry letters, Jul-01, Volume: 24, Issue: 13	2014
Adsorption and desorption characteristics of methamphetamine, 3,4-methylenedioxymethamphetamine, and pseudoephedrine in soils. Environmental science and pollution research international, Volume: 22, Issue: 12	2015
Mephedrone pharmacokinetics after intravenous and oral administration in rats: relation to pharmacodynamics. Psychopharmacology, Volume: 229, Issue: 2	2013
An integrated pharmacokinetic and pharmacodynamic study of a new drug of abuse, methylone, a synthetic cathinone sold as "bath salts". Progress in neuro-psychopharmacology & biological psychiatry, Aug-01, Volume: 45	2013
Distribution and pharmacokinetics of methamphetamine in the human body: clinical implications. PloS one, Dec-07, Volume: 5, Issue: 12	2010
Estimating the intake of abused methamphetamines using experimenter-administered deuterium labeled R-methamphetamine: selection of the R-methamphetamine dose. Therapeutic drug monitoring, Volume: 32, Issue: 4	2010
PG01037, a novel dopamine D3 receptor antagonist, inhibits the effects of methamphetamine in rats. Journal of psychopharmacology (Oxford, England), Volume: 25, Issue: 2	2011
Fast uptake and long-lasting binding of methamphetamine in the human brain: comparison with cocaine. NeuroImage, Volume: 43, Issue: 4	2008
The clinical pharmacology of intranasal l-methamphetamine. BMC clinical pharmacology, Jul-21, Volume: 8	2008
Bioavailability of (+)-methamphetamine in the pigeon following an intramuscular dose. Pharmacology, biochemistry, and behavior, Volume: 90, Issue: 3	2008
Pharmacokinetic studies of (-)-deprenyl and some of its metabolites in mouse. Journal of neural transmission. Supplementum, Issue: 72	2007
Human pharmacology of the methamphetamine stereoisomers. Clinical pharmacology and therapeutics, Volume: 80, Issue: 4	2006
Attenuated microglial activation mediates tolerance to the neurotoxic effects of methamphetamine. Journal of neurochemistry, Volume: 92, Issue: 4	2005
A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. Journal of neural transmission (Vienna, Austria : 1996), Volume: 110, Issue: 11	2003
The bioavailability of intranasal and smoked methamphetamine. Clinical pharmacology and therapeutics, Volume: 74, Issue: 5	2003
Pharmacokinetic evaluation of a selegiline pulsatile oral delivery system. Biopharmaceutics & drug disposition, Volume: 18, Issue: 8	1997
Pharmacokinetics and bioequivalence of the main metabolites of selegiline: desmethylselegiline, methamphetamine and amphetamine after oral administration of selegiline. International journal of clinical pharmacology and therapeutics, Volume: 35, Issue: 1	1997
Bioavailability of two selegiline hydrochloride tablet products. Arzneimittel-Forschung, Volume: 46, Issue: 11	1996
Absorption and presystemic metabolism of selegiline hydrochloride at different regions in the gastrointestinal tract in healthy males. Pharmaceutical research, Volume: 13, Issue: 10	1996
[Neuroleptic properties of Y-20024, a new benzofurancarboxamide derivative]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, Volume: 94, Issue: 5	1989
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Article	Year
Dose-response in modulating brain function with transcranial direct current stimulation: From local to network levels. PLoS computational biology, Volume: 19, Issue: 10	2023
Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiences. Scientific reports, 08-22, Volume: 13, Issue: 1	2023
A qualitative study of interest in and preferences for potential medications to treat methamphetamine use disorder. Addiction science & clinical practice, 08-16, Volume: 18, Issue: 1	2023
The role of orexin-1 receptors within the ventral tegmental area in the extinction and reinstatement of methamphetamine place preference. Behavioural brain research, 09-13, Volume: 453	2023
EGCG attenuates METH self-administration and reinstatement of METH seeking in mice. Addiction biology, Volume: 28, Issue: 8	2023
Methamphetamine-induced vaginal lubrication in rats. The journal of sexual medicine, 08-25, Volume: 20, Issue: 9	2023
Predictors and motives of polydrug use in opioid users. A narrative review. Current opinion in psychiatry, 07-01, Volume: 36, Issue: 4	2023
Effects of chronic methamphetamine exposure on rewarding behavior and neurodegeneration markers in adult mice. Psychopharmacology, Volume: 240, Issue: 6	2023
Increased Lipid Peroxidation and Lowered Antioxidant Defenses Predict Methamphetamine Induced Psychosis. Cells, 11-21, Volume: 11, Issue: 22	2022
Methadone Maintenance Treatment for Opioid Dependents: a Retrospective Study. East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan, Volume: 32, Issue: 3	2022
Diagnostic difficulties in the diagnosis of high acute-phase proteins levels in a teenage drug addicted female patient. BMC psychiatry, 07-28, Volume: 22, Issue: 1	2022
The Rural Opioid Initiative Consortium description: providing evidence to Understand the Fourth Wave of the Opioid Crisis. Addiction science & clinical practice, 07-26, Volume: 17, Issue: 1	2022
Relative reinforcing effects of dibutylone, ethylone, and N-ethylpentylone: self-administration and behavioral economics analysis in rats. Psychopharmacology, Volume: 239, Issue: 9	2022
Selective Inhibition of PDE4B Reduces Methamphetamine Reinforcement in Two C57BL/6 Substrains. International journal of molecular sciences, Apr-28, Volume: 23, Issue: 9	2022
Sex differences in neurobehavioral consequences of methamphetamine exposure in adult mice. Psychopharmacology, Volume: 239, Issue: 7	2022
Exploring the effectiveness of dextroamphetamine for the treatment of stimulant use disorder: a qualitative study with patients receiving injectable opioid agonist treatment. Substance abuse treatment, prevention, and policy, 09-16, Volume: 16, Issue: 1	2021
Caveolin-1 Expression in the Dorsal Striatum Drives Methamphetamine Addiction-Like Behavior. International journal of molecular sciences, Jul-30, Volume: 22, Issue: 15	2021
Effect of Chaihu-jia-Longgu-Muli decoction on withdrawal symptoms in rats with methamphetamine-induced conditioned place preference. Bioscience reports, 08-27, Volume: 41, Issue: 8	2021
Exploring the mediating role of methamphetamine use in the relationship between adverse childhood experiences and attempted suicide. Addictive behaviors, Volume: 123	2021
Substance use & misuse, Volume: 56, Issue: 11	2021
A randomized comparison of 4 vs. 16 weeks of psychosocial treatment for stimulant users. Journal of substance abuse treatment, Volume: 124	2021
Low-normal doses of methiopropamine induce aggressive behaviour in mice. Psychopharmacology, Volume: 238, Issue: 7	2021
The acute effects of multiple doses of methamphetamine on locomotor activity and anxiety-like behavior in adolescent and adult mice. Behavioural brain research, 05-07, Volume: 405	2021
Reinforcing effects of synthetic cathinones in rhesus monkeys: Dose-response and behavioral economic analyses. Pharmacology, biochemistry, and behavior, Volume: 202	2021
Non -fatal overdose among people who inject drugs in Tehran, Iran. Substance abuse treatment, prevention, and policy, 10-14, Volume: 15, Issue: 1	2020
The motivational valence of methamphetamine relates inversely to subsequent methamphetamine self-administration in female C57BL/6J mice. Behavioural brain research, 02-01, Volume: 398	2021
Impact of Recent Methamphetamine Use on Vancomycin Clearance. Psychopharmacology bulletin, 07-23, Volume: 50, Issue: 3	2020
Methamphetamine administration increases hepatic CYP1A2 but not CYP3A activity in female guinea pigs. PloS one, Volume: 15, Issue: 5	2020
TBHQ Attenuates Neurotoxicity Induced by Methamphetamine in the VTA through the Nrf2/HO-1 and PI3K/AKT Signaling Pathways. Oxidative medicine and cellular longevity, Volume: 2020	2020
In vivo reduction of striatal D1R by RNA interference alters expression of D1R signaling-related proteins and enhances methamphetamine addiction in male rats. Brain structure & function, Volume: 225, Issue: 3	2020
Mechanistic PBPK Modeling of Urine pH Effect on Renal and Systemic Disposition of Methamphetamine and Amphetamine. The Journal of pharmacology and experimental therapeutics, Volume: 373, Issue: 3	2020
Methamphetamine use and violence: Findings from a longitudinal birth cohort. Drug and alcohol dependence, 02-01, Volume: 207	2020
Evaluation of commercially available meth-deterrent pseudoephedrine hydrochloride products. International journal of pharmaceutics, Feb-15, Volume: 575	2020
Time and region-dependent manner of increased brain derived neurotrophic factor and TrkB in rat brain after binge-like methamphetamine exposure. Neuroscience letters, 01-10, Volume: 715	2020
Dispersive solid-phase extraction adsorbent of methamphetamine using in-situ synthesized carbon-based conductive polypyrrole nanocomposite: focus on clinical applications in human urine. Journal of separation science, Volume: 43, Issue: 3	2020
Inhibition of naltrexone on relapse in methamphetamine self-administration and conditioned place preference in rats. European journal of pharmacology, Dec-15, Volume: 865	2019
Effects of methamphetamine isomers on d-methamphetamine self-administration and food-maintained responding in male rats. Psychopharmacology, Volume: 236, Issue: 12	2019
Diffusion Kurtosis Imaging Detects Microstructural Changes in a Methamphetamine-Induced Mouse Model of Parkinson's Disease. Neurotoxicity research, Volume: 36, Issue: 4	2019
A Convenient Electrochemiluminescent Immunosensor for Detecting Methamphetamine Antibody. Analytical sciences : the international journal of the Japan Society for Analytical Chemistry, Aug-10, Volume: 35, Issue: 8	2019
Sex influences susceptibility to methamphetamine cardiomyopathy in mice. Physiological reports, Volume: 7, Issue: 6	2019
Dopaminergic Effects of Major Bath Salt Constituents 3,4-Methylenedioxypyrovalerone (MDPV), Mephedrone, and Methylone Are Enhanced Following Co-exposure. Neurotoxicity research, Volume: 36, Issue: 1	2019
Dose-Response Pharmacological Study of Mephedrone and Its Metabolites: Pharmacokinetics, Serotoninergic Effects, and Impact of CYP2D6 Genetic Variation. Clinical pharmacology and therapeutics, Volume: 106, Issue: 3	2019
Evaluation of regional myocardial perfusion in methamphetamine abusers using real-time myocardial contrast echocardiography. Medical ultrasonography, Feb-17, Volume: 21, Issue: 1	2019
Methamphetamine regulates βAPP processing in human neuroblastoma cells. Neuroscience letters, 05-14, Volume: 701	2019
The Stimulant Selective Severity Assessment: A replication and exploratory extension of the Cocaine Selective Severity Assessment. Substance use & misuse, Volume: 54, Issue: 3	2019
Riluzole for treatment of men with methamphetamine dependence: A randomized, double-blind, placebo-controlled clinical trial. Journal of psychopharmacology (Oxford, England), Volume: 33, Issue: 3	2019
Effect of a binge-like dosing regimen of methamphetamine on dopamine levels and tyrosine hydroxylase expressing neurons in the rat brain. Progress in neuro-psychopharmacology & biological psychiatry, 03-08, Volume: 89	2019
Behavioral economic analysis of the reinforcing effects of "bath salts" mixtures: studies with MDPV, methylone, and caffeine in male Sprague-Dawley rats. Psychopharmacology, Volume: 236, Issue: 3	2019
Methamphetamine self-administration in a runway model of drug-seeking behavior in male rats. Pharmacology, biochemistry, and behavior, Volume: 175	2018
Limited modulation of the abuse-related behavioral effects of d-methamphetamine by disulfiram. Experimental and clinical psychopharmacology, Volume: 26, Issue: 5	2018
Development and testing of AAV-delivered single-chain variable fragments for the treatment of methamphetamine abuse. PloS one, Volume: 13, Issue: 6	2018
A recreational dose of methylphenidate, but not methamphetamine, decreases anxiety-like behavior in female rats. Neuroscience letters, 08-24, Volume: 682	2018
Analysis of N,N-dimethylamphetamine in wastewater - a pyrolysis marker and synthesis impurity of methamphetamine. Drug testing and analysis, Volume: 10, Issue: 10	2018
Rapid assessment of the dose-response relationship of methamphetamine using the progressive-dosing procedure. Behavioural pharmacology, Volume: 30, Issue: 1	2019
Relationship between the duration of methamphetamine use and psychotic symptoms: A two-year prospective cohort study. Drug and alcohol dependence, 06-01, Volume: 187	2018
The effect of N-acetylcysteine or bupropion on methamphetamine self-administration and methamphetamine-triggered reinstatement of female rats. Neuropharmacology, Volume: 135	2018
A commentary on the effects of methamphetamine and the status of methamphetamine abuse among youths in South Korea, Japan, and China. Forensic science international, Volume: 286	2018
The Role of Mitochondria in Methamphetamine-induced inhibitory effects on osteogenesis of Mesenchymal Stem Cells. European journal of pharmacology, May-05, Volume: 826	2018
Profile of psychiatric symptoms in methamphetamine users in China: Greater risk of psychiatric symptoms with a longer duration of use. Psychiatry research, Volume: 262	2018
A Single High Dose of Methamphetamine Reduces Monoamines and Impairs Egocentric and Allocentric Learning and Memory in Adult Male Rats. Neurotoxicity research, Volume: 33, Issue: 3	2018
Methamphetamine binge administration dose-dependently enhanced negative affect and voluntary drug consumption in rats following prolonged withdrawal: role of hippocampal FADD. Addiction biology, Volume: 24, Issue: 2	2019
Dose-Dependent Effects of Binge-Like Methamphetamine Dosing on Dopamine and Neurotrophin Levels in Rat Brain. Neuropsychobiology, Volume: 75, Issue: 2	2017
Buspirone maintenance does not alter the reinforcing, subjective, and cardiovascular effects of intranasal methamphetamine. Drug and alcohol dependence, 12-01, Volume: 181	2017
Relative reinforcing effects of second-generation synthetic cathinones: Acquisition of self-administration and fixed ratio dose-response curves in rats. Neuropharmacology, 05-15, Volume: 134, Issue: Pt A	2018
Effects of D1 and D2 receptor antagonists on the discriminative stimulus effects of methylendioxypyrovalerone and mephedrone in male Sprague-Dawley rats trained to discriminate D-amphetamine. Behavioural pharmacology, Volume: 28, Issue: 7	2017
Identification of three new phase II metabolites of a designer drug methylone formed in rats by N-demethylation followed by conjugation with dicarboxylic acids. Xenobiotica; the fate of foreign compounds in biological systems, Volume: 48, Issue: 6	2018
Preclinical Evidence That 5-HT1B Receptor Agonists Show Promise as Medications for Psychostimulant Use Disorders. The international journal of neuropsychopharmacology, 08-01, Volume: 20, Issue: 8	2017
Chronic methamphetamine exposure significantly decreases microglia activation in the arcuate nucleus. Journal of chemical neuroanatomy, Volume: 82	2017
Current understanding of methamphetamine-associated dopaminergic neurodegeneration and psychotoxic behaviors. Archives of pharmacal research, Volume: 40, Issue: 4	2017
Evaluation of blood lead level in methamphetamine users in Tehran. Substance abuse treatment, prevention, and policy, 02-22, Volume: 12, Issue: 1	2017
Inhibiting effects of rhynchophylline on methamphetamine-dependent zebrafish are related with the expression of tyrosine hydroxylase (TH). Fitoterapia, Volume: 117	2017
Polysubstance-induced relapse of schizoaffective disorder refractory to high-dose antipsychotic medications: a case report. Journal of medical case reports, Sep-06, Volume: 10, Issue: 1	2016
Unsafe sexual behaviour associated with hazardous alcohol use among street-involved youth. AIDS care, Volume: 29, Issue: 4	2017
The differential effects of alprazolam and oxazepam on methamphetamine self-administration in rats. Drug and alcohol dependence, Sep-01, Volume: 166	2016
Subjective and Cardiovascular Effects of Intravenous Methamphetamine during Perindopril Maintenance: A Randomized, Double-Blind, Placebo-Controlled Human Laboratory Study. The international journal of neuropsychopharmacology, Volume: 19, Issue: 7	2016
Is the recent emergence of mephedrone injecting in the United Kingdom associated with elevated risk behaviours and blood borne virus infection? Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, May-12, Volume: 21, Issue: 19	2016
Sensitization to the locomotor stimulant effects of "bath salt" constituents, 4-methylmethcathinone (4-MMC) and 3,4-methylenedioxypyrovalerone (MDPV), in male Sprague-Dawley rats. Drug and alcohol dependence, Jul-01, Volume: 164	2016
The Role of Oxidative Stress in Methamphetamine-induced Toxicity and Sources of Variation in the Design of Animal Studies. Current neuropharmacology, Volume: 15, Issue: 2	2017
Ibudilast attenuates subjective effects of methamphetamine in a placebo-controlled inpatient study. Drug and alcohol dependence, 05-01, Volume: 162	2016
Dose-response relationships between exercise intensity, cravings, and inhibitory control in methamphetamine dependence: An ERPs study. Drug and alcohol dependence, Apr-01, Volume: 161	2016
Effects of L-methamphetamine treatment on cocaine- and food-maintained behavior in rhesus monkeys. Psychopharmacology, Volume: 233, Issue: 6	2016
Dental disease patterns in methamphetamine users: Findings in a large urban sample. Journal of the American Dental Association (1939), Volume: 146, Issue: 12	2015
Differential effects of 3,4-methylenedioxypyrovalerone (MDPV) and 4-methylmethcathinone (mephedrone) in rats trained to discriminate MDMA or a d-amphetamine + MDMA mixture. Psychopharmacology, Volume: 233, Issue: 4	2016
Metabolic profile of mephedrone: Identification of nor-mephedrone conjugates with dicarboxylic acids as a new type of xenobiotic phase II metabolites. Toxicology letters, Jan-05, Volume: 240, Issue: 1	2016
Mephedrone related fatalities: a review. European review for medical and pharmacological sciences, Volume: 19, Issue: 19	2015
Methamphetamine oxidative stress, neurotoxicity, and functional deficits are modulated by nuclear factor-E2-related factor 2. Free radical biology & medicine, Volume: 89	2015
"Chemsex" and harm reduction need among gay men in South London. The International journal on drug policy, Volume: 26, Issue: 12	2015
Characterization of binge-dosed methamphetamine-induced neurotoxicity and neuroinflammation. Neurotoxicology, Volume: 50	2015
Illicit Heroin and Methamphetamine Use among Methadone Maintenance Treatment Patients in Dehong Prefecture of Yunnan Province, China. PloS one, Volume: 10, Issue: 7	2015
Effects of active anti-methamphetamine vaccination on intravenous self-administration in rats. Drug and alcohol dependence, Aug-01, Volume: 153	2015
Death following ingestion of methylone. International journal of legal medicine, Volume: 130, Issue: 2	2016
Neuropsychiatric Adverse Effects of Amphetamine and Methamphetamine. International review of neurobiology, Volume: 120	2015
3-Methyl-methcathinone: Pharmacokinetic profile evaluation in pigs in relation to pharmacodynamics. Journal of psychopharmacology (Oxford, England), Volume: 29, Issue: 6	2015
The pharmacokinetics of methamphetamine self-administration in male and female rats. Drug and alcohol dependence, May-01, Volume: 150	2015
Increased Vesicular Monoamine Transporter 2 (VMAT2; Slc18a2) Protects against Methamphetamine Toxicity. ACS chemical neuroscience, May-20, Volume: 6, Issue: 5	2015
The neuroprotective potential of low-dose methamphetamine in preclinical models of stroke and traumatic brain injury. Progress in neuro-psychopharmacology & biological psychiatry, Jan-04, Volume: 64	2016
Differential effects of the dopamine D3 receptor antagonist PG01037 on cocaine and methamphetamine self-administration in rhesus monkeys. Neuropharmacology, Volume: 92	2015
High prevalence of non-fatal overdose among people who inject drugs in Malaysia: Correlates of overdose and implications for overdose prevention from a cross-sectional study. The International journal on drug policy, Volume: 26, Issue: 7	2015
Abuse liability of the dietary supplement dimethylamylamine. Drug and alcohol dependence, Jan-01, Volume: 146	2015
Naltrexone and bupropion, alone or combined, do not alter the reinforcing effects of intranasal methamphetamine. Pharmacology, biochemistry, and behavior, Volume: 129	2015
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Article	Year
The transcranial direct current stimulation over prefrontal cortex combined with the cognitive training reduced the cue-induced craving in female individuals with methamphetamine use disorder: A randomized controlled trial. Journal of psychiatric research, Volume: 134	2021
Bath salts and polyconsumption: in search of drug-drug interactions. Psychopharmacology, Volume: 236, Issue: 3	2019
Mindfulness-based relapse prevention combined with virtual reality cue exposure for methamphetamine use disorder: Study protocol for a randomized controlled trial. Contemporary clinical trials, Volume: 70	2018
Straub tail reaction in mice treated with σ(1) receptor antagonist in combination with methamphetamine. Brain research, Oct-30, Volume: 1482	2012
Simultaneous quantification of amphetamines, caffeine and ketamine in urine by hollow fiber liquid phase microextraction combined with gas chromatography-flame ionization detector. Talanta, Aug-15, Volume: 82, Issue: 3	2010
The cardiovascular and subjective effects of methamphetamine combined with gamma-vinyl-gamma-aminobutyric acid (GVG) in non-treatment seeking methamphetamine-dependent volunteers. Pharmacology, biochemistry, and behavior, Volume: 94, Issue: 1	2009
Sildenafil (Viagra) and club drug use in gay and bisexual men: the role of drug combinations and context. American journal of men's health, Volume: 1, Issue: 2	2007
Sedative and hypothermic effects of gamma-hydroxybutyrate (GHB) in rats alone and in combination with other drugs: assessment using biotelemetry. Drug and alcohol dependence, Aug-01, Volume: 103, Issue: 3	2009
An antihyperkinetic action by the serotonin 1A-receptor agonist osemozotan co-administered with psychostimulants or the non-stimulant atomoxetine in mice. Journal of pharmacological sciences, Volume: 109, Issue: 3	2009
Evaluation of the cardiovascular and subjective effects of rivastigmine in combination with methamphetamine in methamphetamine-dependent human volunteers. The international journal of neuropsychopharmacology, Volume: 11, Issue: 6	2008
Drug interaction between methamphetamine and antihistamines: behavioral changes and tissue concentrations of methamphetamine in rats. European journal of pharmacology, Nov-28, Volume: 505, Issue: 1-3	2004
Behavioral responses induced by repeated treatment with methamphetamine alone and in combination with scopolamine in rats. Neuropsychobiology, Volume: 33, Issue: 1	1996
Anti-serotonin action in combination with noradrenaline-stimulating action is important for inhibiting muricide in midbrain raphe-lesioned rats. Neuropharmacology, Volume: 27, Issue: 2	1988
EEG and behavioral effects of delta9-tetrahydrocannabinol in combination with stimulant drugs in rabbits. Psychopharmacology, Oct-20, Volume: 50, Issue: 1	1976
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Article	Year
The effect of mitragynine on extracellular activity of brain dopamine and its metabolites. Brain research bulletin, Volume: 178	2022
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

methamphetamine

Description

Cross-References

Synonyms (145)

Roles (5)

Drug Classes (2)

Pathways (1)

Protein Targets (11)

Inhibition Measurements

Activation Measurements

Biological Processes (43)

Molecular Functions (27)

Ceullar Components (28)

Bioassays (74)

Research

Studies (10,326)

Study Types

Clinical Trials (134)

Trial Overview

Trial Outcomes

Change in Dim Light Melatonin Onset (DLMO) Phase Shift

Change in Non-school Night Sleep Onset Time

Change in School Night Sleep Onset Time

Change in Dim Light Melatonin Onset (DLMO)

Additional Sedation

Airway Interventions

Alertness Levels

Desaturations

Patient Satisfaction

Adapted Visual Acuity

Initial Visual Acuity

Spectacle Assessment Survey Question 1

Spectacle Assessment Survey Question 2

Spectacle Assessment Survey Question 3

Spectacle Wear Time

Attentional Bias

Delay Discounting for Methamphetamine

Delay Discounting for Money

Diastolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (0 mg) Maintenance.

Diastolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (20 mg) Maintenance.

Diastolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (40 mg) Maintenance.

Diastolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (60 mg) Maintenance.

Heart Rate After Methamphetamine Administration Following Methylphenidate (0 mg) Maintenance.

Heart Rate After Methamphetamine Administration Following Methylphenidate (20 mg) Maintenance.

Heart Rate After Methamphetamine Administration Following Methylphenidate (40 mg) Maintenance.

Heart Rate After Methamphetamine Administration Following Methylphenidate (60 mg) Maintenance.

Reinforcing Effects of Methamphetamine Following Methylphenidate (0 mg; Placebo) Maintenance.

Reinforcing Effects of Methamphetamine Following Methylphenidate (20 mg) Maintenance.

Reinforcing Effects of Methamphetamine Following Methylphenidate (40 mg) Maintenance.

Reinforcing Effects of Methamphetamine Following Methylphenidate (60 mg) Maintenance.

Snaith-Hamilton-Pleasure Scale to Measure Anhedonia (Inability to Experience Pleasure)

Subjective Effects of Methamphetamine (0 mg) Administration Following Methylphenidate (0 mg) Maintenance.

Subjective Effects of Methamphetamine (0 mg) Administration Following Methylphenidate (20 mg) Maintenance.

Subjective Effects of Methamphetamine (0 mg) Administration Following Methylphenidate (40 mg) Maintenance.

Subjective Effects of Methamphetamine (0 mg) Administration Following Methylphenidate (60 mg) Maintenance.

Subjective Effects of Methamphetamine (10 mg) Administration Following Methylphenidate (0 mg) Maintenance.

Subjective Effects of Methamphetamine (10 mg) Administration Following Methylphenidate (20 mg) Maintenance.

Subjective Effects of Methamphetamine (10 mg) Administration Following Methylphenidate (40 mg) Maintenance.

Subjective Effects of Methamphetamine (10 mg) Administration Following Methylphenidate (60 mg) Maintenance.

Subjective Effects of Methamphetamine (20 mg) Administration Following Methylphenidate (0 mg) Maintenance.

Subjective Effects of Methamphetamine (20 mg) Administration Following Methylphenidate (20 mg) Maintenance.

Subjective Effects of Methamphetamine (20 mg) Administration Following Methylphenidate (40 mg) Maintenance.

Subjective Effects of Methamphetamine (20 mg) Administration Following Methylphenidate (60 mg) Maintenance.

Systolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (0 mg) Maintenance.

Systolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (20 mg) Maintenance.

Systolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (40 mg) Maintenance.

Systolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (60 mg) Maintenance.

Temperature After Methamphetamine Administration Following Methylphenidate (0 mg) Maintenance.

Temperature After Methamphetamine Administration Following Methylphenidate (20 mg) Maintenance.

Temperature After Methamphetamine Administration Following Methylphenidate (40 mg) Maintenance.

Temperature After Methamphetamine Administration Following Methylphenidate (60 mg) Maintenance.

Lane Position Deviation

Psycho-motor Vigilance Test (PVT)

"Overall Proportion Saying Yes to Real Prism Glasses"

Mobility Change Score (All Participants Who Completed Crossover)

Mobility Change Score (Only Participants Who Continued Prism Wear in the Long Term)

Mobility Change Score (Only Participants Who Discontinued Prism Wear in the Long Term)

Photostress Recovery Time

Change in Braking Reaction Time From No-glare to Glare (ACRYSOF® IQ IOL + Placebo Filter; Clear IOL + BLF)

Change in Braking Reaction Time From No-glare to Glare (Clear IOLs)